

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61K 39/29, C12N 1/15, 1/21, 5/10, 5/14, 5/16, C12Q 1/70</b>		<b>A1</b>	(11) International Publication Number: <b>WO 98/39031</b>
			(43) International Publication Date: 11 September 1998 (11.09.98)
(21) International Application Number: <b>PCT/US98/04428</b>		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 26 February 1998 (26.02.98)			
(30) Priority Data: 08/811,566 4 March 1997 (04.03.97) US			
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 08/811,566 (CON) Filed on 4 March 1997 (04.03.97)			
(71) Applicant (for all designated States except US): WASHINGTON UNIVERSITY [US/US]; One Brookings Drive, St. Louis, MO 63130 (US).			
(72) Inventors; and (75) Inventors/Applicants (for US only): RICE, Charles, M., III [US/US]; 7316 Colgate Avenue, University City, MO 63130 (US). KOLYKHALOV, Alexander A. [RU/US]; 3557 Sulphur Avenue, St. Louis, MO 63139 (US).		<b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(74) Agents: HOLLAND, Donald, R. et al.; Howell & Haferkamp, L.C., Suite 1400, 7733 Forsyth Boulevard, St. Louis, MO 63105 (US).			
(54) Title: FUNCTIONAL DNA CLONE FOR HEPATITIS C VIRUS (HCV) AND USES THEREOF			
(57) Abstract  The present invention relates to the determination of an authentic HCV genome RNA sequences, to construction of infectious HCV DNA clones, and to use of the clones, or their derivatives, in therapeutic, vaccine, and diagnostic applications. The invention is also directed to HCV vectors, e.g., for gene therapy of gene vaccines.			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## FUNCTIONAL DNA CLONE FOR HEPATITIS C VIRUS (HCV) AND USES THEREOF

### GOVERNMENT SUPPORT

- 5 The research leading to the present invention was supported, at least in part, by grants from United States Public Health Service Grant Nos. CA57973 and AI31501. Accordingly, the Government may have certain rights in the invention.

### FIELD OF THE INVENTION

- 10 The present invention relates to the determination of functional HCV virus genomic RNA sequences, to construction of infectious HCV DNA clones, and to use of the clones, or their derivatives, in therapeutic, vaccine, and diagnostic applications. The invention is also directed to HCV vectors, *e.g.*, for gene therapy or gene vaccines.

### BACKGROUND OF THE INVENTION

#### Brief general overview of hepatitis C virus

- 15 After the development of diagnostic tests for hepatitis A virus and hepatitis B virus, an additional agent, which could be experimentally transmitted to chimpanzees [Alter *et al.*, *Lancet* 1, 459-463 (1978); Hollinger *et al.*, *Intervirology* 10, 60-68 (1978); Tabor *et al.*,  
20 *Lancet* 1, 463-466 (1978)], became recognized as the major cause of transfusion-acquired hepatitis. cDNA clones corresponding to the causative non-A non-B (NANB) hepatitis agent, called hepatitis C virus (HCV), were reported in 1989 [Choo *et al.*, *Science* 244, 359-362 (1989)]. This breakthrough has led to rapid advances in diagnostics, and in our understanding of the epidemiology, pathogenesis and molecular virology of HCV (see  
25 Houghton *et al.*, *Curr Stud Hematol Blood Transfus* 61, 1-11 (1994) for review). Evidence of HCV infection is found throughout the world, and the prevalence of HCV-specific antibodies ranges from 0.4-2% in most countries to more than 14% in Egypt [Hibbs *et al.*, *J. Inf. Dis.* 168, 789-790 (1993)]. Besides transmission via blood or blood products, or less frequently by sexual and congenital routes, sporadic cases, not associated  
30 with known risk factors, occur and account for more than 40% of HCV cases [Alter *et al.*, *J. Am. Med. Assoc.* 264, 2231-2235 (1990); Mast and Alter, *Semin. Virol.* 4, 273-283 (1993)]. Infections are usually chronic [Alter *et al.*, *N. Eng. J. Med.* 327, 1899-1905 (1992)], and clinical outcomes range from an inapparent carrier state to acute hepatitis, chronic active hepatitis, and cirrhosis which is strongly associated with the development of  
35 hepatocellular carcinoma.

- Although interferon (IFN)- $\alpha$  has been shown to be useful for the treatment of a minority of patients with chronic HCV infections [Davis *et al.*, *N. Engl. J. Med.* **321**, 1501-1506 (1989); DiBisceglie *et al.*, *New Engl. J. Med.* **321**, 1506-1510 (1989)] and subunit vaccines show some promise in the chimpanzee model [Choo *et al.*, *Proc. Natl. Acad. Sci. USA* **91**, 1294-1298 (1994)], future efforts are needed to develop more effective therapies and vaccines. The considerable diversity observed among different HCV isolates [for review, see Bukh *et al.*, *Sem. Liver Dis.* **15**, 41-63 (1995)], the emergence of genetic variants in chronically infected individuals [Enomoto *et al.*, *J. Hepatol.* **17**, 415-416 (1993); Hijikata *et al.*, *Biochem. Biophys. Res. Comm.* **175**, 220-228 (1991); Kato *et al.*, *Biochem. Biophys. Res. Comm.* **189**, 119-127 (1992); Kato *et al.*, *J. Virol.* **67**, 3923-3930 (1993); Kurosaki *et al.*, *Hepatology* **18**, 1293-1299 (1993); Lesniewski *et al.*, *J. Med. Virol.* **40**, 150-156 (1993); Ogata *et al.*, *Proc. Natl. Acad. Sci. USA* **88**, 3392-3396 (1991); Weiner *et al.*, *Virology* **180**, 842-848 (1991); Weiner *et al.*, *Proc. Natl. Acad. Sci. USA* **89**, 3468-3472 (1992)], and the lack of protective immunity elicited after HCV infection [Farci *et al.*, *Science* **258**, 135-140 (1992); Prince *et al.*, *J. Infect. Dis.* **165**, 438-443 (1992)] present major challenges towards these goals.

#### Molecular Biology of HCV

- Classification.* Based on its genome structure and virion properties, HCV has been classified as a separate genus in the flavivirus family, which includes two other genera: the flaviviruses (*e.g.*, yellow fever (YF) virus) and the animal pestiviruses (*e.g.*, bovine viral diarrhea virus (BVDV) and classical swine fever virus (CSFV)) [Francki *et al.*, *Arch. Virol. Suppl.* **2**, 223 (1991)]. All members of this family have enveloped virions that contain a positive-strand RNA genome encoding all known virus-specific proteins via translation of a single long open reading frame (ORF).

- Structure and physical properties of the virion.* Little information is available on the structure and replication of HCV. Studies have been hampered by the lack of a cell culture system able to support efficient virus replication and the typically low titers of infectious virus present in serum. The size of infectious virus, based on filtration experiments, is between 30-80 nm [Bradley *et al.*, *Gastroenterology* **88**, 773-779 (1985); He *et al.*, *J. Infect. Dis.* **156**, 636-640 (1987); Yuasa *et al.*, *J. Gen. Virol.* **72**, 2021-2024 (1991)]. Initial measurements of the buoyant density of infectious material in sucrose yielded a range



of values, with the majority present in a low density pool of < 1.1 g/ml [Bradley *et al.*, *J. Med. Virol.* 34, 206-208 (1991)]. Subsequent studies have used RT/PCR to detect HCV-specific RNA as an indirect measure of potentially infectious virus present in sera from chronically infected humans or experimentally infected chimpanzees. From these studies, it has become increasingly clear that considerable heterogeneity exists between different clinical samples, and that many factors can affect the behavior of particles containing HCV RNA [Hijikata *et al.*, *J. Virol.* 67, 1953-1958 (1993); Thomssen *et al.*, *Med. Microbiol. Immunol.* 181, 293-300 (1992)]. Such factors include association with immunoglobulins [Hijikata *et al.*, (1993) *supra*] or low density lipoprotein [Thomssen *et al.*, 1992, *supra*; Thomssen *et al.*, *Med. Microbiol. Immunol.* 182, 329-334 (1993)]. In highly infectious acute phase chimpanzee serum, HCV-specific RNA is usually detected in fractions of low buoyant density (1.03-1.1 g/ml) [Carrick *et al.*, *J. Virol. Meth.* 39, 279-289 (1992); Hijikata *et al.*, (1993) *supra*]. In other samples, the presence of HCV antibodies and formation of immune complexes correlate with particles of higher density and lower infectivity [Hijikata *et al.*, (1993) *supra*]. Treatment of particles with chloroform, which destroys infectivity [Bradley *et al.*, *J. Infect. Dis.* 148, 254-265 (1983); Feinstone *et al.*, *Infect. Immun.* 41, 816-821 (1983)], or with nonionic detergents, produced RNA containing particles of higher density (1.17-1.25 g/ml) believed to represent HCV nucleocapsids [Hijikata *et al.*, (1993) *supra*; Kanto *et al.*, *Hepatology* 19, 296-302 (1994); Miyamoto *et al.*, *J. Gen. Virol.* 73, 715-718 (1992)].

There have been reports of negative-sense HCV-specific RNAs in sera and plasma [see Fong *et al.*, *Journal of Clinical Investigation* 88:1058-60 (1991)]. However, it seems unlikely that such RNAs are essential components of infectious particles since some sera with high infectivity can have low or undetectable levels of negative-strand RNA [Shimizu *et al.*, *Proc. Natl. Acad. Sci. USA* 90: 6037-6041 (1993)].

The virion protein composition has not been rigorously determined, but putative HCV structural proteins include a basic C protein and two membrane glycoproteins, E1 and E2.

**HCV replication.** Early events in HCV replication are poorly understood. Cellular receptors for the HCV glycoproteins have not been identified. The association of some HCV particles with beta-lipoprotein and immunoglobulins raises the possibility that these

host molecules may modulate virus uptake and tissue tropism. Studies examining HCV replication have been largely restricted to human patients or experimentally inoculated chimpanzees. In the chimpanzee model, HCV RNA is detected in the serum as early as three days post-inoculation and persists through the peak of serum alanine aminotransferase (ALT) levels (an indicator of liver damage) [Shimizu *et al.*, *Proc. Natl. Acad. Sci. USA* 87: 6441-6444 (1990)]. The onset of viremia is followed by the appearance of indirect hallmarks of HCV infection of the liver. These include the appearance of a cytoplasmic antigen [Shimizu *et al.*, (1990) *supra*] and ultrastructural changes in hepatocytes such as the formation of microtubular aggregates for which HCV previously was referred to as the chloroform-sensitive "tubule forming agent" or "TFA" [reviewed by Bradley, *Prog. Med. Virol.* 37: 101-135 (1990)]. As shown by the appearance of viral antigens [Blight *et al.*, *Amer. J. Path.* 143: 1568-1573 (1993); Hiramatsu *et al.*, *Hepatology* 16: 306-311 (1992); Krawczynski *et al.*, *Gastroenterology* 103: 622-629 (1992); Yamada *et al.*, *Digest. Dis. Sci.* 38: 882-887 (1993)] and the detection of positive and negative sense RNAs [Fong *et al.*, (1991) *supra*; Gunji *et al.*, *Arch. Virol.* 134: 293-302 (1994); Haruna *et al.*, *J. Hepatol.* 18: 96-100 (1993); Lamas *et al.*, *J. Hepatol.* 16: 219-223 (1992); Nouri Aria *et al.*, *J. Clin. Inves.* 91: 2226-34 (1993); Sherker *et al.*, *J. Med. Virol.* 39: 91-96 (1993); Takehara *et al.*, *Hepatology* 15: 387-390 (1992); Tanaka *et al.*, *Liver* 13: 203-208 (1993)], hepatocytes appear to be a major site of HCV replication, particularly during acute infection [Negro *et al.*, *Proc. Natl. Acad. Sci. USA* 89: 2247-2251 (1992)]. In later stages of HCV infection the appearance of HCV-specific antibodies, the persistence or resolution of viremia, and the severity of liver disease, vary greatly both in the chimpanzee model and in human patients. Although some liver damage may occur as a direct consequence of HCV infection and cytopathogenicity, the emerging consensus is that host immune responses, in particular virus-specific cytotoxic T lymphocytes, may play a more dominant role in mediating cellular damage.

It has been speculated that HCV may also replicate in extra-hepatic reservoir(s). In some cases, RT/PCR or *in situ* hybridization has shown an association of HCV RNA with peripheral blood mononuclear cells including T-cells, B-cells, and monocytes reviewed in Blight and Gowans, *Viral Hepatitis Rev.* 1: 143-155 (1995)]. Such tissue tropism could be relevant to the establishment of chronic infections and might also play a role in the association between HCV infection and certain immunological abnormalities such as mixed

cryoglobulinemia [reviewed by Ferri *et al.*, *Eur. J. Clin. Invest.* 23: 399-405 (1993)], glomerulonephritis, and rare non-Hodgkin's B-lymphomas [Ferri *et al.*, (1993) *supra*; Kagawa *et al.*, *Lancet* 341: 316-317 (1993)]. However, the detection of circulating negative strand RNA in serum, the difficulty in obtaining truly strand-specific RT/PCR [Gunji *et al.*, (1994) *supra*], and the low numbers of apparently infected cells have made it difficult to obtain unambiguous evidence for replication in these tissues *in vivo*.

*Genome structure.* Full-length or nearly full-length genome sequences of numerous HCV isolates have been reported [see Lin *et al.*, *J. Virol.* 68: 5063-5073 (1994a); Okamoto *et al.*, *J. Gen. Virol.* 75: 629-635 (1994); Sakamoto *et al.*, *J. Gen. Virol.* 75: 1761-1768 (1994) and citations therein]. Given the considerable genetic divergence among isolates, it is clear that several major HCV genotypes are distributed throughout the world. Those of greatest importance in the U.S. are genotype 1, subtypes 1a and 1b (see below and Ref. Bukh *et al.*, (1995) *supra* for a discussion of genotype prevalence and distribution). HCV genome RNAs are ~9.6 kilobases in length (Figure 1). The 5' NTR is 341-344 bases long and highly conserved. The length of the long ORF varies slightly among isolates, encoding polypeptides of 3010, 3011 or 3033 amino acids. The reported 3' NTR structures show considerable diversity both in composition and length (28-42 bases), and appear to terminate with poly (U) (see Chen *et al.*, *Virology* 188:102-113 (1992); Okamoto *et al.*, *J. Gen. Virol.* 72:2697-2704 (1991); Tokita *et al.*, *J. Gen. Virol.* 66:1476-83 (1994)] except in one case (HCV-1, type 1a) which appears to contain a 3' terminal poly (A) tract [Han *et al.*, *Proc. Natl. Acad. Sci. USA* 88:1711-1715 (1991)]. In contrast, our recent analysis suggests that the genome RNA of the H-strain (also type 1a) contains an internal polypyrimidine tract followed by a novel RNA element [pending patent application Serial No. 08/520,678, filed August 29, 1995, and International Patent Application No. PCT/US96/14033, filed August 28, 1996]. The results presented in pending application Serial No. 08/520,678 show that the genome RNA of this type 1a isolate does not terminate with a homopolymer tract as previously thought, but rather with a novel sequence of ~98 bases. Furthermore, this 3' NTR structure and the novel 3' terminal element are features common to all HCV genotypes which have thus far been examined [Kolykhalov *et al.*, *J. Virol.* 70: 3363-3371 (1996); Tanaka *et al.*, *Biochem. Biophys. Res. Comm.* 215: 744-749 (1996); Tanaka *et al.*, *J. Virol.* 70:3307-12 (1996); Yamada *et al.*, *Virology* 223:255-261 (1996)].

*Translation and proteolytic processing.* Several studies have used cell-free translation and transient expression in cell culture to examine the role of the 5' NTR in translation initiation [Fukushi *et al.*, *Biochem. Biophys. Res. Comm.* 199: 425-432 (1994); Tsukiyama-Kohara *et al.*, *J. Virol.* 66: 1476-1483 (1992); Wang *et al.*, *J. Virol.* 67: 3338-3344 (1993); Yoo *et al.*, *Virology* 191: 889-899 (1992)]. This highly conserved sequence contains multiple short AUG-initiated ORFs and shows significant homology with the 5' NTR region of pestiviruses [Bukh *et al.*, *Proc. Natl. Acad. Sci. USA* 89: 4942-4946 (1992); Han *et al.*, (1991) *supra*]. A series of stem-loop structures have been proposed on the basis of computer modeling and sensitivity to digestion by different ribonucleases [Brown *et al.*, 10 *Nucl. Acids Res.* 20: 5041-5045 (1992); Tsukiyama-Kohara *et al.*, (1992) *supra*]. The results from several groups indicate that this element functions as an internal ribosome entry site (IRES) allowing efficient translation initiation at the first AUG of the long ORF [Fukushi *et al.*, (1994) *supra*; Tsukiyama-Kohara *et al.*, (1992) *supra*; Wang *et al.*, (1993) *supra*; Yoo *et al.*, (1992) *supra*]. Some of the predicted features of the HCV and pestivirus 15 IRES elements are similar to one another [Brown *et al.*, (1992) *supra*]. The ability of this element to function as an IRES suggests that HCV genome RNAs may lack a 5' cap structure.

The organization and processing of the HCV polyprotein (Figure 1) appears to be most 20 similar to that of the pestiviruses. At least 10 polypeptides have been identified and the order of these cleavage products in the polyprotein is NH<sub>2</sub>-C-E1-E2-p7-NS2-NS3-NS4A-NS4B-NS5A-NS5B-COOH. As shown in Figure 1, proteolytic processing is mediated by host signal peptidase and two HCV-encoded proteinases, the NS2-3 autoprotease and the NS3-4A serine proteinase [see Rice, *In "Fields Virology"* (B. N. Fields, D. M. Knipe and 25 P. M. Howley, Eds.), Vol. pp. 931-960. Raven Press, New York (1996); Shimotohno *et al.*, *J. Hepatol.* 22: 87-92 (1995) for reviews]. C is a basic protein believed to be the viral core or capsid protein; E1 and E2 are putative virion envelope glycoproteins; p7 is a hydrophobic protein of unknown function that is inefficiently cleaved from the E2 glycoprotein [Lin *et al.*, (1994a) *supra*; Mizushima *et al.*, *J. Virol.* 68: 6215-6222 (1994); 30 Selby *et al.*, *Virology* 204: 114-122 (1994)], and NS2-NS5B are likely nonstructural (NS) proteins which function in viral RNA replication complexes. In particular, besides its N-terminal serine proteinase domain, NS3 contains motifs characteristic of RNA helicases and has been shown to possess an RNA-stimulated NTPase activity [Suzich *et al.*, *J. Virol.* 67,

6152-6158 (1993)]; NS5B contains the GDD motif characteristic of the RNA-dependent RNA polymerases of positive-strand RNA viruses.

- HCV RNA replication.* By analogy with flaviviruses, replication of the positive-sense HCV virion RNA is thought to occur via a minus-strand intermediate. This strategy can be described briefly as follows: (i) uncoating of the incoming virus particle releases the genomic plus-strand, which is translated to produce a single long polyprotein that is probably processed co- and post-translationally to produce individual structural and nonstructural proteins; (ii) the nonstructural proteins presumably form a replication complex that utilizes the virion RNA as template for the synthesis of minus strands; (iii) these minus strands in turn serve as templates for synthesis of plus strands, which can be used for additional translation of viral protein, minus strand synthesis, or packaging into progeny virions. Very few details about HCV replication process are available, due to the lack of a good experimental system for virus propagation. Detailed analyses of authentic HCV replication and other steps in the viral life cycle would be greatly facilitated by the development of an efficient system for HCV replication in cell culture.

- Many attempts have been made to infect cultured cells with serum collected from HCV-infected individuals, and low levels of replication have been reported in a number of cell types infected by this method, including B-cell [Bertolini *et al.*, *Res. Virol.* 144: 281-285 (1993); Nakajima *et al.*, *J. Virol.* 70: 9925-9 (1996); Valli *et al.*, *Res. Virol.* 146:285-288 (1995)]. T-cell (Kato *et al.*, *Biochem. Biophys. Res. Commun.* 206:863-9 (1996); Mizutani *et al.*, *Biochem. Biophys. Res. Comm.* 227:822-826; Mizutani *et al.*, *J. Virol.* 70: 7219-7223 (1996); Nakajima *et al.*, (1996) *supra*; Shimizu and Yoshikura, *J Virol*, 68: 8406-8408 (1994); Shimizu *et al.*, *Proc. Natl. Acad. Sci USA*, 89: 5477-5481 (1992); Shimizu *et al.*, *Proc. Natl. Acad. Sci. USA*, 90: 6037-6041 (1993)], and hepatocyte [Kato *et al.*, *Jpn. J. Cancer Res.*, 87: 787-92 (1996); Tagawa, *J. Gastroenterol. and Hepatol.*, 10: 523-527 (1995)] cell lines, as well as peripheral blood mononuclear cells (PBMCs) [Cribier *et al.*, *J. Gen. Virol.*, 76: 2485-2491 (1995)], and primary cultures of human fetal hepatocytes [Carloni *et al.*, *Arch. Virol. Suppl.* 8: 31-39 (1993); Cribier *et al.*, (1995) *supra*; Iacovacci *et al.*, *Res. Virol.*, 144: 275-279 (1993)] or hepatocytes from adult chimpanzees [Lanford *et al.*, *Virology* 202: 606-14 (1994)]. HCV replication has also been detected in primary hepatocytes derived from a human HCV patient that were infected with the virus *in vivo*

- prior to cultivation [Ito *et al.*, *J. Gen. Virol.* 77: 1043-1054 (1996)] and in the human hepatoma cell line Huh7 following transfection with RNA transcribed *in vitro* from an HCV-1 cDNA clone [Yoo *et al.*, *J. Virol.*, 69: 32-38 (1995)]. The reported observation of replication in cells transfected with RNA derived from the HCV-1 clone was puzzling,
- 5 since this clone lacks the 3'NTR sequence downstream of the homopolymer tract (see below). The most well-characterized cell-culture systems for HCV replication utilize a B-cell line (Daudi) or T-cell lines persistently infected with retroviruses (HPB-Ma or MT-2) [Kato *et al.*, (1995) *supra*; Mizutani *et al.*, *Biochem Biophys Res. Comm.*, 227: 822-826 (1996a); Mizutani *et al.*, (1996) *supra*; Nakajima *et al.*, (1996) *supra*; Shimizu and
- 10 Yoshikura, (1994) *supra*]; Shimizu, *Proc. Natl. Acad. Sci. USA*, 90: 6037-6041 (1993)]. HPB-Ma is infected with an amphotropic murine leukemia virus pseudotype of murine sarcoma virus, while MT-2 is infected with human T-cell lymphotropic virus type I (HTLV-I). Clones (HPB-Ma10-2 and MT-2C) that support HCV replication more efficiently than the uncloned population have been isolated for the two T-cell lines HPB-Ma and MT-2
- 15 [Mizutani *et al.* *J. Virol.* (1996) *supra*; Shimizu *et al.*, (1993) *supra*]. However, the maximum levels of RNA replication obtained in these lines or in the Daudi lines after degradation of the input RNA is still only about  $5 \times 10^4$  RNA molecules per  $10^6$  cells [Mizutani *et al.*, (1996) *supra*; Mizutani *et al.*, (1996) *supra*] or  $10^4$  RNA molecules per ml of culture medium [Nakajima *et al.*, (1996) *supra*]. Although the level of replication is
- 20 low, long-term infections of up to 198 days in one system [Mizutani *et al.*, *Biochem. Biophys. Res. Comm.* 227: 822-826 (1996a)] and more than a year in another system [Nakajima *et al.*, (1996) *supra*] have been documented, and infectious virus production has been demonstrated by serial cell-free or cell-mediated passage of the virus to naive cells.
- 25 However, efficient HCV replication has not been observed in any of the cell-culture systems described to date, and all of the groups that have attempted to establish such systems have encountered a number of problems, including the difficulty in distinguishing input RNA from plus strands produced by replication, the false detection of minus strands, and generally low titers of replicated RNA. Thus, despite these advances, more efficient
- 30 cell-culture systems for HCV propagation are needed for the production of concentrated virus stocks, structural analysis of virion components, and improved analyses of intracellular viral processes, including RNA replication.

*Virion assembly and release.* This process has not been examined directly, but the lack of complex glycans, the ER localization of expressed HCV glycoproteins [Dubuisson *et al.*, *J. Virol.* 68: 6147-6160 (1994); Ralston *et al.*, *J. Virol.* 67: 6753-6761 (1993)] and the absence of these proteins on the cell surface [Dubuisson *et al.*, (1994) *supra*; Spaete *et al.*, *Virology* 188: 819-830 (1992)] suggest that initial virion morphogenesis may occur by budding into intracellular vesicles. Thus far, efficient particle formation and release has not been observed in transient expression assays, suggesting that essential viral or host factors are absent or blocked. HCV virion formation and release may be inefficient, since a substantial fraction of the virus remains cell-associated, as found for the pestiviruses. A recent study indicates that extracellular HCV particles partially purified from human plasma contain complex N-linked glycans, although these carbohydrate moieties were not shown to be specifically associated with E1 or E2 [Sato *et al.*, *Virology* 196: 354-357 (1993)]. Complex glycans associated with glycoproteins on released virions would suggest transit through the trans-Golgi and movement of virions through the host secretory pathway. If this is correct, intracellular sequestration of HCV glycoproteins and virion formation might then play a role in the establishment of chronic infections by minimizing immune surveillance and preventing lysis of virus-infected cells via antibody and complement.

*Genetic variability.* As for all positive-strand RNA viruses, the RNA-dependent RNA polymerase (RDRP) of HCV (NS5B) is believed to lack a 3'-5' exonuclease proof reading activity for removal of misincorporated bases. Replication is therefore error-prone, leading to a "quasi-species" virus population consisting of a large number of variants [Martell *et al.*, *J. Virol.* 66: 3225-3229 (1992); Martell *et al.*, *J. Virol.* 68: 3425-3436 (1994)]. This variability is apparent at multiple levels. First, in a chronically infected individual, changes in the virus population occur over time [Ogata *et al.*, (1991) *supra*; Okamoto *et al.*, *Virology* 190: 894-899 (1992)]; and these changes may have important consequences for disease. A particularly interesting example is the N-terminal 30 residue segment of the E2 glycoprotein, which exhibits a much higher degree of variability than the rest of the polyprotein [for examples, see Higashi *et al.*, *Virology* 197, 659-668. 1993; Hijikata *et al.*, (1991) *supra*; Weiner *et al.*, (1991) *supra*]. There is accumulating evidence that this hypervariable region, perhaps analogous to the V3 domain of HIV-1 gp120, may be under immune selection by circulating HCV-specific antibodies [Kato *et al.*, (1993) *supra*; Taniguchi *et al.*, *Virology* 195: 297-301 (1993); Weiner *et al.*, (1992) *supra*. In this

model, antibodies directed against this portion of E2 may contribute to virus neutralization and thus drive the selection of variants with substitutions that permit escape from neutralization. This plasticity suggests that a specific amino acid sequence in the E2 hypervariable region is not essential for other functions of the protein such as virion  
5 attachment, penetration, or assembly.

Genetic variability may also contribute to the spectrum of different responses observed after IFN- $\alpha$  treatment of chronically infected patients. Diminished serum ALT levels and improved liver histology, which usually correlates with a decrease in the level of circulating  
10 HCV RNA, is seen in ~40% of those treated [Greiser-Wilke *et al.*, *J. Gen. Virol.* 72: 2015-2019 (1991)]. After treatment, approximately 70% of the responders relapse. In some cases, after a transient loss of circulating viral RNA, renewed viremia is observed during or after the course of treatment. While this might suggest the existence or generation of IFN-resistant HCV genotypes or variants, further work is needed to  
15 determine the relative contributions of virus genotype and host-specific differences in immune response.

Finally, sequence comparisons of different HCV isolates around the world have revealed enormous genetic diversity [reviewed in Ref. Bukh *et al.*, (1995) *supra*]. Because of the  
20 lack biologically relevant serological assays such as cross-neutralization tests, HCV types (designated by numbers), subtypes (designated by letters), and isolates are currently grouped on the basis of nucleotide or amino acid sequence similarity. Amino acid sequence similarity between the most divergent genotypes can be a little as ~50%, depending upon the protein being compared. This diversity has important biological implications,  
25 particularly for diagnosis, vaccine design, and therapy.

#### Attempts by others to generate infectious HCV transcripts from cDNA

A recent paper [Yoo *et al.*, *J. Virol.* 69: 32-38 (1995)] reports replication of transcribed HCV-1 RNA after transfection of Huh7 cells. In this paper, T7 transcripts from various  
30 derivatives of an HCV-1 cDNA clone were tested for their ability to replicate following transfection of the human hepatoma cell line, Huh7. Possible HCV replication was assessed by strand-specific RT/PCR (using 5' NTR primers) and metabolic labeling of HCV-specific RNAs with <sup>3</sup>H-uridine. Apparently full-length transcripts, terminating with either poly (A) or poly (U), were positive by these assays, but those with a deletion of the



5' terminal 144 bases were not. In some cultures, HCV-specific RNA was detected in the culture media and this putative virus was used to reinfect fresh Huh7 cells.

The present inventors have been unable to reproduce these results. It appears that this report describes transient replication, rather than authentic HCV infection, with replication and virus production. Some of the data appear self-contradictory. For instance, the positive control reported in this paper was productive transfection of Huh7 cells with RNA extracted from 1 ml of high HCV titer chimpanzee plasma. This extracted sample would contain a maximum of  $10^7$  potentially infectious full-length HCV RNA molecules. Under optimum transfection conditions (other than microinjection), greater than  $10^5$  RNA molecules of virion RNA (at least for poliovirus, Sindbis virus, or YF) are typically required to initiate a single infectious event. This suggests that in the reported HCV-1 experiment fewer than 100 cells would be productively transfected. Furthermore, at 16 days post-transfection, both positive- and negative-strand RNAs were reportedly detected after eight hours of metabolic labeling. The detection of negative-strand RNA by this method (both for transfected virion RNA and transcript RNA) suggests that HCV is capable of both efficient replication and spread, and that the level of HCV RNA synthesis is similar to that which would be expected for a more robust flavivirus, such as YF (at the peak of a high multiplicity infection). Yet Yoo *et al.* did not report detection of HCV antigens in these cells using a variety of antisera, nor were they able to report detection of full-length positive- or negative-strands by Northern analysis (which is much more sensitive than metabolic labeling with  $^3\text{H}$ -uridine). Finally, the critical experiment, demonstrating that RNA or virus derived from the HCV-1 clone is infectious in the chimpanzee model, has not been reported.

25

#### Importance of Infectious Clone Technology for HCV Research

Despite the great deal of progress made in the last several years a vast number of questions concerning HCV replication, pathogenesis, and immunity remain unanswered. The field is rapidly reaching a bottleneck where we understand some aspects of the functions of the HCV RNA genome and its encoded proteins, but have no way of experimentally testing structure/function questions in the context of authentic virus replication. Such analyses are critical for understanding each step in the virus life cycle to enable the design of protective vaccines, effective therapy, and HCV diagnostics.

Thus, there is a need in the art for authentic HCV genetic material for expression of infectious HCV RNA.

There is a further need in the art for authentic genetic material for expression of native HCV virions and viral particle proteins, which can, in turn, permit characterization of HCV virion structure.

The art also requires an *in vitro* culture method for infectious HCV, which would permit analysis of HCV receptor binding, cellular infection, replication, virion assembly, and release.

These and other needs in the art are addressed by the present invention.

The citation of any reference herein should not be construed as an admission that such reference is available as "Prior Art" to the instant application.

#### **SUMMARY OF THE INVENTION**

The present invention advantageously provides an authentic hepatitis C virus (HCV) DNA clone capable of replication, expression of functional HCV proteins, and infection *in vivo* and *in vitro* for development of antiviral therapeutics and diagnostics.

In a broad aspect, the present invention is directed to a genetically engineered hepatitis C virus (HCV) nucleic acid clone which comprises from 5' to 3' on the positive-sense nucleic acid a functional 5' non-translated region (NTR) comprising an extreme 5'-terminal conserved sequence, an open reading frame (ORF) encoding at least a portion of an HCV polyprotein whose cleavage products form functional components of HCV virus particles and RNA replication machinery, and a 3' non-translated region (NTR) comprising an extreme 3'-terminal conserved sequence, or a derivative thereof selected from the group consisting of adapted virus, live-attenuated virus, replication-competent non-infectious virus, and defective virus. It has been found by the present inventors that various manipulations, effected using genetic engineering techniques, are required to produce an authentic HCV nucleic acid, *e.g.*, a cDNA that can be transcribed to produce infectious HCV RNA, or an infectious HCV RNA. By providing engineered authentic HCV nucleic acids, the present inventors have for the first time enabled dissection of HCV replication

- machinery and protein activity, and preparation of various HCV derivatives. Previously, since there was uncertainty about whether any given HCV clone contained an error or mutation that led to its inability to function, one could not be certain that starting material for further analysis of HCV was useful or simply due to an artifact. Thus, a major advantage of the present invention is that it provides authentic HCV, thus assuring that any modifications result in real changes rather than artifacts due to errors in the clones provided in the prior art.
- 10 A further advantage of the present invention is recognition of the characteristics of an infectious HCV genome, particularly in the polyprotein coding region. In a specific embodiment, the HCV nucleic acid has a consensus nucleic acid sequence determined from the sequence of a majority of at least three clones of an HCV isolate or genotype. Preferably, the HCV nucleic acid has at least a functional portion of a sequence as shown in
- 15 SEQ ID NO:1, which represents a specific embodiment of the present invention exemplified herein. It should be noted that while SEQ ID NO:1 is a DNA sequence, the present invention contemplates the corresponding RNA sequence, and DNA and RNA complementary sequences as well. In a further embodiment, a region from an HCV isolate is substituted for a homologous region, *e.g.*, of an HCV nucleic acid having a sequence of
- 20 SEQ ID NO:1. In a further preferred embodiment, exemplified herein, the HCV nucleic acid is a DNA that codes on expression for a replication-competent HCV RNA replicon, or is itself a replication-competent HCV RNA replicon. In a specific example, *infra*, an HCV nucleic acid of the invention has a full length sequence as depicted in or corresponding to SEQ ID NO:1. Various modifications of the 5' and 3' are also contemplated by the
- 25 invention. For example, the 5'-terminal sequence can be homologous or complementary to an RNA sequence selected from the group consisting of GCCAGCC; GGCCAGCC; UGCCAGCC; AGCCAGCC; AAGCCAGCC; GAGCCAGCC; GUGCCAGCC; and GCGCCAGCC, wherein the sequence GCCAGCC is the 5'-terminus of SEQ ID NO:3.
- 30 Still another advantage of the present invention is the demonstration of the importance of the complete 3'-NTR for an infectious HCV clone. The 3'-NTR, particularly the approximately 98 base extreme terminal sequence, which is highly conserved among HCV genotypes, is the subject of U.S. Patent Application Serial No. 08/520,678, filed August 29, 1995, which is incorporated herein by reference in its entirety; and PCT International

Application No. PCT/US96/14033, filed August 28, 1996, which is also incorporated herein by reference in its entirety. Thus, in a preferred aspect, the functional 3'-NTR comprises a 3'-terminal sequence of approximately 98 bases that is highly conserved among HCV genotypes. In a specific embodiment, the 3'-NTR extreme terminus is homologous or  
5 complementary to a DNA having the sequence  
5'-GGTGGCTCCATCTTAGCCCTAGTCACGGCTAGCTGTGAAAGGTCCGTGAGCCG  
CATGACTGCAGAGAGTGCTGATACTGGCCTCTCTGCTGATCATGT-3' (SEQ ID  
NO:4). In a specific embodiment, exemplified in SEQ ID NO:1, the 3'-NTR comprises a  
long poly-pyrimidine region (*e.g.*, about 133 bases); however, alternative length poly-  
10 pyrimidine regions are also encompassed, including short regions (about 75 bases), or  
regions that are shorter or longer. Naturally, in a positive strand HCV DNA nucleic acid,  
the poly-pyrimidine region is a poly(T/TC) region, and in an positive strand HCV RNA  
nucleic acid, the poly-pyrimidine region is a poly(U/UC) region.

15 According to various aspects of the invention, and HCV nucleic acid, including the  
polyprotein coding region, can be mutated or engineered to produce variants or derivatives  
with, *e.g.*, silent mutations, conservative mutations, etc. Such clones may also be adapted,  
*e.g.*, by selection for propagation in animals or *in vitro*. The present invention further  
permits creation of HCV chimeras, in which portions of the genome for other genotypes or  
20 isolates are substituted for the homologous region of an HCV clone, such as SEQ ID NO:1  
or the deposited embodiment, *infra*. In still other embodiments, the invention provides  
methods for preparing, and clones comprising, polyprotein coding sequence from an HCV  
genotype selected from the group consisting of the HCV-1, HCV-1a, HCV-1b, HCV-1c,  
HCV-2a, HCV-2b, HCV-2c, HCV-3a, and any "quasi-species" variant thereof. In a  
25 further preferred aspect, silent nucleotide changes in the polyprotein coding regions (*i.e.*,  
variations of the third base of a codon that encodes the same amino acid) are incorporated  
as markers of specific HCV clones.

In a further aspect of the invention, an HCV nucleic acid, including attenuated and  
30 defective variants thereof, can comprise a heterologous gene operatively associated with an  
expression control sequence, wherein the heterologous gene and expression control  
sequence are oriented on the positive-strand nucleic acid molecule. In a specific  
embodiment, the heterologous gene is inserted by a strategy selected from the group  
consisting of in-frame fusion with the HCV polyprotein coding sequence; and creation of an

additional cistron. The heterologous gene can be an antibiotic resistance gene or a reporter gene. Alternatively, the heterologous gene can be a therapeutic gene, or a gene encoding a vaccine antigen, *i.e.*, for gene therapy or gene vaccine applications, respectively. In a specific embodiment, where the heterologous gene is an antibiotic resistance gene, the  
5 antibiotic resistance gene is a neomycin resistance gene operatively associated with an internal ribosome entry site (IRES) inserted in an *Sfi*I site in the 3'-NTR.

Naturally, as noted above, the HCV nucleic acid of the invention is selected from the group consisting of double stranded DNA, positive-sense cDNA, or negative-sense cDNA, or  
10 positive-sense RNA or negative-sense RNA. Thus, where particular sequences of nucleic acids of the invention are set forth, both DNA and corresponding RNA are intended, including positive and negative strands thereof.

An HCV DNA may be inserted in a plasmid vector for translation of the corresponding  
15 HCV RNA. Thus, the HCV DNA may comprise a promoter 5' of the 5'-NTR on positive-sense DNA, whereby transcription of template DNA from the promoter produces replication-competent RNA. The promoter can be selected from the group consisting of a eukaryotic promoter, yeast promoter, plant promoter, bacterial promoter, or viral promoter. In specific examples, *infra*, phage T7 and SP6 promoters are employed. In a  
20 specific embodiment, the present invention is directed to a plasmid clone, p90/HCVFL [long poly(U)], harboring a full-length HCV cDNA which can be transcribed to produce infectious HCV RNA transcripts as deposited with the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Maryland 20852, USA on February 13, 1997, and assigned accession no. 97879, having a sequence as depicted in SEQ ID NO:5.

25 Naturally, the invention also includes a derivative of this plasmid, selected from the group consisting of a derivative wherein a 5'-terminal sequence is homologous or complementary to an RNA sequence selected from the group consisting of GCCAGCC, GGCCAGCC, UGCCAGCC, AGCCAGCC, AAGCCAGCC, GAGCCAGCC, GUGCCAGCC, and GCGCCAGCC, wherein the sequence GCCAGCC is the 5'-terminus of SEQ ID NO:3; and  
30 a derivative wherein a 3'-NTR comprises a short poly-pyrimidine region (since the deposited embodiment has a long poly-pyrimidine region, which may be preferred). In a further embodiment, a derivative of the deposited embodiment may be selected from the group consisting of a derivative produced by substitution of homologous regions from other HCV isolates or genotypes; a derivative produced by mutagenesis; a derivative selected

from the group consisting of adapted, live-attenuated, replication competent non-infectious, and defective variants; a derivative comprising a heterologous gene operatively associated with an expression control sequence; and a derivative consisting of a functional fragment of any of the above-mentioned derivatives. Alternatively, portions of the deposited DNA clone, such as the 5' NTR, the polyprotein coding regions, the 3'-NTR or more generally any coding or non-translated region of the HCV genome, can be substituted with a corresponding region from a different HCV genotype to generate a new chimeric infectious clone, or by extension, infectious clones of other isolates and genotypes. For example, an HCV-1b or -2a polyprotein coding region (or consensus polyprotein coding regions) can be substituted for the HCV-H (1a strain) polyprotein coding region of the deposited clone.

Naturally, the present invention further provides an HCV DNA or RNA transcribed from the full length HCV cDNA harbored in the plasmid clones set forth above.

Thus, the specific HCV genome itself provides an excellent starting material for deriving modified variants of HCV, since any modifications will result from changes to authentic virus, rather than artifacts resulting from an accumulation of changes and errors. The HCV DNA clones or RNAs of the invention can be used in numerous methods, or to derive authentic HCV components, as set forth below.

20

For example, the invention provides a method for identifying a cell line that is permissive for infection with HCV, comprising contacting a cell line in tissue culture with an infectious amount of HCV RNA, *e.g.*, as produced from the plasmid clones recited above, and detecting replication of HCV in cells of the cell line. Naturally, the invention extends as well to a method for identifying an animal that is permissive for infection with HCV, comprising introducing an infectious amount of the HCV RNA, *e.g.*, as produced by the plasmids above, to the animal, and detecting replication of HCV in the animal. By providing authentic infectious HCV, preferably comprising a dominant selectable marker, the invention further provides a method for selecting for HCV with adaptive mutations that permit higher levels of HCV replication in a permissive cell line or animal comprising contacting a cell line in culture, or introducing into an animal, an infectious amount of the HCV RNA, and detecting progressively increasing levels of HCV RNA in the cell line or the animal. In a specific embodiment, the adaptive mutation permits modification of HCV tropism. An immediate implication of this aspect of the invention is creation of new valid

animal models for HCV infection.

The permissive cell lines or animals that are identified using the nucleic acids of the invention are very useful, *inter alia*, for studying the natural history of HCV infection, isolating functional components of HCV, and for sensitive, fast diagnostic applications, in addition to producing authentic HCV virus or components thereof. As noted above, a particular advantage of the invention is that it represents the first successful preparation of an HCV DNA clone capable of initiating a productive infection in animals or cell lines.

Because the HCV DNA, *e.g.*, plasmid vectors, of the invention encode authentic HCV components, expression of such vectors in a host cell line transfected, transformed, or transduced with the HCV DNA can be effected. For example, a baculovirus or plant expression system can be harnessed to express HCV virus particles or components thereof. Thus, a host cell line may be selected from the group consisting of a bacterial cell, a yeast cell, a plant cell, an insect cell, and a mammalian cell.

Because the invention provides, *inter alia*, infectious HCV RNA, the invention provides a method for infecting an animal with HCV which comprises administering an infectious dose of HCV RNA, such as the HCV RNA transcribed from the plasmids described above, to the animal. Naturally, the invention provides a non-human animal infected with HCV of the invention, which non-human animal can be prepared by the foregoing methods.

A further advantage of the present invention is that, by providing a complete functional HCV genome, authentic HCV viral particles or components thereof, which may be produced with native HCV proteins or RNA in a way that is not possible in subunit expression systems, can be prepared. In addition, since each component of HCV of the invention is functional (thus yielding the authentic HCV), any specific HCV component is an authentic component, *i.e.*, lacking any errors that may, at least in part, affect the clones of the prior art. Indeed, a further advantage of the invention is the ability to generate HCV virus particles or virus particle proteins that are structurally identical to or closely related to natural HCV virions or proteins. Thus, in a further embodiment, the invention provides a method for propagating HCV *in vitro* comprising culturing a cell line contacted with an infectious amount of HCV RNA of the invention, *e.g.*, HCV RNA translated from the plasmids described above, under conditions that permit replication of the HCV RNA.

Naturally, the invention extends to an *in vitro* cell line infected with HCV, wherein the HCV has a genomic RNA sequence as described above. In a specific embodiment, the cell line is a hepatocyte cell line. The invention further provides various methods for producing HCV virus particles, including by isolating HCV virus particles from the HCV-infected non-human animal of invention; culturing a cell line of the invention under conditions that permit HCV replication and virus particle formation; or culturing a host expression cell line transfected with HCV DNA under conditions that permit expression of HCV particle proteins; and isolating HCV particles or particle proteins from the cell culture. The present invention extends to an HCV virus particle comprising a replication-competent HCV genome RNA, or a replication-defective HCV genome RNA, corresponding to an HCV nucleic acid of the invention as well.

By providing for insertion of heterologous genes in the HCV nucleic acids, *e.g.*, DNA or RNA vectors, the present invention provides a method for transducing an animal susceptible to HCV infection with a heterologous gene, *e.g.*, for gene therapy or gene vaccination, by administering an amount of the HCV RNA to the animal effective to infect the animal with the HCV RNA. In a specific embodiment, such an HCV vector is generated in HCV harbored in the plasmids, described above.

Also provided is an *in vitro* cell-free assay system for HCV comprising HCV genomic template RNA of the invention, *e.g.*, as transcribed from a plasmid of the invention as set forth above, functional HCV replicase components, and an isotonic buffered medium comprising ribonucleotide triphosphate bases. These elements provide the replication machinery and raw materials (NTPs).

The authentic HCV viral particles and viral particle proteins are a preferred starting material as HCV antigens. Thus, in a further embodiment, the invention provides a method for producing antibodies to HCV comprising administering an immunogenic amount of HCV virus particles to an animal, and isolating anti-HCV antibodies from the animal. Such antibodies may be used diagnostically, *e.g.*, to detect the presence of HCV, or they may be used therapeutically, *e.g.*, in passive immunotherapy. A further method for producing antibodies to HCV comprises screening a human antibody library for reactivity with HCV virus particles of the invention and selecting a clone from the library that expresses an antibody reactive with the HCV virus particle. Naturally, in addition to generating



antibodies, the authentic HCV viral particles and proteins of the invention represent preferred starting materials for an HCV vaccine. Preferably, a vaccine of the invention includes a pharmaceutically acceptable adjuvant.

- 5 The authentic materials provided herein provide a method for screening for agents capable of modulating HCV replication *in vitro* and *in vivo*. Such methods include administering a candidate agent to an HCV infected animal of the invention, and testing for an increase or decrease in a level of HCV infection or activity compared to a level of HCV infection or activity in the animal prior to administration of the candidate agent, wherein a decrease in  
10 the level of HCV infection or activity compared to the level of HCV infection or activity in the animal prior to administration of the candidate agent is indicative of the ability of the agent to inhibit HCV infection or activity. Testing for the level of HCV infection can be performed by measuring viral titer in a tissue sample from the animal; measuring viral proteins in a tissue sample from the animal; or measuring liver enzymes. Alternatively, the  
15 HCV genome used to infect the animal may include a heterologous gene operatively associated with an expression control sequence, wherein the heterologous gene and expression control sequence are oriented on the positive-strand nucleic acid molecule, and testing for the level of HCV activity comprises measuring the level of a marker protein in a tissue sample from the animal.

20

- Alternatively, such analysis can proceed *in vitro*, *e.g.*, by contacting the cell line of claim 32 with a candidate agent; and testing for an increase or decrease in a level of HCV infection or activity compared to a level of HCV infection or activity in a control cell line or in the cell line prior to administration of the candidate agent; wherein a decrease in the  
25 level of HCV infection or activity compared to the level of HCV infection or activity in a control cell line or in the cell line prior to administration of the candidate agent is indicative of the ability of the agent to inhibit HCV infection or activity. Testing for the level of HCV infection *in vitro* can be performed by measuring viral titer in the cells, culture medium, or both; and measuring viral proteins in the cells, culture medium, or both. Alternatively,  
30 when the HCV genome used to infect the cell line includes a heterologous gene operatively associated with an expression control sequence, wherein the heterologous gene and expression control sequence are oriented on the positive-strand nucleic acid molecule, and testing for the level of HCV activity comprises measuring the level of a marker protein in a tissue sample from the animal.

- A further method for screening for agents capable of modulating HCV replication involves the cell free system described above. This method comprises contacting the *in vitro* system of the invention with a candidate agent; and testing for an increase or decrease in a level of HCV replication compared to a level of HCV replication in a control cell system or system prior to administration of the candidate agent; wherein a decrease in the level of HCV replication compared to the level of HCV replication in a control cell line or in the cell line prior to administration of the candidate agent is indicative of the ability of the agent to inhibit HCV infection or activity.
- 10 The invention includes a method for preparing an HCV nucleic acid comprising joining from 5' to 3' on the positive-sense DNA a functional 5' non-translated region (NTR) comprising an extreme 5'-terminal conserved sequence, a polyprotein coding region encoding HCV proteins that provide for expression of functional HCV proteins, and a 3' non-translated region (NTR) comprising an extreme 3'-terminal conserved sequence. The method may further comprise determining a consensus sequence for the 5'-NTR, polyprotein coding sequence, and 3'-NTR from a majority sequence of at least three clones of an HCV isolate or genotype. In a specific embodiment, the 3'-NTR comprises an extreme terminal sequence homologous to a DNA having the sequence
- 5'-GGTGGCTCCATCTTAGCCCTAGTCACGGCTAGCTGTGAAAGGTCCGTGAGCCG  
20 CATGACTGCAGAGAGTGCTGATACTGGCCTCTCTGCTGATCATGT-3' (SEQ ID NO:4). In a further specific embodiment, the HCV nucleic acid has a positive strand sequence as depicted in or corresponding to SEQ ID NO:1 comprising substitution of a homologous region from another HCV isolate or genotype.
- 25 The present invention also has significant diagnostic implications. In one embodiment, the invention provides an *in vitro* method for detecting antibodies to HCV in a biological sample from a subject comprising contacting a biological sample from a subject with HCV virus particles of the invention, *e.g.*, prepared as described above, under conditions that permit binding of HCV-specific antibodies in the sample to the HCV virus particles; and
- 30 detecting binding of antibodies in the sample to the HCV virus particles, wherein detecting binding of antibodies in the sample to the HCV virus particles is indicative of the presence of antibodies to HCV in the sample.

An alternative *in vitro* method for detecting the presence of HCV in a biological sample

from a subject comprises contacting a cell line permissive for productive HCV infection with a biological sample, wherein the cell line has been modified to contain a transgene that express a reporter gene product expressed under control of a trans-acting factor produced by HCV; and detecting expression of the reporter gene product, wherein detection of  
5 expression of the reporter gene product is indicative of the presence of HCV in the biological sample from the subject. In a related embodiment, the invention provides an *in vitro* method for detecting the presence of HCV in a biological sample from a subject comprising contacting a cell line permissive for productive HCV infection with a biological sample, wherein the cell line has been modified to contain a defective virus transgene,  
10 which defective virus transgene will express a reporter gene product at high levels under control of a trans-acting factor produced by HCV; and detecting expression of the reporter gene product, wherein detection of expression of the reporter gene product is indicative of the presence of HCV in the biological sample from the subject. Thus, a significant advantage of the present invention is in providing permissive (or susceptible) cell lines for  
15 these *in vitro* diagnostics. The method according to claim 64, wherein the defective viral transgene produces an engineered alphavirus, the trans-acting helper factor is alphavirus nsP4 polymerase, and wherein the alphavirus nsP4 polymerase is expressed as a chimeric fusion protein with HCV NS4A, such that the alphavirus nsP4 polymerase-HCV NS4A chimeric fusion protein is cleaved by HCV NS3 proteinase to release functional alphavirus  
20 nsP4 polymerase. In the foregoing methods, the biological sample is selected from the group consisting of blood, serum, plasma, blood cells, lymphocytes, and liver tissue biopsy.

In a related aspect, the invention also provides a test kit for HCV comprising authentic  
25 HCV virus components, and a diagnostic test kit for HCV comprising components derived from an authentic HCV virus.

Thus, a primary object of the present invention has been to provide a DNA encoding infectious HCV.

30

A related object of the invention is to provide infectious HCV genomic RNA from DNA clones.

Still another object of the invention is to provide attenuated HCV DNA or genomic RNA

suitable for vaccine development, which can invade a cell but fails to propagate infectious virus.

- Another object of the invention is to provide *in vitro* and *in vivo* models of HCV infection for testing anti-HCV (or antiviral) drugs, for evaluating drug resistance, and for testing attenuated HCV viral vaccines.

- Still another object of the invention is to provide for expression of HCV virions or virus particle proteins that can be used to identify the HCV receptor, receptor binding antagonists, and in neutralization assays. In addition, expressed HCV virions or virus particle proteins can be used to develop more effective HCV vaccines, with antigens that are structurally identical to or closely related to native HCV.

- A further object of the present invention is to provide HCV diagnostics based on the ability to detect infectious HCV using engineered reporter cells.

Yet another object is to provide authentic viral antigens, particularly viral particles, to assay for HCV-specific antibodies or generate HCV-specific antibodies.

- These and other objects of the present invention will be elaborated by the drawings and the Detailed Description of the Invention.

### **BRIEF DESCRIPTION OF THE DRAWINGS**

- FIGURE 1 (PRIOR ART). *HCV genome structure, polyprotein processing, and protein features.* At the top is depicted the viral genome with the structural and nonstructural protein coding regions, and the 5' and 3' NTRs, and the putative 3' secondary structure. Boxes below the genome indicate proteins generated by the proteolytic processing cascade. Putative structural proteins are indicated by shaded boxes and the nonstructural proteins by open boxes. Contiguous stretches of uncharged amino acids are shown by black bars. Asterisks denote proteins with N-linked glycans but do not necessarily indicate the position or number of sites utilized. Cleavage sites shown are for host signalase (♦), the NS2-3 proteinase (curved arrow), and the NS3-4A serine protease (||).

FIGURE 2. *Strategies for expression of heterologous RNAs and proteins using HCV*

vectors. At the top is a diagram of the positive-polarity RNA virus HCV, which expresses mature viral proteins by translation of a single long ORF and proteolytic processing. The regions of the polyprotein encoding the structural proteins (STRUCTURAL) and the nonstructural proteins (REPLICASE) are indicated as lightly-shaded and open boxes, respectively. Below are shown a number of proposed replication-competent "replicon" expression constructs. The first four constructs (A-D) lack structural genes and would therefore require a helper system to enable packaging into infectious virions. Constructs E-G would not require helper functions for replication or packaging. Darkly shaded boxes indicate heterologous or foreign gene sequences (FG). Translation initiation (aug) and termination signals (trm) are indicated by open triangles and solid diamonds, respectively. Internal ribosomes entry sites (IRES) are shown as boxes with vertical stripes. Constructs A and H illustrate the expression of a heterologous product as an in-frame fusion with the HCV polyprotein. Such protein fusion junctions can be engineered such that processing is mediated either by host or viral proteinases (indicated by the arrow).

FIGURE 3. *Engineered cell lines for assaying HCV infection.* Panel A. Depicts a cells expressing the three silent transgenes. Driven by nuclear promoter elements are: (i) an mRNA expressing a polyprotein protein consisting of HCV NS4A fused to Sindbis virus (Sin) nonstructural protein 4 (nsP4), (ii) a defective Sindbis virus replicon lacking the nsP4 coding region but a subgenomic promoter (arrow) driving expression of a reporter gene (black box), (iii) a defective Sindbis virus RNA lacking the nsPS but containing a ubiquitin-nsP4 fusion gene under the control of the subgenomic RNA promoter. The Sindbis replicon and defective RNA contain all the signals necessary for Sindbis virus-specific RNA replication, transcription and packaging signals (stem loop structure), but are silent in the absence of active nsP4. Panel B. Upon productive infection of a susceptible cells by HCV, the virus is uncoated, translated and begins replication (step 1). This results in the production of active NS3 serine proteinase (step 2) which cleaves at the HCV NS4A-Sindbis nsP4 junction (step 3) to produce active nsP4. nsP4 assembles with the other three Sindbis nsPs to form an active Sindbis replication complex (step 4) which can replicate both Sindbis specific RNAs and lead to transcription from the Sindbis virus subgenomic promoters (step 5). Ub-nsP4 expressed from the subgenomic RNA of the defective RNA is cleaved to form a more active form of the nsP4 polymerase which further amplifies replication and transcription of the Sindbis-specific RNAs (step 6). This leads to high levels of reporter gene expression (step 7).

FIGURE 4. *Initial set of constructs tested in the chimpanzee model (chimpanzee experiment I).* Clones tested in the chimpanzee model before the correct HCV 5' and 3' termini had been cloned and determined. Diagrams indicate the T7 or SP6 promoter elements, the HCV cDNA, and the run-off sites used for production of transcripts terminating with either poly (A) or poly (U).

FIGURE 5 (A and B). (A) *Regions of HCV H77 amplified for the combinatorial library.* At the top, a diagram of the HCV H cDNA is shown with the restriction sites used for cloning the combinatorial library (*KpnI* and *NotI*; open box) indicated. The region was cloned into a recipient vector, pTET/HCVΔBgIII/5' + 3' corr. This recipient vector contains HCV H77 consensus sequences for the 5' and 3' terminal regions, as shown in black. Approximate protein boundaries are also indicated. Below, fragments amplified by RT-PCR from HCV H77 RNA are denoted as A through G. The number above each segment refers to the minimum complexity of the region in the library. Primer pairs and exact positions are given in Tables 2 & 3. (B) *Intermediate and final fragments in the assembly of the combinatorial library.* As detailed in Tables 2 and 3, *infra*, intermediates in the assembly PCR process and their approximate locations in the HCV cDNA are shown.

FIGURE 6. *Assembly PCR method.* A general scheme of the assembly PCR method is shown. Specific HCV fragments and primers used in assembly are listed in Table 3.

FIGURE 7. *Example of complexity determination by PCR of cDNA dilutions.* For amplified regions A, D, and G, different dilutions of first-strand cDNA were checked for successful amplification by PCR. Products were analyzed on an agarose gel. From this analysis, the minimum complexity for these regions in the combinatorial library was 80, 10 and 10 molecules of cDNA, respectively.

FIGURE 8 (A and B). *Analysis of transcription efficiency through long poly (U/UC) tracts.* Using conditions for optimal transcription of HCV RNAs *in vitro*, transcription products from several template DNAs are shown. (A) Lane 1, supercoiled pTET/HCVFL CMR/5' 3' corr. DNA; lane 2, *XmnI*-digested pTET/HCVFL CMR/5'3' corr. template (predicted size 11740 bases); lane 3, *Hpa I*-digested pTET/HCVFL CMR/5' 3' corr. template (predicted size ~9600 bases); lanes 4 and 5, transcribed RNA size markers of 11,750 and

9400 bases, respectively. Transcription reactions contained 3 mM UTP and 1 mM A,G, and CTP. (B) Lane 1, *BsmI*-digested p92/HCVFLlong pU/5'GG DNA (predicted size ~9600 bases); lane 2, *XbaI*-digested p92/HCVFLlong pU/5'GG DNA (predicted size ~13000 bases). Transcription reactions in panel B contained all four NTPs at 3mM. In  
 5 both panels, HCV RNA transcripts terminating in the poly (U/UC) tract would be ~9500 bases in length. Lanes M in both panels are *HindIII*-digested lambda DNA size markers.

**FIGURE 9. Sequence alignment for determination of the HCV H77 consensus sequence.**

An alignment of the HCV H sequences determined is shown. The nucleotide and amino  
 10 acid sequences at the bottom of each block are for the HCV H CMR prototype sequence. Numbers of the sequenced clones from the combinatorial library are indicated at the left (SEQ ID NOS:19, 20. GenBank refers to the HCV-H sequence determined by Inchaupé *et al.* [*Proc. Natl. Acad. Sci. USA* 88:10292, 1991; Accession # M67463]. "cons." indicates the HCV H77 consensus sequence [SEQ ID NO:1]. Positions identical to the HCV H CMR  
 15 sequence are indicated by dots; gaps in certain sequences by dashes. Where differences were found, lower case letters indicate silent nucleotide substitutions; upper case letters indicate that a particular nucleotide substitution results in a coding change.

**FIGURE 10. Steps in the directed construction of the consensus clone.** The diagram

20 indicates the region of each sequenced clone used for directed construction of the consensus clone. Primary fragments from each clone are indicated by hatched boxes, intermediate assembly subclones as open boxes, and the final clones and regions used for assembly of the full-length consensus clone as shaded boxes. Table 4 summarizes the details of the cloning steps.

25

**FIGURE 11. Features/markers of the ten full-length clones tested in chimpanzee**

*experiment III.* At the top is a schematic of the HCV H77 cDNA consensus RNA. The ten  
 RNA transcripts used for the successful chimpanzee inoculation experiment are diagrammed  
 below. Additional 5' nucleotides and "short" versus "long" poly (U/UC) tracts are  
 30 indicated. All clones/transcripts included two silent nucleotide substitutions as markers:  
 position 899 (C instead of T; indicated by asterisks); and position 5936 (C instead of A;  
 indicated by circled asterisks). Clones with additional 5' bases contained a mutation  
 inactivating the *XhoI* site at position 514 (triangle). Clones with "short" versus "long" poly

(U/UC) tracts were distinguished by A (black dot) versus G at position 8054, respectively.

FIGURE 12. *Serum samples from inoculated animals do not contain carryover template DNA.* As shown, duplicate RNA samples (from 10  $\mu$ l serum) from the indicated weeks post-inoculation without (lane 1) or with  $10^2$  (lanes 2-7) or  $10^3$  (lanes 8-14) molecules of added competitor RNA were amplified by RT-PCR with (+) or without (-) enzyme in the reverse transcription step [Kolykhalov *et al.*, *J. Virol.* 70:3363 (1996)]. No specific PCR band was detected in the absence of cDNA synthesis, indicating that the HCV-specific nucleic acid signal was due to RNA. The analysis shown is for chimpanzee #1535, which received the highest level of inoculated HCV RNA and where the template DNA had not been degraded by digestion with DNase I.

FIGURE 13. *Circulating HCV RNA from inoculated animals is protected from RNAase.* In lane 1, 10  $\mu$ l serum was mixed with  $3 \times 10^5$  molecules of competitor RNA, digested with 0.5  $\mu$ g RNase A for 15 min at room temperature, extracted with RNAzol and utilized for nested RT-PCR as described in [Kolykhalov, 1996, *supra*]. For the sample shown in lane 2, competitor RNA was added after lysis with RNAzol (no RNase treatment). In lane 3, 10  $\mu$ l serum without competitor RNA was predigested with RNase A prior to extraction with RNAzol as in lane 1. Lane 4 is a negative control for RT-PCR. The experiment demonstrated that HCV RNA containing material from the transfected chimps is RNase-resistant under conditions where an excess of competitor RNA is completely destroyed. The sample analyzed was from chimpanzee #1536 at week 6, in which the RNA titer was  $6 \times 10^6$  molecules/ml.

25

#### DETAILED DESCRIPTION OF THE INVENTION

As pointed out above, the present invention advantageously provides an authentic hepatitis C virus (HCV) nucleic acid, *e.g.*, DNA or RNA, clone. A functional HCV nucleic acid of the invention advantageously provides for infection of susceptible animals and cell lines. Despite arduous efforts, infectious HCV has not previously been successfully cloned, thus precluding systematic evaluation of the virus's mechanisms of replication, receptor binding and cell invasion, development of antiviral therapeutic agents using *in vitro* and *in vivo* assay systems, and development of sensitive *in vitro* diagnostic assay systems. In addition, the clones of the invention now enable expression of HCV particles and particle proteins



under conditions that permit proper processing, and thus expression of proteins that bear the closest possible structural resemblance to native HCV. Such particles and proteins are preferred for anti-HCV vaccine development. In addition, by identifying the elements of the HCV genome that are necessary for infection, the present inventors advantageously harness the properties of HCV that lead to chronic liver infection for preparation of gene therapy vectors. Such vectors are particularly useful since they target the liver, which is a source of many proteins and thus a desirable organ for expression of a soluble factor to supplement a deficiency in a subject.

10 The present invention is based, in part, on generation of a functional genotype 1a cDNA clone, which can be used as a basis for preparation of functional clones for other HCV genotypes (*e.g.*, constructed and verified using similar methods). These products have a variety of applications for development of (i) more effective HCV therapies; (ii) HCV vaccines; (iii) HCV diagnostics; and (iv) HCV-based gene expression vectors. Examples of these applications are described below.

The current invention describes the determination of an HCV consensus sequence and the use of this information to construct full-length HCV cDNA clones capable of yielding replication-competent infectious RNA transcripts. The rigorous determination of terminal sequences, including the discovery of highly conserved sequences at the 5' and 3' ends, the use of less error-prone methods for amplifying and assembling HCV cDNA clones, and the assembly of clones reflecting a consensus sequence, all contributed to the success of the present invention.

The term "authentic" is used herein to refer to an HCV nucleic acid, whether a DNA (*i.e.*, cDNA) or RNA, that provides for full genomic replication and production of functional HCV proteins, or components thereof. In a specific embodiment, an authentic HCV nucleic acid is infectious, *e.g.*, in a chimpanzee model or in tissue culture, forms viral particles (*i.e.*, virions), or both. However, an authentic HCV nucleic acid of the invention may also be attenuated, such that it only produces some (not all) functional HCV proteins, or it can productively infect cells without replication in the absence of a helper cell line or plasmid, etc. The authentic HCV exemplified in the present application contains all of the virus-encoded information, whether in RNA elements or encoded proteins, necessary for initiation of an HCV replication cycle that corresponds to replication of wild-type virus *in*

*vivo*. The specific HCV clones described herein, including the embodiment deposited with the ATCC and variants thereof described or exemplified in this application, represent a preferred starting material for developing HCV therapeutics, vaccines, diagnostics, and expression vectors. In particular, use of the HCV nucleic acids of the invention assures that authentic HCV components are involved, since, unlike the cloned HCVs of the prior art, these components together provide an infectious protein. The specific starting materials described herein, and preferably the deposited plasmid clone harboring authentic HCV cDNA, can be modified as described herein, *e.g.*, by site-directed mutagenesis, to produce a defective or attenuated derivative. Alternatively, sequences from other genotypes or isolates can be substituted for the homologous sequence of the specific embodiments described herein. For example, an authentic HCV nucleic acid of the invention may comprise the consensus 5' and 3' sequences disclosed herein, *e.g.*, on a recipient plasmid, and a polyprotein coding region from another isolate or genotype (either a consensus region or one obtained by very high fidelity cloning) is substituted for the homologous polyprotein coding region of the HCV exemplified herein. In addition, the general characteristics for an authentic HCV as described herein, including but not limited to containing extreme 5' or 3' sequences, or both, containing an ORF that encodes a polyprotein whose cleavage products form functional components of HCV virus particles and RNA replication machinery, and, in a preferred embodiment, incorporate a consensus sequence of a specific isolate or genotype provide for obtaining authentic HCV clones.

In particular, the present invention provides for modifying or "correcting" non-functional HCV clones, *e.g.*, that are incapable of genuine replication, that fail to produce HCV proteins, that do not produce HCV RNA as detected by Northern analysis, or that fail to infect susceptible animals or cell lines *in vitro*. By comparing an authentic HCV nucleic acid sequence of the invention, *e.g.*, the cDNA sequence of SEQ ID NO:1, with the sequence of the non-functional HCV clone, defects in the non-functional clone can be identified and corrected. All of the methods for modifying nucleic acid sequences available to one of skill in the art to effect modifications in the non-functional HCV genome, including but not limited to site-directed mutagenesis, substitution of the functional sequence from an authentic HCV clone, *e.g.*, of SEQ ID NO:1, for the homologous sequence in the non-functional clone, etc.

The term "consensus sequence" is used herein to refer to a functional HCV genomic

sequence, or any portion thereof, including the 5'-NTR, polyprotein coding sequence or portion thereof, and 3'-NTR, which is determined by identifying the consensus residues from three or more, preferably six or more, independent clones of a strain or genotype of HCV. In the Examples, *infra*, 5'-NTR (including some capsid proteins from the polyprotein coding region) and 3'-NTR (including some portion of the genome encoding the C-terminus of the polyprotein) consensus sequences were determined and incorporated in a recipient plasmid (Example 3). Consensus sequences for the majority of the polyprotein coding region from a *KpnI* site to a *NotI* site were also determined, as shown in Figure 8 and Example 4, *infra*, which yielded a consensus sequence. Insertion of the *KpnI* and *NotI* portion of the polyprotein coding sequence are inserted in the recipient plasmid containing consensus 5' and 3' consensus sequences, yields an authentic HCV genomic DNA clone.

The authentic HCV nucleic acid of the invention preferably includes a 5'-NTR extreme conserved sequence comprising the 5'-terminal sequence GCCAGCC, which may have additional bases upstream of this conserved sequence without affecting functional activity of the HCV nucleic acid. In a preferred embodiment, the 5'-GCCAGCC includes from 0 to about 10 additional upstream bases; more preferably it includes from 0 to about 5 upstream bases; more preferably still it includes 0, one, or two upstream bases. In specific embodiments, the extreme 5'-terminal sequence may be GCCAGCC; GGCCAGCC; UGCCAGCC; AGCCAGCC; AAGCCAGCC; GAGCCAGCC; GUGCCAGCC; or GCGCCAGCC, wherein the sequence GCCAGCC is the 5'-terminus of SEQ ID NO:3.

In an authentic HCV nucleic acid of the invention, the 3'-NTR comprises a long polypyrimidine region. In positive-strand HCV RNA, the region corresponds to a poly(U)/poly(UC) tract. Naturally, in positive-strand HCV DNA, this is a poly(T)/poly(TC) tract. The Examples, *infra*, show that the polypyrimidine tract may be of variable length: both short (about 75 bases) and long (133 bases) are effective, although an HCV clone containing a long poly(U/UC) tract is found to be highly infectious. Longer tracts may be found in naturally occurring HCV isolates. Thus, an authentic HCV nucleic acid of the invention may have a variable length polypyrimidine tract.

In a specific embodiment of the invention, plasmid p90/HCVFL [long poly(U)] harboring a cDNA encoding an infectious HCV RNA under control of a phage promoter was deposited with the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville,

Maryland, United States of America on February 13, 1997 on behalf of Washington University School of Medicine for the purpose of compliance with the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Protection in accordance with its provisions, and the provisions of 37 C.F.R. § 1.801 *et seq.*

The benefits of this technology are enormous and far reaching. Of immediate significance is use of HCV cDNA from these functional clones as starting material for studies on the functions of individual HCV proteins and RNA elements using biochemical, cell culture, and transgenic animal approaches. The use of functional cDNA will minimize the chances of obtaining negative or misleading results because of errors introduced during cDNA synthesis or PCR-amplification. Such clones will also provide defined starting material for future molecular genetic studies on many aspects of HCV biology in the context of authentic virus replication. Uses relevant to therapy and vaccine development include: (i) the generation of defined HCV virus stocks to develop *in vitro* and *in vivo* assays for virus neutralization, attachment, penetration and entry; (ii) structure/function studies on HCV proteins and RNA elements and identification of new antiviral targets; (iii) a systematic survey of cell culture systems and conditions to identify those that support HCV RNA replication and particle release; (iv) production of adapted HCV variants capable of more efficient replication in cell culture; (v) production of HCV variants with altered tissue or species tropism; (vi) establishment of alternative animal models for inhibitor evaluation including those supporting HCV replication; (vii) development of cell-free HCV replication assays; (viii) production of immunogenic HCV particles for vaccination; (ix) engineering of attenuated HCV derivatives as possible vaccine candidates; (x) engineering of attenuated or defective HCV derivatives for expression of heterologous gene products for gene therapy and vaccine applications; (xi) utilization of the HCV glycoproteins for targeted delivery of therapeutic agents to the liver or other cell types with appropriate receptors.

Various terms are used herein, which have the following definitions:

The phrase "pharmaceutically acceptable" refers to molecular entities and compositions that are physiologically tolerable and do not typically produce an allergic or similar untoward reaction, such as gastric upset, dizziness and the like, when administered to a human.

Preferably, as used herein, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the compound is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water or aqueous solution saline solutions and aqueous dextrose and glycerol solutions are preferably employed as carriers, particularly for injectable solutions. Suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E.W. Martin.

The phrase "therapeutically effective amount" is used herein to mean an amount sufficient to reduce by at least about 15 percent, preferably by at least 50 percent, more preferably by at least 90 percent, and most preferably prevent, a clinically significant deficit in the activity, function and response of the host. Alternatively, a therapeutically effective amount is sufficient to cause an improvement in a clinically significant condition in the host.

The term "adjuvant" refers to a compound or mixture that enhances the immune response to an antigen. An adjuvant can serve as a tissue depot that slowly releases the antigen and also as a lymphoid system activator that non-specifically enhances the immune response (Hood et al., *Immunology, Second Ed.*, 1984, Benjamin/Cummings: Menlo Park, California, p. 384). Often, a primary challenge with an antigen alone, in the absence of an adjuvant, will fail to elicit a humoral or cellular immune response. Adjuvants include, but are not limited to, complete Freund's adjuvant, incomplete Freund's adjuvant, saponin, mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil or hydrocarbon emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (*bacille Calmette-Guerin*) and *Corynebacterium parvum*. Preferably, the adjuvant is pharmaceutically acceptable.

In a specific embodiment, the term "about" or "approximately" means within 20%, preferably within 10%, and more preferably within 5% of a given value or range.

The following subsections of the application, which further amplify the foregoing

disclosure, are provided for convenience and not by way of limitation.

#### Functional Full-length Clones for Other HCV Isolates and Genotypes

Using the approaches described here, functional full-length clones for the other HCV genotypes can be built and utilized for biological studies and antiviral screening and evaluation. In this extension of the invention, libraries can be constructed using RNA from single-exposure patients with high RNA titers (greater than  $10^6$ /ml) and known clinical history. A consensus sequence for the isolate can be generated from the sequences of individual clones in the library. New recipient plasmids containing a promoter, 5' and 3' terminal consensus sequences (either determined for that isolate or from a different isolate e.g., HCV-H77), and a 3' restriction site for production of run-off transcripts can be constructed.

As less error-prone methods emerge, screening of a limited number of clones from combinatorial libraries may yield function clones. Alternatively, as described here, sequence of derived from multiple clones and directed assembly can be used to produce functional consensus clones.

Thus, the present invention contemplates isolation of other HCV genomic sequences, or consensus genomic sequences. In accordance with the present invention there may be employed conventional molecular biology, microbiology, and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Sambrook, Fritsch & Maniatis, *Molecular Cloning: A Laboratory Manual*, Second Edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (herein "Sambrook *et al.*, 1989"); *DNA Cloning: A Practical Approach*, Volumes I and II (D.N. Glover ed. 1985); *Oligonucleotide Synthesis* (M.J. Gait ed. 1984); *Nucleic Acid Hybridization* [B.D. Hames & S.J. Higgins eds. (1985)]; *Transcription And Translation* [B.D. Hames & S.J. Higgins, eds. (1984)]; *Animal Cell Culture* [R.I. Freshney, ed. (1986)]; *Immobilized Cells And Enzymes* [IRL Press, (1986)]; B. Perbal, *A Practical Guide To Molecular Cloning* (1984); F.M. Ausubel *et al.* (eds.), *Current Protocols in Molecular Biology*, John Wiley & Sons, Inc. (1994).

Therefore, if appearing herein, the following terms shall have the definitions set out below.

It should be appreciated that the terms HCV sequence, such as the "3' terminal sequence element," "3' terminus," "3' sequence element," are meant to encompass all of the following sequences: (i) an RNA sequence of the positive-sense genome RNA; (ii) the complement of this RNA sequence, *i.e.*, the HCV negative-sense RNA; (iii) the DNA sequence corresponding to the positive-sense sequence of the RNA element; and (iv) the DNA sequence corresponding to the negative-sense sequence of the RNA element. Accordingly, nucleotide sequences displaying substantially equivalent or altered properties are likewise contemplated. These modifications may be deliberate, for example, such as modifications obtained through site-directed mutagenesis, or may be accidental, such as those obtained through mutations in hosts that are producers of the complex or its named subunits.

A "vector" is a replicon, such as a plasmid, phage, or cosmid, to which another DNA (or RNA) segment may be joined so as to bring about the replication of the attached segment. A "cassette" refers to a segment of DNA RNA that can be inserted into a vector at specific restriction sites. The segment of DNA or RNA encodes a polypeptide or RNA of interest, and the cassette and restriction sites are designed to ensure insertion of the cassette in the proper reading frame for transcription and translation.

Transcriptional and translational control sequences are DNA or RNA regulatory sequences, such as promoters, enhancers, polyadenylation signals, terminators, IRES elements, and the like, that provide for the expression of a coding sequence in a host cell. A coding sequence is "under the control of" or "operably (also operatively) associated with" transcriptional and translational control sequences in a cell when RNA polymerase transcribes the coding sequence into RNA. RNA sequences can also serve as expression control sequences by virtue of their ability to modulate translation, RNA stability, RNA replication, and RNA transcription (for RNA viruses).

A "promoter sequence" is a DNA or RNA regulatory region capable of binding RNA polymerase in a cell and initiating transcription of a downstream (3' direction) coding or noncoding sequence. Thus, promoter sequences can also be used to refer to analogous RNA sequences or structures of similar function in RNA virus replication and transcription. Preferred promoters for cell-free or bacterial expression of infectious HCV DNA clones of the invention are the phage promoters T7, T3, and SP6. Alternatively, a nuclear promoter,

such as cytomegalovirus immediate-early promoter, can be used. Indeed, depending on the system used, expression may be driven from a eukaryotic, prokaryotic, or viral promoter element. Promoters for expression of HCV RNA can provide for capped or uncapped transcripts.

As used herein, the term "homologous" in all its grammatical forms and spelling variations refers to the relationship between proteins that possess a "common evolutionary origin," including proteins from superfamilies (*e.g.*, the immunoglobulin superfamily) and homologous proteins from different species (*e.g.*, myosin light chain, etc.) [Reeck *et al.*, *Cell* 50:667 (1987)]. Such proteins (and their encoding genes) have a high degree of sequence similarity. The term "sequence similarity" in all its grammatical forms refers to the degree of identity or correspondence between nucleic acid or amino acid sequences of proteins that may or may not share a common evolutionary origin [*see* Reeck *et al.*, *supra*]. However, in common usage and in the instant application, the term "homologous," when modified with an adverb such as "substantially" or "highly," may refer to sequence similarity and not a common evolutionary origin.

In a specific embodiment, two DNA or RNA sequences are "homologous" or "substantially similar" when at least about 50% (preferably at least about 75%, and most preferably at least about 90 or 95%) of the nucleotides match over the defined length of the DNA sequences. Sequences that are substantially homologous can be identified by comparing the sequences using standard software available in sequence data banks, or in a Southern hybridization experiment under, for example, stringent conditions as defined for that particular system. Defining appropriate hybridization conditions is within the skill of the art. See, *e.g.*, Maniatis *et al.*, *supra*; DNA Cloning, Vols. I & II, *supra*; Nucleic Acid Hybridization, *supra*.

Similarly, in a particular embodiment, two amino acid sequences are "homologous" or "substantially similar" when greater than 30% of the amino acids are identical, or greater than about 60% are similar (functionally identical). Preferably, the similar or homologous sequences are identified by alignment using, for example, the GCG (Genetics Computer Group, Program Manual for the GCG Package, Version 7, Madison, Wisconsin) pileup program.



The term "corresponding to" in relation to nucleic acid or amino acid structure is used herein to refer similar or homologous sequences, whether the exact position is identical or different from the molecule to which the similarity or homology is measured. A nucleic acid or amino acid sequence alignment may include gaps. Thus, the term "corresponding to" refers to the sequence similarity or regions of homology, and not the numbering of the amino acid residues or nucleotide bases.

HCV genomic nucleic acids can be isolated from any source of infectious HCV, particularly from tissue samples (blood, plasma, serum, liver biopsy, leukocytes, etc.) from an infected human or simian, or other permissive animal species. Methods for obtaining genomic HCV clones or portions thereof are well known in the art, as described above [see, e.g., Sambrook *et al.*, 1989, *supra*]. HCV isolates, including polyprotein coding region sequences, are described, for example, in International Patent Publication WO 89/04669, published June 1, 1989 by Houghton *et al.*; International Patent Publication WO 90/11089, published October 4, 1990 by Houghton *et al.*; U.S. Patent No. 5,350,671, issued September 27, 1994 to Houghton *et al.*; U.S. Patent No. 5,372,928, issued December 13, 1994 to Miyamura *et al.*; European Patent Application No. EP 0 521 318 A2, published January 7, 1993 for Cho *et al.*; and European Patent Application No. EP 0 510 952 A1, published October 28, 1992, each of which is incorporated herein by reference in its entirety. Representative genotypes further include, but are by no means restricted to, other 1a isolates, 1b, 1c, 2a, 2b, 2c, 3a, etc. [Bukh *et al.*, (1995) *supra*; Simmonds, *Hepatology* 21: 570-83 (1995); Simmonds *et al.*, *Hepatology* 19: 1321-1324 (1994); Simmonds *et al.*, *J. Gen. Virol.* 77: 3013-3024 (1996)]. For many subtypes and genotypes, enough sequence data are available to design primers for RT/PCR and PCR assembly.

In the molecular cloning genomic HCV RNA or DNA, DNA fragments are generated, e.g., by reverse transcription into cDNA and PCR. These fragments may be assembled to form a full length sequence. Preparation of many such fragments provides a combinatorial library of HCV clones. Such a library may yield an infectious clone; more likely, the consensus sequence should be determined by comparing the sequences of all or a significant number of clones from such a library. Enough clones should be evaluated so that a majority of bases at any divergent position are identical. Thus, a consensus may be determined by analyzing the sequence of at least three clones, preferably about five clones, and more preferably six or more clones. Naturally, the more error-prone the cloning

method, the greater the number of clones that should be sequenced to yield an authentic HCV consensus sequence.

The consensus sequence can then be used to prepare an infectious HCV DNA clone. The fidelity of the resulting clones is preferably established by sequencing. However, selection can be carried out on the basis of the properties of the clone, *e.g.*, if the clone encodes an infectious HCV RNA. Thus, successful preparation of an infectious HCV DNA clone may be detected by assays based on the physical, pathological, or immunological properties of an animal or cell culture transfected or infected with the clone. For example, cDNA clones can be selected that produce an HCV virion or virus particle protein that, *e.g.*, has similar or identical physical-chemical, electrophoretic migration, isoelectric focusing, or non-equilibrium pH gel electrophoresis behavior, proteolytic digestion maps, or antigenic properties as known for native HCV or HCV virus particle proteins.

*Components of functional HCV cDNA clones.* Components of the functional HCV cDNA described in this invention can be used to develop cell-free, cell culture, chimeric virus, and animal-based screening assays for known or newly identified HCV antiviral targets as described *infra*. Examples of known or suspected targets and assays include [see Houghton, *In "Fields Virology"* (B. N. Fields, D. M. Knipe and P. M. Howley, Eds.), Vol. pp. 1035-1058. Raven Press, New York (1996); Rice, (1996) *supra*; Rice *et al.*, *Antiviral Therapy* 1, Suppl. 4, 11-17 (1997); Shimotohno, *Hepatology* 21,:887-8 (1995) for reviews], but are not limited to, the following:

The highly conserved 5' NTR, which contains elements essential for translation of the incoming HCV genome RNA, is one target. It is also likely that this sequence, or its complement, contains RNA elements important for RNA replication and/or packaging. Potential therapeutic strategies include: antisense oligonucleotides (*supra*); trans-acting ribozymes (*supra*); RNA decoys; small molecule compounds interfering with the function of this element (these could act by binding to the RNA element itself or to cognate viral or cellular factors required for activity).

Another target is the HCV C (capsid or core) protein which is highly conserved and is associated with the following functions: RNA binding and specific encapsidation of HCV

genome RNA; transcriptional modulation of cellular [Ray *et al.*, *Virus Res.* 37: 209-220 (1995)] and other viral [Shih *et al.*, *J. Virol.* 69: 1160-1171 (1995); Shih *et al.*, *J. Virol.* 67: 5823-5832 (1993)] genes; cellular transformation [Ray *et al.*, *J. Virol.* 70: 4438-4443 (1996a)]; prevention of apoptosis [Ray *et al.*, *Virol.* 226: 176-182 (1996b)]; modulation of host immune response through binding to members of the TNF receptor superfamily [Matsumoto *et al.*, *J. Virol.* 71: 1301-1309 (1997)].

The E1, E2, and E2-p7 glycoproteins which form the components of the virion envelope and are targets for potentially neutralizing antibodies. Key steps for intervention include: signal peptidase mediated cleavage of these precursors from the polyprotein [Lin *et al.*, (1994a) *supra*]; ER assembly of the E1E2 glycoprotein complex and association of these proteins with cellular chaperones and folding machinery [Dubuisson *et al.*, (1994) *supra*; Dubuisson and Rice, *J. Virol.* 70: 778-786 (1996)]; assembly of virus particles including interactions between the nucleocapsid and virion envelope; transport and release of virus particles; the association of virus particles with host components such as VLDL [Hijikata *et al.*, (1993) *supra*; Thomssen *et al.*, (1992) *supra*; Thomssen *et al.*, *Med. Microbiol. Immunol.* 182: 329-334 (1993)] which may play a role in evasion of immune surveillance or in binding and entry of cells expressing the LDL receptor; conserved and variable determinants in the virion which are targets for neutralization by antibodies or which bind to antibodies and facilitate immune-enhanced infection of cells via interaction with cognate Fc receptors; conserved and variable determinants in the virion important for receptor binding and entry; virion determinants participating in entry, fusion with cellular membranes, and uncoating the incoming viral nucleocapsid.

The NS2-3 autoprotease, which is required for cleavage at the 2/3 site is a further target.

The NS3 serine protease and NS4A cofactor which form a complex and mediate four cleavages in the HCV polyprotein [see Rice, (1997) *supra* for review] is yet another suitable target. Targets include the serine protease activity itself; the tetrahedral  $Zn^{2+}$  coordination site in the C-terminal domain of the serine protease; the NS3-NS4A cofactor interaction; the membrane association of NS4A; stabilization of NS3 by NS4A; transforming potential of the NS3 protease region [Sakamuro *et al.*, *J. Virol.* 69: 3893-6 (1995)].

The NS3 RNA-stimulated NTPase [Suzich *et al.*, (1993) *supra*], RNA helicase [Jin and Peterson, *Arch Biochem Biophys* 323: 47-53 (1995); Kim *et al.*, *Biochem. Biophys. Res. Commun.* 215: 160-6 (1995)], and RNA binding [Kanai *et al.*, *FEBS Lett* 376: 221-4 (1995)] activities; the NS4A protein as a component of the RNA replication complex of as yet undefined function; the NS5A protein, another presumed replication component, is phosphorylated predominantly on serine residues [Tanji *et al.*, *J. Virol.* 69: 3980-3986 (1995)] are all targets for drug development. Possible characteristics of the latter which could be targets for therapy include the kinase responsible for NS5A phosphorylation and its interaction with NS5A; the interaction with NS5A and other components of the HCV replication complex.

The NS5B RDRP, which is the enzyme responsible for the actual synthesis of HCV positive and negative-strand RNAs, is another target. Specific aspects of its activity include the polymerase activity itself [Behrens *et al.*, *EMBO J.* 15: 12-22 (1996)]; interactions of NS5B with other replicase components, including the HCV RNAs; steps involved in the initiation of negative- and positive-strand RNA synthesis; phosphorylation of NS5B [Hwang *et al.*, *Virology* 227:438 (1997)].

Other targets include structural or nonstructural protein functions important for HCV RNA replication and/or modulation of host cell function. Possible hydrophobic protein components capable of forming channels important for viral entry, egress or modulation of host cell gene expression may be targeted.

The 3' NTR, especially the highly conserved elements (poly (U/UC) tract; 98-base terminal sequence) can be targeted. Therapeutic approaches parallel those described for the 5' NTR, except that this portion of the genome is likely to play a key role in the initiation of negative-strand synthesis. It may also be involved in other aspects of HCV RNA replication, including translation, RNA stability, or packaging.

The functional HCV cDNA clones encode all of the viral proteins and RNA elements required for RNA packaging. These elements can be targeted for development of antiviral compounds. Electrophoretic mobility shift, UV cross-linking, filter binding, and three-hybrid [SenGupta *et al.*, *Proc. Natl. Acad. Sci. USA* 93: 8496-8501 (1996)] assays can be

used to define the protein and RNA elements important for HCV RNA packaging and to establish assays to screen for inhibitors of this process. Such inhibitors might include small molecules or RNA decoys produced by selection *in vitro* [Gold *et al.*, (1995) *supra*].

Complex HCV libraries can be prepared using PCR shuffling, or by incorporating randomized sequences, such as are generated in "peptide display" libraries. Using the "phage method" [Scott and Smith, 1990, *Science* 249:386-390 (1990); Cwirla, *et al.*, *Proc. Natl. Acad. Sci.*, 87:6378-6382 (1990); Devlin *et al.*, *Science*, 249:404-406 (1990)], very large libraries can be constructed ( $10^6$ - $10^8$  chemical entities). As noted above, and exemplified *infra*, clones from such libraries can be used to generate a consensus genomic sequence.

Due to the degeneracy of nucleotide coding sequences, other DNA sequences that encode substantially the same amino acid sequence as an HCV polyprotein coding region may be used in the practice of the present invention. These include but are not limited to homologous genes from other species, and nucleotide sequences comprising all or portions of HCV polyprotein genes altered by the substitution of different codons that encode the same amino acid residue within the sequence, thus producing a silent change. Such silent changes permit creation of genomic markers, which can be used to identify a particular infectious isolate in a multiple infection animal model. Likewise, the HCV genomic derivatives of the invention include, but are not limited to, those containing, as a primary amino acid sequence, all or part of the amino acid sequence of an HCV polyprotein including altered sequences in which functionally equivalent amino acid residues are substituted for residues within the sequence resulting in a conservative amino acid substitution. For example, one or more amino acid residues within the sequence can be substituted by another amino acid of a similar polarity, which acts as a functional equivalent, resulting in a silent alteration. Substitutes for an amino acid within the sequence may be selected from other members of the class to which the amino acid belongs. For example, the nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine. Amino acids containing aromatic ring structures are phenylalanine, tryptophan, and tyrosine. The polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine. The positively charged (basic) amino acids include arginine, lysine and histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic

acid.

Particularly preferred substitutions are:

- Lys for Arg and vice versa such that a positive charge may be maintained;
- Glu for Asp and vice versa such that a negative charge may be maintained;
- Ser for Thr such that a free -OH can be maintained; and
- Gln for Asn such that a free NH<sub>2</sub> can be maintained.

In another embodiment, an authentic HCV clone can be modified to introduce amino acid substitutions that reduce or eliminate protein function. An authentic HCV clone can also be modified to introduce amino acid substitutions that alter viral tropism.

Moreover, since HCV lacks proofreading activity, the virus itself readily mutates, forming mutant "quasi-species" of HCV that are also contemplated as within the present invention. Such mutations are easily identified by sequencing isolates from a subject, as detailed herein.

The clones encoding HCV derivatives and analogs of the invention can be produced by various methods known in the art. The manipulations which result in their production can occur at the gene or protein level. For example, the cloned HCV genome sequence can be modified by any of numerous strategies known in the art [Sambrook *et al.*, 1989, *supra*]. The genomic sequence can be cleaved at appropriate sites with restriction endonuclease(s), followed by further enzymatic modification if desired, isolated, and ligated *in vitro*. Alternatively, genomic fragments can be joined, *e.g.*, with PCR, to create an HCV genome. In the production of the genomic nucleic acid derivative or analog of HCV, care should be taken to ensure that the modified genome remains within the same translational reading frame as the native HCV genome, uninterrupted by translational stop signals, in the region where the desired activity is encoded.

The HCV polyprotein-encoding nucleic acid sequence can be mutated *in vitro* or *in vivo*, to create and/or destroy translation, initiation, and/or termination sequences, or to create variations in coding regions and/or form new restriction endonuclease sites or destroy preexisting ones, to facilitate further *in vitro* modification. Preferably, such mutations provide for modification of the functional activity of the HCV, *e.g.*, to attenuate viral

activity, or create a defective virus, as set forth *infra*. Any technique for mutagenesis known in the art can be used, including but not limited to, *in vitro* site-directed mutagenesis [Hutchinson, C., *et al.*, 1978, J. Biol. Chem. 253:6551; Zoller and Smith, 1984, DNA 3:479-488; Oliphant *et al.*, 1986, Gene 44:177; Hutchinson *et al.*, 1986, Proc. Natl. Acad. Sci. U.S.A. 83:710], use of TAB<sup>®</sup> linkers (Pharmacia), etc. PCR techniques are preferred for site directed mutagenesis [see Higuchi, 1989, "Using PCR to Engineer DNA", in *PCR Technology: Principles and Applications for DNA Amplification*, H. Erlich, ed., Stockton Press, Chapter 6, pp. 61-70].

*Adaptation of HCV for more efficient replication in cell culture or alternative hosts.* As mentioned earlier, HCV replication in cell culture is inefficient. The engineering of dominant selectable markers under the control of the HCV replication machinery can also be used to select for adaptive mutations in the HCV replication machinery. Such adaptive mutations could be manifested, but are not restricted to: (i) altering the tropism of HCV RNA replication; (ii) altering viral products responsible for deleterious effects on host cells; (iii) increasing or decreasing HCV RNA replication efficiency; (iv) increasing or decreasing HCV RNA packaging efficiency and/or assembly and release of HCV particles; (v) altering cell tropism at the level of receptor binding and entry. Even if the sequence of an HCV original cDNA clone is incompatible with establishing replication in a particular cell type, mutations occurring during *in vitro* transcription, during the initial stages of HCV-mediated RNA synthesis, or incorporated in the template DNA by a variety of chemical or biological methods, *supra*, may allow replication in a particular cellular environment or animal host. The engineered dominant selectable marker, whose expression is dependent upon productive HCV RNA replication, can be used to select for adaptive mutations in either the HCV replication machinery or the transfected host cell, or both.

*Chimeric HCV clones.* Components of these functional clones can also be used to construct chimeric viruses for assay of HCV gene functions and inhibitors thereof [Filocamo *et al.*, *J. Virol.* 71: 1417-1427 (1997); Hahn *et al.*, *Virology* 226: 318-326 (1996); Lu and Wimmer, *Proc Natl Acad Sci U S A* 93: 1412-7 (1996)]. In one such extension of the invention, functional HCV elements such as the 5' IRES, proteases, RNA helicase, polymerase, or 3' NTR are used to create chimeric derivatives of BVDV whose productive replication is dependent on one or more of these HCV elements. Such BVDV/HCV

chimeras can then be used to screen for and evaluate antiviral strategies against these functional components.

In addition, dominant selectable markers can be used to select for mutations in the HCV replication machinery that allow higher levels of RNA replication or particle formation. In one example, engineered HCV derivatives expressing a mutant form of DHFR can be used to confer resistance to methotrexate (MTX). As a dominant selectable marker, mutant DHFR is inefficient since nearly stoichiometric amounts are required for MTX resistance. By successively increasing concentrations of MTX in the medium, increased quantities of DHFR will be required for continued survival of cells harboring the replicating HCV RNA. This selection scheme, or similar ones based on this concept, can result in the selection of mutations in the HCV RNA replication machinery allowing higher levels of HCV RNA replication and RNA accumulation. Similar selections can be applied for mutations allowing production of higher yields of HCV particles in cell culture or for mutant HCV particles with altered cell tropism. Such selection schemes involve harvesting HCV particles from culture supernatants or after cell disruption and selecting for MTX-resistant transducing particles by reinfection of naive cells.

The identified and isolated genomic RNA can be reverse transcribed into its cDNA. cDNA could also be made by "long" PCR to include the promoter and run-off site, or by using 3'-terminal consensus sequence-specific primers for insertion in an appropriate recipient vector. Any of these cDNAs may be inserted into an appropriate cloning vector, *e.g.*, which comprises consensus 5'- and 3'-NTRs, along with a suitable promoter and 3'-runoff sequence. A clone that includes a primer and run-off sequence can be used directly for production of functional HCV RNA. A large number of vector-host systems known in the art may be used. Examples of vectors include, but are not limited to, *E. coli*, bacteriophages such as lambda derivatives, or plasmids such as pBR322 derivatives or pUC plasmid derivatives, *e.g.*, pGEX vectors, pmal-c, pFLAG, pTET, etc. The insertion into a cloning vector can, for example, be accomplished by ligating the DNA fragment into a cloning vector which has complementary cohesive termini. However, if the complementary restriction sites used to fragment the DNA are not present in the cloning vector, the ends of the DNA molecules may be enzymatically modified. Alternatively, any site desired may be produced by ligating nucleotide sequences (linkers) onto the DNA termini; these ligated linkers may comprise specific chemically synthesized oligonucleotides encoding restriction



endonuclease recognition sequences. Recombinant molecules can be introduced into host cells via transformation, transfection, infection, electroporation, etc., so that many copies of the gene sequence are generated.

#### Expression of HCV RNA and Polypeptides

The HCV DNA, which codes for HCV RNA and HCV proteins, particularly HCV RNA replicase or virion proteins, can be inserted into an appropriate expression vector, *i.e.*, a vector which contains the necessary elements for the transcription and translation of the inserted protein-coding sequence. Such elements are termed herein a "promoter." Thus, the HCV DNA of the invention is operationally (or operably) associated with a promoter in an expression vector of the invention. An expression vector also preferably includes a replication origin. The necessary transcriptional and translational signals can be provided on a recombinant expression vector. In a preferred embodiment for *in vitro* synthesis of functional RNAs, the T7, T3, or SP6 promoter is used.

Potential host-vector systems include but are not limited to mammalian cell systems infected with virus recombinant (*e.g.*, vaccinia virus, adenovirus, Sindbis virus, Semliki Forest virus, etc.); insect cell systems infected with recombinant viruses (*e.g.*, baculovirus); microorganisms such as yeast containing yeast vectors; plant cells; or bacteria transformed with bacteriophage, DNA, plasmid DNA, or cosmid DNA. The expression elements of vectors vary in their strengths and specificities. Depending on the host-vector system utilized, any one of a number of suitable transcription and translation elements may be used.

The cell into which the recombinant vector comprising the HCV DNA clone has been introduced is cultured in an appropriate cell culture medium under conditions that provide for expression of HCV RNA or such HCV proteins by the cell. Any of the methods previously described for the insertion of DNA fragments into a cloning vector may be used to construct expression vectors containing a gene consisting of appropriate transcriptional/translational control signals and the protein coding sequences. These methods may include *in vitro* recombinant DNA and synthetic techniques and *in vivo* recombination (genetic recombination).

Expression of HCV RNA or protein may be controlled by any promoter/enhancer element

known in the art, but these regulatory elements must be functional in the host selected for expression. Promoters which may be used to control expression include, but are not limited to, the SV40 early promoter region (Benoist and Chambon, 1981, *Nature* 290:304-310), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto, *et al.*, 1980, *Cell* 22:787-797), the herpes thymidine kinase promoter (Wagner *et al.*, 1981, *Proc. Natl. Acad. Sci. U.S.A.* 78:1441-1445), the regulatory sequences of the metallothionein gene (Brinster *et al.*, 1982, *Nature* 296:39-42); prokaryotic expression vectors such as the  $\beta$ -lactamase promoter (Villa-Kamaroff, *et al.*, 1978, *Proc. Natl. Acad. Sci. U.S.A.* 75:3727-3731), or the *tac* promoter (DeBoer, *et al.*, 1983, *Proc. Natl. Acad. Sci. U.S.A.* 80:21-25); see also "Useful proteins from recombinant bacteria" in *Scientific American*, 1980, 242:74-94; promoter elements from yeast or other fungi such as the Gal 4 promoter, the ADC (alcohol dehydrogenase) promoter, PGK (phosphoglycerol kinase) promoter, alkaline phosphatase promoter; and the animal transcriptional control regions, which exhibit tissue specificity and have been utilized in transgenic animals: elastase I gene control region which is active in pancreatic acinar cells (Swift *et al.*, 1984, *Cell* 38:639-646; Ornitz *et al.*, 1986, *Cold Spring Harbor Symp. Quant. Biol.* 50:399-409; MacDonald, 1987, *Hepatology* 7:425-515); insulin gene control region which is active in pancreatic  $\beta$  cells (Hanahan, 1985, *Nature* 315:115-122), immunoglobulin gene control region which is active in lymphoid cells (Grosschedl *et al.*, 1984, *Cell* 38:647-658; Adames *et al.*, 1985, *Nature* 318:533-538; Alexander *et al.*, 1987, *Mol. Cell. Biol.* 7:1436-1444), mouse mammary tumor virus control region which is active in testicular, breast, lymphoid and mast cells (Leder *et al.*, 1986, *Cell* 45:485-495), albumin gene control region which is active in liver (Pinkert *et al.*, 1987, *Genes and Devel.* 1:268-276), alpha-fetoprotein gene control region which is active in liver (Krumlauf *et al.*, 1985, *Mol. Cell. Biol.* 5:1639-1648; Hammer *et al.*, 1987, *Science* 235:53-58), alpha 1-antitrypsin gene control region which is active in the liver (Kelsey *et al.*, 1987, *Genes and Devel.* 1:161-171), beta-globin gene control region which is active in myeloid cells (Mogram *et al.*, 1985, *Nature* 315:338-340; Kollias *et al.*, 1986, *Cell* 46:89-94), myelin basic protein gene control region which is active in oligodendrocyte cells in the brain (Readhead *et al.*, 1987, *Cell* 48:703-712), myosin light chain-2 gene control region which is active in skeletal muscle (Sani, 1985, *Nature* 314:283-286), and gonadotropic releasing hormone gene control region which is active in the hypothalamus (Mason *et al.*, 1986, *Science* 234:1372-1378).

A wide variety of host/expression vector combinations may be employed in expressing the DNA sequences of this invention. Useful expression vectors, for example, may consist of segments of chromosomal, non-chromosomal and synthetic DNA sequences. Suitable vectors include derivatives of SV40 and known bacterial plasmids, *e.g.*, *E. coli* plasmids col E1, pCR1, pBR322, pMal-C2, pET, pGEX [Smith *et al.*, 1988, Gene 67:31-40], pMB9 and their derivatives, plasmids such as RP4; phage DNAs, *e.g.*, the numerous derivatives of phage  $\lambda$ , *e.g.*, NM989, and other phage DNA, *e.g.*, M13 and filamentous single stranded phage DNA; yeast plasmids such as the 2 $\mu$  plasmid or derivatives thereof; vectors useful in eukaryotic cells, such as vectors useful in insect or mammalian cells; vectors derived from combinations of plasmids and phage DNAs, such as plasmids that have been modified to employ phage DNA or other expression control sequences; and the like known in the art.

In addition to the preferred sequencing analysis, expression vectors containing an HCV DNA clone of the invention can be identified by four general approaches: (a) PCR amplification of the desired plasmid DNA or specific mRNA, (b) nucleic acid hybridization, (c) presence or absence of selection marker gene functions, (d) analysis with appropriate restriction endonucleases and (e) expression of inserted sequences. In the first approach, the nucleic acids can be amplified by PCR to provide for detection of the amplified product. In the second approach, the presence of a foreign gene inserted in an expression vector can be detected by nucleic acid hybridization using probes comprising sequences that are homologous to the HCV DNA. In the third approach, the recombinant vector/host system can be identified and selected based upon the presence or absence of certain "selection marker" gene functions (*e.g.*,  $\beta$ -galactosidase activity, thymidine kinase activity, resistance to antibiotics, transformation phenotype, occlusion body formation in baculovirus, etc.) caused by the insertion of foreign genes in the vector. In the fourth approach, recombinant expression vectors are identical by digestion with appropriate restriction enzymes. In the fifth approach, recombinant expression vectors can be identified by assaying for the activity, biochemical, or immunological characteristics of the gene product expressed by the recombinant, *e.g.*, HCV RNA, HCV virions, or HCV viral proteins.

For example, in a baculovirus expression systems, both non-fusion transfer vectors, such as but not limited to pVL941 (*Bam*HI cloning site; Summers), pVL1393 (*Bam*HI, *Sma*I, *Xba*I,

*EcoRI*, *NotI*, *XmaIII*, *BglII*, and *PstI* cloning site; Invitrogen), pVL1392 (*BglII*, *PstI*, *NotI*, *XmaIII*, *EcoRI*, *XbaI*, *SmaI*, and *BamHI* cloning site; Summers and Invitrogen), and pBlueBacIII (*BamHI*, *BglII*, *PstI*, *NcoI*, and *HindIII* cloning site, with blue/white recombinant screening possible; Invitrogen), and fusion transfer vectors, such as but not limited to pAc700 (*BamHI* and *KpnI* cloning site, in which the *BamHI* recognition site begins with the initiation codon; Summers), pAc701 and pAc702 (same as pAc700, with different reading frames), pAc360 (*BamHI* cloning site 36 base pairs downstream of a polyhedrin initiation codon; Invitrogen(195)), and pBlueBacHisA, B, C (three different reading frames, with *BamHI*, *BglII*, *PstI*, *NcoI*, and *HindIII* cloning site, an N-terminal peptide for ProBond purification, and blue/white recombinant screening of plaques; Invitrogen) can be used.

Examples of mammalian expression vectors contemplated for use in the invention include vectors with inducible promoters, such as the dihydrofolate reductase (DHFR) promoter, e.g., any expression vector with a *DHFR* expression vector, or a *DHFR*/methotrexate co-amplification vector, such as pED (*PstI*, *SalI*, *SbaI*, *SmaI*, and *EcoRI* cloning site, with the vector expressing both the cloned gene and *DHFR*; [see Kaufman, *Current Protocols in Molecular Biology*, 16.12 (1991)]. Alternatively, a glutamine synthetase/methionine sulfoximine co-amplification vector, such as pEE14 (*HindIII*, *XbaI*, *SmaI*, *SbaI*, *EcoRI*, and *BclI* cloning site, in which the vector expresses glutamine synthase and the cloned gene; Celltech). In another embodiment, a vector that directs episomal expression under control of Epstein Barr Virus (EBV) can be used, such as pREP4 (*BamHI*, *SfiI*, *XhoI*, *NotI*, *NheI*, *HindIII*, *NheI*, *PvuII*, and *KpnI* cloning site, constitutive RSV-LTR promoter, hygromycin selectable marker; Invitrogen), pCEP4 (*BamHI*, *SfiI*, *XhoI*, *NotI*, *NheI*, *HindIII*, *NheI*, *PvuII*, and *KpnI* cloning site, constitutive hCMV immediate early gene, hygromycin selectable marker; Invitrogen), pMEP4 (*KpnI*, *PvuI*, *NheI*, *HindIII*, *NotI*, *XhoI*, *SfiI*, *BamHI* cloning site, inducible methallothionein IIa gene promoter, hygromycin selectable marker; Invitrogen), pREP8 (*BamHI*, *XhoI*, *NotI*, *HindIII*, *NheI*, and *KpnI* cloning site, RSV-LTR promoter, histidinol selectable marker; Invitrogen), pREP9 (*KpnI*, *NheI*, *HindIII*, *NotI*, *XhoI*, *SfiI*, and *BamHI* cloning site, RSV-LTR promoter, G418 selectable marker; Invitrogen), and pEBVHis (RSV-LTR promoter, hygromycin selectable marker, N-terminal peptide purifiable via ProBond resin and cleaved by enterokinase; Invitrogen). Regulatable mammalian expression vectors, can be used, such as Tet and rTet [Gossen and Bujard,

*Proc. Natl. Acad. Sci. USA* 89:5547-51 (1992); Gossen *et al.*, *Science* 268:1766-1769 (1995)]. Selectable mammalian expression vectors for use in the invention include pRc/CMV (*Hind*III, *Bst*XI, *Not*I, *Sba*I, and *Apa*I cloning site, G418 selection; Invitrogen), pRc/RSV (*Hind*III, *Spe*I, *Bst*XI, *Not*I, *Xba*I cloning site, G418 selection; Invitrogen), and others. Vaccinia virus mammalian expression vectors [see, Kaufman (1991) *supra*] for use according to the invention include but are not limited to pSC11 (*Sma*I cloning site, TK- and  $\beta$ -gal selection), pMJ601 (*Sa*II, *Sma*I, *Afl*II, *Nar*I, *Bsp*MI, *Bam*HI, *Apa*I, *Nhe*I, *Sac*II, *Kpn*I, and *Hind*III cloning site; TK- and  $\beta$ -gal selection), and pTKgptF1S (*Eco*RI, *Pst*I, *Sa*II, *Acc*I, *Hind*II, *Sba*I, *Bam*HI, and *Hpa*I cloning site, TK or XPRT selection).

Examples of yeast expression systems include the non-fusion pYES2 vector (*Xba*I, *Sph*I, *Sho*I, *Not*I, *Gst*XI, *Eco*RI, *Bst*XI, *Bam*HI, *Sac*I, *Kpn*I, and *Hind*III cloning site; Invitrogen) or the fusion pYESHisA, B, C (*Xba*I, *Sph*I, *Sho*I, *Not*I, *Bst*XI, *Eco*RI, *Bam*HI, *Sac*I, *Kpn*I, and *Hind*III cloning site, N-terminal peptide purified with ProBond resin and cleaved with enterokinase; Invitrogen), to mention just two, can be employed according to the invention.

In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Different host cells have characteristic and specific mechanisms for the translational and post-translational processing and modification (*e.g.*, glycosylation, cleavage [*e.g.*, of signal sequence]) of proteins. Expression in yeast can produce a glycosylated product. Expression in eukaryotic cells can increase the likelihood of "native" glycosylation and folding of an HCV protein. Moreover, expression in mammalian cells can provide a tool for reconstituting, or constituting, native HCV virions or virus particle proteins.

Furthermore, different vector/host expression systems may affect processing reactions, such as proteolytic cleavages, to a different extent.

A variety of transfection methods, useful for other RNA virus studies, are enabled herein. Examples include microinjection, cell fusion, calcium-phosphate-cationic liposomes such as lipofectin [Rice *et al.*, *New Biol.* 1:285-296 (1989); see "HCV-based Gene Expression Vectors", *infra*], DE-dextran [Rice *et al.*, *J. Virol.* 61: 3809-3819 (1987)], and electroporation [Bredenbeek *et al.*, *J. Virol.* 67: 6439-6446 (1993); Liljeström *et al.*, *J.*

*Virol.* 65: 4107-4113 (1991)]. Scrape loading [Kumar *et al.*, *Biochem. Mol. Biol. Int.* 32: 1059-1066 (1994)] and ballistic methods [Burkholder *et al.*, *J. Immunol. Meth.* 165: 149-156 (1993)] may also be considered for cell types refractory to transfection by these other methods. A DNA vector transporter may be considered [see, *e.g.*, Wu *et al.*, 1992, *J. Biol. Chem.* 267:963-967; Wu and Wu, 1988, *J. Biol. Chem.* 263:14621-14624; Hartmut *et al.*, Canadian Patent Application No. 2,012,311, filed March 15, 1990].

#### In Vitro Infection With HCV

*Identification of cell lines supporting HCV replication.* An important aspect of the invention is a method it provides for developing new and more effective anti-HCV therapy by conferring the ability to evaluate the efficacy of different therapeutic strategies using an authentic and standardized *in vitro* HCV replication system. Such assays are invaluable before moving on to trials using rare and valuable experimental animals, such as the chimpanzee, or HCV-infected human patients. As mentioned in the Background of the Invention, at best only trace levels of HCV replication have been observed in cell culture and most of the systems reported are not amenable for drug screening or evaluation. The most promising system reported to date is the HTLV1-infected MT-2C T-lymphocyte subline, which has been shown to support HCV replication with a signal:noise ratio of about 1000:1 [Mizutani *et al.*, *J. Virol.*, 70: 7219-23 (1996)]. It should be noted, however, that replication in this system is initiated by infection with a patient inoculum. Such a system may have utility, but will be limited by differences between inocula which affect cell tropism and the detection of replication.

The HCV infectious clone technology can be used to establish *in vitro* and *in vivo* systems for analysis of HCV replication and packaging. These include, but are not restricted to, (i) identification or selection of permissive cell types (for RNA replication, virion assembly and release); (ii) investigation of cell culture parameters (*e.g.*, varying culture conditions, cell activation, etc.) or selection of adaptive mutations that increase the efficiency of HCV replication in cell cultures; and (iii) definition of conditions for efficient production of infectious HCV particles (either released into the culture supernatant or obtained after cell disruption). These and other readily apparent extensions of the invention have broad utility for HCV therapeutic, vaccine, and diagnostic development.

General approaches for identifying permissive cell types are outlined below. Optimal methods for RNA transfection (see also, *supra*) vary with cell type and are determined using RNA reporter constructs. These include, for example, bicistronic RNAs [Wang *et al.*, *J. Virol.* 67: 3338-44 (1993)] with the structure 5'-CAT-HCV IRES-LUC-3' which are used both to optimize transfection conditions (CAT; chloramphenicol acetyltransferase activity) and to determine if the cell type is permissive for HCV IRES-mediated translation (LUC; luciferase activity). For actual HCV RNA transfection experiments, cotransfection with a 5' capped luciferase reporter RNA [Wang *et al.*, (1993) *supra*] provides an internal standard for productive transfection and translation. Examples of cell types potentially permissive for HCV replication include, but are not restricted to, primary human cells (*e.g.*, hepatocytes, T-cells, B-cells, foreskin fibroblasts) as well as continuous human cell lines (*e.g.*, HepG2, Huh7, HUT78, HPB-Ma, MT-2, MT-2C, and other HTLV-1 and HTLV-II infected T-cell lines, Namalawa, Daudi, EBV-transformed LCLs). In addition, cell lines of other species, especially those which are readily transfected with RNA and permissive for replication of flaviviruses or pestiviruses (*e.g.*, SW-13, Vero, BHK-21, COS, PK-15, MBCK, etc.), can be tested. Cells are transfected using a method as described *supra*.

For replication assays, RNA transcripts are prepared using the functional clone and the corresponding non-functional, *e.g.*,  $\Delta$ GDD (see Examples) derivative, is used as a negative control for persistence of HCV RNA and antigen in the absence of productive replication. Template DNA (which complicates later analyses) is removed by repeated cycles of DNaseI treatment and acid phenol extraction followed by purification by either gel electrophoresis or gel filtration (less than one molecule of amplifiable DNA per  $10^9$  molecules of transcript RNA). DNA-free RNA transcripts will be mixed with LUC reporter RNA and used to transfect cell cultures using optimal conditions determined above. After recovery of the cells, RNaseA is added to the media to digest excess input RNA and the cultures incubated for various periods of time. An early timepoint ( $\sim 1$  day post-transfection) will be harvested and analyzed for LUC activity (to verify productive transfection) and positive-strand RNA levels in the cells and supernatant (as a baseline). Samples are collected periodically for 2-3 weeks and assayed for positive-strand RNA levels by QC-RT/PCR [see Kolykhalov *et al.*, (1996) *supra*]. Cell types showing a clear and reproducible difference between the intact infectious transcript and the non-functional derivative, *e.g.*,  $\Delta$ GDD

deletion, control can be subjected to more thorough analyses to verify authentic replication. Such assays include measurement of negative-sense HCV RNA accumulation by QC-RT/PCR [Gunji *et al.*, (1994) *supra*; Lanford *et al.*, *Virology* 202: 606-14 (1994)], Northern-blot hybridization, or metabolic labeling [Yoo *et al.*, (1995) *supra*] and single cell methods, such as *in situ* hybridization [ISH; Gowans *et al.*, In "Nucleic Acid Probes" (R. H. Symons, Eds.), Vol. pp. 139-158. CRC Press, Boca Raton. (1989)], *in situ* PCR [followed by ISH to detect only HCV-specific amplification products; Haase *et al.*, *Proc. Natl. Acad. Sci. USA* 87: 4971-4975 (1990)], and immunohistochemistry.

*HCV particles for studying virus-receptor interactions.* In combination with the identification of cell lines which are permissive for HCV infection and replication, defined HCV stocks produced using the infectious clone technology can be used to evaluate the interaction of the HCV with cellular receptors. Assays can be set up which measure binding of the virus to susceptible cells or productive infection, and then used to screen for inhibitors of these processes.

*Identification of cell lines for characterization of HCV receptors.* Cell lines permissive for HCV RNA replication, as assayed by RNA transfection, can be screened for their ability to be infected by the virus. Cell lines permissive for RNA replication but which cannot be infected by the homologous virus may lack one or more host receptors required for HCV binding and entry. Such cells provide valuable tools for (i) functional identification and molecular cloning of HCV receptors and co-receptors; (ii) characterization of virus-receptor interactions; and (iii) developing assays to screen for compounds or biologics (*e.g.*, antibodies, SELEX RNAs [Bartel and Szostak, In "RNA-protein interactions" (K. Nagai and I. W. Mattaj, Eds.), Vol. pp. 82-102. IRL Press, Oxford (1995); Gold *et al.*, *Annu. Rev. Biochem.* 64: 763-797 (1995)], etc.) that inhibit these interactions.

Once defined in this manner, these HCV receptors serve not only as therapeutic targets but may also be expressed in transgenic animals rendering them susceptible to HCV infection [Koike *et al.*, *Dev Biol Stand* 78: 101-7 (1993); Ren and Racaniello, *J Virol* 66: 296-304 (1992)]. Such transgenic animal models supporting HCV replication and spread have important applications for evaluating anti-HCV drugs.



The ability to manipulate the HCV glycoprotein structure using infectious clone technology, or by genetic manipulations as described *supra*, may also be used to create HCV variants with altered receptor specificity. In one example, HCV glycoproteins can be modified to express a heterologous binding domain for a known cell surface receptor. The approach should allow the engineering of HCV derivatives with altered tropism and perhaps extend infection to non-chimeric small animal models.

*Alternative approaches for identifying permissive cell lines.* Besides using the unmodified HCV RNA transcripts derived from functional clones, these functional HCV clones can be engineered to provide selectable markers for HCV replication. For instance, genes encoding dominant selectable markers can be expressed as part of the HCV polyprotein, or as separate cistrons located in permissive regions of the HCV RNA genome. Such engineered derivatives [see Bredenbeek and Rice, *Semin. Virol.* 3: 297-310 (1992) for review] have been successfully constructed for other RNA viruses such as Sindbis virus [Frolov *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 93: 11371-11377 (1996)] or the flavivirus Kunjin [Khromykh and Westaway, *J. Virol.* 71: 1497-1505 (1997)]. Examples of selectable markers for mammalian cells include, but are not limited to, the genes encoding dihydrofolate reductase (DHFR; methotrexate resistance), thymidine kinase (tk; methotrexate resistance), puromycin acetyl transferase (pac; puromycin resistance), neomycin resistance (neo; resistance to neomycin or G418), mycophenolic acid resistance (gpt), hygromycin resistance, and resistance to zeocin. Other selectable markers can be used in different hosts such as yeast (*ura3*, *his3*, *leu2*, *trp1*). Strategies for functional expression of heterologous genes have been described [see Bredenbeek and Rice, (1992) *supra* for review]. Examples include (Figure 2): (i) in-frame insertion into the viral polyprotein with cleavage(s) to produce the selectable marker protein mediated by cellular or viral proteases; (ii) creation of separate cistrons using engineered translational start and stop signals. Examples include, but are not restricted to, the use of internal ribosome entry site (IRES) RNA elements derived from cellular or viral mRNAs [Jang *et al.*, *Enzyme* 44: 292-309 (1991); Macejak and Sarnow, *Nature* 353: 90-94 (1991); Molla *et al.*, *Nature* 356: 255-257 (1992)]. In a particular manifestation, a cassette including the EMCV IRES element and the neomycin resistance gene is inserted in the HCV H77 3' NTR hypervariable region. Transcribed RNAs are used to transfect human hepatocyte or other cell lines and the antibiotic G418 used for selecting resistant cell populations. In one

manifestation of this approach, transcripts from pHCVFL/3'EMCVIRESneo (*infra*) are used to transfect a variety of different cell lines.

Alterations of the HCV cDNA can be made to produce lines expressing convenient assayable markers as indirect indicators of HCV replication. Such self-replicating RNAs might include the entire HCV genome RNA or RNA replicons, where regions non-essential for RNA replication have been deleted. Assayable genes might include a second dominant selectable marker, or those encoding proteins with convenient assays. Examples include, but are not restricted to,  $\beta$ -galactosidase,  $\beta$ -glucuronidase, firefly or bacterial luciferase, green fluorescent protein (GFP) and humanized derivatives thereof, cell surface markers, and secreted markers. Such products are either assayed directly or may activate the expression or activity of additional reporters.

#### Animal Models for HCV Infection and Replication

In addition to chimpanzees, the present invention permits development of alternative animal models for studying HCV replication and evaluating novel therapeutics. Using the authentic HCV cDNA clones described in this invention as starting material, multiple approaches can be envisioned for establishing alternative animal models for HCV replication. In one manifestation, well-defined HCV stocks, produced by transfection of chimpanzees or by replication in cell culture, could be used to inoculate immunodeficient mice harboring human tissues capable of supporting HCV replication. An example of this art is the SCID:Hu mouse, where mice with a severe combined immunodeficiency are engrafted with various human (or chimpanzee) tissues, which could include, but are not limited to, fetal liver, adult liver, spleen, or peripheral blood mononuclear cells. Besides SCID mice, normal irradiated mice can serve as recipients for engraftment of human or chimpanzee tissues. These chimeric animals would then be substrates for HCV replication after either *ex vivo* or *in vivo* infection with defined virus-containing inocula.

In another manifestation, adaptive mutations allowing HCV replication in alternative species may produce variants which will be permissive for replication in these animals. For instance, adaptation HCV for replication and spread in either continuous rodent cell lines or primary tissues (such as hepatocytes) enables the virus to replicate in small rodent models. Alternatively, complex libraries of HCV variants created by chemical or biological [Stemmer, *Proc. Natl. Acad. Sci. USA* 91:10747 (1994)] methods can be created and used

for inoculation of potentially susceptible animals. Such animals could be either immunocompetent or immunodeficient, as described above. Variants capable of replication can be isolated, molecularly cloned and then the adaptive mutations incorporated into a full-length clone, which is functional for replication in the selected non-human species.

The functional activity of HCV can be evaluated transgenically. In this respect, a transgenic mouse model can be used [see, e.g., Wilmut *et al.*, *Experientia* 47:905 (1991)]. The HCV RNA or DNA clone can be used to prepare transgenic vectors, including viral vectors, or cosmid clones (or phage clones). Cosmids may be introduced into transgenic mice using published procedures [Jaenisch, *Science*, 240:1468-1474 (1988)]. In the preparation of transgenic mice, embryonic stem cells are obtained from blastocyst embryos [Joyner, *In Gene Targeting: A Practical Approach. The Practical Approach Series*, Rickwood, D., and Hames, B. D., Eds., IRL Press: Oxford (1993)] and transfected with HCV DNA or RNA. Transfected cells are injected into early embryos, e.g., mouse embryos, as described [Hammer *et al.*, *Nature* 315:680 (1985); Joyner, *supra*]. Various techniques for preparation of transgenic animals have been described [U.S. Patent No. 5,530,177, issued June 25, 1996; U.S. Patent No. 5,898,604, issued December 31, 1996]. Of particular interest are transgenic animal models in which the phenotypic or pathogenic effects of a transgene are studied. For example, the effects of a rat phosphoenolpyruvate carboxykinase-bovine growth hormone fusion gene has been studied in pigs [Wiegart *et al.*, *J. Reprod. Fert., Suppl.* 41:89-96 (1996)]. Transgenic mice that express of a gene encoding a human amyloid precursor protein associated with Alzheimer's disease are used to study this disease and other disorders [International Patent Publication WO 96/06927, published March 7, 1996; Quon *et al.*, *Nature* 352:239 (1991)]. Transgenic mice have also been created for the hepatitis delta agent [Polo *et al.*, *J. Virol.* 69:5203 (1995)] and for hepatitis B virus [Chisar, *Curr. Top. Microbiol. Immunol.* 206:149 (1996)], and replication occurs in these engineered animals.

Thus, the functional cDNA clones described here, or parts thereof, can be used to create transgenic models relevant to HCV replication and pathogenesis. In one example, transgenic animals harboring the entire HCV genome can be created. Appropriate constructs for transgenic expression of the entire HCV genome in a transgenic mouse of the invention could include a nuclear promoter engineered to produce transcripts with the

appropriate 5' terminus, the full-length HCV cDNA sequence, a cis-cleaving delta ribozyme [Ball, *J. Virol.* 66: 2335-2345 (1992); Pattnaik *et al.*, *Cell* 69: 1011-1020 (1992)] to produce an authentic 3' terminus, followed possibly by signals that promote proper nuclear processing and transport to the cytoplasm (where HCV RNA replication occurs). Besides the entire HCV genome, animals can be engineered to express individual or various combinations of HCV proteins and RNA elements. For example, animals engineered to express an HCV gene product or reporter gene under the control of the HCV IRES can be used to evaluate therapies directed against this specific RNA target. Similar animal models can be envisioned for most known HCV targets.

Such alternative animal models are useful for (i) studying the effects of different antiviral agents on HCV replication in a whole animal system; (ii) examining potential direct cytotoxic effects of HCV gene products on hepatocytes and other cell types, defining the underlying mechanisms involved, and identifying and testing strategies for therapeutic intervention; and (iii) studying immune-mediated mechanisms of cell and tissue damage relevant to HCV pathogenesis and identifying and testing strategies for interfering with these processes.

#### Selection and Analysis of Drug-Resistant Variants

Cell lines and animal models supporting HCV replication can be used to examine the emergence of HCV variants with resistance to existing and novel therapeutics. Like all RNA viruses, the HCV replicase is presumed to lack proofreading activity and RNA replication is therefore error prone, giving rise to a high level of variation [Bukh *et al.*, (1995) *supra*]. The variability manifests itself in the infected patient over time and in the considerable diversity observed between different isolates. The emergence of drug-resistant variants is likely to be an important consideration in the design and evaluation of HCV mono and combination therapies. HCV replication systems of the invention can be used to study the emergence of variants under various therapeutic formulations. These might include monotherapy or various combination therapies (*e.g.*, IFN- $\alpha$ , ribavirin, and new antiviral compounds). Resistant mutants can then be used to define the molecular and structural basis of resistance and to evaluate new therapeutic formulations, or in screening assays for effective anti-HCV drugs (*infra*).

#### Screening For Anti-HCV Agents

HCV-permissive cell lines or animal models (preferably rodent models) can be used to screen for novel inhibitors or to evaluate candidate anti-HCV therapies. Such therapies include, but would not be limited to, (i) antisense oligonucleotides or ribozymes targeted to conserved HCV RNA targets; (ii) injectable compounds capable of inhibiting HCV replication; and (iii) orally bioavailable compounds capable of inhibiting HCV replication. Targets for such formulations include, but are not restricted to, (i) conserved HCV RNA elements important for RNA replication and RNA packaging; (ii) HCV-encoded enzymes; (iii) protein-protein and protein-RNA interactions important for HCV RNA replication, virus assembly, virus release, viral receptor binding, viral entry, and initiation of viral RNA replication; (iv) virus-host interactions modulating the ability of HCV to establish chronic infections; (v) virus-host interactions modulating the severity of liver damage, including factors affecting apoptosis and hepatotoxicity; (vi) virus-host interactions leading to the development of more severe clinical outcomes including cirrhosis and hepatocellular carcinoma; and (vii) virus-host interactions resulting in other, less frequent, HCV-associated human diseases.

*Evaluation of antisense and ribozyme therapies.* The present invention extends to the preparation of antisense nucleotides and ribozymes that may be tested for the ability to interfere with HCV replication. This approach utilizes antisense nucleic acid and ribozymes to block translation of a specific mRNA, either by masking that mRNA with an antisense nucleic acid or cleaving it with a ribozyme.

Antisense nucleic acids are DNA or RNA molecules that are complementary to at least a portion of a specific mRNA molecule [see Marcus-Sekura, *Anal. Biochem.* 172:298 (1988)]. In the cell, they hybridize to that mRNA, forming a double stranded DNA:RNA or RNA:RNA molecule. The cell does not translate an mRNA in this double-stranded form. Therefore, antisense nucleic acids interfere with the expression of mRNA into protein. Oligomers of about fifteen nucleotides and molecules that hybridize to the AUG initiation codon will be particularly efficient, since they are easy to synthesize and are likely to pose fewer problems than larger molecules when introducing them into organ cells. Antisense methods have been used to inhibit the expression of many genes *in vitro* [Marcus-Sekura, 1988, *supra*; Hambor *et al.*, *J. Exp. Med.* 168:1237 (1988)]. Preferably synthetic antisense nucleotides contain phosphoester analogs, such as phosphorothiolates, or thioesters, rather than natural phosphoester bonds. Such phosphoester bond analogs are

more resistant to degradation, increasing the stability, and therefore the efficacy, of the antisense nucleic acids.

In the genetic antisense approach, expression of the wild-type allele is suppressed because of expression of antisense RNA. This technique has been used to inhibit TK synthesis in tissue culture and to produce phenotypes of the *Kruppel* mutation in *Drosophila*, and the *Shiverer* mutation in mice [Izant *et al.*, *Cell*, 36:1007-1015 (1984); Green *et al.*, *Annu. Rev. Biochem.*, 55:569-597 (1986); Katsuki *et al.*, *Science*, 241:593-595 (1988)]. An important advantage of this approach is that only a small portion of the gene need be expressed for effective inhibition of expression of the entire cognate mRNA. The antisense transgene will be placed under control of its own promoter or another promoter expressed in the correct cell type, and placed upstream of the SV40 polyA site.

Ribozymes are RNA molecules possessing the ability to specifically cleave other single stranded RNA molecules in a manner somewhat analogous to DNA restriction endonucleases. Ribozymes were discovered from the observation that certain mRNAs have the ability to excise their own introns. By modifying the nucleotide sequence of these RNAs, researchers have been able to engineer molecules that recognize specific nucleotide sequences in an RNA molecule and cleave it [Cech, *J. Am. Med. Assoc.* 260:3030 (1988)]. Because they are sequence-specific, only mRNAs with particular sequences are inactivated.

Investigators have identified two types of ribozymes, *Tetrahymena*-type and "hammerhead"-type. *Tetrahymena*-type ribozymes recognize four-base sequences, while "hammerhead"-type recognize eleven- to eighteen-base sequences. The longer the recognition sequence, the more likely it is to occur exclusively in the target mRNA species. Therefore, hammerhead-type ribozymes are preferable to *Tetrahymena*-type ribozymes for inactivating a specific mRNA species, and eighteen base recognition sequences are preferable to shorter recognition sequences.

*Screening compound libraries for anti-HCV activity.* Various natural product or synthetic libraries can be screened for anti-HCV activity in the *in vitro* or *in vivo* models provided by the invention. One approach to preparation of a combinatorial library uses primarily chemical methods, of which the Geysen method [Geysen *et al.*, *Molecular Immunology*

23:709-715 (1986); Geysen *et al.* [*J. Immunologic Method* 102:259-274 (1987)] and the method of Fodor *et al.* [*Science* 251:767-773 (1991)] are examples. Furka *et al.* [14th *International Congress of Biochemistry, Volume 5*, Abstract FR:013 (1988); Furka, *Int. J. Peptide Protein Res.* 37:487-493 (1991)], Houghton [U.S. Patent No. 4,631,211, issued December 1986] and Rutter *et al.* [U.S. Patent No. 5,010,175, issued April 23, 1991] describe methods to produce a mixture of peptides that can be tested for anti-HCV activity.

In another aspect, synthetic libraries [Needels *et al.*, *Proc. Natl. Acad. Sci. USA* 90:10700-4 (1993); Ohlmeyer *et al.*, *Proc. Natl. Acad. Sci. USA* 90:10922-10926 (1993); Lam *et al.*, International Patent Publication No. WO 92/00252; Kocis *et al.*, International Patent Publication No. WO 9428028], and the like can be used to screen for anti-HCV compounds according to the present invention. These references, describe adaption of the library screening techniques in biological assays.

*Defined/engineered HCV virus particles for neutralization assays.* The functional clones described herein can be used to produce defined stocks of HCV-H particles for infectivity and neutralization assays. Homogeneous stocks can be produced in the chimpanzee model, in cell culture systems, or using various heterologous expression systems (*e.g.*, baculovirus, yeast, mammalian cells; see *supra*). As described above, besides homogenous virus preparations of HCV-H, stocks of other genotypes or isolates can be produced. These stocks can be used in cell culture or *in vivo* assays to define molecules or gene therapy approaches capable of neutralizing HCV particle production or infectivity. Examples of such molecules include, but are not restricted to, polyclonal antibodies, monoclonal antibodies, artificial antibodies with engineered/optimized specificity, single-chain antibodies (see the section on antibodies, *infra*), nucleic acids or derivatized nucleic acids selected for specific binding and neutralization, small orally bioavailable compounds, etc. Such neutralizing agents, targeted to conserved viral or cellular targets, can be either genotype or isolate-specific or broadly cross-reactive. They could be used either prophylactically or for passive immunotherapy to reduce viral load and perhaps increase the chances of more effective treatment in combination with other antiviral agents (*e.g.*, IFN- $\alpha$ , ribavirin, etc.). Directed manipulation of HCV infectious clones can also be used to produce HCV stocks with defined changes in the glycoprotein hypervariable regions or in other epitopes to study mechanisms of antibody neutralization, CTL recognition, immune

escape and immune enhancement. These studies will lead to identification of other virus-specific functions for anti-viral therapy.

#### Dissection of HCV Replication

*Other HCV replication assays.* For the first time, this invention allows directed molecular genetic dissection of HCV replication. Such analyses are expected to (i) validate antiviral targets which are currently being pursued; and (ii) uncover unexpected new aspects of HCV replication amenable to therapeutic intervention. Targets for immediate validation through mutagenesis studies include the following: the 5' NTR, the HCV polyprotein and cleavage products, and the 3' NTR. As described above, analyses using the infectious clone technology and permissive cell cultures can be used to compare parental and mutant replication phenotypes after transfection of cell cultures with infectious RNA. Even though RT-PCR allows sensitive detection of viral RNA accumulation, mutations which decrease the efficiency of RNA replication may be difficult to analyze, unless conditional mutations are recovered. As a complement to first cycle analyses, *trans*-complementation assays can be used to facilitate analysis of HCV mutant phenotypes and inhibitor screening. Heterologous systems (vaccinia, Sindbis, or non-viral) can be used to drive expression of the HCV RNA replicase proteins and/or packaging machinery [see Lemm and Rice, *J. Virol.* 67: 1905-1915 (1993a); Lemm and Rice, *J. Virol.* 67: 1916-1926 (1993b); Lemm *et al.*, *EMBO J.* 13: 2925-2934 (1994); Li *et al.*, *J. Virol.* 65: 6714-6723 (1991)]. If these elements are capable of functioning in *trans*, then co-expression of RNAs with appropriate *cis*-elements should result in RNA replication/packaging. Such systems therefore mimic steps in authentic RNA replication and virion assembly, but uncouple production of viral components from HCV replication. If HCV replication is somehow self-limiting, heterologous systems may drive significantly higher levels of RNA replication or particle production, facilitating analysis of mutant phenotypes and antiviral screening. A third approach is to devise cell-free systems for HCV template-dependent RNA replication. A coupled translation/replication and assembly system has been described for poliovirus in HeLa cells [Barton and Flanagan, *J. Virol.* 67: 822-831 (1993); Molla *et al.*, *Science* 254: 1647-1651 (1991)], and a template-dependent *in vitro* assay for initiation of negative-strand synthesis has been established for Sindbis virus. Similar *in vitro* systems for HCV are invaluable for studying many aspects of HCV replication as well as for inhibitor screening and evaluation. An example of each of these strategies follows.



*Trans-complementation of HCV RNA replication and/or packaging using viral or non-viral expression systems.* Heterologous systems can be used to drive HCV replication. For example, the vaccinia/T7 cytoplasmic expression system has been extremely useful for trans-complementation of RNA virus replicase and packaging functions [see Ball, (1992) *supra*; Lemm and Rice, (1993a) *supra*; Lemm and Rice, (1993b) *supra*; Lemm *et al.*, (1994) *supra*; Pattnaik *et al.*, (1992) *supra*; Pattnaik *et al.*, *Virology* 206: 760-4 (1995); Porter *et al.*, *J. Virol.* 69: 1548-1555 (1995)]. In brief, a vaccinia recombinant (vTF7-3) is used to express T7 RNA polymerase (T7RNApol) in the cell type of interest. Target cDNAs, positioned downstream from the T7 promoter, are delivered either as vaccinia recombinants or by plasmid transfection. This system leads to high level RNA and protein expression. A variation of this approach, which obviates the need for vaccinia (which could interfere with HCV RNA replication or virion formation), is the pT7T7 system where the T7 promoter drives expression of T7RNApol [Chen *et al.*, *Nucleic Acids Res.* 22: 2114-2120. (1994)]. pT7T7 is mixed with T7RNApol (the protein) and co-transfected with the T7-driven target plasmid of interest. Added T7RNApol initiates transcription, leading to its own production and high level expression of the target gene. Using either approach, RNA transcripts with precise 5' and 3' termini can be produced using the T7 transcription start site (5') and the cis-cleaving HCV ribozyme (Rz) (3') [Ball, (1992) *supra*; Pattnaik *et al.*, (1992) *supra*].

These or similar expression systems can be used to establish assays for HCV RNA replication and particle formation, and for evaluation of compounds which might inhibit these processes. In another extension of the HCV functional clone technology, T7-driven protein expression constructs and full-length HCV clones incorporating the HCV ribozyme following the 3' NTR are used. A typical experimental plan to validate the assay is described for pT7T7, although essentially similar assays can be envisioned using vTF7-3 or cell lines expressing the T7 RNA polymerase. HCV-permissive cells are co-transfected with pT7T7+T7RNApol+p90/HCVFLlong pU Rz (or a negative control, such as  $\Delta$ GDD). At different times post-transfection, accumulation of HCV proteins and RNAs, driven by the pT7T7 system, are followed by Western and Northern blotting, respectively. To assay for HCV-specific replicase function, Act. D is added to block DNA-dependent T7 transcription [Lemm and Rice, (1993a), *supra*] and Act. D-resistant RNA synthesis is

monitored by metabolic labeling. Radioactivity will be incorporated into full-length HCV RNAs for p90/HCVFL long pU/Rz, but not for p90/HCVFL $\Delta$ GDD/Rz. This assay system, or elaborated derivatives, can be used to screen for inhibitors and to study their effects on HCV RNA replication.

*Cell-free systems for assaying HCV replication and inhibitors thereof.* Cell-free assays for studying HCV RNA replication and inhibitor screening can also be established using the functional cDNA clones described in this invention. Either virion or transcribed RNAs are used as substrate RNA. For HCV, full-length HCV RNAs transcribed *in vitro* can be used to program such *in vitro* systems and replication assayed essentially as described for poliovirus [see Barton *et al.*, (1995) *supra*]. In case hepatocyte-specific or other factors are required for HCV RNA replication, the system can be supplemented with hepatocyte or other cell extracts, or alternatively, a comparable system can be established using cell lines which have been shown to be permissive for HCV replication.

One concern about this approach is that proper cell-free synthesis and processing of the HCV polyprotein must occur. Sufficient quantities of properly processed replicase components may be difficult to produce. To circumvent this problem, the T7 expression system can be used to express high levels of HCV replicase components in appropriate cells [see Lemm *et al.*, (1997) *supra*]. P15 membrane fractions from these cells (with added buffer,  $Mg^{2+}$ , an ATP regenerating system, and NTPs) should be able to initiate and synthesize full-length negative-strand RNAs upon addition of HCV-specific template RNAs.

Establishment of either or both of these assays allows rapid and precise analysis of the effects of HCV mutations, host factors, involved in replication and inhibitors of the various steps in HCV RNA replication. These systems will also establish the requirements for helper systems for preparing replication-deficient HCV vectors.

#### Vaccination and Protective Immunity

There are still many unknown parameters that impact on development of effective HCV vaccines. It is clear in both man and the chimpanzee that some individuals can clear the infection. Also, 10-20% of those treated with IFN appear to show a sustained response as evidenced by lack of circulating HCV RNA. Other studies have shown a lack of protective immunity, as evidenced by successful reinfection with both homologous virus as well as

with more distantly related HCV types [Farci *et al.*, (1992) *supra*; Prince *et al.*, (1992) *supra*]. Nonetheless, chimpanzees immunized with subunit vaccines consisting of E1E2 oligomers and vaccinia recombinants expressing these proteins are partially protected against low dose challenges [Choo *et al.*, *Proc. natl. Acad. Sci. USA* 91:1294 (1994)]. The infectious clone technology described in this invention has utility not only for basic studies aimed at understanding the nature of protective immune responses against HCV, but also for novel vaccine production methods.

Active immunity against HCV can be induced by immunization (vaccination) with an immunogenic amount of an attenuated or inactivated HCV virion, or HCV virus particle proteins, preferably with an immunologically effective adjuvant. An "immunologically effective adjuvant" is a material that enhances the immune response.

Selection of an adjuvant depends on the subject to be vaccinated. Preferably, a pharmaceutically acceptable adjuvant is used. For example, a vaccine for a human should avoid oil or hydrocarbon emulsion adjuvants, including complete and incomplete Freund's adjuvant. One example of an adjuvant suitable for use with humans is alum (alumina gel). A vaccine for an animal, however, may contain adjuvants not appropriate for use with humans.

An alternative to a traditional vaccine comprising an antigen and an adjuvant involves the direct *in vivo* introduction of DNA or RNA encoding the antigen into tissues of a subject for expression of the antigen by the cells of the subject's tissue. Such vaccines are termed herein "DNA vaccines," "genetic vaccination," or "nucleic acid-based vaccines." Methods of transfection as described above, such as DNA vectors or vector transporters, can be used for DNA vaccines.

DNA vaccines are described in International Patent Publication WO 95/20660 and International Patent Publication WO 93/19183, the disclosures of which are hereby incorporated by reference in their entireties. The ability of directly injected DNA that encodes a viral protein or genome to elicit a protective immune response has been demonstrated in numerous experimental systems [Conry *et al.*, *Cancer Res.*, 54:1164-1168 (1994); Cox *et al.*, *Virol.*, 67:5664-5667 (1993); Davis *et al.*, *Hum. Mole. Genet.*, 2:1847-

1851 (1993); Sedegah *et al.*, *Proc. Natl. Acad. Sci.*, **91**:9866-9870 (1994); Montgomery *et al.*, *DNA Cell Bio.*, **12**:777-783 (1993); Ulmer *et al.*, *Science*, **259**:1745-1749 (1993); Wang *et al.*, *Proc. Natl. Acad. Sci.*, **90**:4156-4160 (1993); Xiang *et al.*, *Virology*, **199**:132-140 (1994)]. Studies to assess this strategy in neutralization of influenza virus have used both envelope and internal viral proteins to induce the production of antibodies, but in particular have focused on the viral hemagglutinin protein (HA) [Fynan *et al.*, *DNA Cell Biol.*, **12**:785-789 (1993A); Fynan *et al.*, *Proc. Natl. Acad. Sci.*, **90**:11478-11482 (1993B); Robinson *et al.*, *Vaccine*, **11**:957, (1993); Webster *et al.*, *Vaccine*, **12**:1495-1498 (1994)].

Vaccination through directly injecting DNA or RNA that encodes a protein to elicit a protective immune response produces both cell-mediated and humoral responses. This is analogous to results obtained with live viruses [Raz *et al.*, *Proc. Natl. Acad. Sci.*, **91**:9519-9523 (1994); Ulmer, 1993, *supra*; Wang, 1993, *supra*; Xiang, 1994, *supra*]. Studies with ferrets indicate that DNA vaccines against conserved internal viral proteins of influenza, together with surface glycoproteins, are more effective against antigenic variants of influenza virus than are either inactivated or subvirion vaccines [Donnelly *et al.*, *Nat. Medicine*, **6**:583-587 (1995)]. Indeed, reproducible immune responses to DNA encoding nucleoprotein have been reported in mice that last essentially for the lifetime of the animal [Yankauckas *et al.*, *DNA Cell Biol.*, **12**: 771-776 (1993)].

A vaccine of the invention can be administered via any parenteral route, including but not limited to intramuscular, intraperitoneal, intravenous, intraarterial (*e.g.*, hepatic artery) and the like. Preferably, since the desired result of vaccination is to elucidate an immune response to HCV, administration directly, or by targeting or choice of a viral vector, indirectly, to lymphoid tissues, *e.g.*, lymph nodes or spleen. Since immune cells are continually replicating, they are ideal target for retroviral vector-based nucleic acid vaccines, since retroviruses require replicating cells.

Passive immunity can be conferred to an animal subject suspected of suffering an infection with HCV by administering antiserum, neutralizing polyclonal antibodies, or a neutralizing monoclonal antibody against HCV to the patient. Although passive immunity does not confer long term protection, it can be a valuable tool for the treatment of an acute infection of a subject who has not been vaccinated. Preferably, the antibodies administered for

passive immune therapy are autologous antibodies. For example, if the subject is a human, preferably the antibodies are of human origin or have been "humanized," in order to minimize the possibility of an immune response against the antibodies. In addition, genes encoding neutralizing antibodies can be introduced in vectors for expression *in vivo*, *e.g.*, in hepatocytes.

*Antibodies for passive immune therapy.* Preferably, HCV virions or virus particle proteins prepared as described above are used as an immunogen to generate antibodies that recognize HCV. Such antibodies include but are not limited to polyclonal, monoclonal, chimeric, single chain, Fab fragments, and an Fab expression library. Various procedures known in the art may be used for the production of polyclonal antibodies to HCV. For the production of antibody, various host animals can be immunized by injection with the HCV virions or polypeptide, *e.g.*, as describe *infra*, including but not limited to rabbits, mice, rats, sheep, goats, etc. Various adjuvants may be used to increase the immunological response, depending on the host species, including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (*bacille Calmette-Guerin*) and *Corynebacterium parvum*.

For preparation of monoclonal antibodies directed toward HCV as described above, any technique that provides for the production of antibody molecules by continuous cell lines in culture may be used. These include but are not limited to the hybridoma technique originally developed by Kohler and Milstein [*Nature* 256:495-497 (1975)], as well as the trioma technique, the human B-cell hybridoma technique [Kozbor *et al.*, *Immunology Today* 4:72 1983]; Cote *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 80:2026-2030 (1983)], and the EBV-hybridoma technique to produce human monoclonal antibodies [Cole *et al.*, in *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96 (1985)]. In an additional embodiment of the invention, monoclonal antibodies can be produced in germ-free animals [International Patent Publication No. WO 89/12690, published 28 December 1989]. In fact, according to the invention, techniques developed for the production of "chimeric antibodies" [Morrison *et al.*, *J. Bacteriol.* 159:870 (1984); Neuberger *et al.*, *Nature* 312:604-608 (1984); Takeda *et al.*, *Nature* 314:452-454 (1985)] by splicing the genes from

a mouse antibody molecule specific for HCV together with genes from a human antibody molecule of appropriate biological activity can be used; such antibodies are within the scope of this invention. Such human or humanized chimeric antibodies are preferred for use in therapy of human diseases or disorders (described *infra*), since the human or humanized antibodies are much less likely than xenogenic antibodies to induce an immune response, in particular an allergic response, themselves.

According to the invention, techniques described for the production of single chain antibodies [U.S. Patent Nos. 5,476,786 and 5,132,405 to Huston; U.S. Patent 4,946,778] can be adapted to produce HCV-specific single chain antibodies. An additional embodiment of the invention utilizes the techniques described for the construction of Fab expression libraries [Huse *et al.*, *Science* 246:1275-1281 (1989)] to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity.

Antibody fragments which contain the idiotype of the antibody molecule can be generated by known techniques. For example, such fragments include but are not limited to: the  $F(ab')_2$  fragment which can be produced by pepsin digestion of the antibody molecule; the Fab' fragments which can be generated by reducing the disulfide bridges of the  $F(ab')_2$  fragment, and the Fab fragments which can be generated by treating the antibody molecule with papain and a reducing agent.

*HCV particles for subunit vaccination.* The functional HCV-H cDNA clone, and similarly constructed and verified clones for other genotypes, can be used to produce HCV-like particles for vaccination. Proper glycosylation, folding, and assembly of HCV particles may be important for producing appropriately antigenic and protective subunit vaccines. Several methods can be used for particle production. They include engineering of stable cell lines for inducible or constitutive expression of HCV-like particles (using bacterial, yeast or mammalian cells), or the use of higher level eukaryotic heterologous expression systems such as recombinant baculoviruses, vaccinia viruses [Moss, *Proc. Natl. Acad. Sci. U.S.A.* 93: 11341-11348 (1996)], or alphaviruses [Frolov *et al.*, (1996) *supra*]. HCV particles for immunization may be purified from either the media or disrupted cells, depending upon their localization. Such purified HCV particles or mixtures of particles representing a spectrum of HCV genotypes, can be injected with or without various adjuvants to enhance immunogenicity.

*Infectious non-replicating HCV particles.* In another manifestation, HCV particles capable of receptor binding, entry, and translation of genome RNA can be produced. Heterologous expression approaches for production of such particles include, but are not restricted to, *E. coli*, yeast, or mammalian cell lines, appropriate host cells infected or harboring recombinant baculoviruses, recombinant vaccinia viruses, recombinant alphaviruses or RNA replicons, or recombinant adenoviruses, engineered to express appropriate HCV RNAs and proteins. In one example, two recombinant baculoviruses are engineered. One baculovirus expresses the HCV structural proteins (*e.g.* C-E1-E2-p7) required for assembly of HCV particles. A second recombinant expresses the entire HCV genome RNA, with precise 5' and 3' ends, except that a deletion, such as  $\Delta$ GDD, is included to inactivate the HCV NS5B RDRP. Other mutations abolishing productive HCV replication could also be utilized instead or in combination. Coinfection of appropriate host cells (Sf9, Sf21, etc.) with both recombinants will produce high levels of HCV structural proteins and genome RNA for packaging into HCV-like particles. Such particles can be produced at high levels, purified, and used for vaccination. Once introduced into the vaccinee, such particles will exhibit normal receptor binding and infection of HCV-susceptible cells. Entry will occur and the genome RNA will be translated to produce all of the normal HCV antigens, except that further replication of the genome will be completely blocked given the inactivated 5B polymerase. Such particles are expected to elicit effective CTL responses against structural and nonstructural HCV protein antigens. This vaccination strategy alone or preferably in conjunction with the subunit strategy described above can be used to elicit high levels of both neutralizing antibodies and CTL responses to help clear the virus. A variety of different HCV genome RNA sequences can be utilized to ensure broadly cross-reactive and protective immune responses. In addition, modification of the HCV particles, either through genetic engineering, or by derivatization *in vitro*, could be used to target infection to cells most effective at eliciting protective and long lasting immune responses.

*Live-attenuated HCV derivatives.* The ability to manipulate the HCV genome RNA sequence and thereby produce mutants with altered pathogenicity provides a means of constructing live-attenuated HCV mutants appropriate for vaccination. Such vaccine candidates express protective antigens but would be impaired in their ability to cause disease, establish chronic infections, trigger autoimmune responses, and transform cells. Naturally, infectious HCV virus of the invention can be attenuated, inactivated, or killed by

chemical or heat treatment.

#### HCV-based Gene Expression Vectors

Some of the same properties of HCV leading to chronic liver infection of humans may also be of great utility for designing vectors for gene expression in cell culture systems, genetic vaccination, and gene therapy. The functional clones described herein can be engineered to produce chimeric RNAs designed for the expression of heterologous gene products (RNAs and proteins). Strategies have been described above and elsewhere [Bredenbeek and Rice, (1992) *supra*; Frolov *et al.*, (1996) *supra*] and include, but are not limited to (i) in-frame fusion of the heterologous coding sequences with the HCV polyprotein; (ii) creation of additional cistrons in the HCV genome RNA; and (iii) inclusion of IRES elements to create multicistronic self-replicating HCV vector RNAs capable of expressing one or more heterologous genes (Figure 2). Functional HCV RNA backbones utilized for such vectors include, but are not limited to, (i) live-attenuated derivatives capable of replication and spread; (ii) RNA replication competent "dead end" derivatives lacking one or more viral components required (*e.g.* the structural proteins) required for viral spread; (iii) mutant derivatives capable of high and low levels of HCV-specific RNA synthesis and accumulation; (iv) mutant derivatives adapted for replication in different human cell types; (v) engineered or selected mutant derivatives capable of prolonged noncytopathic replication in human cells. Vectors competent for RNA replication but not packaging or spread can be introduced either as naked RNA, DNA, or packaged into virus-like particles. Such virus-like particles can be produced as described above and composed of either unmodified or altered HCV virion components designed for targeted infection of the hepatocytes or other human cell types. Alternatively, HCV RNA vectors can be encapsidated and delivered using heterologous viral packaging machineries or encapsulated into liposomes modified for efficient gene delivery. These packaging strategies, and modifications thereof, can be utilized to efficiently target HCV vectors RNAs to specific cell types. Using methods detailed above, similar HCV-derived vector systems, competent for replication and expression in other species, can also be derived.

Various methods, *e.g.*, as set forth *supra* in connection with transfection of cells and DNA vaccines, can be used to introduce an HCV vector of the invention. Of primary interest is direct injection of functional HCV RNA or virions, *e.g.*, in the liver. Targeted gene delivery is described in International Patent Publication WO 95/28494, published October



1995. Alternatively, the vector can be introduced *in vivo* by lipofection. For the past decade, there has been increasing use of liposomes for encapsulation and transfection of nucleic acids *in vitro*. Synthetic cationic lipids designed to limit the difficulties and dangers encountered with liposome mediated transfection can be used to prepare liposomes for *in vivo* transfection of a gene encoding a marker [Felgner, et. al., *Proc. Natl. Acad. Sci. U.S.A.* **84**:7413-7417 (1987); see Mackey, et al., *Proc. Natl. Acad. Sci. U.S.A.* **85**:8027-8031 (1988); Ulmer et al., *Science* **259**:1745-1748 (1993)]. The use of cationic lipids may promote encapsulation of negatively charged nucleic acids, and also promote fusion with negatively charged cell membranes [Felgner and Ringold, *Science* **337**:387-388 (1989)]. The use of lipofection to introduce exogenous genes into the specific organs *in vivo* has certain practical advantages. Molecular targeting of liposomes to specific cells represents one area of benefit. It is clear that directing transfection to particular cell types would be particularly advantageous in a tissue with cellular heterogeneity, such as pancreas, liver, kidney, and the brain. Lipids may be chemically coupled to other molecules for the purpose of targeting [see Mackey, et. al., *supra*]. Targeted peptides, e.g., hormones or neurotransmitters, and proteins such as antibodies, or non-peptide molecules could be coupled to liposomes chemically. Receptor-mediated DNA delivery approaches can also be used [Curiel et al., *Hum. Gene Ther.* **3**:147-154 (1992); Wu and Wu, *J. Biol. Chem.* **262**:4429-4432 (1987)].

Examples of applications for gene therapy include, but are not limited to, (i) expression of enzymes or other molecules to correct inherited or acquired metabolic defects; (ii) expression of molecules to promote wound healing; (iii) expression of immunomodulatory molecules to promote immune-mediated regression or elimination of human cancers; (iv) targeted expression of toxic molecules or enzymes capable of activating cytotoxic drugs in tumors; (v) targeted expression of anti-viral or anti-microbial agents in pathogen-infected cells. Various therapeutic heterologous genes can be inserted in a gene therapy vector of the invention, such as but not limited to adenosine deaminase (ADA) to treat severe combined immunodeficiency (SCID); marker genes or lymphokine genes into tumor infiltrating (TIL) T cells [Kasis et al., *Proc. Natl. Acad. Sci. U.S.A.* **87**:473 (1990); Culver et al., *ibid.* **88**:3155 (1991)]; genes for clotting factors such as Factor VIII and Factor IX for treating hemophilia [Dwarki et al. *Proc. Natl. Acad. Sci. USA*, **92**:1023-1027 (19950); Thompson, *Thromb. and Haemostatis*, **66**:119-122 (1991)]; and various other well known

therapeutic genes such as, but not limited to,  $\beta$ -globin, dystrophin, insulin, erythropoietin, growth hormone, glucocerebrosidase,  $\beta$ -glucuronidase,  $\alpha$ -antitrypsin, phenylalanine hydroxylase, tyrosine hydroxylase, ornithine transcarbamylase, apolipoproteins, and the like. In general, see U.S. Patent No. 5,399,346 to Anderson *et al.*

Examples of applications for genetic vaccination (for protection from pathogens other than HCV) include, but are not limited to, expression of protective antigens from bacterial (*e.g.*, uropathogenic *E. coli*, *Streptococci*, *Staphylococci*, *Nisseria*), parasitic (*e.g.*, *Plasmodium*, *Leishmania*, *Toxoplasma*), fungal (*e.g.*, *Candida*, *Histoplasma*), and viral (*e.g.*, HIV, HSV, CMV, influenza) human pathogens. Immunogenicity of protective antigens expressed using HCV-derived RNA expression vectors can be enhanced using adjuvants, including co-expression of immunomodulatory molecules, such as cytokines (*e.g.*, IL-2, GM-CSF) to facilitate development of desired Th1 versus Th2 responses. Such adjuvants can be either incorporated and co-expressed by HCV vectors themselves or administered in combination with these vectors using other methods.

#### Diagnostic Methods for Infectious HCV

*Diagnostic cell lines.* The invention described herein can also be used to derive cell lines for sensitive diagnosis of infectious HCV in patient samples. In concept, functional HCV components are used to test and create susceptible cell lines (as identified above) in which easily assayed reporter systems are selectively activated upon HCV infection. Examples include, but are not restricted to, (i) defective HCV RNAs lacking replicase components that are incorporated as transgenes and whose replication is upregulated or induced upon HCV infection; (ii) sensitive heterologous amplifiable reporter systems activated by HCV infection. In the first manifestation, cis RNA signals required for HCV RNA amplification flank a convenient reporter gene, such as luciferase, green fluorescent protein (GFP),  $\beta$ -galactosidase, or a selectable marker (see above). Expression of such chimeric RNAs is driven by an appropriate nuclear promoter and elements required for proper nuclear processing and transport to the cytoplasm. Upon infection of the engineered cell line with HCV, cytoplasmic replication and amplification of the transgene is induced, triggering higher levels of reporter expression, as an indicator of productive HCV infection.

In the second example, cell lines are designed for more tightly regulated but highly inducible reporter gene amplification and expression upon HCV infection. Although this

amplified system is described in the context of specific components, other equivalent components can be used. In one such system, diagrammed in Figure 3, an engineered alphavirus replicon transgene is created which lacks the alphavirus nsP4 polymerase, an enzyme absolutely required for alphavirus RNA amplification and normally produced by cleavage from the nonstructural polyprotein. Additional features of this defective alphavirus replicon include a subgenomic RNA promoter, driving expression of a luciferase or GFP reporter gene. This promoter element is quiescent in the absence of productive cytoplasmic alphavirus replication. The cell line contains a second transgene for expression of gene fusion consisting of the HCV NS4A protein and the alphavirus nsP4 RDRP. This fused gene is expressed and targeted to the cytoplasmic membrane compartment, but this form of nsP4 would be inactive as a functional component of the alphavirus replication complex because a discrete nsP4 protein, with a precise N terminus is required for nsP4 activity [Lemm *et al.*, *EMBO J.* 13:2925 (1994)]. An optional third transgene expresses a defective alphavirus RNA with *cis* signals for replication, transcription of subgenomic RNA encoding a ubiquitin-nsP4 fusion, and an alphavirus packaging signal. Upon infection of such a cell line by HCV, the HCV NS3 proteinase is produced and mediate *trans* cleavage of the NS4A-nsP4 fusion protein, activating the nsP4 polymerase. This active polymerase, which functions in *trans* and is effective in minute amounts, then forms a functional alphavirus replication complex leading to amplification of the defective alphavirus replicon as well as the defective alphavirus RNA encoding ubiquitin-nsP4. Ubiquitin-nsP4, expressed from its subgenomic RNA, is cleaved efficiently by cellular ubiquitin carboxyterminal hydrolase to product additional nsP4, in case this enzyme is limiting. Once activated, this system would produce extremely high levels of the reporter protein. The time scale of such an HCV infectivity assay is expected to take just hours (for sufficient reporter gene expression).

*Antibody diagnostics.* In addition to the cell lines described here, HCV virus particles (virions) produced by the transfected or infected cell lines, or isolated from an infected animal, may be used as antigens to detect anti-HCV antibodies in patient blood or blood products. Because the HCV virus particles are derived from an authentic HCV genome, they are likely to have structural characteristics that more closely resemble or are identical to natural HCV virus. These reagents can be used to establish that a patient is infected with HCV by detecting seroconversion, *i.e.*, generation of a population of HCV-specific antibodies.

Alternatively, antibodies generated to the authentic HCV products prepared as described herein can be used to detect the presence of HCV in biological samples from a subject.

The present invention may be better understood by reference to the following non-limiting Examples, which are provided as exemplary of the invention.

### **EXAMPLES**

The following examples report on the background experimental work, initial unsuccessful efforts to prepare an HCV DNA encoding infectious HCV RNA, and finally generation of a functional clone.

#### **EXAMPLE 1. Analysis of HCV-H Genome Structure and Expression**

*Rationale for the HCV-H strain, cDNA cloning, sequence analysis, and assembly of nearly full-length cDNA clones.* HCV-H strain was chosen for the initial studies since this isolate has been extensively characterized in chimpanzees by Purcell and colleagues [see Shimizu *et al.*, (1990) *supra*] and more recently *in vitro* by Shimizu and coworkers [Hijikata *et al.*, (1993) *supra*; Shimizu *et al.*, *J. Virol.* 68: 1494-1500 (1994); Shimizu *et al.*, *Proc. Natl. Acad. Sci USA* 89: 5477-5481 (1992); Shimizu *et al.*, *Proc. Natl. Acad. Sci. USA* 90, 6037-6041 (1993)]. HCV-H is a genotype 1a human isolate from an American with posttransfusion NANB hepatitis [Feinstone *et al.*, *J. Infect. Dis.* 144: 588-598 (1981)].

*Initial cDNA cloning and sequence analysis of HCV-H.* The original HCV-H77 isolate was passaged twice in chimpanzees, both of whom developed elevated serum ALT levels and acute hepatitis. Liver tissue from the second chimpanzee passage was used for preparation of crude RNA suitable for cDNA synthesis and nested PCR amplification. PCR-amplified cDNA was cloned into plasmid expression vectors and several independent clones were isolated and used for sequence analysis, expression studies and reconstructing longer cDNA clones. Utilizing partial sequence data and restriction enzyme mapping, a clone containing the nearly the entire HCV-H cDNA, called pTET/T7HCVFLCMR, was assembled and sequenced [Daemer *et al.*, unpublished; Grakoui *et al.*, *J. Virol.* 67: 1385-1395 (1993c)]. The HCV sequence contained in this plasmid is subsequently referred to as HCV-H CMR (SEQ ID NO:19). The sequence of this clone is colinear and 98.5% homologous (at the nucleotide level) to the chimp-passaged HCV-H77 sequence published by Inchauspe *et*

*al.* [Inchauspe *et al.*, *Proc. Natl. Acad. Sci. USA* 88: 10292-10296 (1991)] and shows even greater similarity to the partial HCV-H90 sequences published by Ogata *et al.* [Ogata *et al.*, (1991) *supra*].

*Characterization of a prototype HCV-H clone.* HCV-H cDNA clones and immune reagents have been used in cell-free translation and cell culture transient expression assays to provide a fairly detailed picture of HCV-H gene expression. In general terms, these results are similar to those obtained by others for different HCV genotypes. This work included: (i) the identification and mapping of HCV-H polyprotein cleavage products [Grakoui *et al.*, (1993c) *supra*; Lin *et al.*, (1994a) *supra*]; (ii) determining the sites of proteolytic processing [Grakoui *et al.*, *J. Virol.* 67: 2832-2843 (1993a); Grakoui *et al.*, *Proc. Natl. Acad. Sci. USA* 90: 10583-10587 (1993b); Lin *et al.*, (1994a) *supra*]; (iii) characterization of the NS2-3 autoprotease [Grakoui *et al.*, (1993b) *supra*; Reed *et al.*, *J. Virol.* 69: 4127-4136 (1995)], the NS3-4A serine proteinase [Grakoui *et al.*, (1993a) *supra*; Lin *et al.*, *J. Virol.* 68: 8147-8157 (1994b); Lin and Rice, *Proc. Natl. Acad. Sci. USA* 92: 7622-7626 (1995); Lin *et al.*, *J. Virol.* 69: 4373-4380 (1995)] and their cleavage requirements [Kolykhalov *et al.*, *J. Virol.* 68: 7525-7533 (1994); Reed *et al.*, (1995) *supra*]; (iv) studies on the NS4A serine proteinase cofactor and its association with NS3 [Lin *et al.*, (1994b) *supra*; Lin and Rice, (1995) *supra*; Lin *et al.*, (1995) *supra*]; and (v) an examination of HCV glycoprotein biogenesis including folding and association with calnexin, oligomer formation, and subcellular localization [Dubuisson *et al.*, (1994) *supra*; Dubuisson and Rice, (1996) *supra*]. Assays for other biologically important activities have been developed using the prototype HCV-H cDNA clones, including RNA-stimulated NTPase and RNA helicase activities associated with partially purified NS3 [Suzich *et al.*, (1993) *supra*] and an RNA-dependent RNA polymerase activity. Antigens expressed from this cloned cDNA can also be recognized by sera [see Ref. Grakoui *et al.*, (1993c) *supra*] and cytotoxic T lymphocytes [Battegay *et al.*, *J. Virol.* 69: 2462-2470 (1995); Koziel *et al.*, *J. Clin. Invest.* 96:2311-21 (1995)] from patients with chronic HCV infections.

For the present invention, the work on HCV polyprotein processing provided a means of prescreening candidate full-length clones for a functional IRES element, an intact ORF, and proper membrane topology and active viral proteinases as evidenced by the production of all 10 polyprotein cleavage products.

**EXAMPLE 2. First Attempt At Recovery of Functional HCV from cDNA**

**Plasmid constructions.** The preferred strategy for production of high specific infectivity potentially infectious HCV RNA transcripts [see Ahlquist *et al.*, *Proc. Natl. Acad. Sci. USA* 81: 7066-7070 (1984); Rice *et al.*, *New Biol.* 1: 285-296 (1989); Rice *et al.*, (1987) *supra* and refs. therein], involved cloning of candidate full-length HCV cDNAs immediately downstream from a bacteriophage promoter (SP6 or T7) with a unique restriction site following the HCV 3' terminus for production of run off RNA transcripts (Figure 4). The T7 or SP6 transcription systems were chosen for production of potentially infectious RNAs for several reasons. First, numerous examples exist for other RNA viruses where either T7 or SP6 have been successfully used to transcribe high yields of relatively high specific infectivity capped or uncapped RNA transcripts [Boyer and Haenni, *J. Gen. Virol.* 198: 415-426 (1994)]. In addition, the T7 system is particularly useful since it allows not only *in vitro* synthesis of defined RNAs for transfection, but also several *in vivo* approaches using transfection of plasmid DNA. One example is the vaccinia-T7 system where a vaccinia recombinant expressing the T7 RNA polymerase allows cytoplasmic transcription of transfected plasmid templates [Fuerst *et al.*, *Proc. Natl. Acad. Sci. USA* 83: 8122-8126 (1986)]. A second *in vivo* approach, obviating the need for vaccinia virus, is cotransfection of a plasmid expressing T7 RNA polymerase [Chen *et al.*, (1994) *supra*]. Transfection with HCV plasmid DNAs, designed for production of transcripts with defined 5' and 3' termini, might be advantageous given the susceptibility of long RNAs to degradation during transfection procedures [Ball, (1992) *supra*; Pattnaik *et al.*, (1992) *supra*]. However, these *in vivo* methods do not allow precise control over the structure of the transcribed RNA and their export to the cytoplasm where HCV RNA replication is believed to occur. Hence, the *in vitro* transcription method has usually employed in our work.

The sequenced prototype HCV-H cDNA clone used for the majority of the processing studies was the starting material for these constructions. Since the terminal sequences of the HCV-H genome RNA were unknown when these experiments were initiated, sequences reported for other isolates were used to engineer the 5' and 3' ends by PCR. For the first set of constructs tested (Figure 4), the additional 5' terminal sequence was derived from HCV-1 isolate [Han *et al.*, (1991) *supra*]. For the 3' NTR, plasmids with two alternative structures were constructed. One pair (SP6 or T7) contained the 3' NTR and terminal poly

(A) tract reported for HCV-1 by Han [Han *et al.*, (1991) *supra*]. A second pair was constructed using a consensus 3' NTR sequence for all other isolates followed by a 3' terminal poly (U) tract.

*Methods for assaying infectivity of HCV RNA.* A desirable method for initial identification of potentially functional clones would be to screen for RNA replication after transfection of permissive cell cultures. While several laboratories have reported infection and replication in various cell cultures (see Background of the Invention, *supra*, and below), these systems are extremely inefficient, poorly characterized, and difficult to reproduce. Factors precluding efficient replication *in vitro* are unknown but may involve one or multiple stages in the virus life cycle (attachment, entry, RNA replication, assembly or release). Furthermore, no one has shown that HCV produced in cell culture is "authentic", *e.g.*, capable of causing disease in the chimpanzee model. For these reasons, as well the technical difficulties associated with unambiguously demonstrating replication after RNA transfection, the chimpanzee model was used to identify functional clones from the library. Surgical procedures and direct intrahepatic inoculation were used, since this technique had been successful for demonstrating infectivity of rabbit hemorrhagic disease virus virion RNA [Ohlinger *et al.*, *J. Virol.* 64: 3331-3336 (1990)] and for hepatitis A virus RNA produced by *in vitro* transcription [Emerson *et al.*, *J. Virol.* 66: 6649-6654 (1992)].

#### Chimpanzee experiment I

Capped or uncapped full-length RNA transcripts were synthesized from each of the four linearized plasmid templates and assayed for infectivity by direct intrahepatic inoculation of chimpanzee liver using a percutaneous liver biopsy technique. Briefly, after RNA transcription, reactions were digested with DNase, extracted with phenol, and the RNAs collected by ethanol precipitation. The yield and integrity of each transcript RNA was determined by agarose gel electrophoresis under denaturing conditions. Equal amounts of each of the poly (U)- or poly (A)-containing transcripts (SP6, T7, capped, uncapped) were pooled and assayed separately in two animals. These animals had not previously been exposed to HCV or pooled blood products and were HCV antibody and RNA negative. For each animal, two injection sites were used. At one site, 200  $\mu$ g pooled RNA in 1 ml RNase-free PBS was injected. At the second site, 200  $\mu$ g pooled RNA mixed with 0.8 ml RNase-free PBS and 200  $\mu$ l LIPOFECTIN (BRL) was injected. Pre- and post-inoculation

plasma and liver biopsy samples were collected weekly. Plasma samples were assayed for ALT and GGTP (indicators of liver damage), for HCV-specific antibodies using available serological assays, and for evidence of circulating HCV RNA by RT/PCR. Besides histologic examination of liver biopsy tissue, samples were also stored for possible analysis by immunofluorescence and electron microscopy. Despite following the animals for 6 months, no evidence of productive HCV infection was found using any of these assays.

Using methods described more fully below, transcripts from these clones were also assayed for infectivity in several different cell types. In some cases, HCV antigens could be detected in transfected cells for several days; however, similar results were obtained using control HCV transcripts containing a deletion in the NS5B RDRP, which should be inactive for replication. Thus, no convincing evidence for replication was obtained in the first set of experiments.

### EXAMPLE 3. Second Attempt to Recover HCV from cDNA

*Possible reasons for failure of Attempt 1.* Several possible explanations, alone or in combination, could account for previous unsuccessful attempts to recover infectious HCV RNA from prototype HCV-H clones (pTET/HCVFLCMR). These include missing or incorrect terminal sequences, internal errors deleterious or lethal for HCV replication, or inadequate methods for assaying infectivity and replication. To address the first concern, the HCV-H 5' and 3' terminal sequences were rigorously determined. To increase the chances of recovering a full-length clone free of deleterious errors, high fidelity RT/PCR and assembly PCR was used to construct a new library of full-length HCV-H clones which included the new terminal sequences. Multiple clones from the library were tested for infectivity in the chimpanzee model.

*Rationale for rigorously determining the HCV-H termini.* As mentioned above, the 5' and 3' terminal sequences of HCV-H were unknown; the previous attempts (Example 2) to generate functional transcripts were from cDNA clones bearing terminal sequences determined for other HCV isolates. Study in other RNA virus systems has shown that specific terminal sequences are critical for the generation of functional, replication competent RNAs [reviewed in Boyer and Haenni, (1994) *supra*]. Such sequences are believed to be involved in initiation of negative- and positive-strand RNA synthesis. In some cases, a few additional bases, or even longer non-viral sequences, are tolerated at the



5' and 3' termini; these sequences are typically lost or selected against during authentic viral replication. For other RNA viruses, extra bases, particularly at the 5' terminus, are deleterious. In contrast, transcripts lacking authentic terminal sequences are usually non-functional. For instance, deletion of the 3' terminal secondary structure or conserved sequence elements in the 3' NTR of flavivirus genome RNA is lethal for YF or TBE RNA replication. Given the importance of these sequence elements for other viruses, we have attempted to more rigorously determine the HCV-H terminal sequences.

*Structure of the HCV-H 5' NTR.* Methods used to amplify and clone the extreme 5' termini of RNAs include homopolymer tailing or ligation of synthetic oligonucleotides to first-strand cDNA (5' RACE) [Schaefer, *Anal. Biochem.* 227: 255-273 (1995)], cyclization of first-strand cDNA followed by inverse PCR [Zeiner and Gehring, *BioTechniques* 17: 1051-1053 (1994)], or cyclization of genome RNA with RNA ligase (after treatment to remove 5' cap structures, if necessary) followed by cDNA synthesis and PCR amplification across the 5'-3' junction [Mandl *et al.*, *Biotechniques* 10: 486 (1991)]. Each of these approaches has its own set of problems, especially for rare RNAs. Despite this, 5' terminal sequences have been determined for a number of HCV isolates and are in general agreement. For HCV-H, both the cyclization/inverse PCR and 5' RACE methods were used to determine a 5'-terminal consensus sequence for HCV-H RNA from high titer H77 plasma (new data for HCV-H are shown in bold):

5'-GCCAGCCCCCTGATGGGGGCGACACTCCACCATGAATC...-3' (SEQ ID NO:3)

This sequence is highly homologous to those determined for other isolates, but differs from our prototype full-length cDNA sequence at two positions (underlined). At lower frequency, clones with additional 5' residues (usually 1 additional G) were also recovered. Table 1 summarizes the results of the 5' terminal analyses.

Table 1. Results of the 5' end analysis of the HCV H cDNA clones.

Number of Clones	5' end
18	GCCAGCC...
3*	NCCAGCC...
18*	NNCCAGCC...
9	GGCCAGCC...
3	TGCCAGCC...
1	AGCCAGCC...
2	AAGCCAGCC...
1	GCGCCAGCC...

\*Sequences were not determined; the number of nucleotides on the 5' end was determined by relative electrophoretic mobility of restriction fragments.

Eighteen clones began with the sequence 5'-GCCAGCC...-3'; nine clones with the sequence 5'-GGCCAGCC...-3'; three clones with the sequence 5'-UGCCAGCC...-3'; one clone with the sequence 5'-AGCCAGCC...-3'; two clones with the sequence 5'-AAGCCAGCC...-3'; and three clones with the sequence 5'-GCGCCAGCC...-3'. Besides these sequenced clones, eighteen clones with one additional 5' base were identified by restriction analysis. Of note is the observation that a sequence reported for a genotype 1b isolate initiates with a U residue (5'-UGCCA...-3'). Although these results might indicate the presence of additional sequences or heterogeneity at the HCV 5' terminus, the additional bases may be artifactual and created by partial copying of a 5' cap structure or addition of non-templated 3' bases by reverse transcriptase during first-strand cDNA synthesis. It cannot be excluded that the 5' terminus of HCV genome RNA contains a 5' cap structure or a covalently linked terminal protein such as VPg of the picornaviruses [Vartapetian and Bogdanov, *Prog Nucleic Acid Res Mol Biol* 34: 209-51 (1987)]. These possibilities will remain unresolved until it becomes possible to directly determine the structure of the 5' terminus of HCV genome RNA. For the pestiviruses, recent results suggest that genome RNAs may not contain a 5' cap [Brock *et al.*, *J. Virol. Meth.* 38: 39-46 (1992)] and that this structure is not required for infectivity of transcribed RNA [Meyers *et al.*, *J. Virol.* 70: 8606-8613 (1996a); Meyers *et al.*, *J Virol* 70: 1588-95 (1996b); Moormann *et al.*, *J Virol* 70: 763-70 (1996); Ruggli *et al.*, *J Virol* 70: 3478-87

(1996); Vassilev *et al.*, *J. Virol.* 71: 471-478 (1997)].

*Structure of the HCV-H 3' NTR.* Determination of the extreme 3' terminal HCV sequences is describe in co-pending, co-owned U.S. Patent Application Serial No. 08/520,678, filed August 29, 1995, which is incorporated herein by reference in its entirety, and PCT International Application No. PCT/US96/14033, filed August 28, 1996. Briefly, these results showed that the HCV 3' NTR consists of three elements (positive-sense, 5' to 3'): (i) a short sequence with significant variability among genotypes; (ii) a homopolymeric poly (U) tract followed by a polypyrimidine stretch consisting of mainly U with interspersed C residues and; (iii) a novel sequence of 98 bases. This novel 98-base sequence was not present in human genomic DNA and is highly conserved among HCV genotypes. The 3'-terminal 46 bases are predicted to form a stable stem-loop structure. Using a quantitative-competitive RT/PCR assay, a substantial fraction of HCV genome RNAs from a high specific-infectivity inoculum were found to contain this 3' terminal sequence element. These results indicated that the HCV genome RNA terminates with a highly conserved RNA element, which is likely to be required for authentic HCV replication and therefore, for recovery of infectious RNA from cDNA. These results have been confirmed by two other groups [Tanaka *et al.*, (1995) *supra*; Tanaka *et al.*, (1996) *supra*; Yamada *et al.*, (1996) *supra*]. A large number of clinical isolates have also been examined and shown to contain the novel conserved 3' terminal element [Umlauf *et al.*, *J. Clin. Invest.* 34: 2552-2558 (1996)].

*Recipient vector containing the HCV H77 5' and 3' consensus sequences.* Based on our analysis of the HCV H terminal sequences, a recipient vector was constructed that contained the determined consensus H77 sequences 5' to the *KpnI* (580) and 3' fo the *NotI* (9219) site (these terminal HCV sequences are identical to those in p90/HCVFlong pU, see below, SEQ ID NO:5). This vector is designated pTET/T7HCVΔBg1II/5'3' corr. and was used for construction of the combinatorial full-length library described below.

*Additional considerations for construction of full-length cDNA libraries for the HCV-H strain.* As for the previous attempt (Example 2), the strategy for the second try involved the construction of full-length cDNA templates in plasmid vectors that could be transcribed

*in vitro* or *in vivo* using bacteriophage DNA-dependent RNA polymerases. Besides having correct 5' and 3' termini, RNA transcripts must also encode a full complement of functional HCV polypeptides. To minimize the possibility of cloning defective HCV genomes, high specific infectivity HCV-H plasma (H77) was used as a source of virion RNA for our new libraries (as mentioned earlier, the previous clone was assembled from cDNA made from infected chimp liver RNA). However, reverse transcription and multiple cycles of amplification prior to cDNA cloning raised the chances that HCV cDNA templates would contain one or more mutations deleterious for virus replication. For these reasons, complex libraries of full-length clones were constructed using high fidelity assembly PCR and then screened in pools for production of infectious RNA.

*Construction of a new library of full-length HCV-H cDNA clones.* We screened 41 HCV primer pairs and found 11 sets useful for amplifying overlapping 1-4 kb portions of the genome RNA (Figure 5 and Tables 2 and 3).

Table 2. Oligonucleotides used for amplification of HCV-H cDNA.

Name	Sequence (5' to 3')	SEQ ID NO:	position in HCV-H and orientation
SF49	GGCGAACTCCACCATAGATC	6	(+) 18-38
SF128	TGGCACTACCCTCCAAGACC	7	(+) 1800-1819
SF162	ATGACACAAGGGGGCGCTCCG CACACT	8	(-) 2027-2053
SF131	TCCTGCTTGTGGATGATG	9	(+) 2538-2555
SF152	TAGTTTGGTGATGTCA	10	(-) 2999-3014
PCL10067	ACATAGGTGCCAGTAAG	11	(-) 3171-3188
PCL10066	CTGGCAACGTGCATCA	12	(+) 3549-3564
CMR115	GGGTGAGAACAATTACCA	13	(+) 4183-4200
CMR117	ATTGATGCCCAATGCG	14	(-) 4565-4580
SF140	ACTGCCTGGGATTCCCT	15	(+) 6347-6363
SF155	CCACAGTGGCAGCGAGTG	16	(-) 6419-6436
SF156	CATGGACGTCAACACG	17	(-) 6848-6863
SF1045	AATCTTCACCGTTGGGGAGG AGGTAGATG	18	(-) 9353-9391

Table 3. Fragments and primers used in original and assembly PCR.

Fragments in assembly	Primer pairs	Resulting fragment†	Position in start*	HCV genome end*
Original PCR	SF49, SF162	A	39	2026
Original PCR	SF128, SF152	B	1820	2998
Original PCR	SF128, PLC10067	C	1820	3170
Original PCR	SF131, CMR117	D	2556	4564
Original PCR	PCL10066, SF155	E	3565	6418
Original PCR	CMR115, SF156	F	4201	6847
Original PCR	SF140, SF1045	G	6364	9352
A+B	SF49, SF152	H	39	2998
A+C	SF49, PCL10067	J	39	3170
B+D	SF128, CMR117	L	1820	4564
J+L	SF49, CMR117	K	39	4564
F+G	CMR115, SF1045	M	4201	9352
E+G	PCL10066, SF1045	N	3565	9352
L+M	SF128, SF1045	O	1820	9352
H+O	SF49, SF1045	#2	39	9352
J+O	SF49, SF1045	#3	39	9352
K+N	SF49, SF1045	#5	39	9352
K+M	SF49, SF1045	#6	39	9352

\*excluding primer

† see Figure 5

A mixture of thermostable enzymes were used to reduce error frequency and enhance synthesis of full-length products [Barnes, *Proc. Natl. Acad. Sci. USA* 91: 2216-2220 (1994); Lundberg *et al.*, *Gene* 108: 1-6 (1991)]. Such intermediate PCR products were combined to produce full-length HCV cDNA using sequential rounds of assembly PCR [Mullis *et al.*, *Cold Spring Harbor Symp.* 51: 263-273 (1986); Stemmer, (1994) *supra*]. Assembly PCR utilized primers at the extreme termini of the two overlapping fragments to be combined and a limited number of amplification cycles (Figure 6). This approach has the advantage of generating complex combinatorial libraries which should contain some fraction of functional error-free HCV cDNA templates. A prime consideration for this approach is

making sure that the library contains sufficient complexity to assure that some clones will be error-free. For each of the initial amplification reactions, dilutions of the first-strand cDNA were tested (Figure 7) to show that multiple independent cDNA molecules were being amplified (greater than 7 to 100; indicated in Figure 5). As shown in Figure 7, the full-length library contained greater than  $5.6 \times 10^5$  ( $80 \times 7 \times 10 \times 10 \times 10$ ) different combinations. Possible deleterious mutations could have been introduced into half of the clones if the primer sequences chosen for PCR amplification and assembly were incorrect. However, it was later verified that no heterogeneity existed in the sequences corresponding to the primers used for PCR.

The majority of the HCV-H77 genome (from nucleotide 39-9352) was assembled and amplified in this manner and cloned as a *KpnI* (580)-*NotI* (9219) fragment into recipient plasmid (pTET/T7HCV $\Delta$ BglII5'3'corr.) to produce the full-length library. As described above, pTET/T7HCV $\Delta$ BglII5'3'corr. contains the T7 promoter, the consensus HCV-H 5' and 3'-terminal sequences 5' to the *KpnI* site and 3' from the *NotI* site, and a *HpaI* site for template linearization and production of run-off RNA transcripts. It should be noted that linearization with *HpaI* is predicted to produce run-off transcripts that contain one extra 3' U residue.

Clones from the library were chosen for infectivity assays based on two criteria. First, series of restriction digests were performed to eliminate clones that had obvious deletions or insertions in the HCV cDNA. Two hundred thirty-three clones were analyzed and clones passing this screen were then analyzed using the vaccinia-T7 transient expression system [see Grakoui *et al.*, (1993a) *supra*; Grakoui *et al.*, (1993c) *supra*] for production of the expected HCV polyprotein cleavage products. Full-length clones could be analyzed directly using this technique, since preliminary studies in BHK cells showed that the HCV IRES functions nearly as efficiently as the EMCV IRES for expression of HCV polypeptides. One hundred twenty-nine clones were screened using a polyclonal antiserum from a patient with chronic HCV (JHF; Grakoui *et al.*, 1993c); 49 clones were analyzed for production of NS5B, the C-terminal protein in the HCV-H ORF [Grakoui *et al.*, 1993a; Grakoui *et al.*, 1993c). Thirty-four clones passing these tests (expected restriction pattern; intact ORF and proper processing; NS5B production) were selected for *in vitro* transcription of potentially infectious RNA and infectivity analysis.

*Special conditions for transcription of full-length HCV RNA containing the internal poly (U/UC) tract and the 98-base element.* For T7-driven transcription, *in vitro* transcription conditions were optimized and showed that the resulting RNAs contain the extreme 3' terminal sequence. This was of special concern since the T7 RNA polymerase termination signals (a secondary structure followed by poly-U) resemble the HCV sequences preceding the 3' novel element and we observed termination at this site. In addition, the enzyme seemed to be prone to premature termination inside the poly (U/UC) tract. As shown in Figure 8A, by raising the UTP concentration to 3 mM in the transcription reaction, high yields of full-length HCV RNA transcripts were obtained. T7 polymerase was clearly better in this regard than SP6 polymerase, which exhibited significant premature termination in the poly (U) tract even at relatively high concentrations of UTP.

#### Chimpanzee experiment II

Essentially as described above (Example 2), surgical procedures and direct intrahepatic inoculation were used to assay the infectivity of transcribed RNAs. Three animals, not previously used for HCV work and negative for HCV serology and RNA, were inoculated. Each of two of the animals were injected with RNA transcripts from 17 independent clones, with inoculations at 34 separate sites in the liver. Two separate inoculations used for each transcript preparation were: 50-100  $\mu$ g RNA in PBS injected at one site and 1  $\mu$ g RNA mixed with 10  $\mu$ g lipofectin (a cationic liposome which enhances RNA transfection [see Rice *et al.*, (1989) *supra*] at a second site. This procedure was intended to maximize the chances of productive transfection for each clone/RNA preparation. As a negative control, a third animal (Chimp 1557) was similarly inoculated at 34 sites with transcripts (~1500  $\mu$ g) which contained a 21 residue in-frame deletion in NS5B encompassing the active site of the HCV RNA-dependent RNA polymerase (called  $\Delta$ GDD). Following inoculation, serum samples were collected (at weekly intervals) and analyzed for HCV RNA, elevation of liver transaminases, and HCV-specific antibody. Neither experimental animal nor the negative control animal ( $\Delta$ GDD) exhibited signs of productive infection (circulating HCV RNA, elevated liver enzymes, histopathology). Of note for future experiments was the complete absence of detectable circulating HCV RNA even as early as one week after inoculation.

#### EXAMPLE 4: Successful Recovery of Infectious HCV from cDNA

*Determination of the HCV-H consensus sequence.* Since the limited pool screening approach was unsuccessful, we determined a complete consensus sequence for the HCV-H



strain. Segments of these sequenced clones were used for directed assembly of full-length HCV-H clones having the consensus sequence. This procedure was expected to eliminate lethal mutations, which might have occurred during cDNA synthesis or PCR amplification, or which existed in the original HCV population. Accordingly, the consensus method had a strong chance of producing functional HCV.

Table 4. Sequence information used to determine an HCV-H consensus sequence

<u>Designation</u>	<u>Description</u>
HCV-H CMR	CMR prototype HCV-H cDNA clone; infected chimp liver RNA (SEQ ID NO:19)
HCV-H GenBank	HCV-H sequence
AAK#83	Combinatorial library clone #83; H77 serum
AAK#84	Combinatorial library clone #84; H77 serum
AAK#86	Combinatorial library clone #86; H77 serum
AAK#87	Combinatorial library clone #87; H77 serum
AAK#89	Combinatorial library clone #89; H77 serum
AAK#90	Combinatorial library clone #90; H77 serum
AAK#92	Combinatorial library clone #92; H77 serum
AAK#93	Combinatorial library clone #93; H77 serum
AAK#96	Combinatorial library clone #96; H77 serum
AAK#99	Combinatorial library clone #99; H77 serum
AAK#101	Combinatorial library clone #101; H77 serum
AAK#248	Combinatorial library clone #248; H77 serum
AAK#227	Combinatorial library clone #227; H77 serum
AAK#213	Combinatorial library clone #213; H77 serum

AAK#211	Combinatorial library clone #211; H77 serum
AAK#209	Combinatorial library clone #209; H77 serum
AAK#12	Combinatorial library clone #12; H77 serum

Complete sequences between the *KpnI* (580) and *NotI* (9219) sites in the HCV cDNA were determined for clones AAK#248, AAK#227, AAK#213, AAK#211, AAK#209, and AAK#12. Sequences for the prototype HCV-H CMR [Daemer *et al.*, *supra*; Grakoui *et al.*, (1993c) *supra*] and HCV-H GenBank [Inchauspe *et al.*, (1991) *supra*] had been determined previously. These sequences are aligned in Figure 9. Dots indicate positions identical to the HCV-H CMR sequence, shown at the bottom (SEQ ID NOS:19 and 20); dashes indicate gaps; the sequence "PCR seq" was determined by direct sequencing of PCR-amplified HCV-H77 cDNA. Sequences of additional clones from our combinatorial library (AAK#83, #84, #86, #87, #89, #90, #92, #93, #95, #96, #99, #101) were determined for the HVR1 hypervariable region in E2 (most were sequenced between nucleotides 1464-1823; see below). Inspection of the alignment reveals an HCV H77 consensus sequence (SEQ ID NO:1) at most positions. At some positions, however, no clear consensus sequence emerged. These variable positions were: 2170 (Gac versus Aac; variable base is indicated in upper case type), 3940 (gAg versus gGg), and 5560 (caA versus caT). In these cases, the sequence used in the consensus clone corresponded to the nucleotide yielding the amino acid found at that position for the majority of sequenced HCV isolates.

Regarding determination of a consensus sequence, additional areas of the HCV genome deserve further comment. First, the N-terminal portion of E2 is highly variable and believed to be the target of immune selection [Houghton, (1996) *supra*]. In the H77 sample, considerable variability exists in HVR1 [see Nakajima *et al.*, *J Virol* 70: 3325-9 (1996); Ogata *et al.*, (1991) *supra*]. Multiple independent clones from this region were sequenced and the predominant HVR1 sequence in each position was used in the consensus clones. The predominant sequence utilized differs in one position from that determined by others [Inchauspe *et al.*, (1991) *supra*; Nakajima *et al.*, (1996) *supra*; Ogata *et al.*, (1991) *supra*]. However, it is highly similar to that of the prototype HCV-H clone, which was derived from liver RNA isolated from an H77-inoculated chimpanzee. Hence, it seemed that this sequence would be tolerated for HCV replication in chimps. As shown below, this

sequence was functional but it is likely that many other HVR sequence variations will also be tolerated.

A second region of the HCV-H sequence, the length and composition of the 3' NTR poly (U/UC) tract, was not determined unambiguously. Sufficient quantities of double-stranded cDNA could not be obtained for direct cloning of this region without resorting to PCR amplification. PCR amplification can contract and possibly expand the length of this homopolymer tract. Thus, clones resulting from this procedure may not reflect the native HCV genome RNA structure. In multiple independent clones derived by PCR amplification, the length of this tract varied from 41 to 133 nucleotides (see Kolykhalov *et al.*, 1996 and Patent Application Serial No. 08/520,678). Hence, two different lengths of poly (U/UC) tract were tested: "short" (75 bases) or "long" (133 bases). The length of the "short" tract is actually about the medium length for all sequences (from different genotypes) reported by us [Kolykhalov *et al.*, (1996) *supra*] or others [Tanaka *et al.*, (1995) *supra*; Tanaka *et al.*, (1996) *supra*; Yamada *et al.*, (1996), *supra*]. The "long" tract was only recovered in one HCV-H clone (pGEM3Zf(-)HCV-H3'NTR#10); a tract of similar length was recovered in one clone of genotype 4 isolate WD [Kolykhalov *et al.*, (1996) *supra*]. Such long poly (U/UC) tracts have not yet been reported by others Tanaka *et al.*, (1995) *supra*; Tanaka *et al.*, (1996) *supra*; Yamada *et al.*, (1996) *supra*].

*Variations in 5'-terminal sequences, silent markers, length of 3' NTR poly (U/UC) tracts, and 3' run-off site.* Given that additional bases were found at the 5' end of some HCV cDNA clones and the uncertainty about the length of the poly (U/UC) tract, several alternative clones were created. Silent nucleotide substitutions were incorporated in the ORF to serve as markers for identifying which derivatives were functional in later analyses and to demonstrate that replicating virus was in fact recovered from the assembled cDNA clones. Replacing the previously used *HpaI* site, a *BsmI* site was created following the 3' end of the HCV cDNA to allow for production of run-off transcripts corresponding to the precise 3' end of HCV genome RNA. Details describing these constructions follow:

*Additional bases at the 5' terminus.* A recipient clone containing the most frequent 5' terminal sequence (5'-GCCA...-3') called pTET/T7HCVΔBglII/5'+3'corr. was modified by subcloning a *BssHII* (479) to *KpnI* (580) fragment from pTET/HCV5'T7G3'AFL, one of

the prototype HCV-H cDNA clones tested in chimpanzees, to create p67/HCV $\Delta$ BglII/5' + 3'/XhoI-. These clones differ by presence of a XhoI site at position 514 (pTET/T7HCV $\Delta$ BglII/5' + 3'corr.) or its absence (p67/HCV $\Delta$ BglII/5' + 3'/XhoI-). p67/HCV $\Delta$ BglII/5' + 3'/XhoI- was then used as the vector for construction of four derivatives with different 5' terminal sequences. These are:

Plasmid	5' sequence of T7 transcript	Marker (position)
p70/HCV $\Delta$ BglII/5' + 3'/XhoI-/GG	5'-GGCCA...-3'	XhoI- (514)
p71/HCV $\Delta$ BglII/5' + 3'/XhoI-/GAG	5'-GAGCCA...-3'	XhoI- (514)
p72/HCV $\Delta$ BglII/5' + 3'/XhoI-/GUG	5'-GUGCCA...-3'	XhoI- (514)
p73/HCV $\Delta$ BglII/5' + 3'/XhoI-/GCG	5'-GCGCCA...-3'	XhoI- (514)

These derivatives were constructed using appropriate synthetic oligonucleotides and PCR amplification and their structures verified by sequence analysis.

*Assembly of a clone containing the consensus sequence between KpnI (580) and NotI (9219).* A schematic of the assembly steps is shown in Figure 10. The 7 sequenced HCV-H clones were used to assemble a prototype consensus clone. The plasmid source, position in the HCV cDNA, and restriction sites used for assembly are summarized in Table 5.

Table 5. Clones, fragments, and restriction sites used for consensus clone construction.

Source of fragment number of clones	Position in HCV genome	Restriction sites used
313	580-1046	KpnI-Xho I
248	1046-1174	Xho I-PpuM I
12	1174-1357	PpuM I-BamH I
209	1357-1482	BamH I-Sal I
227	1482-1748	Sal I-PpuM I
209	1748-1908	PpuM I-Asc I
227	1908-2108	Asc I-BspE I
312	2108-2322	BspE I-Sst I
CMR	2322-2440	Sst I-Sca I

213	2440-2526	<i>Sca</i> I- <i>Bss</i> H II
CMR	2526-2828	<i>Bss</i> H II- <i>Hinf</i> I
211	2828-2978	<i>Hinf</i> I- <i>Bsr</i> G I
209	2978-3236	<i>Bsr</i> G I- <i>Bgl</i> II
227	3236-3478	<i>Bgl</i> II- <i>Bgl</i> I
209	3478-3733	<i>Bgl</i> I- <i>Sex</i> A I
12	3733-3942	<i>Sex</i> A I- <i>Bfa</i> I
211	3942-4069	<i>Bfa</i> I- <i>Spl</i> I
227	4069-4545	<i>Spl</i> I- <i>Sst</i> I
248	4545-4646	<i>Sst</i> I- <i>Sal</i> I
211	4646-4976	<i>Sal</i> I- <i>Sma</i> I
227	4976-5610	<i>Sma</i> I- <i>Xho</i> I
209	5610-5750	<i>Xho</i> I- <i>Eae</i> I
CMR	5750-6209	<i>Eae</i> I- <i>Bsu</i> 36 I
213	6209-6302	<i>Bsu</i> 36 I- <i>Blp</i> I
227	6302-7529	<i>Blp</i> I- <i>Blp</i> I- <i>Bam</i> H I
213	7529-9219	<i>Bam</i> H I- <i>Not</i> I
209	7861-8205	<i>Hind</i> III- <i>Eco</i> R I

The final step in the assembly involved subcloning the *Kpn*I-*Not*I consensus region into recipient vector pTET/T7HCV $\Delta$ BglII/5' + 3'corr to produce p61/HCVFLcons.

*Introduction of a BsmI substitution in the HCV cDNA and a BsmI run off site.* Since the previously used *Hpa*I run off site resulted in transcripts with an additional 3' terminal U residue which might be deleterious, clones were re-engineered so that transcripts terminating at the exact HCV 3' nucleotide could be synthesized. This was accomplished by positioning a *Bsm*I site at an appropriate position downstream from the HCV 3' terminus. Cleavage with *Bsm*I produces a template strand which terminates at the position corresponding to the HCV 3' terminus. Since the H77 consensus sequence contains a *Bsm*I site at position 5934, this site was inactivated with a translationally silent substitution engineered by site-directed mutagenesis.

The first step in this series of constructions was to inactivate the *BsmI* site in the HCV H77 cDNA. This clone, called p62/HCVFLcons/Bsm(-) was created in a four fragment ligation which included: (1) annealed synthetic oligos between *SacI* (5923) and *Sau3AI* (5942) which contained a silent substitution inactivating the *BsmI* site (C instead of A at position 5934); (2) *NsiI* (5282) to *SacI* (5923) fragment from p61/HCVFLcons; (3) *Sau3AI* (5942) to *Bsu36I* (6209) from p61/HCVFLcons; (4) *Bsu36I* (6209) and *NsiI* (5282) digested p61/HCVFLcons. p62/HCVFLcons/Bsm(-) was sequenced completely verifying the structure of the assembled consensus clone, the presence of a silent marker mutation at position 899 (C instead of T), the ablated *BsmI* site, and a silent marker mutation at position 8054 (see below).

Intermediate plasmid p65/3'HCVBsm(+)/Not-Mlu, containing the 3' *BsmI* run off site, was created by the following three fragment ligation: (1) annealed synthetic oligos between *Sau3AI* (9639) and *MluI* (9656) containing the *BsmI* site [5'-tgTgcattc-3' (SEQ ID NO:21)]; the nucleotides in bold indicate the *BsmI* site, the upper case nucleotide corresponds to the 3' terminal base of the HCV genome]; (2) *NotI* (9219) to *Sau3AI* (9639) fragment from p62/HCVFLcons/Bsm(-); (3) *MluI* (9656) to *NotI* (9219) from p61/HCVFLcons. Note that this clone contains both the internal *BsmI* site (5934) and the engineered *BsmI* run-off site.

The original consensus full-length clone, p61/HCVFLcons, contained a silent substitution in the NS5B coding region (A instead of G at position 8054). This substitution was used as a marker to distinguish between clones containing "short" poly (U/UC) tracts (these clones contain A at position 8054) or "long" poly (U/UC) tracts (with G at position 8054). p90/HCVFLlong pU (SEQ ID NO:5), containing long poly (U/UC) and G at position 8054, was constructed by ligation of four fragments: (1) *XbaI* (-20) to *HindIII* (7861) from p62/HCVFLcons/Bsm(-); (2) *HindIII* (7861) to *EcoRI* (8205) from library clone AAK#209 (Figure 9) containing the G residue at position 8054; *EcoRI* (8205) to *NotI* (9219) from p62/HCVFLcons/Bsm(-); *NotI* (9219) to *XbaI* (-20) from p65/3'HCVBsm(+)/Not-Mlu.

p91/HCVFLshort pU, a derivative containing the "short" poly (U/UC) tract and the silent marker A at position 8054, was created by ligation of the following fragments: (1) *BglI* (9398) to *NheI* (9520) from pGEM3Zf(-)HCV-H3'NTR#8; (2) *NheI* (9520) to *MluI* (9597)

from p65/3'HCVBsm(+)/Not-Mlu; *MluI* (9597) to *NotI* (9219) from p62/HCVFLcons/Bsm(-). Note that numbering for this construction refers to the final p91/HCVFLshort pU sequence.

To generate the final set of full-length constructs with long poly (U/UC) and additional nucleotides at the 5' terminus, the *KpnI* (580) to *MluI* (9656) fragment from p90/HCVFLlong pU was cloned into p70/HCVΔBglII/5' + 3'/XhoI-/GG, p71/HCVΔBglII/5' + 3'/XhoI-/GAG, p72/HCVΔBglII/5' + 3'/XhoI-/GUG, and p73/HCVΔBglII/5' + 3'/XhoI-/GCG to create p92/HCVFLlong pU/5'GG, p93/HCVFLlong pU/5'GAG, p94/HCVFLlong pU/5'GUG, p95/HCVFLlong pU/5'GCG, respectively.

To generate the analogous set of full-length constructs with short poly (U/UC), the *KpnI* (580) to *MluI* (9597) fragment from p91/HCVFLshort pU was cloned into p70/HCVΔBglII/5' + 3'/XhoI-/GG, p71/HCVΔBglII/5' + 3'/XhoI-/GAG, p72/HCVΔBglII/5' + 3'/XhoI-/GUG, and p73/HCVΔBglII/5' + 3'/XhoI-/GCG to create p96/HCVFLshort pU/5'GG, p97/HCVFLshort pU/5'GAG, p98/HCVFLshort pU/5'GUG, p99/HCVFLshort pU/5'GCG, respectively.

The salient features of these 10 clones [5' bases, silent markers, poly (U/UC) length] are summarized in Figure 11. Plasmids were propagated in *E. coli* (tet<sup>r</sup> SURE strain) and purified plasmid DNAs were prepared by standard methods, including twice banding on CsCl gradients [Ausubel *et al.*, Current protocols in molecular biology. eds. Greene Publishing Associates, New York (1993); Sambrook *et al.*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1989)].

**Transcription of full-length RNAs.** As mentioned above, increasing the UTP concentration to 3 mM in T7 transcription reactions increased the yield of full-length HCV RNAs, by facilitating readthrough of the poly (U/UC) tract. The skewed ratio of UTP (3 mM) to the other rNTPs (1 mM) could lead to increased misincorporation of U residues, in particular late in the transcription reaction when the other NTPs were substantially depleted. This concern was avoided by increasing the concentration of the other three NTPs to 3 mM. Purified plasmid DNAs were digested to completion with *BsmI*, extracted once with phenol-chloroform and precipitated with ethanol [Ausubel *et al.*, (1993) *supra*; Sambrook *et al.*,

(1989) *supra*]. DNA pellets were washed with EtOH to remove salts and resuspended in RNase-free H<sub>2</sub>O. Transcription reactions (100  $\mu$ l) contained the following components: 10  $\mu$ g *BsmI*-linearized template DNA, 40 mM Tris-Cl, pH 7.8, 16 mM MgCl<sub>2</sub>, 5 mM DTT, 10 mM NaCl, 3 mM each rNTP, 100 units T7 RNA polymerase, and 0.02 U inorganic pyrophosphatase. After a 1 hour incubation at 37°C, typical yields were approximately 300  $\mu$ g with greater than 80% full-length RNA as estimated by gel electrophoresis (Figure 8B).

### Chimpanzee experiment III

Transcripts from the ten consensus clones were used to inoculate two different animals, using essentially the same surgical procedures described above. Protocols were reviewed and approved by the FDA and NIH Animal Studies Committees. Animals were seronegative for all hepatitis viruses, negative for HCV RNA by nested RT-PCR, and had normal baseline levels of liver enzymes. Two different inoculation/transfection protocols were employed. For chimpanzee #1535, the 100  $\mu$ l transcription reactions were diluted with 400  $\mu$ l PBS and stored frozen at -80°C until used for inoculation. These storage conditions were tested and shown to have no observable effect on the integrity of HCV RNA transcripts. Prior to inoculation, samples were thawed and each sample was injected intrahepatically at two sites (~0.25 ml/site). Injection sites for the 10 clones were distributed in three lobes of the liver. As a positive control for this procedure, chimpanzee #1557 was inoculated similarly with RNA transcripts from two different hepatitis A virus clones. In this case, 80-100  $\mu$ g of transcribed RNA per clone was inoculated at two sites. A third animal, chimpanzee #1536, was inoculated with smaller amounts of RNA which had been mixed with lipofectin. In this case, the same transcript RNAs from the 10 full-length HCV-H77 clones were treated with DNaseI to remove template DNA and 0.15  $\mu$ g, 0.5  $\mu$ g, and 1.5  $\mu$ g portions were diluted to 50  $\mu$ l with PBS and stored at -80°C until used for inoculation. After thawing, 100  $\mu$ l PBS containing 9  $\mu$ g lipofectin (Besthesda Research Laboratory) was added to each sample, mixed, and injected into a single site. Hence, each clone/transcript preparation with different RNA/lipofectin ratios was injected at three separate sites.

Serum samples and liver biopsies were taken pre-inoculation and at weekly intervals thereafter. For nearly two months post-inoculation, samples have been assayed for liver enzymes (ALT, ICD, GGTP) hepatitis virus serology, and viremia by quantitative competitive RT-PCR [Kolykhalov *et al.*, (1996) *supra*].



*Evidence for successful initiation of infection and replication.* The results of our analyses thus far are summarized in Table 6.

Table 6. Results of chimpanzee experiment III.

Chimp 1535 (RNA-DNA IN PBS):						
week	ALT	ICD	GGTP	anti-HCV ab	HCV RNA bDNA (Meg/ml)	QC RT-PCR
-5	43	453	28	0.2	-	-
-2-3	32	325	27	0.1	-	-
-1	36	600	27	0.2	-	-
0	40	430	28	0.1	<0.2	<10 <sup>2</sup> /ml
1	42	490	24	0	0.445	1x10 <sup>5</sup> /ml
2	96C	1000	53	0	0.283	3x10 <sup>5</sup> /ml
3	81C	780	55	0	0.593	6x10 <sup>5</sup> /ml
4	78	640	52	0.2	2.026	1x10 <sup>6</sup> /ml
5	60	510	57	0.1	2.609	2x10 <sup>6</sup> /ml
6	49	670	50	0.1	3.286	T.B.D.
7	49	525	44	0	5.708	T.B.D.
8	56	485	50	.01	T.B.D.	T.B.D.
9	67	500	67	0.1	T.B.D.	T.B.D.
10	98	725	79	0.2	T.B.D.	T.B.D.
11	86	525	85	0.2	T.B.D.	T.B.D.

Chimp 1536 (RNA + lipofectin):						
week	ALT	ICD	GGTP	anti-HCV ab	HCB RNA bDNA (Meg/ml)	QC RT-PCR
-9	27	368	33	0.1	-	-
-5	45/4 5	524/49 6	82/77R	0.2	-	-

-2-3	28	375	52	0.1	-	-
-1	34	475	41	0.1	-	-
0	36	680	44	0.1	<0.2	<10 <sup>2</sup> /ml
1	45	660	42	0	<0.2	1x10 <sup>4</sup> /ml
2	44	875	51	0	0.252	3x10 <sup>5</sup> /ml
3	49	760	55	0	0.469	1x10 <sup>6</sup> /ml
4	41	465	52	0.2	0.862	2x10 <sup>6</sup> /ml
5	42	500	49	0.1	0.904	3x10 <sup>6</sup> /ml
6	50	730	60	0.00	1.489	6x10 <sup>6</sup> /ml
7	43	490	55	0.1	3.413	T.B.D.
8	53	700	64	0.1	13.00	T.B.D.
9	38	505	65	0.1	3.271	T.B.D.
10	133	1270	120	0.4	T.B.D.	T.B.D.
11	324	1485	258	1.3	T.B.D.	T.B.D.

Chimp 1557 (HAV RNA + DNA in PBS), positive control:				
week	ALT	ICD	GGTP	anti-HAV
0	33	405	19	(-)
1	42	360	14	(-)
2	33	345	16	0.6
3	26	520	14	0.7
4	62	1330	24	3.5
5	43	700	28	21.4
6	23	650	27	27.9
7	22	540	25	14.6
8	20	490	22	T.B.D.

R = repeated

C = confirmed

T.B.D. = to be determined

Chimp #1535 showed a peak in liver enzymes at week 2 post-inoculation, which has gradually declined to the pre-inoculation baseline. At week 10, a second peak of liver

enzymes was observed. HCV RNA titers were below our detection limit pre-inoculation ( $< 10^2$ ), increased to  $10^5$ /ml by week 1, and continued to climb steadily reaching  $2 \times 10^6$ /ml by week 5. This represents a 20-fold increase relative to week 1.

Chimp #1536 showed less evidence of early liver damage with only a minor peak in the ICD level at week 2 and fluctuating values thereafter. However, highly elevated levels of enzymes were observed in weeks 10 and 11. The animal also became HCV-seropositive on weeks 10 and 11. On week 1, the HCV RNA titer was  $10^4$ /ml and has climbed to  $6 \times 10^6$ /ml by week 6. This represents a 600-fold increase relative to week 1.

The positive control inoculated with HAV transcripts (chimpanzee #1557) showed a sharp peak in liver enzymes on week 4 and had clearly seroconverted by this time. HAV-specific immunoreactivity increased sharply on week 5 and continued at high levels thereafter. These results show clear evidence of HAV infection and validate the inoculation method used for chimpanzee #1535.

All of the samples analyzed for HCV RNA were also assayed for the presence of residual template DNA by omitting the enzyme in the reverse transcription step. No products were obtained, demonstrating that the signals detected in the quantitative competitive PCR assay were due to RNA (Figure 12). In addition, the HCV RNA containing material in these samples was resistant to RNase digestion under the same conditions that completely degraded naked competitor RNA mixed with serum being analyzed (Figure 13). These are the expected results if the RNAs are packaged into enveloped RNase-resistant virus particles, as opposed to residual inoculated RNA. Moreover, the total amount of transcript RNA used for inoculation was  $\sim 3000 \mu\text{g}$  for chimpanzee #1535 and only  $\sim 22 \mu\text{g}$  for chimpanzee #1536. In spite of being inoculated with  $\sim 150$ -fold less RNA, chimpanzee #1536 showed higher levels of viremia than chimpanzee #1535. Thus the level of viremia does not correlate with input RNA, which is again indicative of virus amplification and spread. Finally, in the previous negative experiment using the non-consensus combinatorial library clones and the  $\Delta\text{GDD}$  negative control (Example 3), 1000-2000  $\mu\text{g}$  of HCV-specific RNA were inoculated per animal using similar procedures. No HCV RNA was detected at week 1 or thereafter, again suggesting that signal observed here is due to authentic virus replication and release into the serum.

Proof that the infections observed in these animals stemmed from the inoculated transcript RNA was obtained by restriction enzyme and sequence analysis of recovered virus for the presence of engineered markers. Two silent mutations marked all of the transfected RNAs. These were the substitution at position 899 (C instead of T) and the substitution at position 5936 (C instead of A) ablating the internal *BsmI* site (5934). For the nucleotide 899 marker, the region between 466 to 950 was amplified by nested RT-PCR, sequenced directly, and shown to have the expected H77 sequence including the silent C (instead of T) marker at position 899. The region from 5801 to 6257 was also amplified by nested RT-PCR and shown to be resistant to digestion with *BsmI*. The expected digestion products were obtained, however, for four other enzymes cleaving in this region [*SstI* (5923); *BspHI* (5944); *Bsu36I* (6209); *RsaI* (6244)] of the H77 cDNA sequence. These analyses were conducted for both chimpanzee #1535 (week 5) and chimpanzee #1536 (week 6).

The pathogenesis profiles for the RNA-inoculated animals are reminiscent of those obtained in previous experiments in which chimpanzees were inoculated with the H77 material or other HCV-containing samples. The course of this disease in chimpanzees, like man, is highly variable with respect to the extent of liver damage, progression to chronicity, level of viremia, and timing of seroconversion.

*Identification of functional "infectious" clones by evaluating silent markers present in virus recovered from infected animals.* As detailed above, additional silent markers were incorporated in order to help identify the 5' terminal sequence(s) and the length(s) of poly (U/UC) tract which were required or preferred for initiating infection.

Transcripts containing a single G (5'-GCCA...-3') were distinguished from those with additional 5' residues by the presence of the *XhoI* (514) silent marker in the C protein coding region. The region containing this marker was amplified by RT-PCR under conditions that ensured that a representative number of independent cDNAs were analyzed (greater than 50 in this case). The resulting products were analyzed for digestion with either *XhoI* or as a control, *AccI*, an enzyme which should digest this fragment for all input clones. For chimpanzee #1535 (week 3 sample), the fraction of the products digested with *XhoI* paralleled the input inoculum: approximately 20% was digested with *XhoI* (both 4 U and 30 U); 80% was resistant to digestion (values were determined by scanning ethidium bromide-stained digestion patterns with an IC1000 Imaging System). Complete digestion

was observed for *AccI*. In the week 4 sample analyzed for chimpanzee #1536, 55% was digested with *XhoI*; 45% was resistant to digestion. Again, complete digestion was observed for *AccI*. Thus, in the second animal an advantage was observed for transcripts with only a single G (5'-GCCA...-3'). Although it is not possible to draw firm quantitative conclusions from these data regarding possible differences in specific infectivity, the results clearly demonstrate that the transcripts without additional nucleotides are infectious (clones p90/HCVFLlong pU and p91/HCVFLshort pU). Furthermore, transcripts with additional nucleotides can also initiate infection, although our analysis thus far does not allow us to distinguish among the various clones.

Transcripts containing "short" or "long" poly (U/UC) tracts were distinguished by the silent marker at position 8054 of the NS5B coding region. The region between 7955 and 8088 was amplified by RT-PCR, using enough cDNA to ensure the amplification of greater than 100 independent cDNA molecules, and molecularly cloned. Sequences of ten and nine independent clones were determined for chimpanzee #1535 (week 3) and chimpanzee #1536 (week 4), respectively. Nine of ten clones (90%) for chimpanzee #1535 contained the G at position 8054, indicative of the "long" poly (U/UC) tract. Six of nine clones (66%) for chimpanzee #1536 contained the G at position 8054, indicative of the "long" poly (U/UC) tract. The results demonstrate that transcripts containing either "short" or "long" poly (U/UC) tracts are infectious but that the "long" poly (U/UC) tract appears to be preferred. We can not, however, rule out the possibility that this effect is due to deleterious effects of the marker mutation at 8054. These additional analyses provide further confirmation that the viremia observed in these animals was initiated by transcripts derived from our full-length clones.

The functional genotype 1a cDNA clones described in this Example, or functional clones for other HCV genotypes (constructed and verified using similar methods), have a variety of applications for development of (i) more effective HCV therapies; (ii) HCV vaccines; (iii) HCV diagnostics; and (iv) HCV-based gene expression vectors.

#### EXAMPLE 5: Productive HCV Infection of a Hepatocyte Line

The *EcoRI*-*Bst*BI fragment from pCEN was cloned into the unique *Sfi*I site of p90/HCVFLlong pU. Prior to ligation, protruding termini were blunt ended using

T4 DNA polymerase in the presence of dNTPs. The *EcoRI-BstBI* fragment from pCEN contains the EMCV IRES element followed by the neomycin-resistance (NEO) coding region. This IRES NEO cassette is essentially identical to that described in Ghattas *et al.* [*Mol. Cell. Biol.* 11:5848 (1991)]. A clone containing this cassette in the correct orientation (positive-sense with respect to HCV genome RNA) was identified by digestion with appropriate restriction enzymes.

EMCV IRES NEO cassette was inserted into the *SfiI* site in the 3' NTR of p90/HCVFL long pU. This transcribed RNA was used to transfect a human hepatocyte cell line, which was then selected for neomycin resistance using G418. Most cells died, but a G418 population grew up over the course of a few months. Remarkably, HCV RNA appears to be still present in these cells at a copy number of ~1000 RNA molecules per cell. It is believed that the neomycin resistance is mediated by HCV RNA because there is no evidence for integration of contaminating template DNA in the genome of these cells.

The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and the accompanying figures. Such modifications are intended to fall within the scope of the appended claims.

It is further to be understood that all base sizes or amino acid sizes, and all molecular weight or molecular mass values, given for nucleic acids or polypeptides are approximate, and are provided for description.

Various publications are cited herein, the disclosures of which are incorporated by reference in their entireties.

148

Trp Phe Cys Leu Leu Leu Leu Ala Ala Gly Val Gly Ile Tyr Leu Leu  
2995 3000 3005

Pro Asn Arg  
3010

## (2) INFORMATION FOR SEQ ID NO:21:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

TGTCGCATTC

10

Ala Ala Arg Arg Ala Ala Gly Leu Gln Asp Cys Thr Met Leu Val Cys  
 2725 2730 2735

Gly Asp Asp Leu Val Val Ile Cys Glu Ser Ala Gly Val Gln Glu Asp  
 2740 2745 2750

Ala Ala Ser Leu Arg Ala Phe Thr Glu Ala Met Thr Arg Tyr Ser Ala  
 2755 2760 2765

Pro Pro Gly Asp Pro Pro Gln Pro Glu Tyr Asp Leu Glu Leu Ile Thr  
 2770 2775 2780

Ser Cys Ser Ser Asn Val Ser Val Ala His Asp Gly Ala Gly Lys Arg  
 2785 2790 2795 2800

Val Tyr Tyr Leu Thr Arg Asp Pro Thr Thr Pro Leu Ala Arg Ala Ala  
 2805 2810 2815

Trp Glu Thr Ala Arg His Thr Pro Val Asn Ser Trp Leu Gly Asn Ile  
 2820 2825 2830

Ile Met Phe Ala Pro Thr Leu Trp Ala Arg Met Ile Leu Met Thr His  
 2835 2840 2845

Phe Phe Ser Val Leu Ile Ala Arg Asp Gln Leu Glu Gln Ala Leu Asn  
 2850 2855 2860

Cys Glu Ile Tyr Ala Ala Cys Tyr Ser Ile Glu Pro Leu Asp Leu Pro  
 2865 2870 2875 2880

Pro Ile Ile Gln Arg Leu His Gly Leu Ser Ala Phe Leu Leu His Ser  
 2885 2890 2895

Tyr Ser Pro Gly Glu Val Asn Arg Val Ala Ala Cys Leu Arg Lys Leu  
 2900 2905 2910

Gly Val Pro Pro Leu Arg Ala Trp Arg His Arg Ala Arg Ser Val Arg  
 2915 2920 2925

Ala Arg Leu Leu Ser Arg Gly Gly Arg Ala Ala Ile Cys Gly Lys Tyr  
 2930 2935 2940

Leu Phe Asn Trp Ala Val Arg Thr Lys Leu Lys Leu Thr Pro Ile Ala  
 2945 2950 2955 2960

Ala Ala Gly Arg Leu Asp Leu Ser Gly Trp Phe Thr Ala Gly Tyr Ser  
 2965 2970 2975

Gly Gly Asp Ile Tyr His Ser Val Ser His Ala Arg Pro Arg Trp Phe  
 2980 2985 2990



Ser Leu Leu Arg His His Asn Leu Val Tyr Ser Thr Thr Ser Arg Ser  
 2450 2455 2460  
 Ala Cys Gln Arg Gln Lys Lys Val Thr Phe Asp Arg Leu Gln Val Leu  
 2465 2470 2475 2480  
 Asp Ser His Tyr Gln Asp Val Leu Lys Glu Val Lys Ala Ala Ala Ser  
 2485 2490 2495  
 Lys Val Lys Ala Asn Leu Leu Ser Val Glu Glu Ala Cys Ser Leu Thr  
 2500 2505 2510  
 Pro Pro His Ser Ala Lys Ser Lys Phe Gly Tyr Gly Ala Lys Asp Val  
 2515 2520 2525  
 Arg Cys His Ala Arg Lys Ala Val Ala His Ile Asn Ser Val Trp Lys  
 2530 2535 2540  
 Asp Leu Leu Glu Asp Ser Val Thr Pro Ile Asp Thr Ile Ile Met Ala  
 2545 2550 2555 2560  
 Lys Asn Glu Val Phe Cys Val Gln Pro Glu Lys Gly Gly Arg Lys Pro  
 2565 2570 2575  
 Ala Arg Leu Ile Val Phe Pro Asp Leu Gly Val Arg Val Cys Glu Lys  
 2580 2585 2590  
 Met Ala Leu Tyr Asp Val Val Ser Lys Leu Pro Leu Ala Val Met Gly  
 2595 2600 2605  
 Ser Ser Tyr Gly Phe Gln Tyr Ser Pro Gly Gln Arg Val Glu Phe Leu  
 2610 2615 2620  
 Val Gln Ala Trp Lys Ser Lys Lys Thr Pro Met Gly Phe Pro Tyr Asp  
 2625 2630 2635 2640  
 Thr Arg Cys Phe Asp Ser Thr Val Thr Glu Ser Asp Ile Arg Thr Glu  
 2645 2650 2655  
 Glu Ala Ile Tyr Gln Cys Cys Asp Leu Asp Pro Gln Ala Arg Val Ala  
 2660 2665 2670  
 Ile Lys Ser Leu Thr Glu Arg Leu Tyr Val Gly Gly Pro Leu Thr Asn  
 2675 2680 2685  
 Ser Arg Gly Glu Asn Cys Gly Tyr Arg Arg Cys Arg Ala Ser Gly Val  
 2690 2695 2700  
 Leu Thr Thr Ser Cys Gly Asn Thr Leu Thr Cys Tyr Ile Lys Ala Arg  
 2705 2710 2715 2720

145

Asp Pro Ser His Ile Thr Ala Glu Ala Ala Gly Arg Arg Leu Ala Arg  
 2180 2185 2190

Gly Ser Pro Pro Ser Met Ala Ser Ser Ser Ala Ser Gln Leu Ser Ala  
 2195 2200 2205

Pro Ser Leu Lys Ala Thr Cys Thr Ala Asn His Asp Ser Pro Asp Ala  
 2210 2215 2220

Glu Leu Ile Glu Ala Asn Leu Leu Trp Arg Gln Glu Met Gly Gly Asn  
 2225 2230 2235 2240

Ile Thr Arg Val Glu Ser Glu Asn Lys Val Val Ile Leu Asp Ser Phe  
 2245 2250 2255

Asp Pro Leu Val Ala Glu Glu Asp Glu Arg Glu Val Ser Val Pro Ala  
 2260 2265 2270

Glu Ile Leu Arg Lys Ser Arg Arg Phe Ala Arg Ala Leu Pro Val Trp  
 2275 2280 2285

Ala Arg Pro Asp Tyr Asn Pro Pro Leu Val Glu Thr Trp Lys Lys Pro  
 2290 2295 2300

Asp Tyr Glu Pro Pro Val Val His Gly Cys Pro Leu Pro Pro Pro Arg  
 2305 2310 2315 2320

Ser Pro Pro Val Pro Pro Pro Arg Lys Lys Arg Thr Val Val Leu Thr  
 2325 2330 2335

Glu Ser Thr Leu Pro Thr Ala Leu Ala Glu Leu Ala Thr Lys Ser Phe  
 2340 2345 2350

Gly Ser Ser Ser Thr Ser Gly Ile Thr Gly Asp Asn Met Thr Thr Ser  
 2355 2360 2365

Ser Glu Pro Ala Pro Ser Gly Cys Pro Pro Asp Ser Asp Val Glu Ser  
 2370 2375 2380

Tyr Ser Ser Met Pro Pro Leu Glu Gly Glu Pro Gly Asp Pro Asp Phe  
 2385 2390 2395 2400

Ser Asp Gly Ser Trp Ser Thr Val Ser Ser Gly Ala Asp Thr Glu Asp  
 2405 2410 2415

Val Val Cys Cys Ser Met Ser Tyr Thr Trp Thr Gly Ala Leu Val Thr  
 2420 2425 2430

Pro Cys Ala Ala Glu Glu Gln Lys Leu Pro Ile Asn Ala Leu Ser Asn  
 2435 2440 2445

His Val Gly Pro Gly Glu Gly Ala Val Gln Trp Met Asn Arg Leu Ile  
 1905 1910 1915 1920  
 Ala Phe Ala Ser Arg Gly Asn His Val Ser Pro Thr His Tyr Val Pro  
 1925 1930 1935  
 Glu Ser Asp Ala Ala Ala Arg Val Thr Ala Ile Leu Ser Ser Leu Thr  
 1940 1945 1950  
 Val Thr Gln Leu Leu Arg Arg Leu His Gln Trp Ile Ser Ser Glu Cys  
 1955 1960 1965  
 Thr Thr Pro Cys Ser Gly Ser Trp Leu Arg Asp Ile Trp Asp Trp Ile  
 1970 1975 1980  
 Cys Glu Val Leu Ser Asp Phe Lys Thr Trp Leu Lys Ala Lys Leu Met  
 1985 1990 1995 2000  
 Pro Gln Leu Pro Gly Ile Pro Phe Val Ser Cys Gln Arg Gly Tyr Arg  
 2005 2010 2015  
 Gly Val Trp Arg Gly Asp Gly Ile Met His Thr Arg Cys His Cys Gly  
 2020 2025 2030  
 Ala Glu Ile Thr Gly His Val Lys Asn Gly Thr Met Arg Ile Val Gly  
 2035 2040 2045  
 Pro Arg Thr Cys Arg Asn Met Trp Ser Gly Thr Phe Pro Ile Asn Ala  
 2050 2055 2060  
 Tyr Thr Thr Gly Pro Cys Thr Pro Leu Pro Ala Pro Asn Tyr Lys Phe  
 2065 2070 2075 2080  
 Ala Leu Trp Arg Val Ser Ala Glu Glu Tyr Val Glu Ile Arg Arg Val  
 2085 2090 2095  
 Gly Asp Phe His Tyr Val Ser Gly Met Thr Thr Asp Asn Leu Lys Cys  
 2100 2105 2110  
 Pro Cys Gln Ile Pro Ser Pro Glu Phe Phe Thr Glu Leu Asp Gly Val  
 2115 2120 2125  
 Arg Leu His Arg Phe Ala Pro Pro Cys Lys Pro Leu Leu Arg Glu Glu  
 2130 2135 2140  
 Val Ser Phe Arg Val Gly Leu His Glu Tyr Pro Val Gly Ser Gln Leu  
 2145 2150 2155 2160  
 Pro Cys Glu Pro Glu Pro Asp Val Ala Val Leu Thr Ser Met Leu Thr  
 2165 2170 2175

143

Asn Glu Val Thr Leu Thr His Pro Ile Thr Lys Tyr Ile Met Thr Cys		
1635	1640	1645
Met Ser Ala Asp Leu Glu Val Val Thr Ser Thr Trp Val Leu Val Gly		
1650	1655	1660
Gly Val Leu Ala Ala Leu Ala Ala Tyr Cys Leu Ser Thr Gly Cys Val		
1665	1670	1675 1680
Val Ile Val Gly Arg Ile Val Leu Ser Gly Lys Pro Ala Ile Ile Pro		
	1685	1690 1695
Asp Arg Glu Val Leu Tyr Gln Glu Phe Asp Glu Met Glu Glu Cys Ser		
	1700	1705 1710
Gln His Leu Pro Tyr Ile Glu Gln Gly Met Met Leu Ala Glu Gln Phe		
	1715	1720 1725
Lys Gln Lys Ala Leu Gly Leu Leu Gln Thr Ala Ser Arg His Ala Glu		
	1730	1735 1740
Val Ile Thr Pro Ala Val Gln Thr Asn Trp Gln Lys Leu Glu Val Phe		
	1745	1750 1755 1760
Trp Ala Lys His Met Trp Asn Phe Ile Ser Gly Ile Gln Tyr Leu Ala		
	1765	1770 1775
Gly Leu Ser Thr Leu Pro Gly Asn Pro Ala Ile Ala Ser Leu Met Ala		
	1780	1785 1790
Phe Thr Ala Ala Val Thr Ser Pro Leu Thr Thr Gly Gln Thr Leu Leu		
	1795	1800 1805
Phe Asn Ile Leu Gly Gly Trp Val Ala Ala Gln Leu Ala Ala Pro Gly		
	1810	1815 1820
Ala Ala Thr Ala Phe Val Gly Ala Gly Leu Ala Gly Ala Ala Ile Gly		
	1825	1830 1835 1840
Ser Val Gly Leu Gly Lys Val Leu Val Asp Ile Leu Ala Gly Tyr Gly		
	1845	1850 1855
Ala Gly Val Ala Gly Ala Leu Val Ala Phe Lys Ile Met Ser Gly Glu		
	1860	1865 1870
Val Pro Ser Thr Glu Asp Leu Val Asn Leu Leu Pro Ala Ile Leu Ser		
	1875	1880 1885
Pro Gly Ala Leu Val Val Gly Val Val Cys Ala Ala Ile Leu Arg Arg		
	1890	1895 1900

142

Asn Ile Glu Glu Val Ala Leu Ser Thr Thr Gly Glu Ile Pro Phe Tyr  
 1365 1370 1375

Gly Lys Ala Ile Pro Leu Glu Val Ile Lys Gly Gly Arg His Leu Ile  
 1380 1385 1390

Phe Cys His Ser Lys Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu Val  
 1395 1400 1405

Ala Leu Gly Ile Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val Ser  
 1410 1415 1420

Val Ile Pro Thr Asn Gly Asp Val Val Val Val Ser Thr Asp Ala Leu  
 1425 1430 1435 1440

Met Thr Gly Phe Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn Thr  
 1445 1450 1455

Cys Val Thr Gln Thr Val Asp Phe Ser Leu Asp Pro Thr Phe Thr Ile  
 1460 1465 1470

Glu Thr Thr Thr Leu Pro Gln Asp Ala Val Ser Arg Thr Gln Arg Arg  
 1475 1480 1485

Gly Arg Thr Gly Arg Gly Lys Pro Gly Ile Tyr Arg Phe Val Ala Pro  
 1490 1495 1500

Gly Glu Arg Pro Ser Gly Met Phe Asp Ser Ser Val Leu Cys Glu Cys  
 1505 1510 1515 1520

Tyr Asp Ala Gly Cys Ala Trp Tyr Glu Leu Met Pro Ala Glu Thr Thr  
 1525 1530 1535

Val Arg Leu Arg Ala Tyr Met Asn Thr Pro Gly Leu Pro Val Cys Gln  
 1540 1545 1550

Asp His Leu Glu Phe Trp Glu Gly Val Phe Thr Gly Leu Thr His Ile  
 1555 1560 1565

Asp Ala His Phe Leu Ser Gln Thr Lys Gln Ser Gly Glu Asn Phe Pro  
 1570 1575 1580

Tyr Leu Val Ala Tyr Gln Ala Thr Val Cys Ala Arg Ala Gln Ala Pro  
 1585 1590 1595 1600

Pro Pro Ser Trp Asp Gln Met Trp Lys Cys Leu Ile Arg Leu Lys Pro  
 1605 1610 1615

Thr Leu His Gly Pro Thr Pro Leu Leu Tyr Arg Leu Gly Ala Val Gln  
 1620 1625 1630

141

Thr Ile Ala Ser Pro Lys Gly Pro Val Ile Gln Met Tyr Thr Asn Val  
 1090 1095 1100

Asp Gln Asp Leu Val Gly Trp Pro Ala Pro Gln Gly Ser Arg Ser Leu  
 1105 1110 1115 1120

Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg His  
 1125 1130 1135

Ala Asp Val Ile Pro Val Arg Arg Arg Gly Asp Ser Arg Gly Ser Leu  
 1140 1145 1150

Leu Ser Pro Arg Pro Ile Ser Tyr Leu Lys Gly Ser Ser Gly Gly Pro  
 1155 1160 1165

Leu Leu Cys Pro Ala Gly His Ala Val Gly Leu Phe Arg Ala Ala Val  
 1170 1175 1180

Cys Thr Arg Gly Val Thr Lys Ala Val Asp Phe Ile Pro Val Glu Asn  
 1185 1190 1195 1200

Leu Glu Thr Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser Pro  
 1205 1210 1215

Pro Ala Val Pro Gln Ser Phe Gln Val Ala His Leu His Ala Pro Thr  
 1220 1225 1230

Gly Ser Gly Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Gln Gly  
 1235 1240 1245

Tyr Lys Val Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly Phe  
 1250 1255 1260

Gly Ala Tyr Met Ser Lys Ala His Gly Val Asp Pro Asn Ile Arg Thr  
 1265 1270 1275 1280

Gly Val Arg Thr Ile Thr Thr Gly Ser Pro Ile Thr Tyr Ser Thr Tyr  
 1285 1290 1295

Gly Lys Phe Leu Ala Asp Gly Gly Cys Ser Gly Gly Ala Tyr Asp Ile  
 1300 1305 1310

Ile Ile Cys Asp Glu Cys His Ser Thr Asp Ala Thr Ser Ile Leu Gly  
 1315 1320 1325

Ile Gly Thr Val Leu Asp Gln Ala Glu Thr Ala Gly Ala Arg Leu Val  
 1330 1335 1340

Val Leu Ala Thr Ala Thr Pro Pro Gly Ser Val Thr Val Ser His Pro  
 1345 1350 1355 1360

140

Ser Cys Gly Gly Val Val Leu Val Gly Leu Met Ala Leu Thr Leu Ser  
 820 825 830

Pro Tyr Tyr Lys Arg Tyr Ile Ser Trp Cys Met Trp Trp Leu Gln Tyr  
 835 840 845

Phe Leu Thr Arg Val Glu Ala Gln Leu His Val Trp Val Pro Pro Leu  
 850 855 860

Asn Val Arg Gly Gly Arg Asp Ala Val Ile Leu Leu Met Cys Val Val  
 865 870 875 880

His Pro Thr Leu Val Phe Asp Ile Thr Lys Leu Leu Leu Ala Ile Phe  
 885 890 895

Gly Pro Leu Trp Ile Leu Gln Ala Ser Leu Leu Lys Val Pro Tyr Phe  
 900 905 910

Val Arg Val Gln Gly Leu Leu Arg Ile Cys Ala Leu Ala Arg Lys Ile  
 915 920 925

Ala Gly Gly His Tyr Val Gln Met Ala Ile Ile Lys Leu Gly Ala Leu  
 930 935 940

Thr Gly Thr Tyr Val Tyr Asn His Leu Thr Pro Leu Arg Asp Trp Ala  
 945 950 955 960

His Asn Gly Leu Arg Asp Leu Ala Val Ala Val Glu Pro Val Val Phe  
 965 970 975

Ser Arg Met Glu Thr Lys Leu Ile Thr Trp Gly Ala Asp Thr Ala Ala  
 980 985 990

Cys Gly Asp Ile Ile Asn Gly Leu Pro Val Ser Ala Arg Arg Gly Gln  
 995 1000 1005

Glu Ile Leu Leu Gly Pro Ala Asp Gly Met Val Ser Lys Gly Trp Arg  
 1010 1015 1020

Leu Leu Ala Pro Ile Thr Ala Tyr Ala Gln Gln Thr Arg Gly Leu Leu  
 1025 1030 1035 1040

Gly Cys Ile Ile Thr Ser Leu Thr Gly Arg Asp Lys Asn Gln Val Glu  
 1045 1050 1055

Gly Glu Val Gln Ile Val Ser Thr Ala Thr Gln Thr Phe Leu Ala Thr  
 1060 1065 1070

Cys Ile Asn Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Thr Arg  
 1075 1080 1085

139

Pro Leu Gly Asn Trp Phe Gly Cys Thr Trp Met Asn Ser Thr Gly Phe  
 545 550 555 560  
 Thr Lys Val Cys Gly Ala Pro Pro Cys Val Ile Gly Gly Val Gly Asn  
 565 570 575  
 Asn Thr Leu Leu Cys Pro Thr Asp Cys Phe Arg Lys His Pro Glu Ala  
 580 585 590  
 Thr Tyr Ser Arg Cys Gly Ser Gly Pro Trp Ile Thr Pro Arg Cys Met  
 595 600 605  
 Val Asp Tyr Pro Tyr Arg Leu Trp His Tyr Pro Cys Thr Ile Asn Tyr  
 610 615 620  
 Thr Ile Phe Lys Val Arg Met Tyr Val Gly Gly Val Glu His Arg Leu  
 625 630 635 640  
 Glu Ala Ala Cys Asn Trp Thr Arg Gly Glu Arg Cys Asp Leu Glu Asp  
 645 650 655  
 Arg Asp Arg Ser Glu Leu Ser Pro Leu Leu Leu Ser Thr Thr Gln Trp  
 660 665 670  
 Gln Val Leu Pro Cys Ser Phe Thr Thr Leu Pro Ala Leu Ser Thr Gly  
 675 680 685  
 Leu Ile His Leu His Gln Asn Ile Val Asp Val Gln Tyr Leu Tyr Gly  
 690 695 700  
 Val Gly Ser Ser Ile Ala Ser Trp Ala Ile Lys Trp Glu Tyr Val Val  
 705 710 715 720  
 Leu Leu Phe Leu Leu Leu Ala Asp Ala Arg Val Cys Ser Cys Leu Trp  
 725 730 735  
 Met Met Leu Leu Ile Ser Gln Ala Glu Ala Ala Leu Glu Asn Leu Val  
 740 745 750  
 Ile Leu Asn Ala Ala Ser Leu Ala Gly Thr His Gly Leu Val Ser Phe  
 755 760 765  
 Leu Val Phe Phe Cys Phe Ala Trp Tyr Leu Lys Gly Arg Trp Val Pro  
 770 775 780  
 Gly Ala Val Tyr Ala Phe Tyr Gly Met Trp Pro Leu Leu Leu Leu Leu  
 785 790 795 800  
 Leu Ala Leu Pro Gln Arg Ala Tyr Ala Leu Asp Thr Glu Val Ala Ala  
 805 810 815



138

Ser Ala Leu Tyr Val Gly Asp Leu Cys Gly Ser Val Phe Leu Val Gly  
 275 280 285

Gln Leu Phe Thr Phe Ser Pro Arg Arg His Trp Thr Thr Gln Ser Cys  
 290 295 300

Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His Arg Met Ala Trp  
 305 310 315 320

Asp Met Met Met Asn Trp Ser Pro Thr Ala Ala Leu Val Val Ala Gln  
 325 330 335

Leu Leu Arg Ile Pro Gln Ala Ile Met Asp Met Ile Ala Gly Ala His  
 340 345 350

Trp Gly Val Leu Ala Gly Ile Ala Tyr Phe Ser Met Val Gly Asn Trp  
 355 360 365

Ala Lys Val Leu Val Val Leu Leu Leu Phe Ala Gly Val Asp Ala Glu  
 370 375 380

Thr His Val Thr Gly Gly Ser Ala Gly His Thr Thr Ala Gly Leu Val  
 385 390 395 400

Gly Leu Leu Thr Pro Gly Ala Lys Gln Asn Ile Gln Leu Ile Asn Thr  
 405 410 415

Asn Gly Ser Trp His Ile Asn Ser Thr Ala Leu Asn Cys Asn Asp Ser  
 420 425 430

Leu Thr Thr Gly Trp Leu Ala Gly Leu Phe Tyr Arg His Lys Phe Asn  
 435 440 445

Ser Ser Gly Cys Pro Glu Arg Leu Ala Ser Cys Arg Arg Leu Thr Asp  
 450 455 460

Phe Ala Gln Gly Trp Gly Pro Ile Ser Tyr Ala Asn Gly Ser Gly Leu  
 465 470 475 480

Asp Glu Arg Pro Tyr Cys Trp His Tyr Pro Pro Arg Pro Cys Gly Ile  
 485 490 495

Val Pro Ala Lys Ser Val Cys Gly Pro Val Tyr Cys Phe Thr Pro Ser  
 500 505 510

Pro Val Val Val Gly Thr Thr Asp Arg Ser Gly Ala Pro Thr Tyr Ser  
 515 520 525

Trp Gly Ala Asn Asp Thr Asp Val Phe Val Leu Asn Asn Thr Arg Pro  
 530 535 540

137

Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn  
 1 5 10 15  
 Arg Arg Pro Gln Asp Val Glu Phe Pro Gly Gly Gly Gln Ile Val Gly  
 20 25 30  
 Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala  
 35 40 45  
 Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro  
 50 55 60  
 Ile Pro Lys Ala Arg Arg Pro Glu Gly Arg Thr Trp Ala Gln Pro Gly  
 65 70 75 80  
 Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Cys Gly Trp Ala Gly Trp  
 85 90 95  
 Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Thr Asp Pro  
 100 105 110  
 Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys  
 115 120 125  
 Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu  
 130 135 140  
 Gly Gly Ala Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp  
 145 150 155 160  
 Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile  
 165 170 175  
 Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Tyr  
 180 185 190  
 Gln Val Arg Asn Ser Ser Gly Leu Tyr His Val Thr Asn Asp Cys Pro  
 195 200 205  
 Asn Ser Ser Ile Val Tyr Glu Ala Ala Asp Ala Ile Leu His Thr Pro  
 210 215 220  
 Gly Cys Val Pro Cys Val Arg Glu Gly Asn Ala Ser Arg Cys Trp Val  
 225 230 235 240  
 Ala Val Thr Pro Thr Val Ala Thr Arg Asp Gly Lys Leu Pro Thr Thr  
 245 250 255  
 Gln Leu Arg Arg His Ile Asp Leu Leu Val Gly Ser Ala Thr Leu Cys  
 260 265 270

CTAGCTGTGG TAACACCCCTC ACTTGCTACA TCAAGGCCCG GGCAGCCCGT CGAGCCGCAG	8520
GGCTCCAGGA CTGCACCATG CTCGTGTGTG GCGACGACTT AGTCGTTATC TGTGAAAGTG	8580
CGGGGGTCCA GGAGGACGCG GCGAGCCTGA GAGCCTTTAC GGAGGCTATG ACCAGGTACT	8640
CCGCCCCCCC CGGGGACCCC CCACAACCAG AATACGACTT GGAGCTTATA ACATCATGCT	8700
CCTCCAACGT GTCAGTCGCC CACGACGGCG CTGGAAAAAG GGTCTACTAC CTTACCCGTG	8760
ACCCTACAAC CCCCTCGCG AGAGCCGCGT GGGAGACAGC AAGACACACT CCAGTCAATT	8820
CCTGGCTAGG CAACATAATC ATGTTTGCCC CCACACTGTG GGCGAGGATG ATACTGATGA	8880
CCCATTTCTT TAGCGTCCTC ATAGCCAGGG ATCAGCTTGA ACAGGCTCTT AACTGTGAGA	8940
TCTACGCAGC CTGCTACTCC ATAGAACCAC TGGATCTACC TCCAATCATT CAAAGACTCC	9000
ATGGCCTCAG CGCATTTTTA CTCCACAGTT ACTCTCCAGG TGAAGTCAAT AGGGTGGCCG	9060
CATGCCTCAG AAAACTTGGG GTCCCGCCCT TGCGAGCTTG GAGACACCGG GCCCGGAGCG	9120
TCCGCGCTAG GCTTCTGTCC AGGGGAGGCA GGGCTGCCAT ATGTGGCAAG TACCTCTTCA	9180
ACTGGGCAGT AAGAACAAAG CTCAAACCTCA CTCCAATAGC GGCCGCTGGC CGGCTGGACT	9240
TGTCCGGTTG GTTCACGGCT GGCTACAGCG GGGGAGACAT TTATCACAGC GTGTCTCATG	9300
CCCGGCCCCG CTGGTTCTGG TTTTGCTTAC TCCTGCTCGC TGCAGGGGTA GGCATCTACC	9360
TCCTCCCCAA CCGGTGAAGA TTGGGCTAAC CACTCCAGGC CAATAGGCCA TCCCCT	9416

## (2) INFORMATION FOR SEQ ID NO:20:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 3011 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (iii) HYPOTHETICAL: NO

## (v) FRAGMENT TYPE: N-terminal

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

GGAGAAGGTT GGCAGAGAGG TCACCCCTT CTATGGCCAG CTCCTCGGCC AGCCAGCTGT	6960
CCGCTCCATC TCTCAAGGCA ACTTGACCG CCAACCATGA CCCCCCTGAC GCCGAGCTCA	7020
TAGAGGCTAA CCTCCTGTGG AGGCAGGAGA TGGGCGGCAA CATCACCAGG GTTGAGTCAG	7080
AGAACAAAGT GGTGATTCTG GACTCCTTCG ATCCGCTTGT GGCAGAGGAG GATGAGCGGG	7140
AGGTCTCCGT ACCCGCAGAA ATTCTGCGGA AGTCTCGGAG ATTCGCCCCG GCCCTGCCCC	7200
TTTGGGCGCG GCCGACTAC AACCCCCGC TAGTAGAGAC GTGGAAAAAG CCTGACTACG	7260
AACCACCTGT GGTCCATGGC TGCCCGCTAC CACCTCCACG GTCCCTCCT GTGCCTCCGC	7320
CTCGGAAAAA GCGTACGGTG GTCCTACCG AATCAACCCT ACCTACTGCC TTGGCCGAGC	7380
TTGCCACCAA AAGTTTTGGC AGCTCCTCAA CTTCCGGCAT TACGGGCGAC AATATGACAA	7440
CATCCTCTGA GCCCGCCCCT TCTGGCTGCC CCCCCGACTC CGACGTTGAG TCCTATTCTT	7500
CCATGCCCCC CCTGGAGGGG GAGCCTGGGG ATCCGGATTT CAGCGACGGG TCATGGTCGA	7560
CGGTCAGTAG TGGGGCCGAC ACGBAAGATG TCGTGTGCTG CTCAATGTCT TATACCTGGA	7620
CAGGCGCACT CGTCACCCCG TCGCTGCGG AAGAACAAA ACTGCCCATC AACGCACTGA	7680
GCAACTCGTT GCTACGCCAT CACAATCTGG TATATCCAC CACTTCACGC AGTGCTTGCC	7740
AAAGGCAGAA GAAAGTCACA TTTGACAGAC TGCAAGTTCT GGACAGCCAT TACCAGGACG	7800
TGCTCAAGGA GGTCAAAGCA GCGGCGTCAA AAGTGAAGGC TAACTTGCTA TCCGTAGAGG	7860
AAGCTTGCA GCTGACGCC CCACATTCAG CCAAATCCAA GTTTGGCTAT GGGGCAAAAG	7920
ACGTCCGTTG CCATGCCAGA AAGGCCGTAG CCCACATCAA CTCCGTGTGG AAAGACCTTC	7980
TGGAAGACAG TGTAACACCA ATAGACACTA TCATCATGGC CAAGAACGAG GTCTTCTGCG	8040
TTCAGCCTGA GAAGGGGGT CGTAAGCCAG CTCGTCTCAT CGTGTTCCCC GACCTGGGCG	8100
TGCGCGTGTG CGAGAAGATG GCCCTGTACG ACGTGGTTAG CAAACTCCCC CTGGCCGTGA	8160
TGGGAAGCTC CTACGGATTC CAATACTCAC CAGGACAGCG GGTGAATTC CTCGTGCAAG	8220
CGTGGAAGTC CAAGAAGACC CCGATGGGGT TCCCGTATGA TACCGCTGT TTTGACTCCA	8280
CAGTCACTGA GAGCGACATC CGTACGGAGG AGGCAATTTA CCAATGTTGT GACCTGGACC	8340
CCCAAGCCCG CGTGGCCATC AAGTCCCTCA CTGAGAGGCT TTATGTTGGG GGCCCTCTTA	8400
CCAATTCAAG GGGGAAAAC TCGGCTATC GCAGGTGCCG CGCGAGCGGC GTACTGACAA	8460

TGGCTGCTCT GGCCGCGTAT TGCCTGTCAA CAGGCTGCGT GGTCATAGTG GGCAGGATTG 5400  
TCTTGTCGGG GAAGCCGGCA ATTATACCTG ACAGGGAGGT TCTCTACCAG GAGTTCGATG 5460  
AGATGGAAGA GTGCTCTCAG CACTTACCGT ACATCGAGCA AGGGATGATG CTCGCTGAGC 5520  
AGTTCAAGCA GAAGGCCCTC GGCCTCCTGC AGACCGCGTC CCGCCATGCA GAGGTTATCA 5580  
CCCCTGCTGT CCAGACCAAC TGGCAGAAAC TCGAGGTCTT CTGGGCGAAG CACATGTGGA 5640  
ATTTCATCAG TGGGATACAA TATTGGCGG GCCTGTCAAC GCTGCCTGGT AACCCCGCCA 5700  
TTGCTTCATT GATGGCTTTT ACAGCTGCCG TCACCAGCCC ACTAACCCT GGCCAAACCC 5760  
TCCTCTTCAA CATATTGGGG GGGTGGGTGG CTGCCCAGCT CGCCGCCCCC GGTGCCGCTA 5820  
CCGCCTTTGT GGGCGCTGGC TTAGCTGGCG CCGCCATCGG CAGCGTTGGA CTGGGGAAGG 5880  
TCCTCGTGGA CATTCTTGCA GGGTATGGCG CGGGCGTGCG GGGAGCTCTT GTAGCATTCA 5940  
AGATCATGAG CGGTGAGGTC CCCTCCACGG AGGACCTGGT CAATCTGCTG CCCGCCATCC 6000  
TCTCGCCTGG AGCCCTTGTA GTCGGTGTGG TCTGCGCAGC AATACTGCGC CGGCACGTTG 6060  
GCCCCGGCGA GGGGGCAGTG CAATGGATGA ACCGGCTAAT AGCCTTCGCC TCCCGGGGGA 6120  
ACCATGTTTC CCCCACGCAC TACGTGCCGG AGAGCGATGC AGCCGCCCCG GTCATGCCA 6180  
TACTCAGCAG CCTCACTGTA ACCCAGCTCC TGAGGCGACT ACATCAGTGG ATAAGCTCGG 6240  
AGTGTAACAC TCCATGCTCC GGCTCCTGGC TAAGGGACAT CTGGGACTGG ATATGCGAGG 6300  
TGCTGAGCGA CTTTAAGACC TGGCTGAAAG CCAAGCTCAT GCCACAAC TG CCTGGGATTG 6360  
CCTTTGTGTC CTGCCAGCGC GGGTATAGGG GGGTCTGGCG AGGAGACGGC ATTATGCACA 6420  
CTCGCTGCCA CTGTGGAGCT GAGATCACTG GACATGTCAA AAACGGGACG ATGAGGATCG 6480  
TCGGTCCTAG GACCTGCAGG AACATGTGGA GTGGGACGTT CCCCATTAAC GCCTACACCA 6540  
CGGGCCCCCTG TACTCCCCTT CCTGCGCCGA ACTATAAGTT CGCGCTGTGG AGGGTGTCTG 6600  
CAGAGGAATA CGTGGAGATA AGGCGGGTGG GGGACTTCCA CTACGTATCG GGTATGACTA 6660  
CTGACAATCT TAAATGCCCC TGCCAGATCC CATCGCCCGA ATTTTTCACA GAATTGGACG 6720  
GGGTGCGCCT ACATAGGTTT GCGCCCCCTT GCAAGCCCTT GCTGCGGGAG GAGGTATCAT 6780  
TCAGAGTAGG ACTCCACGAG TACCCGGTGG GGTGCAATT ACCTTGCGAG CCCGAACCGG 6840  
ACGTAGCCGT GTTGACGTCC ATGCTCACTG ATCCCTCCCA TATAACAGCA GAGGCGGCCG 6900

ATAGCAGGGG TAGCCTGCTT TCGCCCCGGC CCATTTTCCTA CCTAAAAGGC TCCTCGGGGG	3840
GTCCGCTGTT GTGCCCCGCG GGACACGCCG TGGGCCTATT CAGGGCCGCG GTGTGCACCC	3900
GTGGAGTGAC CAAGGCGGTG GACTTTATCC CTGTGGAGAA CCTAGAGACA ACCATGAGAT	3960
CCCCGGTGTT CACGGACAAC TCCTCTCCAC CAGCAGTGCC CCAGAGCTTC CAGGTGGCCC	4020
ACCTGCATGC TCCCACCGGC AGTGGTAAGA GCACCAAGGT CCCGGCTGCG TACGCAGCCC	4080
AGGGCTACAA GGTGTTGGTG CTCAACCCCT CTGTTGCTGC AACGCTGGGC TTTGGTGCTT	4140
ACATGTCCAA GGCCCATGGG GTCGATCCTA ATATCAGGAC CGGGGTGAGA ACAATTACCA	4200
CTGGCAGCCC CATCACGTAC TCCACCTACG GCAAGTTCCT TGCCGACGGC GGGTGCTCAG	4260
GAGGCGCTTA TGACATAATA ATTTGTGACG AGTGCCACTC CACGGATGCC ACATCCATCT	4320
TGGGCATCGG CACTGTCCTT GACCAAGCAG AGACTGCGGG GGCGAGATTG GTTGTGCTCG	4380
CCACTGCTAC CCCTCCGGGC TCCGTCACTG TGTCCCATCC TAACATCGAG GAGGTTGCTC	4440
TGTCCACCAC CGGAGAGATC CCTTTCTACG GCAAGGCTAT CCCCTCGAG GTGATCAAGG	4500
GGGGAAGACA TCTCATCTTC TGTCACTCAA AGAAGAAGTG CGACGAGCTC GCCGCGAAGC	4560
TGGTCGCATT GGGCATCAAT GCCGTGGCCT ACTACCGCGG ACTTGACGTG TCTGTCATCC	4620
CGACCAACGG CGATGTTGTC GTCGTGTCGA CCGATGCTCT CATGACTGGC TTTACCGGCG	4680
ACTTCGACTC TGTGATAGAC TGCAACACGT GTGTCACTCA GACAGTCGAT TTCAGCCTTG	4740
ACCCTACCTT TACCATTGAG ACAACCACGC TCCCCAGGA TGCTGTCTCC AGGACTCAGC	4800
GCCGGGGCAG GACTGGCAGG GGGAAAGCCAG GCATCTACAG ATTTGTGGCA CCGGGGGAGC	4860
GCCCCCTCCG CATGTTGAC TCGTCCGTCC TCTGTGAGTG CTATGACGCG GGCTGTGCTT	4920
GGTATGAGCT CATGCCCCGCC GAGACTACAG TTAGGCTACG AGCGTACATG AACACCCCGG	4980
GGCTTCCCGT GTGCCAGGAC CATCTTGAAT TTTGGGAGGG CGTCTTTACG GGCCTCACCC	5040
ATATAGATGC CCACTTTCTA TCCCAGACAA AGCAGAGTGG GGAGAACTTT CCTTACCTGG	5100
TAGCGTACCA AGCCACCGTG TGCGCTAGGG CTCAAGCCCC TCCCCATCG TGGGACCAGA	5160
TGTGGAAGTG TTTGATCCGC CTTAAACCCA CCCTCCATGG GCCAACACCC CTGCTATACA	5220
GACTGGGCGC TGTTCAGAAT GAAGTCACCC TGACGCACCC AATCACCAA TACATCATGA	5280
CATGCATGTC GGCCGACCTG GAGGTCGTCA CGAGCACCTG GGTGCTCGTT GGCGGCGTCC	5340

TCAAAGTCAG GATGTACGTG GGAGGGGTCG AGCACAGGCT GGAAGCGGCC TGCAACTGGA 2280  
 CGCGGGGCGA ACGCTGTGAT CTGGAAGACA GGGACAGGTC CGAGCTCAGC CCATTGCTGC 2340  
 TGTCCACCAC ACAGTGGCAG GTCCTTCCGT GTTCTTTTAC GACCCGTGCCA GCCTTGTCCA 2400  
 CCGGCCTCAT CCACCTCCAC CAGAACATTG TGGACGTGCA GTACTTGTA GGGGTGGGGT 2460  
 CAAGCATCGC GTCCTGGGCC ATTAAGTGGG AGTACGTCGT TCTCCTGTTC CTTCTGCTTG 2520  
 CAGACGCGCG CGTCTGCTCC TGCTTGTGGA TGATGTTACT CATATCCCAA GCGGAGGCGG 2580  
 CTTTGAGAGAA CCTCGTAATA CTCAATGCAG CATCCCTGGC CGGGACGCAC GGTCTTGTGT 2640  
 CCTTCTCGT GTTCTTCTGC TTTGCGTGGT ATCTGAAGGG TAGGTGGGTG CCCGGAGCGG 2700  
 TCTACGCCTT CTACGGGATG TGGCCTCTCC TCCTGCTCCT GCTGGCGTTG CCTCAGCGGG 2760  
 CATA CGCACT GGACACGGAG GTGGCCGCGT CGTGTGGCGG CGTTGTTCTT GTCGGGTAA 2820  
 TGGCGCTGAC TCTGTACCA TATTACAAGC GCTATATCAG CTGGTGCATG TGGTGGCTTC 2880  
 AGTATTTTCT GACCAGAGTA GAAGCGCAAC TGCACGTGTG GGTCCCCC CTCAACGTCC 2940  
 GGGGGGGGCG CGATGCCGTC ATCTTACTCA TGTGTGTTGT ACACCCGACT CTGGTATTTG 3000  
 ACATCACCAA ACTACTCCTG GCCATCTTCG GACCCCTTTG GATTCTTCAA GCCAGTTTGC 3060  
 TTAAAGTCCC CTACTTCGTG CGCGTTCAAG GCCTTCTCCG GATCTGCGCG CTAGCGCGGA 3120  
 AGATAGCCGG AGGTCATTAC GTGCAAATGG CCATCATCAA GTTGGGGGCG CTTACTGGCA 3180  
 CCTATGTGTA TAACCATCTC ACCCCTCTTC GAGACTGGGC GCACAACGGC CTGCGAGATC 3240  
 TGGCCGTGGC TGTGGAACCA GTCGTCTTCT CCCGAATGGA GACCAAGCTC ATCACGTGGG 3300  
 GGGCAGATAC CGCCGCGTGC GGTGACATCA TCAACGGCTT GCCCGTCTCT GCCCGTAGGG 3360  
 GCCAGGAGAT ACTGCTTGGA CCAGCCGACG GAATGGTCTC CAAGGGGTGG AGGTTGCTGG 3420  
 CGCCCATCAC GCGGTACGCC CAGCAGACGA GAGGCCTCCT AGGGTGTATA ATCACCAGCC 3480  
 TGA CTGGCCG GGACAAAAC CAAGTGGAGG GTGAGGTCCA GATCGTGTC ACTGCTACCC 3540  
 AAACCTTCCT GGCAACGTGC ATCAATGGGG TATGCTGGAC TGTCTACCAC GGGGCCGGAA 3600  
 CGAGGACCAT CGCATACCC AAGGGTCCTG TCATCCAGAT GTATACCAAT GTGGACCAAG 3660  
 ACCTTGTGGG CTGGCCCGCT CCTCAAGGTT CCCGCTCATT GACACCCTGC ACCTGCGGCT 3720  
 CCTCGGACCT TTACCTGGTT ACGAGGCACG CCGACGTCAT TCCCGTGCGC CGGCGAGGTG 3780

GGGGCCCCAC AGACCCCCGG CGTAGGTCGC GCAATTTGGG TAAGGTCATC GATACCCTTA	720
CGTGCGGCTT CGCCGACCTC ATGGGGTACA TACCGCTCGT CGGCGCCCCT CTTGGAGGCG	780
CTGCCAGGGC CCTGGCGCAT GCGGTCCGGG TTCTGGAAGA CGGCGTGAAC TATGCAACAG	840
GGAACCTTCC TGGTTGCTCT TTCTCTATCT TCCTTCTGGC CCTGCTCTCT TGCCTGACTG	900
TGCCCCGCTC AGCCTACCAA GTGCGCAATT CCTCGGGGCT TTACCATGTC ACCAATGATT	960
GCCCTAATTC GAGTATTGTG TACGAGGCGG CCGATGCCAT CCTGCACACT CCGGGGTGTG	1020
TCCCTTGCGT TCGCGAGGGT AACGCCTCGA GGTGTTGGGT GCGGTGACC CCCACGGTGG	1080
CCACCAGGGA CGGCAAATC CCCACAACGC AGCTTCGACG TCATATCGAT CTGCTTGTCG	1140
GGAGCGCCAC CCTCTGCTCA GCCCTCTACG TGGGGGACCT GTGCGGGTCT GTTTTTCTTG	1200
TTGGTCAACT GTTTACCTTC TCTCCCAGGC GCCACTGGAC GACGCAAAGC TGCAATTGTT	1260
CTATCTATCC CGGCCATATA ACGGGTCATC GCATGGCATG GGATATGATG ATGAACTGGT	1320
CCCCTACGGC AGCGTTGGTG GTAGCTCAGC TGCTCCGGAT CCCACAAGCC ATCATGGACA	1380
TGATCGCTGG TGCTCACTGG GGAGTCCTGG CGGGCATAGC GTATTTCTCC ATGGTGGGGA	1440
ACTGGGCGAA GGTCTGGTA GTGCTGCTGC TATTTGCCGG CGTCGACGCG GAAACCCACG	1500
TCACCGGGGG AAGTGCCGGC CACACCACGG CTGGGCTTGT TGGTCTCCTT ACACCAGGCG	1560
CCAAGCAGAA CATCCAATG ATCAACACCA ACGGCAGTTG GCACATCAAT AGCACGGCCT	1620
TGAACTGCAA CGATAGCCTT ACCACCGGCT GGTTAGCAGG GCTCTTCTAT CGCCACAAAT	1680
TCAACTCTTC AGGCTGTCCT GAGAGGTTGG CCAGCTGCCG ACGCCTTACC GATTTTGCCC	1740
AGGGCTGGGG TCCCATCAGT TATGCCAACG GAAGCGGCCT TGACGAACGC CCCTACTGTT	1800
GGCACTACCC TCCAAGACCT TGTGGCATTG TGCCCGCAAA GAGCGTGTGT GGCCCGGTAT	1860
ATTGCTTCAC TCCAGCCCC GTGGTGGTGG GAACGACCGA CAGGTCGGGC GCGCCTACCT	1920
ACAGCTGGGG TGCAAATGAT ACGGATGTCT TCGTCCTTAA CAACACCAGG CCACCGCTGG	1980
GCAATTGGTT CGGTTGTACC TGGATGAACT CAACTGGATT CACCAAAGTG TGCGGAGCGC	2040
CCCCTTGTT CATCGGAGGG GTGGGCAACA ACACCTTGCT CTGCCCCACT GATTGCTTCC	2100
GCAAACATCC GGAAGCCACA TACTCTCGGT GCGGCTCCGG TCCCTGGATT ACACCCAGGT	2160
GCATGGTCGA CTACCCGTAT AGGCTTTGGC ACTATCCTTG TACTATCAAT TACACCATAT	2220



(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

AATCTTCACC GGTGGGGAG GAGGTAGATG

30

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 9416 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

GCCAGCC	CCC TGATGGGGG	GCACTCCAC	CATAGATCAC	TCCCCTGTGA	GGAACACTG	60
TCTTCACGCA	GAAAGCGTCT	AGCCATGGCG	TTAGTATGAG	TGTCGTGCAG	CCTCCAGGAC	120
CCCCCTCCC	GGGAGAGCCA	TAGTGGTCTG	CGGAACCGGT	GAGTACACCG	GAATTGCCAG	180
GACGACCGGG	TCCTTTCTTG	GATAAACCCG	CTCAATGCCT	GGAGATTTGG	GCGTGCCCCC	240
GCAAGACTGC	TAGCCGAGTA	GTGTTGGGTC	GCGAAAGGCC	TTGTGGTACT	GCCTGATAGG	300
GTGCTTGCGA	GTGCCCCGGG	AGGTCTCGTA	GACCGTGCAC	CATGAGCACG	AATCCTAAAC	360
CTCAAAGAAA	AACCAAACGT	AACACCAACC	GTCGCCACAC	GGACGTCGAG	TTCCCGGGTG	420
GCGGTCAGAT	CGTTGGTGGA	GTTTACTTGT	TGCCGCGCAG	GGGCCCTAGA	TTGGGTGTGC	480
GCGCGACGAG	GAAGACTTCC	GAGCGGTCGC	AACCTCGTGG	TAGACGTCAG	CCTATCCCCA	540
AGGCACGTCG	GCCCCAGGGC	AGGACCTGGG	CTCAGCCCGG	GTACCCTTGG	CCCCTCTATG	600
GCAATGAGGG	TTGCGGGTGG	GCGGGATGGC	TCCTGTCTCC	CCGTGGCTCT	CGGCCTAGCT	660

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

ACTGCCTGGG ATTCCCT

17

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

CCACAGTGGC AGCGAGTG

18

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

CATGGACGTC AACACG

16

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double

128

CTGGCAACGT GCATCA

16 \_

## (2) INFORMATION FOR SEQ ID NO:13:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 18 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: double
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

GGGTGAGAAC AATTACCA

18

## (2) INFORMATION FOR SEQ ID NO:14:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 16 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: double
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

ATTGATGCCC AATGCG

16

## (2) INFORMATION FOR SEQ ID NO:15:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 17 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: double
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

127

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

TAGTTTGGTG ATGTCA

16

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 17 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

ACATAGGTGC CAGTAAG

17

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

126

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

TGGCACTACC CTCCAAGACC

20

(2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 27 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: double
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

ATGACACAAG GGGGCGCTCC GCACACT

27

(2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 18 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: double
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

TCCTGCTTGT GGATGATG

18

(2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 16 base pairs

125

CTGGAAGCTC CCTCGTGCGC TCTCCTGTTC CGACCCTGCC GCTTACCGGA TACCTGTCCG	12420
CCTTTCTCCC TTCGGGAAGC GTGGCGCTTT CTCATAGCTC ACGCTGTAGG TATCTCAGTT	12480
CGGTGTAGGT CGTTGCTCC AAGCTGGGCT GTGTGCACGA ACCCCCCGTT CAGCCCGACC	12540
GCTGCGCCTT ATCCGGTAAC TATCGTCTTG AGTCCAACCC GGTAAGACAC GACTTATCGC	12600
CACTGGCAGC AGCCACTGGT AACAGGATTA GCAGAGCGAG STATGTAGGC GGTGCTACAG	12660
AGTTCTTGAA GTGGTGGCCT AACTACGGCT AACTAGAAG GACAGTATT GGTATCTGCG	12720
CTCTGCTGAA GCCAGTTACC TTCGGAAAAA GAGTTGGTAG CTCTTGATCC GGCAAACAA	12780
CCACCGCTGG TAGCGGTGGT TTTTGTGTTT GCAAGCAGCA GATTACGCGC AGAAAAAAG	12840
GATCTCAAGA AGATCCTTTG ATCTTTTCTA CGGGGTCTGA CGCTCAGTGG AACGAAACT	12900
CACGTTAAGG GATTTTGGTC ATGAGATTAT CAAAAGGAT CTTCACCTAG ATCCTTTTCT	12960
AGATAATACG ACTCACTATA	12980

## (2) INFORMATION FOR SEQ ID NO:6:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA (genomic)

## (iii) HYPOTHETICAL: NO

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

GGCGACACTC CACCATAGAT C

21

## (2) INFORMATION FOR SEQ ID NO:7:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA (genomic)

ACCATCAGGG ACAGCTTCAA GGATCGCTCG CGGCTCTTAC CAGCCTAACT TCGATCACTG	10860
GACCGTCTGAT CGTCACGGCG ATTTATGCCG CCTCGGCGAG CACATGGAAC GGGTTGGCAT	10920
GGATTGTAGG CGCCGCCCTA TACCTTGTCT GCCTCCCCGC GTTGCGTCGC GGTGCATGGA	10980
GCCGGGCCAC CTCGACCTGA ATGGAAGCCG GCGGCACCTC GCTAACGGAT TCACCACTCC	11040
AAGAATTGGA GCCAATCAAT TCTTGCGGAG AACTGTGAAT GCGCAAACCA ACCCTTGGA	11100
GAACATATCC ATCGCGTCCG CCATCTCCAG CAGCCGCACG CGGCGCATCT CGGGCAGCGT	11160
TGGGTCTTGG CCACGGGTGC GCATGATCGT GCTCCTGTCTG TTGAGGACCC GGCTAGGCTG	11220
GCGGGGTGTC CTTACTGGTT AGCAGAATGA ATCACCATA CGCGAGCGAA CGTGAAGCGA	11280
CTGCTGCTGC AAAACGTCTG CGACCTGAGC AACAACATGA ATGGTCTTCG GTTCCGTGT	11340
TTCGTAAAGT CTGGAACGC GGAAGTCAGC GCCCTGCACC ATTATGTTCC GGATCTGCAT	11400
CGCAGGATGC TGCTGGCTAC CCTGTGGAAC ACCTACATCT GTATTAACGA AGCGCTGGCA	11460
TTGACCCTGA GTGATTTTTC TCTGGTCCCG CCGCATCCAT ACCGCCAGTT GTTTACCCTC	11520
ACAACGTTCC AGTAACCGGG CATGTTTCATC ATCAGTAACC CGTATCGTGA GCATCCTCTC	11580
TCGTTTCATC GGTATCATTA CCCCCATGAA CAGAAATTC CCCTTACACG GAGGCATCAA	11640
GTGACCAAAC AGGAAAAAAC CGCCCTTAAC ATGGCCCGCT TTATCAGAAG CCAGACATTA	11700
ACGCTTCTGG AGAAACTCAA CGAGCTGGAC GCGGATGAAC AGGCAGACAT CTGTGAATCG	11760
CTTCACGACC ACGCTGATGA GCTTTACCGC AGCTGCCTCG CGCGTTTCGG TGATGACGGT	11820
GAAAACCTCT GACACATGCA GCTCCCGGAG ACGGTCACAG CTTGTCTGTA AGCGGATGCC	11880
GGGAGCAGAC AAGCCCGTCA GGGCGCGTCA GCGGGTGTTG GCGGGTGTCG GGGCGCAGCC	11940
ATGACCCAGT CACGTAGCGA TAGCGGAGTG TATACTGGCT TAACTATGCG GCATCAGAGC	12000
AGATTGTACT GAGAGTGCAC CATATGCGGT GTGAAATACC GCACAGATGC GTAAGGAGAA	12060
AATACCGCAT CAGGCGCTCT TCCGCTTCCT CGCTCACTGA CTCGCTGCGC TCGGTCGTTT	12120
GGCTGCGGCG AGCGGTATCA GCTCACTCAA AGGCGGTAAT ACGGTTATCC ACAGAATCAG	12180
GGGATAACGC AGGAAAGAAC ATGTGAGCAA AAGGCCAGCA AAAGGCCAGG AACCGTAAAA	12240
AGGCCGCGTT GCTGGCGTTT TTCCATAGGC TCCGCCCCC TGACGAGCAT CACAAAAATC	12300
GACGCTCAAG TCAGAGGTGG CGAAACCCGA CAGGACTATA AAGATACCAG GCGTTTCCCC	12360

TGTCGGTTG GTTCACGGCT GGCTACAGCG GGGGAGACAT TTATCACAGC GTGTCTCATG	9300
CCCGCCCCCG CTGGTTCTGG TTTTGCCTAC TCCTGCTCGC TGCAGGGGTA GGCATCTACC	9360
TCCTCCCCAA CCGATGAAGG TTGGGGTAAA CACTCCGGCC TCTTAGGCCA TTTCTGTTT	9420
TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT CTTTTTTTTT	9480
TTTTTTTTTCC TTTTTTTTTT TTTTTTTTTT CTTTCCTTCT TTTTTCCTTT CTTTTCCTTC	9540
CTTCTTTAAT GGTGGCTCCA TCTTAGCCCT AGTCACGGCT AGCTGTGAAA GGTCCGTGAG	9600
CCGCATGACT GCAGAGAGTG CTGATACTGG CCTCTCTGCA GATCATGTCTG CATTCACGCG	9660
TTCGAATTAA TTAAC TAGTG GGAATACGCG GGGTATGCCG CGTTTTAGCA TATTGACGAC	9720
CCAATTCTCA TGTTTGACAG CTTATCATCG ATAAGCTTTA ATGCGGTAGT TTATCACAGT	9780
TAAATTGCTA ACGCAGTCAG GCACCGTGTA TGAAATCTAA CAATGCGCTC ATCGTCATCC	9840
TCGGCACCGT CACCCTGGAT GCTGTAGGCA TAGGCTTGGT TATGCCGGTA CTGCCGGGCC	9900
TCTTGCGGGA TATCGTCCAT TCCGACAGCA TCGCCAGTCA CTATGGCGTG CTGCTAGCGC	9960
TATATGCGTT GATGCAATTT CTATGCGCAC CCGTTCTCGG AGCACTGTCC GACCGCTTTG	10020
GCCGCCGCC AGTCCTGCTC GCTTCGCTAC TTGGAGCCAC TATCGACTAC GCGATCATGG	10080
CGACCACACC CGTCCTGTGG ATCCTCTACG CCGGACGCAT CGTGGCCGGC ATCACCGGCG	10140
CCACAGGTGC GGTGCTGGC GCCTATATCG CCGACATCAC CGATGGGGAA GATCGGGCTC	10200
GCCACTTCGG GTCATGAGC GCTTGTTTCG GCGTGGGTAT GGTGGCAGGC CCCGTGGCCG	10260
GGGGA CTGTT GGGCGCCATC TCCTTGCATG CACCATTCTT TGCGGCGGCG GTGCTCAACG	10320
GCCTCAACCT ACTACTGGGC TGCTTCCTAA TGCAGGAGTC GCATAAGGGA GAGCGTCGAC	10380
CGATGCCCTT GAGAGCCTTC AACCAGTCA GCTCCTTCCG GTGGGCGCGG GGCATGACTA	10440
TCGTCGCCGC ACTTATGACT GTCTTCTTTA TCATGCAACT CGTAGGACAG GTGCCGGCAG	10500
CGCTCTGGGT CATTTTCGGC GAGGACCGCT TTCGCTGGAG CGCGACGATG ATCGGCCTGT	10560
CGCTTGCGGT ATTCGGAATC TTGCACGCCC TCGCTCAAGC CTTCTGCTACT GTTCCCGCCA	10620
CCAAACGTTT CGGCGAGAAG CAGGCCATTA TCGCCGSCAT GCGGCGCGAC GCGCTGGGCT	10680
ACGTCTTGCT GCGTTTCGCG ACGCGAGGCT GGATGGCCTT CCCCATTATG ATTCTTCTCG	10740
CTTCCGGCGG CATCGGGATG CCCGCGTTGC AGGCCATGCT GTCCAGGCAG GTAGATGACG	10800



GCAACTCGTT GCTACGCCAT CACAATCTGG TGTATTCCAC CACTTCACGC AGTGCTTGCC	7740
AAAGGCAGAA GAAAGTCACA TTTGACAGAC TGCAAGTTCT GGACAGCCAT TACCAGGACG	7800
TGCTCAAGGA GGTCAAAGCA GCGGCGTCAA AAGTGAAGGC TAACTTGCTA TCCGTAGAGG	7860
AAGCTTGACAG CCTGACGCCC CCACATTGAG CCAAATCCAA GTTTGGCTAT GGGGCAAAAG	7920
ACGTCCGTTG CCATGCCAGA AAGGCCGTAG CCCACATCAA CTCCGTGTGG AAAGACCTTC	7980
TGGAAGACAG TGTAACACCA ATAGACACTA CCATCATGGC CAAGAACGAG GTTTTCTGCG	8040
TTGAGCCTGA GAAGGGGGGT CGTAAGCCAG CTCGTCTCAT CGTGTTCCCC GACCTGGGCG	8100
TGCGCGTGTG CGAGAAGATG GCCCTGTACG ACGTGGTTAG CAAGCTCCCC CTGGCCGTGA	8160
TGGGAAGCTC CTACGGATTC CAATACTCAC CAGGACAGCG GGTGAATTC CTCGTGCAAG	8220
CGTGGAAGTC CAAGAAGACC CCGATGGGGT TCTCGTATGA TACCCGCTGT TTTGACTCCA	8280
CAGTCACTGA GAGCGACATC CGTACGGAGG AGGCAATTTA CCAATGTTGT GACCTGGACC	8340
CCCAAGCCCC CGTGGCCATC AAGTCCCTCA CTGAGAGGCT TTATGTTGGG GGCCCTCTTA	8400
CCAATTCAAG GGGGGAAC TGCGGCTACC GCAGGTGCCG CGCGAGCGGC GTACTGACAA	8460
CTAGCTGTGG TAACACCCTC ACTTGCTACA TCAAGGCCCC GGCAGCCTGT CGAGCCGAG	8520
GGCTCCAGGA CTGCACCATG CTCGTGTGTG GCGACGACTT AGTCGTTATC TGTGAAAGTG	8580
CGGGGGTCCA GGAGGACGCG GCGAGCCTGA GAGCCTTCAC GGAGGCTATG ACCAGGTACT	8640
CCGCCCCCCC CGGGGACCCC CCACAACCAG AATACGACTT GGAGCTTATA ACATCATGCT	8700
CCTCCAACGT GTCAGTCGCC CACGACGGCG CTGGAAGAG GGTCTACTAC CTTACCCGTG	8760
ACCCTACAAC CCCCTCGCG AGAGCCGCGT GGGAGACAGC AAGACACACT CCAGTCAATT	8820
CCTGGCTAGG CAACATAATC ATGTTTGCCC CCACACTGTG GGCAGGATG ATACTGATGA	8880
CCCATTCTTT TAGCGTCCTC ATAGCCAGG ATCAGCTTGA ACAGGCTCTT AACTGTGAGA	8940
TCTACGGAGC CTGCTACTCC ATAGAACCAC TGGATCTACC TCCAATCATT CAAAGACTCC	9000
ATGGCCTCAG CGCATTTTCA CTCCACAGTT ACTCTCCAGG TGAAATCAAT AGGGTGGCCG	9060
CATGCCTCAG AAAACTTGGG GTCCCGCCCT TGCAGCTTG GAGACACCGG GCCCGGAGCG	9120
TCCGCGCTAG GCTTCTGTCC AGAGGAGGCA GGGCTGCCAT ATGTGGCAAG TACCTCTTCA	9180
ACTGGGCAGT AAGAACAAG CTCAAATCA CTCCAATAGC GGCCGCTGGC CGGCTGGACT	9240

ACCATGTTTC	CCCCACGCAC	TACGTGCCGG	AGAGCGATGC	AGCCGCCCCG	GTCAGTGCCA	6180
TACTCAGCAG	CCTCACTGTA	ACCCAGCTCC	TGAGGCGACT	GCATCAGTGG	ATAAGCTCGG	6240
AGTGTACCAC	TCCATGCTCC	GGTTCCTGGC	TAAGGGACAT	CTGGGACTGG	ATATGCGAGG	6300
TGCTGAGCGA	CTTTAAGACC	TGGCTGAAAG	CCAAGCTCAT	GCCACAACCTG	CCTGGGATTC	6360
CCTTTGTGTC	CTGCCAGCGC	GGGTATAGGG	GGGTCTGGCG	AGGAGACGGC	ATTATGCACA	6420
CTCGCTGCCA	CTGTGGAGCT	GAGATCACTG	GACATGTCAA	AAACGGGACG	ATGAGGATCG	6480
TCGGTCCTAG	GACCTGCAGG	AACATGTGGA	GTGGGACGTT	CCCCATTAAC	GCCTACACCA	6540
CGGGCCCCCTG	TACTCCCCTT	CCTGCGCCGA	ACTATAAGTT	CGCGCTGTGG	AGGGTGTCTG	6600
CAGAGGAATA	CGTGGAGATA	AGGCGGGTGG	GGGACTTCCA	CTACGTATCG	GGTATGACTA	6660
CTGACAATCT	TAAATGCCCC	TGCCAGATCC	CATCGCCCCG	ATTTTTCACA	GAATTGGACG	6720
GGGTGCGCCT	ACATAGGTTT	GCGCCCCCTT	GCAAGCCCTT	GCTGCGGGAG	GAGGTATCAT	6780
TCAGAGTAGG	ACTCCACGAG	TACCCGGTGG	GGTCGCAATT	ACCTTGCGAG	CCCGAACCGG	6840
ACGTAGCCGT	GTTGACGTCC	ATGCTCACTG	ATCCCTCCCA	TATAACAGCA	GAGGCGGCCG	6900
GGAGAAGGTT	GGCGAGAGGG	TCACCCCCTT	CTATGGCCAG	CTCCTCGGCC	AGCCAGCTGT	6960
CCGCTCCATC	TCTCAAGGCA	ACTTGACCCG	CCAACCATGA	CTCCCCTGAC	GCCGAGCTCA	7020
TAGAGGCTAA	CCTCCTGTGG	AGGCAGGAGA	TGGGCGGCAA	CATCACCAGG	GTTGAGTCAG	7080
AGAACAAAGT	GGTGATTCTG	GACTCCTTCG	ATCCGCTTGT	GGCAGAGGAG	GATGAGCGGG	7140
AGGTCTCCGT	ACCCGCAGAA	ATTCTGCGGA	AGTCTCGGAG	ATTGCCCCGG	GCCCTGCCCC	7200
TTTGGGCGCG	GCCGGACTAC	AACCCCCCGC	TAGTAGAGAC	GTGGAAAAAG	CCTGACTACG	7260
AACCACCTGT	GGTCCATGGC	TGCCCCGTAC	CACCTCCACG	GTCCCCTCCT	GTGCCTCCGC	7320
CTCGGAAAAA	GCGTACGGTG	GTCCTCACCG	AATCAACCCT	ATCTACTGCC	TTGGCCGAGC	7380
TTGCCACCAA	AAGTTTTGGC	AGCTCCTCAA	CTTCCGGCAT	TACGGGCGAC	AATACGACAA	7440
CATCCTCTGA	GCCCCCCCCCT	TCTGGCTGCC	CCCCCGACTC	CGACGTTGAG	TCCTATTCTT	7500
CCATGCCCCC	CCTGGAGGGG	GAGCCTGGGG	ATCCGGATCT	CAGCGACGGG	TCATGGTCGA	7560
CGGTGAGTAG	TGGGGCCGAC	ACGGAAGATG	TCGTGTGCTG	CTCAATGTCT	TATTCTCTGA	7620
CAGGCGCACT	CGTCACCCCG	TGCGCTGCGG	AAGAACAAAA	ACTGCCCATC	AACGCACTGA	7680

TGGTCGCATT GGGCATCAAT GCCGTGGCCT ACTACCGCG TCTTGACGTG TCTGTCATCC 4620  
CGACCAGCGG CGATGTTGTC GTCGTGTCGA CCGATGCTCT CATGACTGGC TTTACCGGCG 4680  
ACTTCGACTC TGTGATAGAC TGCAACACGT GTGTCACTCA GACAGTCGAT TTCAGCCTTG 4740  
ACCCTACCTT TACCATTGAG ACAACCACGC TCCCCCAGGA TGCTGTCTCC AGGACTCAAC 4800  
GCCGGGGCAG GACTGGCAGG GGAAGCCAG GCATCTACAG ATTTGTGGCA CCGGGGGAGC 4860  
GCCCCCTCCG CATGTTTCGAC TCGTCCGTCC TCTGTGAGTG CTATGACGCG GGCTGTGCTT 4920  
GGTATGAGCT CACGCCCCGCC GAGACTACAG TTAGGCTACG AGCGTACATG AACACCCCGG 4980  
GGCTTCCCGT GTGCCAGGAC CATCTTGAAT TTTGGGAGGG CGTCTTTACG GGCCTCACTC 5040  
ATATAGATGC CCACTTTCTA TCCCAGACAA AGCAGAGTGG GGAGAACTTT CCTTACCTGG 5100  
TAGCGTACCA AGCCACCGTG TGCCTAGGG CTCAAGCCCC TCCCCCATCG TGGGACCAGA 5160  
TGTGGAAGTG TTTGATCCGC CTAAACCCA CCCTCCATGG GCCAACACCC CTGCTATACA 5220  
GACTGGGCGC TGTTCAGAAT GAAGTCACCC TGACGCACCC AATCACCAA TACATCATGA 5280  
CATGCATGTC GGCCGACCTG GAGGTCGTCA CGAGCACCTG GGTGCTCGTT GGCGGCGTCC 5340  
TGGCTGCTCT GGCCGCGTAT TGCCTGTCAA CAGGCTGCGT GGTCATAGTG GGCAGGATTG 5400  
TCTTGTCCGG GAAGCCGGCA ATTATACCTG ACAGGGAGGT TCTCTACCAG GAGTTCGATG 5460  
AGATGGAAGA GTGCTCTCAG CACTTACCGT ACATCGAGCA AGGGATGATG CTCGCTGAGC 5520  
AGTTCAAGCA GAAGGCCCTC GGCCTCCTGC AGACCGCGTC CCGCCAAGCA GAGGTTATCA 5580  
CCCCTGCTGT CCAGACCAAC TGGCAGAAAC TCGAGGTCTT CTGGGCGAAG CACATGTGGA 5640  
ATTTTCATCAG TGGGATACAA TACTTGGCGG GCCTGTCAAC GCTGCCTGGT AACCCCGCCA 5700  
TTGCTTCATT GATGGCTTTT ACAGCTGCCG TCACCAGCCC ACTAACCCT GGCCAAACCC 5760  
TCCTCTTCAA CATATTGGGG GGGTGGGTGG CTGCCCAGCT CGCCGCCCCC GGTGCCGCTA 5820  
CCGCCTTTGT GGGCGCTGGC TTAGCTGGCG CCGCCATCGG CAGCGTTGGA CTGGGGAAGG 5880  
TCCTCGTGGA CATTCTTGCA GGGTATGGCG CGGGCGTGGC GGGAGCTCTT GTAGCCTTCA 5940  
AGATCATGAG CGGTGAGGTC CCCTCCACGG AGGACCTGGT CAATCTGCTG CCCGCCATCC 6000  
TCTCGCCTGG AGCCCTTGTA GTCGGTGTGG TCTGCGCAGC AATACTGCGC CGGCACGTTG 6060  
GCCCCGGCGA GGGGGCAGTG CAATGGATGA ACCGGCTAAT AGCCTTCGCC TCCCGGGGGA 6120

ACATCACCAA ACTACTCCTG GCCATCTTCG GACCCCTTTG GATTCTTCAA GCCAGTTTGC 3060  
TTAAAGTCCC CTACTTCGTG CGCGTTCAAG GCCTTCTCCG GATCTGCGCG CTAGCGCGGA 3120  
AGATAGCCGG AGGTCATTAC GTGCAAATGG CCATCATCAA GTTAGGGGCG CTTACTGGCA 3180  
CCTATGTGTA TAACCATCTC ACCCCTCTTC GAGACTGGGC GCACAACGGC CTGCGAGATC 3240  
TGGCCGTGGC TGTGGAACCA GTCGTCTTCT CCCGAATGGA GACCAAGCTC ATCACGTGGG 3300  
GGGCAGATAC CGCCGCGTGC GGTGACATCA TCAACGGCTT GCCCGTCTCT GCCCGTAGGG 3360  
GCCAGGAGAT ACTGCTTGGG CCAGCCGACG GAATGGTCTC CAAGGGGTGG AGGTTGCTGG 3420  
CGCCCATCAC GCGGTACGCC CAGCAGACGA GAGGCCTCCT AGGGTGTATA ATCACCAGCC 3480  
TGACTGGCCG GGACAAAAC CAAGTGGAGG GTGAGGTCCA GATCGTGTCA ACTGCTACCC 3540  
AAACCTTCCT GGCAACGTGC ATCAATGGGG TATGCTGGAC TGTCTACCAC GGGGCCGGAA 3600  
CGAGGACCAT CGCATCACCC AAGGGTCCTG TCATCCAGAT GTATACCAAT GTGGACCAAG 3660  
ACCTTGTTGG CTGGCCCGCT CCTCAAGGTT CCCGCTCATT GACACCCTGC ACCTGCGGCT 3720  
CCTCGGACCT TTACCTGGTC ACGAGGCACG CCGATGTCAT TCCCGTGCGC CGGCGAGGTG 3780  
ATAGCAGGGG TAGCCTGCTT TCGCCCCGGC CCATTTCTTA CTTGAAAGGC TCCTCGGGGG 3840  
GTCCGCTGTT GTGCCCCGCG GGACACGCCG TGGGCCTATT CAGGGCCGCG GTGTGCACCC 3900  
GTGGAGTGGC TAAGGCGGTG GACTTTATCC CTGTGGAGAA CCTAGAGACA ACCATGAGAT 3960  
CCCCGGTGTT CACGGACAAC TCCTCTCCAC CAGCAGTGCC CCAGAGCTTC CAGGTGGCCC 4020  
ACCTGCATGC TCCCACCGGC AGCGGTAAGA GCACCAAGGT CCCGGCTGCG TACGCAGCCC 4080  
AGGGCTACAA GGTGTTGGTG CTCAACCCCT CTGTTGCTGC AACGCTGGGC TTTGGTGCTT 4140  
ACATGTCCAA GGCCCATGGG GTTGATCCTA ATATCAGGAC CGGGGTGAGA ACAATTACCA 4200  
CTGGCAGCCC CATCACGTAC TCCACCTACG GCAAGTTCCT TGCCGACGGC GGGTGCTCAG 4260  
GAGGTGCTTA TGACATAATA ATTTGTGACG AGTGCCACTC CACGGATGCC ACATCCATCT 4320  
TGGGCATCGG CACTGTCCTT GACCAAGCAG AGACTGCGGG GGCGAGACTG GTTGTGCTCG 4380  
CCACTGCTAC CCCTCCGGGC TCCGTCACTG TGTCCTATCC TAACATCGAG GAGGTTGCTC 4440  
TGTCACCAC CGGAGAGATC CCCTTTTACG GCAAGGCTAT CCCCCTCGAG GTGATCAAGG 4500  
GGGGAAGACA TCTCATCTTC TGCCACTCAA AGAAGAAGTG CGACGAGCTC GCCGGAAGC 4560

ACTGGGCGAA GGTCTGGTA GTGCTGCTGC TATTTGCCGG CGTCGACGCG GAAACCCACG 1500  
TCACCGGGGG AAGTGCCGGC CGCACCACGG CTGGGCTTGT TGGTCTCCTT ACACCAGGCG 1560  
CCAAGCAGAA CATCCAAGT ATCAACACCA ACGGCAGTTG GCACATCAAT AGCACGGCCT 1620  
TGAAGTCAA TGAAAGCCTT AACACCGGCT GGTAGCAGG GCTCTTCTAT CAGCACAAAT 1680  
TCAACTCTTC AGGCTGTCTT GAGAGTTGG CCAGCTGCCG ACGCCTTACC GATTTTGCCC 1740  
AGGGCTGGGG TCCTATCAGT TATGCCAACG GAAGCGGCCT CGACGAACGC CCCTACTGCT 1800  
GGCACTACCC TCCAAGACCT TGTGGCATTG TGCCCGCAAA GAGCGTGTGT GGCCCGGTAT 1860  
ATTGCTTCAC TCCCAGCCCC GTGGTGGTGG GAACGACCGA CAGGTCGGGC GCGCCTACCT 1920  
ACAGCTGGGG TGCAAATGAT ACGGATGTCT TCGTCCTTAA CAACACCAGG CCACCGCTGG 1980  
GCAATTGGTT CGGTTGTACC TGGATGAACT CAACTGGATT CACCAAAGTG TCGGAGCGC 2040  
CCCCTTGTGT CATCGGAGGG GTGGGCAACA ACACCTTGCT CTGCCCCACT GATTGTTTCC 2100  
GCAAGCATCC GGAAGCCACA TACTCTCGGT GCGGCTCCGG TCCCTGGATT ACACCCAGGT 2160  
GCATGGTCGA CTACCCGTAT AGGCTTTGGC ACTATCCTTG TACCATCAAT TACACCATAT 2220  
TCAAAGTCAG GATGTACGTG GGAGGGGTCG AGCACAGGCT GGAAGCGGCC TGCAACTGGA 2280  
CGCGGGGCGA ACGCTGTGAT CTGGAAGACA GGGACAGGTC CGAGCTCAGC CCATTGCTGC 2340  
TGTCCACCAC ACAGTGGCAG GTCCTTCCGT GTTCTTTCAC GACCCTGCCA GCCTTGTTCA 2400  
CCGGCCTCAT CCACCTCCAC CAGAACATTG TGGACGTGCA GTACTTGTTAC GGGGTAGGGT 2460  
CAAGCATCGC GTCCTGGGCC ATTAAGTGGG AGTACGTCGT TCTCCTGTTC CTCCTGCTTG 2520  
CAGACGCGCG CGTCTGCTCC TGCTTGTTGA TGATGTTACT CATATCCCAA GCGGAGGCGG 2580  
CTTTGGAGAA CCTCGTAATA CTCAATGCAG CATCCCTGGC CGGGACGCAC GGTCTTGTGT 2640  
CCTTCCTCGT GTTCTTCTGC TTTGCGTGGT ATCTGAAGGG TAGGTGGGTG CCCGGAGCGG 2700  
TCTACGCCTT CTACGGGATG TGGCCTCTCC TCCTGCTCCT GCTGGCGTTG CCTCAGCGGG 2760  
CATACGCACT GGACACGGAG GTGGCCGCGT CGTGTGGCGG CGTTGTTCTT GTCGGGTTAA 2820  
TGGCGCTGAC TCTGTCGCA TATTACAAGC GCTACATCAG CTGGTGATG TGGTGGCTTC 2880  
AGTATTTTCT GACCAGAGTA GAAGCGCAAC TGCACGTGTG GGTCCCCCCT CTCAACGTCC 2940  
GGGGGGGGCG CGATGCCGTC ATCTTACTCA TGTGTGTTGT ACACCCGACT CTGGTATTTG 3000

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

GCCAGCCCC	TGATGGGGG	GACACTCCAC	CATGAATCAC	TCCCCTGTGA	GGAACACTG	60
TCTTCACGCA	GAAAGCGTCT	AGCCATGGCG	TTAGTATGAG	TGTCGTGCAG	CCTCCAGGAC	120
CCCCCTCCC	GGGAGAGCCA	TAGTGGTCTG	CGGAACCGGT	GAGTACACCG	GAATTGCCAG	180
GACGACCGGG	TCCTTTCTTG	GATAAACCCG	CTCAATGCCT	GGAGATTTGG	GCGTGCCCCC	240
GCAAGACTGC	TAGCCGAGTA	GTGTTGGGTC	GCGAAAGGCC	TTGTGGTACT	GCCTGATAGG	300
GTGCTTGCGA	GTGCCCCGGG	AGGTCTCGTA	GACCGTGCAC	CATGAGCACG	AATCCTAAAC	360
CTCAAAGAAA	AACCAAACGT	AACACCAACC	GTCGCCACAC	GGACGTCAAG	TTCCCGGGTG	420
GCGGTCAGAT	CGTTGGTGGA	GTTTACTTGT	TGCCGCGCAG	GGGCCCTAGA	TTGGGTGTGC	480
GCGCGACGAG	GAAGACTTCC	GAGCGGTGCG	AACCTCGAGG	TAGACGTCAG	CCTATCCCCA	540
AGGCACGTCG	GCCCCAGGGC	AGGACCTGGG	CTCAGCCCGG	GTACCCTTGG	CCCCTCTATG	600
GCAATGAGGG	TTGCGGGTGG	GCGGGATGGC	TCCTGTCTCC	CCGTGGCTCT	CGGCCTAGCT	660
GGGGCCCCAC	AGACCCCCGG	CGTAGGTCGC	GCAATTTGGG	TAAGGTCATC	GATACCCTTA	720
CGTGCGGCTT	CGCCGACCTC	ATGGGGTACA	TACCGCTCGT	CGGCGCCCCCT	CTTGAGGGCG	780
CTGCCAGGGC	CCTGGCGCAT	GGCGTCCGGG	TTCTGGAAGA	CGGCGTGAAC	TATGCAACAG	840
GGAACCTTCC	TGTTTGCTCT	TTCTCTATCT	TCCTTCTGGC	CCTGCTCTCT	TGCCTGACCG	900
TGCCCCGCTC	AGCCTACCAA	GTGCGCAATT	CCTCGGGGCT	TTACCATGTC	ACCAATGATT	960
GCCCTAACTC	GAGTATTGTG	TACGAGGCGG	CCGATGCCAT	CCTGCACACT	CCGGGGTGTG	1020
TCCCTTGCGT	TCGCGAGGGT	AACGCCTCGA	GGTGTGGGGT	GGCGGTGACC	CCCACGGTGG	1080
CCACCAGGGA	CGGCAAATC	CCCACAACGC	AGCTTCGACG	TCATATCGAT	CTGCTTGTGC	1140
GGAGCGCCAC	CCTCTGCTCG	GCCCTCTACG	TGGGGGACCT	GTGCGGGTCT	GTCTTTCTTG	1200
TTGGTCAACT	GTTTACCTTC	TCTCCCAGGC	GCCACTGGAC	GACGCAAGAC	TGCAATTGTT	1260
CTATCTATCC	CGGCCATATA	ACGGGTCATC	GCATGGCATG	GGATATGATG	ATGAACTGGT	1320
CCCCTACGGC	AGCGTTGGTG	GTAGCTCAGC	TGCTCCGGAT	CCCACAAGCC	ATCATGGACA	1380
TGATCGCTGG	TGCTCACTGG	GGAGTCCTGG	CGGGCATAGC	GTATTTCTCC	ATGGTGGGGA	1440

116

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

GCCAGCCCCC TGATGGGGGC GACACTCCAC CATGAATC

38

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 101 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: double
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

AATGGTGGCT CCATCTTAGC CCTAGTCACG GCTAGCTGTG AAAGGTCCGT GAGCCGCATG

60

ACTGCAGAGA GTGCTGATAC TGGCCTCTCT GCTGATCATG T

101

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 12980 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: double
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

2770	2775	2780
Ser Cys Ser Ser Asn Val Ser Val Ala His Asp Gly Ala Gly Lys Arg		
2785	2790	2795 2800
Val Tyr Tyr Leu Thr Arg Asp Pro Thr Thr Pro Leu Ala Arg Ala Ala		
	2805	2810 2815
Trp Glu Thr Ala Arg His Thr Pro Val Asn Ser Trp Leu Gly Asn Ile		
	2820	2825 2830
Ile Met Phe Ala Pro Thr Leu Trp Ala Arg Met Ile Leu Met Thr His		
	2835	2840 2845
Phe Phe Ser Val Leu Ile Ala Arg Asp Gln Leu Glu Gln Ala Leu Asn		
	2850	2855 2860
Cys Glu Ile Tyr Gly Ala Cys Tyr Ser Ile Glu Pro Leu Asp Leu Pro		
	2865	2870 2875 2880
Pro Ile Ile Gln Arg Leu His Gly Leu Ser Ala Phe Ser Leu His Ser		
	2885	2890 2895
Tyr Ser Pro Gly Glu Ile Asn Arg Val Ala Ala Cys Leu Arg Lys Leu		
	2900	2905 2910
Gly Val Pro Pro Leu Arg Ala Trp Arg His Arg Ala Arg Ser Val Arg		
	2915	2920 2925
Ala Arg Leu Leu Ser Arg Gly Gly Arg Ala Ala Ile Cys Gly Lys Tyr		
	2930	2935 2940
Leu Phe Asn Trp Ala Val Arg Thr Lys Leu Lys Leu Thr Pro Ile Ala		
	2945	2950 2955 2960
Ala Ala Gly Arg Leu Asp Leu Ser Gly Trp Phe Thr Ala Gly Tyr Ser		
	2965	2970 2975
Gly Gly Asp Ile Tyr His Ser Val Ser His Ala Arg Pro Arg Trp Phe		
	2980	2985 2990
Trp Phe Cys Leu Leu Leu Leu Ala Ala Gly Val Gly Ile Tyr Leu Leu		
	2995	3000 3005
Pro Asn Arg Glx		
	3010	

## (2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 38 base pairs



114

2500	2505	2510
Pro Pro His Ser Ala Lys Ser Lys Phe Gly Tyr Gly Ala Lys Asp Val 2515	2520	2525
Arg Cys His Ala Arg Lys Ala Val Ala His Ile Asn Ser Val Trp Lys 2530	2535	2540
Asp Leu Leu Glu Asp Ser Val Thr Pro Ile Asp Thr Thr Ile Met Ala 2545	2550	2555 2560
Lys Asn Glu Val Phe Cys Val Gln Pro Glu Lys Gly Gly Arg Lys Pro 2565	2570	2575
Ala Arg Leu Ile Val Phe Pro Asp Leu Gly Val Arg Val Cys Glu Lys 2580	2585	2590
Met Ala Leu Tyr Asp Val Val Ser Lys Leu Pro Leu Ala Val Met Gly 2595	2600	2605
Ser Ser Tyr Gly Phe Gln Tyr Ser Pro Gly Gln Arg Val Glu Phe Leu 2610	2615	2620
Val Gln Ala Trp Lys Ser Lys Lys Thr Pro Met Gly Phe Ser Tyr Asp 2625	2630	2635 2640
Thr Arg Cys Phe Asp Ser Thr Val Thr Glu Ser Asp Ile Arg Thr Glu 2645	2650	2655
Glu Ala Ile Tyr Gln Cys Cys Asp Leu Asp Pro Gln Ala Arg Val Ala 2660	2665	2670
Ile Lys Ser Leu Thr Glu Arg Leu Tyr Val Gly Gly Pro Leu Thr Asn 2675	2680	2685
Ser Arg Gly Glu Asn Cys Gly Tyr Arg Arg Cys Arg Ala Ser Gly Val 2690	2695	2700
Leu Thr Thr Ser Cys Gly Asn Thr Leu Thr Cys Tyr Ile Lys Ala Arg 2705	2710	2715 2720
Ala Ala Cys Arg Ala Ala Gly Leu Gln Asp Cys Thr Met Leu Val Cys 2725	2730	2735
Gly Asp Asp Leu Val Val Ile Cys Glu Ser Ala Gly Val Gln Glu Asp 2740	2745	2750
Ala Ala Ser Leu Arg Ala Phe Thr Glu Ala Met Thr Arg Tyr Ser Ala 2755	2760	2765
Pro Pro Gly Asp Pro Pro Gln Pro Glu Tyr Asp Leu Glu Leu Ile Thr		

2225                      2230                      2235                      2240

Ile Thr Arg Val Glu Ser Glu Asn Lys Val Val Ile Leu Asp Ser Phe  
2245                      2250                      2255

Asp Pro Leu Val Ala Glu Glu Asp Glu Arg Glu Val Ser Val Pro Ala  
2260                      2265                      2270

Glu Ile Leu Arg Lys Ser Arg Arg Phe Ala Arg Ala Leu Pro Val Trp  
2275                      2280                      2285

Ala Arg Pro Asp Tyr Asn Pro Pro Leu Val Glu Thr Trp Lys Lys Pro  
2290                      2295                      2300

Asp Tyr Glu Pro Pro Val Val His Gly Cys Pro Leu Pro Pro Pro Arg  
2305                      2310                      2315                      2320

Ser Pro Pro Val Pro Pro Pro Arg Lys Lys Arg Thr Val Val Leu Thr  
2325                      2330                      2335

Glu Ser Thr Leu Ser Thr Ala Leu Ala Glu Leu Ala Thr Lys Ser Phe  
2340                      2345                      2350

Gly Ser Ser Ser Thr Ser Gly Ile Thr Gly Asp Asn Thr Thr Thr Ser  
2355                      2360                      2365

Ser Glu Pro Ala Pro Ser Gly Cys Pro Pro Asp Ser Asp Val Glu Ser  
2370                      2375                      2380

Tyr Ser Ser Met Pro Pro Leu Glu Gly Glu Pro Gly Asp Pro Asp Leu  
2385                      2390                      2395                      2400

Ser Asp Gly Ser Trp Ser Thr Val Ser Ser Gly Ala Asp Thr Glu Asp  
2405                      2410                      2415

Val Val Cys Cys Ser Met Ser Tyr Ser Trp Thr Gly Ala Leu Val Thr  
2420                      2425                      2430

Pro Cys Ala Ala Glu Glu Gln Lys Leu Pro Ile Asn Ala Leu Ser Asn  
2435                      2440                      2445

Ser Leu Leu Arg His His Asn Leu Val Tyr Ser Thr Thr Ser Arg Ser  
2450                      2455                      2460

Ala Cys Gln Arg Gln Lys Lys Val Thr Phe Asp Arg Leu Gln Val Leu  
2465                      2470                      2475                      2480

Asp Ser His Tyr Gln Asp Val Leu Lys Glu Val Lys Ala Ala Ala Ser  
2485                      2490                      2495

Lys Val Lys Ala Asn Leu Leu Ser Val Glu Glu Ala Cys Ser Leu Thr

1955	1960	1965
Thr Thr Pro Cys Ser Gly Ser Trp Leu Arg Asp Ile Trp Asp Trp Ile 1970	1975	1980
Cys Glu Val Leu Ser Asp Phe Lys Thr Trp Leu Lys Ala Lys Leu Met 1985	1990	1995 2000
Pro Gln Leu Pro Gly Ile Pro Phe Val Ser Cys Gln Arg Gly Tyr Arg 2005	2010	2015
Gly Val Trp Arg Gly Asp Gly Ile Met His Thr Arg Cys His Cys Gly 2020	2025	2030
Ala Glu Ile Thr Gly His Val Lys Asn Gly Thr Met Arg Ile Val Gly 2035	2040	2045
Pro Arg Thr Cys Arg Asn Met Trp Ser Gly Thr Phe Pro Ile Asn Ala 2050	2055	2060
Tyr Thr Thr Gly Pro Cys Thr Pro Leu Pro Ala Pro Asn Tyr Lys Phe 2065	2070	2075 2080
Ala Leu Trp Arg Val Ser Ala Glu Glu Tyr Val Glu Ile Arg Arg Val 2085	2090	2095
Gly Asp Phe His Tyr Val Ser Gly Met Thr Thr Asp Asn Leu Lys Cys 2100	2105	2110
Pro Cys Gln Ile Pro Ser Pro Glu Phe Phe Thr Glu Leu Asp Gly Val 2115	2120	2125
Arg Leu His Arg Phe Ala Pro Pro Cys Lys Pro Leu Leu Arg Glu Glu 2130	2135	2140
Val Ser Phe Arg Val Gly Leu His Glu Tyr Pro Val Gly Ser Gln Leu 2145	2150	2155 2160
Pro Cys Glu Pro Glu Pro Asp Val Ala Val Leu Thr Ser Met Leu Thr 2165	2170	2175
Asp Pro Ser His Ile Thr Ala Glu Ala Ala Gly Arg Arg Leu Ala Arg 2180	2185	2190
Gly Ser Pro Pro Ser Met Ala Ser Ser Ser Ala Ser Gln Leu Ser Ala 2195	2200	2205
Pro Ser Leu Lys Ala Thr Cys Thr Ala Asn His Asp Ser Pro Asp Ala 2210	2215	2220
Glu Leu Ile Glu Ala Asn Leu Leu Trp Arg Gln Glu Met Gly Gly Asn		

	1685	1690	1695
Asp Arg Glu Val Leu Tyr Gln Glu Phe Asp Glu Met Glu Glu Cys Ser	1700	1705	1710
Gln His Leu Pro Tyr Ile Glu Gln Gly Met Met Leu Ala Glu Gln Phe	1715	1720	1725
Lys Gln Lys Ala Leu Gly Leu Leu Gln Thr Ala Ser Arg Gln Ala Glu	1730	1735	1740
Val Ile Thr Pro Ala Val Gln Thr Asn Trp Gln Lys Leu Glu Val Phe	1745	1750	1755
Trp Ala Lys His Met Trp Asn Phe Ile Ser Gly Ile Gln Tyr Leu Ala	1765	1770	1775
Gly Leu Ser Thr Leu Pro Gly Asn Pro Ala Ile Ala Ser Leu Met Ala	1780	1785	1790
Phe Thr Ala Ala Val Thr Ser Pro Leu Thr Thr Gly Gln Thr Leu Leu	1795	1800	1805
Phe Asn Ile Leu Gly Gly Trp Val Ala Ala Gln Leu Ala Ala Pro Gly	1810	1815	1820
Ala Ala Thr Ala Phe Val Gly Ala Gly Leu Ala Gly Ala Ala Ile Gly	1825	1830	1835
Ser Val Gly Leu Gly Lys Val Leu Val Asp Ile Leu Ala Gly Tyr Gly	1845	1850	1855
Ala Gly Val Ala Gly Ala Leu Val Ala Phe Lys Ile Met Ser Gly Glu	1860	1865	1870
Val Pro Ser Thr Glu Asp Leu Val Asn Leu Leu Pro Ala Ile Leu Ser	1875	1880	1885
Pro Gly Ala Leu Val Val Gly Val Val Cys Ala Ala Ile Leu Arg Arg	1890	1895	1900
His Val Gly Pro Gly Glu Gly Ala Val Gln Trp Met Asn Arg Leu Ile	1905	1910	1915
Ala Phe Ala Ser Arg Gly Asn His Val Ser Pro Thr His Tyr Val Pro	1925	1930	1935
Glu Ser Asp Ala Ala Ala Arg Val Thr Ala Ile Leu Ser Ser Leu Thr	1940	1945	1950
Val Thr Gln Leu Leu Arg Arg Leu His Gln Trp Ile Ser Ser Glu Cys			

1410	1415	1420
Val Ile Pro Thr Ser Gly Asp Val Val Val Val Ser Thr Asp Ala Leu		
1425	1430	1435 1440
Met Thr Gly Phe Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn Thr		
	1445	1450 1455
Cys Val Thr Gln Thr Val Asp Phe Ser Leu Asp Pro Thr Phe Thr Ile		
	1460	1465 1470
Glu Thr Thr Thr Leu Pro Gln Asp Ala Val Ser Arg Thr Gln Arg Arg		
	1475	1480 1485
Gly Arg Thr Gly Arg Gly Lys Pro Gly Ile Tyr Arg Phe Val Ala Pro		
	1490	1495 1500
Gly Glu Arg Pro Ser Gly Met Phe Asp Ser Ser Val Leu Cys Glu Cys		
	1505	1510 1515 1520
Tyr Asp Ala Gly Cys Ala Trp Tyr Glu Leu Thr Pro Ala Glu Thr Thr		
	1525	1530 1535
Val Arg Leu Arg Ala Tyr Met Asn Thr Pro Gly Leu Pro Val Cys Gln		
	1540	1545 1550
Asp His Leu Glu Phe Trp Glu Gly Val Phe Thr Gly Leu Thr His Ile		
	1555	1560 1565
Asp Ala His Phe Leu Ser Gln Thr Lys Gln Ser Gly Glu Asn Phe Pro		
	1570	1575 1580
Tyr Leu Val Ala Tyr Gln Ala Thr Val Cys Ala Arg Ala Gln Ala Pro		
	1585	1590 1595 1600
Pro Pro Ser Trp Asp Gln Met Trp Lys Cys Leu Ile Arg Leu Lys Pro		
	1605	1610 1615
Thr Leu His Gly Pro Thr Pro Leu Leu Tyr Arg Leu Gly Ala Val Gln		
	1620	1625 1630
Asn Glu Val Thr Leu Thr His Pro Ile Thr Lys Tyr Ile Met Thr Cys		
	1635	1640 1645
Met Ser Ala Asp Leu Glu Val Val Thr Ser Thr Trp Val Leu Val Gly		
	1650	1655 1660
Gly Val Leu Ala Ala Leu Ala Ala Tyr Cys Leu Ser Thr Gly Cys Val		
	1665	1670 1675 1680
Val Ile Val Gly Arg Ile Val Leu Ser Gly Lys Pro Ala Ile Ile Pro		

1140	1145	1150
Leu Ser Pro Arg Pro Ile Ser Tyr Leu Lys Gly Ser Ser Gly Gly Pro		
1155	1160	1165
Leu Leu Cys Pro Ala Gly His Ala Val Gly Leu Phe Arg Ala Ala Val		
1170	1175	1180
Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe Ile Pro Val Glu Asn		
1185	1190	1195
Leu Glu Thr Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser Pro		
1205	1210	1215
Pro Ala Val Pro Gln Ser Phe Gln Val Ala His Leu His Ala Pro Thr		
1220	1225	1230
Gly Ser Gly Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Gln Gly		
1235	1240	1245
Tyr Lys Val Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly Phe		
1250	1255	1260
Gly Ala Tyr Met Ser Lys Ala His Gly Val Asp Pro Asn Ile Arg Thr		
1265	1270	1275
Gly Val Arg Thr Ile Thr Thr Gly Ser Pro Ile Thr Tyr Ser Thr Tyr		
1285	1290	1295
Gly Lys Phe Leu Ala Asp Gly Gly Cys Ser Gly Gly Ala Tyr Asp Ile		
1300	1305	1310
Ile Ile Cys Asp Glu Cys His Ser Thr Asp Ala Thr Ser Ile Leu Gly		
1315	1320	1325
Ile Gly Thr Val Leu Asp Gln Ala Glu Thr Ala Gly Ala Arg Leu Val		
1330	1335	1340
Val Leu Ala Thr Ala Thr Pro Pro Gly Ser Val Thr Val Ser His Pro		
1345	1350	1355
Asn Ile Glu Glu Val Ala Leu Ser Thr Thr Gly Glu Ile Pro Phe Tyr		
1365	1370	1375
Gly Lys Ala Ile Pro Leu Glu Val Ile Lys Gly Gly Arg His Leu Ile		
1380	1385	1390
Phe Cys His Ser Lys Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu Val		
1395	1400	1405
Ala Leu Gly Ile Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val Ser		

865	870	875	880
His Pro Thr Leu Val Phe Asp Ile Thr Lys Leu Leu Leu Ala Ile Phe			
885		890	895
Gly Pro Leu Trp Ile Leu Gln Ala Ser Leu Leu Lys Val Pro Tyr Phe			
900		905	910
Val Arg Val Gln Gly Leu Leu Arg Ile Cys Ala Leu Ala Arg Lys Ile			
915		920	925
Ala Gly Gly His Tyr Val Gln Met Ala Ile Ile Lys Leu Gly Ala Leu			
930		935	940
Thr Gly Thr Tyr Val Tyr Asn His Leu Thr Pro Leu Arg Asp Trp Ala			
945		950	955
His Asn Gly Leu Arg Asp Leu Ala Val Ala Val Glu Pro Val Val Phe			
	965	970	975
Ser Arg Met Glu Thr Lys Leu Ile Thr Trp Gly Ala Asp Thr Ala Ala			
	980	985	990
Cys Gly Asp Ile Ile Asn Gly Leu Pro Val Ser Ala Arg Arg Gly Gln			
	995	1000	1005
Glu Ile Leu Leu Gly Pro Ala Asp Gly Met Val Ser Lys Gly Trp Arg			
1010		1015	1020
Leu Leu Ala Pro Ile Thr Ala Tyr Ala Gln Gln Thr Arg Gly Leu Leu			
1025		1030	1035
Gly Cys Ile Ile Thr Ser Leu Thr Gly Arg Asp Lys Asn Gln Val Glu			
	1045	1050	1055
Gly Glu Val Gln Ile Val Ser Thr Ala Thr Gln Thr Phe Leu Ala Thr			
	1060	1065	1070
Cys Ile Asn Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Thr Arg			
	1075	1080	1085
Thr Ile Ala Ser Pro Lys Gly Pro Val Ile Gln Met Tyr Thr Asn Val			
	1090	1095	1100
Asp Gln Asp Leu Val Gly Trp Pro Ala Pro Gln Gly Ser Arg Ser Leu			
1105		1110	1115
Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg His			
	1125	1130	1135
Ala Asp Val Ile Pro Val Arg Arg Arg Gly Asp Ser Arg Gly Ser Leu			

595	600	605
Val Asp Tyr Pro Tyr Arg Leu Trp His Tyr Pro Cys Thr Ile Asn Tyr		
610	615	620
Thr Ile Phe Lys Val Arg Met Tyr Val Gly Gly Val Glu His Arg Leu		
625	630	635
Glu Ala Ala Cys Asn Trp Thr Arg Gly Glu Arg Cys Asp Leu Glu Asp		
645	650	655
Arg Asp Arg Ser Glu Leu Ser Pro Leu Leu Leu Ser Thr Thr Gln Trp		
660	665	670
Gln Val Leu Pro Cys Ser Phe Thr Thr Leu Pro Ala Leu Ser Thr Gly		
675	680	685
Leu Ile His Leu His Gln Asn Ile Val Asp Val Gln Tyr Leu Tyr Gly		
690	695	700
Val Gly Ser Ser Ile Ala Ser Trp Ala Ile Lys Trp Glu Tyr Val Val		
705	710	715
Leu Leu Phe Leu Leu Leu Ala Asp Ala Arg Val Cys Ser Cys Leu Trp		
725	730	735
Met Met Leu Leu Ile Ser Gln Ala Glu Ala Ala Leu Glu Asn Leu Val		
740	745	750
Ile Leu Asn Ala Ala Ser Leu Ala Gly Thr His Gly Leu Val Ser Phe		
755	760	765
Leu Val Phe Phe Cys Phe Ala Trp Tyr Leu Lys Gly Arg Trp Val Pro		
770	775	780
Gly Ala Val Tyr Ala Phe Tyr Gly Met Trp Pro Leu Leu Leu Leu Leu		
785	790	795
Leu Ala Leu Pro Gln Arg Ala Tyr Ala Leu Asp Thr Glu Val Ala Ala		
805	810	815
Ser Cys Gly Gly Val Val Leu Val Gly Leu Met Ala Leu Thr Leu Ser		
820	825	830
Pro Tyr Tyr Lys Arg Tyr Ile Ser Trp Cys Met Trp Trp Leu Gln Tyr		
835	840	845
Phe Leu Thr Arg Val Glu Ala Gln Leu His Val Trp Val Pro Pro Leu		
850	855	860
Asn Val Arg Gly Gly Arg Asp Ala Val Ile Leu Leu Met Cys Val Val		



	325		330		335
Leu Leu Arg Ile Pro Gln Ala Ile Met Asp Met Ile Ala Gly Ala His					
	340		345		350
Trp Gly Val Leu Ala Gly Ile Ala Tyr Phe Ser Met Val Gly Asn Trp					
	355		360		365
Ala Lys Val Leu Val Val Leu Leu Leu Phe Ala Gly Val Asp Ala Glu					
	370		375		380
Thr His Val Thr Gly Gly Ser Ala Gly Arg Thr Thr Ala Gly Leu Val					
	385		390		395
					400
Gly Leu Leu Thr Pro Gly Ala Lys Gln Asn Ile Gln Leu Ile Asn Thr					
	405		410		415
Asn Gly Ser Trp His Ile Asn Ser Thr Ala Leu Asn Cys Asn Glu Ser					
	420		425		430
Leu Asn Thr Gly Trp Leu Ala Gly Leu Phe Tyr Gln His Lys Phe Asn					
	435		440		445
Ser Ser Gly Cys Pro Glu Arg Leu Ala Ser Cys Arg Arg Leu Thr Asp					
	450		455		460
Phe Ala Gln Gly Trp Gly Pro Ile Ser Tyr Ala Asn Gly Ser Gly Leu					
	465		470		475
					480
Asp Glu Arg Pro Tyr Cys Trp His Tyr Pro Pro Arg Pro Cys Gly Ile					
	485		490		495
Val Pro Ala Lys Ser Val Cys Gly Pro Val Tyr Cys Phe Thr Pro Ser					
	500		505		510
Pro Val Val Val Gly Thr Thr Asp Arg Ser Gly Ala Pro Thr Tyr Ser					
	515		520		525
Trp Gly Ala Asn Asp Thr Asp Val Phe Val Leu Asn Asn Thr Arg Pro					
	530		535		540
Pro Leu Gly Asn Trp Phe Gly Cys Thr Trp Met Asn Ser Thr Gly Phe					
	545		550		555
					560
Thr Lys Val Cys Gly Ala Pro Pro Cys Val Ile Gly Gly Val Gly Asn					
	565		570		575
Asn Thr Leu Leu Cys Pro Thr Asp Cys Phe Arg Lys His Pro Glu Ala					
	580		585		590
Thr Tyr Ser Arg Cys Gly Ser Gly Pro Trp Ile Thr Pro Arg Cys Met					

105

50		55		60
Ile Pro Lys Ala Arg Arg Pro Glu Gly Arg Thr Trp Ala Gln Pro Gly				
65		70		80
Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Cys Gly Trp Ala Gly Trp				
	85		90	95
Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Thr Asp Pro				
	100		105	110
Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys				
	115		120	125
Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu				
	130		135	140
Gly Gly Ala Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp				
	145		150	155
Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile				
	165		170	175
Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Tyr				
	180		185	190
Gln Val Arg Asn Ser Ser Gly Leu Tyr His Val Thr Asn Asp Cys Pro				
	195		200	205
Asn Ser Ser Ile Val Tyr Glu Ala Ala Asp Ala Ile Leu His Thr Pro				
	210		215	220
Gly Cys Val Pro Cys Val Arg Glu Gly Asn Ala Ser Arg Cys Trp Val				
	225		230	235
Ala Val Thr Pro Thr Val Ala Thr Arg Asp Gly Lys Leu Pro Thr Thr				
	245		250	255
Gln Leu Arg Arg His Ile Asp Leu Leu Val Gly Ser Ala Thr Leu Cys				
	260		265	270
Ser Ala Leu Tyr Val Gly Asp Leu Cys Gly Ser Val Phe Leu Val Gly				
	275		280	285
Gln Leu Phe Thr Phe Ser Pro Arg Arg His Trp Thr Thr Gln Asp Cys				
	290		295	300
Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His Arg Met Ala Trp				
	305		310	315
Asp Met Met Met Asn Trp Ser Pro Thr Ala Ala Leu Val Val Ala Gln				

ATGGCCTCAG CGCATTTTCA CTCCACAGTT ACTCTCCAGG TGAAATCAAT AGGGTGGCCG 9060  
 CATGCCTCAG AAAACTTGGG GTCCCGCCCT TGCGAGCTTG GAGACACCGG GCCCGGAGCG 9120  
 TCCGCGCTAG GCTTCTGTCC AGAGGAGGCA GGGCTGCCAT ATGTGGCAAG TACCTCTTCA 9180  
 ACTGGGCAGT AAGAACAAAG CTCAAACCTCA CTCCAATAGC GGCCGCTGGC CGGCTGGACT 9240  
 TGTCCGGTTG GTTCACGGCT GGCTACAGCG GGGGAGACAT TTATCACAGC GTGTCTCATG 9300  
 CCCGGCCCCG CTGGTTCTGG TTTTGCCTAC TCCTGCTCGC TGCAGGGGTA GGCATCTACC 9360  
 TCCTCCCCAA CCGATGAAGG TTGGGGTAAA CACTCCGGCC TCTTAGGCCA TTTCCTGTTT 9420  
 TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTCT TTTTTTTTTT 9480  
 TTTTTTCCTT TTTTTTTTTT TTTTTTTTCT TTCCTTCTTT TTTCCTTTCT TTCCTTCCT 9540  
 TCTTTAATGG TGGCTCCATC TTAGCCCTAG TCACGGCTAG CTGTGAAAGG TCCGTGAGCC 9600  
 GCATGACTGC AGAGAGTGCT GATACTGGCC TCTCTGCAGA TCATGT 9646

## (2) INFORMATION FOR SEQ ID NO:2:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 3012 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (iii) HYPOTHETICAL: NO

## (v) FRAGMENT TYPE: N-terminal

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn  
 1 5 10 15

Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly  
 20 25 30

Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala  
 35 40 45

Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro

CATCCTCTGA GCCCGCCCCT TCTGGCTGCC CCCCCGACTC CGACGTTGAG TCCTATTCTT	7500
CCATGCCCCC CCTGGAGGGG GAGCCTGGGG ATCCGGATCT CAGCGACGGG TCATGGTCGA	7560
CGGTCAAGTAG TGGGGCCGAC ACGGAAGATG TCGTGTGCTG CTCAATGTCT TATTCTTGGA	7620
CAGGCGCACT CGTCACCCCG TGCGCTGCGG AAGAACAAAA ACTGCCCATC AACGCACTGA	7680
GCAACTCGTT GCTACGCCAT CACAATCTGG TGTATTCCAC CACTTCACGC AGTGCTTGCC	7740
AAAGGCAGAA GAAAGTCACA TTTGACAGAC TGCAAGTTCT GGACAGCCAT TACCAGGACG	7800
TGCTCAAGGA GGTCAAAGCA GCGGCGTCAA AAGTGAAGGC TAACTTGCTA TCCGTAGAGG	7860
AAGCTTGCAG CCTGACGCCC CCACATTCAG CCAAATCCAA GTTTGGCTAT GGGGCAAAAG	7920
ACGTCCGTTG CCATGCCAGA AAGGCCGTAG CCCACATCAA CTCCTGTGG AAAGACCTTC	7980
TGGAAGACAG TGTAACACCA ATAGACACTA CCATCATGGC CAAGAACGAG GTTTTCTGCG	8040
TTACAGCTGA GAAGGGGGGT CGTAAGCCAG CTCGTCTCAT CGTGTTCCTT GACCTGGGCG	8100
TGCGCGTGTG CGAGAAGATG GCCCTGTACG ACGTGGTTAG CAAGCTCCCC CTGGCCGTGA	8160
TGGGAAGCTC CTACGGATTG CAATACTCAC CAGGACAGCG GGTGAATTC CTCGTGCAAG	8220
CGTGGAAGTC CAAGAAGACC CCGATGGGGT TCTCGTATGA TACCCGCTGT TTTGACTCCA	8280
CAGTCACTGA GAGCGACATC CGTACGGAGG AGGCAATTTA CCAATGTTGT GACCTGGACC	8340
CCCAAGCCCG CGTGGCCATC AAGTCCCTCA CTGAGAGGCT TTATGTTGGG GGCCCTCTTA	8400
CCAATTCAAG GGGGGAAAAC TGCGGCTACC GCAGGTGCCG CGCGAGCGGC GTACTGACAA	8460
CTAGCTGTGG TAACACCCTC ACTTGCTACA TCAAGGCCCG GGCAGCCTGT CGAGCCGCAG	8520
GGCTCCAGGA CTGCACCATG CTCGTGTGTG GCGACGACTT AGTCGTTATC TGTGAAAGTG	8580
CGGGGGTCCA GGAGGACGCG GCGAGCCTGA GAGCCTTCAC GGAGGCTATG ACCAGGTACT	8640
CCGCCCCCCC CGGGGACCCC CCACAACCAG AATACGACTT GGAGCTTATA ACATCATGCT	8700
CCTCCAACGT GTCAGTCGCC CACGACGGCG CTGGAAGAG GGTCTACTAC CTTACCCGTG	8760
ACCCTACAAC CCCCCTCGCG AGAGCCGCGT GGGAGACAGC AAGACACACT CCAGTCAATT	8820
CCTGGCTAGG CAACATAATC ATGTTTGGCC CCACACTGTG GGCGAGGATG ATACTGATGA	8880
CCCATTCTT TAGCGTCCTC ATAGCCAGGG ATCAGCTTGA ACAGGCTCTT AACTGTGAGA	8940
TCTACGGAGC CTGCTACTCC ATAGAACCAC TGGATCTACC TCCAATCATT CAAAGACTCC	9000

TCCTCGTGGA CATTCTTGCA GGGTATGGCG CGGGCGTGGC GGGAGCTCTT GTAGCATTCA 5940  
AGATCATGAG CGGTGAGGTC CCCTCCACGG AGGACCTGGT CAATCTGCTG CCCGCCATCC 6000  
TCTCGCCTGG AGCCCTTGTA GTCGGTGTGG TCTGCGCAGC AATACTGCGC CGGCACGTTG 6060  
GCCCCGGCGA GGGGGCAGTG CAATGGATGA ACCGGCTAAT AGCCTTCGCC TCCCGGGGGA 6120  
ACCATGTTTC CCCCACGCAC TACGTGCCGG AGAGCGATGC AGCCGCCCCG GTCACTGCCA 6180  
TACTCAGCAG CCTCACTGTA ACCCAGCTCC TGAGGCGACT GCATCAGTGG ATAAGCTCGG 6240  
AGTGTAACAC TCCATGCTCC GGTTCCTGGC TAAGGGACAT CTGGGACTGG ATATGCGAGG 6300  
TGCTGAGCGA CTTTAAGACC TGGCTGAAAG CCAAGCTCAT GCCACAAC TG CCTGGGATTC 6360  
CCTTTGTGTC CTGCCAGCGC GGGTATAGGG GGGTCTGGCG AGGAGACGGC ATTATGCACA 6420  
CTCGCTGCCA CTGTGGAGCT GAGATCACTG GACATGTCAA AAACGGGACG ATGAGGATCG 6480  
TCGGTCCTAG GACCTGCAGG AACATGTGA GTGGGACGTT CCCCATTAAC GCCTACACCA 6540  
CGGGCCCCTG TACTCCCCCTT CCTGCGCCGA ACTATAAGTT CGCGCTGTGG AGGGTGTCTG 6600  
CAGAGGAATA CGTGGAGATA AGGCGGGTGG GGGACTTCCA CTACGTATCG GGTATGACTA 6660  
CTGACAATCT TAAATGCCCC TGCCAGATCC CATCGCCCCG ATTTTTCACA GAATTGGACG 6720  
GGGTGCGCCT ACATAGGTTT GCGCCCCCTT GCAAGCCCTT GCTGCGGGAG GAGGTATCAT 6780  
TCAGAGTAGG ACTCCACGAG TACCCGGTGG GGTGCAATT ACCTTGCGAG CCCGAACCGG 6840  
ACGTAGCCGT GTTGACGTCC ATGCTCACTG ATCCCTCCA TATAACAGCA GAGGCGGCCG 6900  
GGAGAAGGTT GCGGAGAGGG TCACCCCTT CTATGGCCAG CTCCTCGGCC AGCCAGCTGT 6960  
CCGCTCCATC TCTCAAGGCA ACTTGACCG CCAACCATGA CTCCCCTGAC GCCGAGCTCA 7020  
TAGAGGCTAA CCTCCTGTGG AGGCAGGAGA TGGGCGGCAA CATCACCAGG GTTGAGTCAG 7080  
AGAACAAAGT GGTGATTCTG GACTCCTTCG ATCCGCTTGT GGCAGAGGAG GATGAGCGGG 7140  
AGGTCTCCGT ACCCGCAGAA ATTCTGCGGA AGTCTCGGAG ATTCGCCCCG GCCCTGCCCC 7200  
TTTGGGCGCG GCCGGACTAC AACCCCCCG TAGTAGAGAC GTGGAAAAAG CCTGACTACG 7260  
AACCACCTGT GTTCATGGC TGCCCCGTAC CACCTCCACG GTCCCCTCCT GTGCCTCCGC 7320  
CTCGGAAAAA GCGTACGGTG GTCCTACCG AATCAACCCT ATCTACTGCC TTGGCCGAGC 7380  
TTGCCACCAA AAGTTTGGC AGCTCCTCAA CTCCGGCAT TACGGGCGAC AATACGACAA 7440

TGGGCATCGG CACTGTCCTT GACCAAGCAG AGACTGCGGG GCGGAGACTG GTTGTGCTCG 4380  
CCACTGCTAC CCTCCGGGC TCCGTCAGTG TGTCCCATCC TAACATCGAG GAGGTTGCTC 4440  
TGTCCACCAC CGGAGAGATC CCTTTTACG GCAAGGCTAT CCCCTCGAG GTGATCAAGG 4500  
GGGGAAGACA TCTCATCTTC TGCCACTCAA AGAAGAAGTG CGACGAGCTC GCCGCGAAGC 4560  
TGGTCGCATT GGGCATCAAT GCCGTGGCCT ACTACCGCGG TCTTGACGTG TCTGTCATCC 4620  
CGACCAGCGG CGATGTTGTC GTCGTGTCGA CCGATGCTCT CATGACTGGC TTTACCGGCG 4680  
ACTTCGACTC TGTGATAGAC TGCAACACGT GTGTCACTCA GACAGTCGAT TTCAGCCTTG 4740  
ACCTTACCTT TACCATTGAG ACAACCACGC TCCCCAGGA TGCTGTCTCC AGGACTCAAC 4800  
GCCGGGGCAG GACTGGCAGG GGAAGCCAG GCATCTACAG ATTTGTGGCA CCGGGGGAGC 4860  
GCCCTCCGG CATGTTGAC TCGTCCGTCC TCTGTGAGTG CTATGACGCG GGCTGTGCTT 4920  
GGTATGAGCT CACGCCCGCC GAGACTACAG TTAGGCTACG AGCGTACATG AACACCCCGG 4980  
GGCTTCCCGT GTGCCAGGAC CATCTTGAAT TTTGGGAGGG CGTCTTACG GGCCTCACTC 5040  
ATATAGATGC CCACTTTCTA TCCCAGACAA AGCAGAGTGG GGAGAACTTT CCTTACCTGG 5100  
TAGCGTACCA AGCCACCGTG TGCCTAGGG CTCAAGCCCC TCCCCATCG TGGGACCAGA 5160  
TGTGGAAGTG TTTGATCCGC CTAAACCCA CCTCCATGG GCCAACACCC CTGCTATACA 5220  
GACTGGGCGC TGTTCAAGAT GAAGTCACCC TGACGCACCC AATCACCAA TACATCATGA 5280  
CATGCATGTC GGCCGACCTG GAGGTCGTCA CGAGCACCTG GGTGCTCGTT GGCGGCGTCC 5340  
TGGCTGCTCT GGCCGCGTAT TGCCTGTCAA CAGGCTGCGT GGTGATAGTG GGCAGGATTG 5400  
TCTTGTCCGG GAAGCCGGCA ATTATACCTG ACAGGGAGGT TCTCTACCAG GAGTTCGATG 5460  
AGATGGAAGA GTGCTCTCAG CACTTACCGT ACATCGAGCA AGGGATGATG CTCGCTGAGC 5520  
AGTTCAAGCA GAAGGCCCTC GGCCTCCTGC AGACCGCGTC CCGCCAAGCA GAGGTTATCA 5580  
CCCCTGCTGT CCAGACCAAC TGCCAGAAAC TCGAGGTCTT CTGGGCGAAG CACATGTGGA 5640  
ATTTTCATCAG TGGGATACAA TACTTGGCGG GCCTGTCAAC GCTGCCTGGT AACCCCGCCA 5700  
TTGCTTCATT GATGGCTTTT ACAGCTGCCG TCACCAGCCC ACTAACCCT GGCCAAACCC 5760  
TCCTCTTCAA CATATTGGGG GGGTGGGTGG CTGCCCAGCT CGCCGCCCCC GGTGCCGCTA 5820  
CCGCCTTTGT GGGCGCTGGC TTAGCTGGCG CCGCCATCGG CAGCGTTGGA CTGGGGAAGG 5880

CATACGCACT GGACACGGAG GTGGCCGCGT CGTGTGGCGG CGTTGTTCTT GTCGGGTAA	2820
TGGCGCTGAC TCTGTCGCCA TATTACAAGC GCTACATCAG CTGGTGCATG TGGTGGCTTC	2880
AGTATTTTCT GACCAGAGTA GAAGCGCAAC TGCACGTGTG GGTTCCTCCC CTCAACGTCC	2940
GGGGGGGGCG CGATGCCGTC ATCTTACTCA TGTGTGTTGT ACACCCGACT CTGTTATTTG	3000
ACATCACCAA ACTACTCCTG GCCATCTTCG GACCCCTTTG GATTCTTCAA GCCAGTTTGC	3060
TTAAAGTCCC CTAATTCGTG CGCGTTCAG GCCTTCTCCG GATCTGCGCG CTAGCGCGGA	3120
AGATAGCCGG AGGTCATTAC GTGCAAATGG CCATCATCAA GTTAGGGGCG CTTACTGGCA	3180
CCTATGTGTA TAACCATCTC ACCCCTCTTC GAGACTGGGC GCACAACGGC CTGCGAGATC	3240
TGGCCGTGGC TGTGGAACCA GTCGTCTTCT CCCGAATGGA GACCAAGCTC ATCACGTGGG	3300
GGGCAGATAC CGCCGCGTGC GGTGACATCA TCAACGGCTT GCGCGTCTCT GCGCGTAGGG	3360
GCCAGGAGAT ACTGCTTGGG CCAGCCGACG GAATGGTCTC CAAGGGGTGG AGGTTGCTGG	3420
CGCCCATCAC GCGGTACGCC CAGCAGACGA GAGGCCTCCT AGGGTGTATA ATCACCAGCC	3480
TGACTGGCCG GGACAAAAAC CAAGTGGAGG GTGAGGTCCA GATCGTGTCA ACTGCTACCC	3540
AAACCTTCCT GGCAACGTGC ATCAATGGGG TATGCTGGAC TGTCTACCAC GGGGCCGGAA	3600
CGAGGACCAT CGCATCAGCC AAGGGTCTCG TCATCCAGAT GTATACCAAT GTGGACCAAG	3660
ACCTTGTTGGG CTGGCCCGCT CCTCAAGGTT CCCGCTCATT GACACCCTGC ACCTGCGGCT	3720
CCTCGGACCT TTACCTGGTC ACGAGGCACG CCGATGTCAT TCCCGTGCGC CGGCGAGGTG	3780
ATAGCAGGGG TAGCCTGCTT TCGCCCCGGC CCATTTCTTA CTTGAAAGGC TCCTCGGGGG	3840
GTCCGCTGTT GTGCCCCGCG GGACACGCGG TGGGCCTATT CAGGGCCGCG GTGTGCACCC	3900
GTGGAGTGGC TAAGGCGGTG GACTTTATCC CTGTGGAGAA CCTAGAGACA ACCATGAGAT	3960
CCCCGGTGT CACGGACAAC TCCTCTCCAC CAGCAGTGCC CCAGAGCTTC CAGGTGGCCC	4020
ACCTGCATGC TCCACCGGC AGCGGTAAGA GCACCAAGGT CCCGGCTGCG TACGCAGCCC	4080
AGGGCTACAA GGTGTTGGTG CTCAACCCCT CTGTTGCTGC AACGCTGGGC TTTGGTGCTT	4140
ACATGTCCAA GGCCCATGGG GTTGATCCTA ATATCAGGAC CGGGGTGAGA ACAATTACCA	4200
CTGGCAGCCC CATCAGTAC TCCACCTACG GCAAGTTCCT TGCCGACGCG GGGTGCTCAG	4260
GAGGTGCTTA TGACATAATA ATTTGTGACG AGTGCCACTC CACGGATGCC ACATCCATCT	4320

TTGGTCAACT GTTTACCTTC TCTCCCAGGC GCCACTGGAC GACGCAAGAC TGCAATTGTT	1260
CTATCTATCC CGGCCATATA ACGGGTCATC GCATGGCATG GGATATGATG ATGAACTGGT	1320
CCCCTACGGC AGCGTTGGTG GTAGCTCAGC TGCTCCGGAT CCCACAAGCC ATCATGGACA	1380
TGATCGCTGG TGCTCACTGG GGAGTCCTGG CGGGCATAGC GTATTCTCTCC ATGGTGGGGA	1440
ACTGGGCGAA GGTCTGGTA GTGCTGCTGC TATTTGCCGG CGTCGACGG GAAACCCACG	1500
TCACCGGGGG AAGTGCCGGC CGCACCACGG CTGGGCTTGT TGGTCTCCTT ACACCAGGCG	1560
CCAAGCAGAA CATCCAACG ATCAACACCA ACGGCAGTTG GCACATCAAT AGCACGGCCT	1620
TGAACTGCAA TGAAAGCCTT AACACCGGCT GGTTAGCAGG GCTCTTCTAT CAGCACAAAT	1680
TCAACTCTTC AGGCTGTCCT GAGAGGTTGG CCAGCTGCCG ACGCCTTACC GATTTTGCCC	1740
AGGGCTGGGG TCCTATCAGT TATGCCAACG GAAGCGGCCT CGACGAACGC CCCTACTGCT	1800
GGCACTACCC TCCAAGACCT TGTGGCATTG TGCCCGCAA GAGCGTGTGT GGCCCGGTAT	1860
ATTGCTTCAC TCCCAGCCCC GTGGTGGTGG GAACGACCGA CAGGTCGGGC GCGCCTACCT	1920
ACAGCTGGGG TGCAAATGAT ACGGATGTCT TCGTCTTAA CAACACCAGG CCACCGCTGG	1980
GCAATTGGTT CGGTTGTACC TGGATGAACT CAACTGGATT CACCAAAGTG TGCGGAGCGC	2040
CCCCTTGTGT CATCGGAGGG GTGGGCAACA ACACCTTGCT CTGCCCCACT GATTGTTTCC	2100
GCAAGCATCC GGAAGCCACA TACTCTCGGT GCGGCTCCGG TCCCTGGATT ACACCCAGGT	2160
GCATGGTCGA CTACCCGTAT AGGCTTTGGC ACTATCCTTG TACCATCAAT TACACCATAT	2220
TCAAAGTCAG GATGTACGTG GGAGGGGTCG AGCACAGGCT GGAAGCGGCC TGCAACTGGA	2280
CGCGGGGCGA ACGCTGTGAT CTGGAAGACA GGGACAGGTC CGAGCTCAGC CCATTGCTGC	2340
TGTCCACCAC ACAGTGGCAG GTCCTTCCGT GTTCTTTCAC GACCCTGCCA GCCTTGTTCA	2400
CCGGCCTCAT CCACCTCCAC CAGAACATTG TGGACGTGCA GTACTTGTTAC GGGGTAGGGT	2460
CAAGCATCGC GTCCTGGGCC ATTAAGTGGG AGTACGTCGT TCTCCTGTTC CTCCTGCTTG	2520
CAGACGCGCG CGTCTGCTCC TGCTTGTGGA TGATGTTACT CATATCCCAA GCGGAGGCGG	2580
CTTTGGAGAA CCTCGTAATA CTCAATGCAG CATCCCTGGC CGGGACGCAC GGTCTTGTGT	2640
CCTTCCTCGT GTTCTTCTGC TTTGCGTGGT ATCTGAAGGG TAGGTGGGTG CCCGAGCGG	2700
TCTACGCCTT CTACGGGATG TGGCCTCTCC TCCTGCTCCT GCTGGCGTTG CCTCAGCGGG	2760



(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GCCAGCCCCC TGATGGGGGC GACACTCCAC CATGAATCAC TCCCCTGTGA GGAAC TACTG 60  
TCTTCACGCA GAAAGCGTCT AGCCATGGCG TTAGTATGAG TGTCGTGCAG CCTCCAGGAC 120  
CCCCCTCCC GGGAGAGCCA TAGTGGTCTG CGGAACCGGT GAGTACACCG GAATTGCCAG 180  
GACGACCGGG TCCTTTCTTG GATAAACCCG CTCAATGCCT GGAGATTTGG GCGTGCCCCC 240  
GCAAGACTGC TAGCCGAGTA GTGTTGGGTC GCGAAAGGCC TTGTGGTACT GCCTGATAGG 300  
GTGCTTGCGA GTGCCCCGGG AGGTCTCGTA GACCGTGCAC CATGAGCACG AATCCTAAAC 360  
CTCAAAGAAA AACCAAACGT AACACCAACC GTCGCCACCA GGACGTCAAG TTCCCGGGTG 420  
GCGGTCAGAT CGTTGGTGGA GTTTACTTGT TGCCGCGCAG GGGCCCTAGA TTGGGTGTGC 480  
GCGCGACGAG GAAGACTTCC GAGCGGTCGC AACCTCGAGG TAGACGTCAG CCTATCCCCA 540  
AGGCACGTCG GCCCGAGGGC AGGACCTGGG CTCAGCCCCG GTACCCTTGG CCCCTCTATG 600  
GCAATGAGGG TTGCGGGTGG GCGGGATGGC TCCTGTCTCC CCGTGGCTCT CGGCCTAGCT 660  
GGGGCCCCAC AGACCCCCGG CGTAGGTCGC GCAATTTGGG TAAGGTCATC GATACCCTTA 720  
CGTGCGGCTT CGCCGACCTC ATGGGGTACA TACCGCTCGT CGGCGCCCCT CTTGGAGGCG 780  
CTGCCAGGGC CCTGGCGCAT GGCCTCCGGG TTCTGGAAGA CGCGGTGAAC TATGCAACAG 840  
GGAACCTTCC TGGTTGCTCT TTCTCTATCT TCCTTCTGGC CCTGCTCTCT TGCCTGACTG 900  
TGCCCGCTTC AGCCTACCAA GTGCGCAATT CCTCGGGGCT TTACCATGTC ACCAATGATT 960  
GCCCTAACTC GAGTATTGTG TACGAGGCGG CCGATGCCAT CCTGCACACT CCGGGGTGTG 1020  
TCCCTTGCGT TCGCGAGGGT AACGCCTCGA GGTGTTGGGT GGCGGTGACC CCCACGGTGG 1080  
CCACCAGGGA CGGCAAACTC CCCACAACGC AGCTTCGACG TCATATCGAT CTGCTTGTCG 1140  
GGAGCGCCAC CCTCTGCTCG GCCCTCTACG TGGGGGACCT GTGCGGGTCT GTCTTTCTTG 1200

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

- (i) APPLICANT: Rice, Charles et al.
- (ii) TITLE OF INVENTION: FUNCTIONAL DNA CLONE FOR HEPATITIS C VIRUS (HCV) AND USES THEREOF
- (iii) NUMBER OF SEQUENCES: 21
- (iv) CORRESPONDENCE ADDRESS:
  - (A) ADDRESSEE: David A. Jackson, Esq.
  - (B) STREET: 411 Hackensack Ave, Continental Plaza, 4th Floor
  - (C) CITY: Hackensack
  - (D) STATE: New Jersey
  - (E) COUNTRY: USA
  - (F) ZIP: 07601
- (v) COMPUTER READABLE FORM:
  - (A) MEDIUM TYPE: Floppy disk
  - (B) COMPUTER: IBM PC compatible
  - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
  - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
  - (A) APPLICATION NUMBER: US
  - (B) FILING DATE: 03-MAR-1997
  - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
  - (A) NAME: Jackson Esq., David A.
  - (B) REGISTRATION NUMBER: 26,742
  - (C) REFERENCE/DOCKET NUMBER: 1113-1-006
- (ix) TELECOMMUNICATION INFORMATION:
  - (A) TELEPHONE: 201-487-5800
  - (B) TELEFAX: 201-343-1684

## (2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 9646 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: double
  - (D) TOPOLOGY: linear

WHAT IS CLAIMED IS:

1. A genetically engineered hepatitis C virus (HCV) nucleic acid clone which comprises from 5' to 3' on the positive-sense nucleic acid a functional 5' non-translated region (NTR) comprising an extreme 5'-terminal conserved sequence, an open reading frame (ORF) encoding at least a portion of an HCV polyprotein whose cleavage products form functional components of HCV virus particles and RNA replication machinery, and a 3' non-translated region (NTR) comprising an extreme 3'-terminal conserved sequence, or a derivative thereof selected from the group consisting of adapted virus, live-attenuated virus, replication-competent non-infectious virus, and defective virus.
2. The HCV nucleic acid of claim 1 which has a consensus nucleic acid sequence determined from the sequence of a majority of at least three clones of an HCV isolate or genotype.
3. The HCV nucleic acid of claim 2 having at least a functional portion of a sequence as shown in SEQ ID NO:1.
4. The HCV nucleic acid of claim 1 or 3, wherein a region from an HCV isolate is substituted for a homologous region.
5. The HCV nucleic acid of claim 1 which is a DNA that codes on expression for a replication-competent HCV RNA replicon, or which is a replication-competent HCV RNA replicon.
6. An HCV nucleic acid of claim 1, 3, or 5 which has the full length sequence as depicted in or corresponding to SEQ ID NO:1.

7. The HCV nucleic acid of claim 1 wherein the 5'-terminal sequence is homologous or complementary to an RNA sequence selected from the group consisting of GCCAGCC; GGCCAGCC; UGCCAGCC; AGCCAGCC; AAGCCAGCC; GAGCCAGCC; GUGCCAGCC; and GCGCCAGCC, wherein the sequence GCCAGCC is the 5'-terminus of SEQ ID NO:3.
8. The HCV nucleic acid of claim 1 wherein the 3'-NTR extreme terminus is homologous or complementary to a DNA having the sequence  
5'-GGTGGCTCCATCTTAGCCCTAGTCACGGCTAGCTGTGAAAGGTCCGTGAG  
CCGCATGACTGCAGAGAGTGCTGATACTGGCCTCTCTGCTGATCATGT-3'  
(SEQ ID NO:4).
9. The HCV nucleic acid of claim 1 wherein the 3'-NTR comprises a long polypyrimidine region.
10. The HCV nucleic acid of claim 1, 3, or 5 further comprising a heterologous gene operatively associated with an expression control sequence, wherein the heterologous gene and expression control sequence are oriented on the positive-strand nucleic acid molecule.
11. The HCV nucleic acid of claim 10 wherein the heterologous gene is inserted by a strategy selected from the group consisting of:
- a) in-frame fusion with the HCV polyprotein coding sequence; and
  - b) creation of an additional cistron.
12. The HCV nucleic acid of claim 10, wherein the heterologous gene is an antibiotic resistance gene or a reporter gene.

13. The HCV nucleic acid of claim 11, wherein the antibiotic resistance gene is a neomycin resistance gene operatively associated with an internal ribosome entry site (IRES) inserted in an *Sfi*I site in the 3'-NTR.
14. The HCV nucleic acid of claim 1, 3, or 5 which is selected from the group consisting of double stranded DNA, positive-sense cDNA, or negative-sense cDNA.
15. The HCV nucleic acid of claim 1, 3, or 5 which is positive-sense RNA or negative-sense RNA.
16. The HCV DNA of claim 14 further comprising a promoter 5' of the 5'-NTR on positive-sense DNA, whereby transcription of template DNA from the promoter produces replication-competent RNA.
17. A plasmid clone harboring a full-length HCV cDNA which can be transcribed to produce infectious HCV RNA transcripts as deposited with the American Type Culture Collection and assigned accession no. 97879, having a sequence as depicted in SEQ ID NO:5, or a derivative thereof selected from the group consisting of
- a) a derivative wherein a 5'-terminal sequence is homologous or complementary to an RNA sequence selected from the group consisting of GCCAGCC, GGCCAGCC, UGCCAGCC, AGCCAGCC, AAGCCAGCC, GAGCCAGCC, GUGCCAGCC, and GCGCCAGCC, wherein the sequence GCCAGCC is the 5'-terminus of SEQ ID NO:3; and
  - b) a derivative wherein a 3'-NTR comprises a short poly-pyrimidine region.
18. A plasmid clone harboring a full-length HCV cDNA which can be transcribed to produce infectious HCV RNA transcripts as deposited with the American Type

Culture Collection and assigned accession no. 97879, having a sequence as depicted in SEQ ID NO:5, or a derivative thereof selected from the group consisting of

- a) a derivative produced by substitution of homologous regions from other HCV isolates or genotypes;
- b) a derivative produced by mutagenesis;
- c) a derivative selected from the group consisting of adapted, live-attenuated, replication competent non-infectious, and defective variants;
- d) a derivative comprising a heterologous gene operatively associated with an expression control sequence;
- e) a derivative consisting of a functional fragment of any of the abovementioned derivatives.

19. An HCV DNA or RNA transcribed from the full length HCV cDNA harbored in the plasmid clone of claim 17 or 18.

20. A method for identifying a cell line that is permissive for infection with HCV, comprising contacting a cell line in tissue culture with an infectious amount of the HCV RNA of claim 15, and detecting replication of HCV in cells of the cell line.

21. A method for identifying a cell line that is permissive for infection with HCV, comprising contacting a cell line in tissue culture with an infectious amount of an infectious HCV RNA of claim 19 under conditions that select for cells that express the heterologous expression control sequence.

22. A method for identifying an animal that is permissive for infection with HCV, comprising introducing an infectious amount of the HCV RNA of claim 15 to the animal, and detecting replication of HCV in the animal.

23. A method for selecting for HCV with adaptive mutations that permit higher levels of HCV replication in a permissive cell line comprising contacting a cell line in culture with an infectious amount of the HCV RNA of claim 15, and detecting progressively increasing levels of HCV RNA in the cell line.
24. The method according to claim 23, wherein the adaptive mutation permits modification of HCV tropism.
25. A host cell line transfected, transformed, or transduced with the HCV DNA of claim 16.
26. The host cell line of claim 25 selected from the group consisting of a bacterial cell, a yeast cell, a plant cell, an insect cell, and a mammalian cell.
27. A method for infecting an animal with HCV which comprises administering an infectious dose of HCV RNA of claim 15 to the animal.
28. A method for infecting an animal with HCV which comprises administering an infectious dose of HCV RNA of claim 19 to the animal.
29. A non-human animal infected with HCV, wherein the HCV has a genomic RNA sequence corresponding to the HCV nucleic acid of claim 1, 3, or 5.
30. A method for propagating HCV *in vitro* comprising culturing a cell line contacted with an infectious amount of HCV RNA of claim 15 under conditions that permit replication of the HCV RNA.
31. A method for propagating HCV *in vitro* comprising culturing a cell line

contacted with an infectious amount of HCV RNA of claim 19 under conditions that permit replication of the HCV RNA.

32. An *in vitro* cell line infected with HCV, wherein the HCV has a genomic RNA sequence corresponding to the HCV nucleic acid of claim 1, 3, or 5.

33. The cell line of claim 32 which is a hepatocyte cell line.

34. A method for transducing an animal susceptible to HCV infection with a heterologous gene, comprising administering an amount of the HCV nucleic acid of claim 10 to the animal effective to infect the animal with the HCV.

35. A method for transducing an animal susceptible to HCV infection with a heterologous gene, comprising administering an amount of the HCV RNA of claim 19 to the animal effective to infect the animal with the HCV RNA.

36. A method for producing HCV virus particles comprising isolating HCV virus particles from the HCV-infected non-human animal of claim 29.

37. A method for producing HCV virus particles comprising:

- a) culturing the cell line of claim 25 under conditions that permit HCV replication and virus particle formation; and
- b) isolating HCV virus particles from the cell line culture.

38. A method for producing HCV virus particles comprising:

- a) culturing the cell line of claim 32 under conditions that permit HCV replication and virus particle formation; and
- b) isolating HCV virus particles from the cell line culture.



39. A method for producing HCV particle proteins comprising:
- a) culturing a host expression cell line transfected with the HCV DNA of claim 16 under conditions that permit expression of HCV particle proteins; and
  - b) isolating HCV particle proteins from the cell culture.
40. An HCV virus particle comprising a replication-competent HCV genome RNA corresponding to the HCV nucleic acid of claim 1, 3, or 5.
41. An HCV virus particle comprising a replication-defective HCV genome RNA corresponding to the HCV nucleic acid of claim 1, 3, or 5.
42. An *in vitro* cell-free assay system for HCV comprising HCV genomic template RNA of claim 15, functional HCV replicase components, and an isotonic buffered medium comprising ribonucleotide triphosphate bases.
43. An *in vitro* cell-free assay system for HCV comprising HCV genomic template RNA of claim 19, functional HCV replicase components, and an isotonic buffered medium comprising ribonucleotide triphosphate bases.
44. A method for producing antibodies to HCV comprising administering an immunogenic amount of HCV virus particles of claim 41 to an animal, and isolating anti-HCV antibodies from the animal.
45. A method for producing antibodies to HCV comprising administering an immunogenic amount of HCV virus particles of claim 42 to an animal, and isolating anti-HCV antibodies from the animal.
46. A method for producing antibodies to HCV comprising screening a human

antibody library for reactivity with HCV virus particles of claim 41 and selecting a clone from the library that expresses an antibody reactive with the HCV virus particle.

47. A method for producing antibodies to HCV comprising screening a human antibody library for reactivity with HCV virus particles of claim 42 and selecting a clone from the library that expresses an antibody reactive with the HCV virus particle.

48. An HCV vaccine comprising HCV virus particles of claim 41 in a pharmaceutically acceptable adjuvant.

49. An HCV vaccine comprising HCV virus particles of claim 42 in a pharmaceutically acceptable adjuvant.

50. A method for screening for agents capable of modulating HCV replication comprising:

a) administering a candidate agent to an HCV infected animal of claim 29;

and

b) testing for an increase or decrease in a level of HCV infection or activity compared to a level of HCV infection or activity in the animal prior to administration of the candidate agent;

wherein a decrease in the level of HCV infection or activity compared to the level of HCV infection or activity in the animal prior to administration of the candidate agent is indicative of the ability of the agent to inhibit HCV infection or activity.

51. The method according to claim 47 wherein testing for the level of HCV infection is selected from the group consisting of:

a) measuring viral titer in a tissue sample from the animal;

b) measuring viral proteins in a tissue sample from the animal; and

- c) measuring liver enzymes.

52. The method according to claim 50 wherein the HCV genome used to infect the animal includes a heterologous gene operatively associated with an expression control sequence, wherein the heterologous gene and expression control sequence are oriented on the positive-strand nucleic acid molecule, and wherein testing for the level of HCV activity comprises measuring the level of a marker protein in a tissue sample from the animal.

53. A method for screening for agents capable of modulating HCV replication comprising:

- a) contacting the cell line of claim 32 with a candidate agent; and
- b) testing for an increase or decrease in a level of HCV infection or activity compared to a level of HCV infection or activity in a control cell line or in the cell line prior to administration of the candidate agent;

wherein a decrease in the level of HCV infection or activity compared to the level of HCV infection or activity in a control cell line or in the cell line prior to administration of the candidate agent is indicative of the ability of the agent to inhibit HCV infection or activity.

54. The method according to claim 53 wherein testing for the level of HCV infection is selected from the group consisting of:

- a) measuring viral titer in the cells, culture medium, or both; and
- b) measuring viral proteins in the cells, culture medium, or both.

55. The method according to claim 53 wherein the HCV genome used to infect the cell line includes a heterologous gene operatively associated with an expression control sequence, wherein the heterologous gene and expression control sequence are oriented

on the positive-strand nucleic acid molecule, and wherein testing for the level of HCV activity comprises measuring the level of a marker protein in a tissue sample from the animal.

56. A method for screening for agents capable of modulating HCV replication comprising:

- a) contacting the *in vitro* system of claim 43 with a candidate agent; and
- b) testing for an increase or decrease in a level of HCV replication compared to a level of HCV replication in a control cell system or system prior to administration of the candidate agent;

wherein a decrease in the level of HCV replication compared to the level of HCV replication in a control cell line or in the cell line prior to administration of the candidate agent is indicative of the ability of the agent to inhibit HCV infection or activity.

57. A method for preparing an HCV nucleic acid comprising joining from 5' to 3' on the positive-sense DNA a functional 5' non-translated region (NTR) comprising an extreme 5'-terminal conserved sequence, a polyprotein coding region encoding HCV proteins that provide for expression of functional HCV proteins, and a 3' non-translated region (NTR) comprising an extreme 3'-terminal conserved sequence.

58. The method according to claim 56 further comprising determining a consensus sequence for the 5'-NTR, polyprotein coding sequence, and 3'-NTR from a majority sequence of at least three clones of an HCV isolate or genotype.

59. The method according to claim 56 wherein the 3'-NTR comprises an extreme terminal sequence homologous to a DNA having the sequence  
5'-GGTGGCTCCATCTTAGCCCTAGTCACGGCTAGCTGTGAAAGGTCCGTGAG

CCGCATGACTGCAGAGAGTGCTGATACTGGCCTCTCTGCTGATCATGT-3' -  
(SEQ ID NO:4).

60. The method according to claim 56 wherein the HCV nucleic acid has a positive strand sequence as depicted in or corresponding to SEQ ID NO:1 comprising substitution of a homologous region from another HCV isolate or genotype.

61. An *in vitro* method for detecting antibodies to HCV in a biological sample from a subject comprising:

- a) contacting a biological sample from a subject with HCV virus particles of claim 41 under conditions that permit binding of HCV-specific antibodies in the sample to the HCV virus particles; and
- b) detecting binding of antibodies in the sample to the HCV virus particles,

wherein detecting binding of antibodies in the sample to the HCV virus particles is indicative of the presence of antibodies to HCV in the sample.

62. An *in vitro* method for detecting antibodies to HCV in a biological sample from a subject comprising:

- a) contacting a biological sample from a subject with HCV virus particles of claim 42 under conditions that permit binding of HCV-specific antibodies in the sample to the HCV virus particles; and
- b) detecting binding of antibodies in the sample to the HCV virus particles,

wherein detecting binding of antibodies in the sample to the HCV virus particles is indicative of the presence of antibodies to HCV in the sample.

63. An *in vitro* method for detecting the presence of HCV in a biological sample from a subject comprising:

- a) contacting a cell line permissive for productive HCV infection with a

biological sample, wherein the cell line has been modified to contain a transgene that express a reporter gene product expressed under control of a trans-acting factor produced by HCV; and

b) detecting expression of the reporter gene product,

wherein detection of expression of the reporter gene product is indicative of the presence of HCV in the biological sample from the subject.

64. An *in vitro* method for detecting the presence of HCV in a biological sample from a subject comprising:

a) contacting a cell line permissive for productive HCV infection with a biological sample, wherein the cell line has been modified to contain a defective virus transgene, which defective virus transgene will express a reporter gene product at high levels under control of a trans-acting factor produced by HCV;

and

b) detecting expression of the reporter gene product,

wherein detection of expression of the reporter gene product is indicative of the presence of HCV in the biological sample from the subject.

65. The method according to claim 64, wherein the defective viral transgene produces an engineered alphavirus, the trans-acting helper factor is alphavirus nsP4 polymerase, and wherein the alphavirus nsP4 polymerase is expressed as a chimeric fusion protein with HCV NS4A, such that the alphavirus nsP4 polymerase-HCV NS4A chimeric fusion protein is cleaved by HCV NS3 proteinase to release functional alphavirus nsP4 polymerase.

66. The method according to claim 63 or 64 wherein the biological sample is selected from the group consisting of blood, serum, plasma, blood cells, lymphocytes, and liver tissue biopsy.

67. A test kit for HCV comprising authentic HCV virus components. -
68. A diagnostic test kit for HCV comprising components derived from an authentic HCV virus.

1113-1-006




Figure 1



1113-1-006




Figure 2

3143





Figure 3

1113-1-006

4/43





Figure 4

5/43

1113-1-006

A.



B.




Figure 5

1113-1-006

6/43




Figure 6

7/43

1113-1-006




Figure 7

8143

1113-1-006




Figure 8

9/43

1113-1-006

AA

```
#248 .....
#227 .....
#213 .....
#211 .....
#209 .....
#12 .....
GenBank .....
PCR-seq .....
cons. ....
564 ACCTGGGCTCAGCCCGGTACCTTGGCCCCCTATGGCAATGAGGGTTGCCGGTGGGCG 623
75 T W A Q P G Y P W P L Y G N E G C G W A 94

#248 .....
#227 .....
#213 .....
#211 .....
#209 ...C.....
#12 .....
GenBank .....
cons. ....
624 GGATGGCTCCTGTCTCCCGTGGCTCTCGGCCTAGCTGGGGCCCCACAGACCCCGCGT 683
95 G W L L S P R G S R P S W G P T D P R R 114

#248 .....
#227 .....
#213 .....
#211 .....
#209 .....A.....
#12 .....
GenBank .....
cons. ....
684 AGGTCGCGCAATTGGGTAAAGTCAATCGATACCCCTACGTGCGGCTTCGCCGACCTCATG 743
115 R S R N L G K V I D T L T C G F A D L M 134

#248 .....
#227 .....
#213 .....
#211 .....
#209 .....
#12 .....
GenBank .....
cons. ....
744 GGGTACATACCGCTCGTCGGCGCCCTCTTGGAGGCGCTGCCAGGGCCCTGGCGCATGGC 803
135 G Y I P L V G A P L G G A A R A L A H G 154

#248 .....
#227 .....
#213 .....
#211 .....t.....
#209 .....t.....
#12 .....
GenBank .....
cons. ....
804 GTCCGGGTTCTGGAAGACGGCGTGAACATGCAACAGGGAACCTTCTGGTTGCTCTTTC 863
155 V R V L E D G V N Y A T G N L P G C S F 174
```

Figure 9



10/43

1113-1-006

AB

```
#248 .....
#227 .....
#213 .....c.....
#211 .....a.....
#209 .....a.....
#12 .....
GenBank .....
cons. ....
864 TCTATCTTCCTTCTGGCCCTGCTCTCTTGCCTGACTGTGCCCGCTTCAGCCTACCAAGTG 923
175 S I F L L A L L S C L T V P A S A Y Q V 194
```

```
#248 .....
#227 .....c.....
#213 .....c.....
#211 .....c.....
#209 .....c.....
#12 .....c.....
GenBank .....
cons. ....
924 CGCAATTCCTCGGGGCTTTACCATGTCCACCAATGATTGCCCTAATTCGAGTATTGTGTAC 983
195 R N S S G L Y H V T N D C P N S S I V Y 214
```

```
#248 .....G.....
#227 .....G.....
#213 .....
#211 .....A.....
#209 .....A.....t
#12 .....
GenBank .....
cons. ....
984 GAGGCGGCCGATGCCATCCTGCACACTCCGGGGTGTGTCCCTTGCCTTCGCGAGGGTAAC 1043
215 E A A D A I L H T P G C V P C V R E G N 234
```

```
#248 .....
#227 .....G.....t.....
#213 .....
#211 .....G.....
#209 .....
#12 .....
GenBank .....
cons. ....
1044 GCCTCGAGGTGTGTGGGTGGCGGTGACCCCCACGGTGGCCACCCAGGGACGGCAAACCTCCCC 1103
235 A S R C W V A V T P T V A T R D G K L P 254
```

```
#248 .....g...
#227 .....g.T.
#213 .....g.T.
#211 .....g...
#209 .....c...
#12 .....g...
GenBank .....
cons. ....
1104 ACAACGCAGCTTCGACGTCATATCGATCTGCTTGTGGGAGCGCCACCCTCTGCTCAGCC 1163
255 T T Q L R R H I D L L V G S A T L C S A 274
```

Figure 9

11/43

1113-1-006

AC

```
#248 .....
#227 .....C.....
#213 .....C.....
#211 .....C.....
#209 .....C.....
#12 .....C.....
GenBank .....C.....
cons. ....
1164 CTCTACGTGGGGACCTGTGCGGGTCTGTTTTCTTGTGGTCAACTGTTACCTTCTCT 1223
275 L Y V G D L C G S V F L V G Q L F T F S 294

#248 .....GA.....
#227 .....GA.....
#213 .....GA.....
#211 .....GA.....
#209 .....GA.....
#12 .....GA.....
GenBank .....GA.....
cons. ....
1224 CCCAGGCGCCACTGGACGACGCAAGCTGCAATTGTTCTATCTATCCCGGCCATATAACG 1283
295 P R R H W T T Q S C N C S I Y P G H I T 314

#248 .....
#227 .....G.....
#213 .....
#211 .....C.....C.....
#209 .....C.....C.....
#12 .....C.....C.....
GenBank .....A.....
cons. ....
1284 GGTCAATCGCATGGCATGGATATGATGATGAAGTGGTCCCTACGGCAGCGTTGGTGGTA 1343
315 G H R M A W D M M M N W S P T A A L V V 334

#248 .....C.....
#227 .....
#213 .....
#211 .....
#209 .....C.....
#12 .....C.....C.....
GenBank .....a.....
PCR-seq .....
cons. ....
1344 GCTCAGCTGCTCCGGATCCACAGCCATCATGGACATGATCGCTGGTGGTCACTGGGGA 1403
335 A Q L L R I P Q A I M D M I A G A H W G 354

#248 .....
#227 .....T.....
#213 .....T.....
#211 .....
#209 .....G.....
#12 .....AA.....
GenBank .....AA.....
PCR-seq .....
cons. ....
1404 GTCCTGGCGGGCATAGCGTATTCTCCATGGTGGGGAAGTGGCGAAGGTCTGGTAGTG 1463
355 V L A G I A Y F S M V G N W A K V L V V 374
```

Figure 9

12/43

1113-1-006

AD

```

#83 .....G.
#84 .....t.....
#86 .....A.....G.
#87 .....
#89 .....G.
#90 .....G.
#92 .....t.....A.....
#93 .....A.....G.
#95 .....A.....G.
#96 .....G.
#99 .....A.....G.
#101 .....A.....G.
#248 .....t.....
#227 .....G.
#213 .....A.....G.
#211 .....G.
#209 .....
#12 .....t.....
GenBank .....A.....G.
PCR-seq .....R.....G.
cons. ....G.
1464 CTGCTGCTATTTGCCGGCGTCGACGCGGAAACCCACGTCACCGGGGAAGTGCCGGCCAC 1523
375 L L L F A G V D A E T H V T G G S A G H 394

#83 ....TA....cT..AC.....
#84 .....C.....T.....
#86 .....C.....
#87 ....G.....A..C.....T.....T.....
#89 ....TA....cT..AC.....
#90 ....TA....cT..AC.....
#92 ....Gt....C.....T.....T.....
#93 .....
#95 .....
#96 ....TA....cT..AC.....
#99 .....
#101 .....A.....G.....
#248 .....C.....T.....
#227 .....
#213 .....A.....
#211 ....TA....cT..AC.....
#209 .....C.....
#12 .....C.....T.....
GenBank .....
PCR-seq .....
cons. ....
1524 ACCACGGCTGGGCTTGTGGTCTCCTTACACCAGGCCCAAGCAGAACATCCAACGTGATC 1583
395 T T A G L V G L L T P G A K Q N I Q L I 414

```

Figure 9

13/43

1113-1-006

AE

```
#83 .....c.....t.....
#84 .....t.....t.....A.
#86 .....t.....t.....A.
#87 .....c.....t.....
#89 .....c.....t.....
#90 .....t.....t.....A.
#92 .....a.....t.....A.
#93 .....y.....t.....A.
#95 .....t.....t.....
#96 .....c.....t.....A.
#99 .....G.....t.....A.
#101 .....t.....t.....A.
#248 .....t.....t.....A.
#227 .....t.....t.....A.
#213 .....c.....t.....
#211 .....t.....t.....A.
#209 .....t.....t.....A.
#12 .....t.....t.....A.
GenBank .....t.....A.
PCR-seq .....t.....A.
cons. ....t.....A.
1584 AACACCAACGGCAGTTGGCACATCAATAGCACGGCCTTGAAC TGCAACGATAGCCTTACC 1643
415 N T N G S W H I N S T A L N C N D S L T 434

#83 .....Aa.....
#84 .....Aa.....
#86 .....Aa.....
#87 .....G.....TA.....T.
#89 .....Aa.....
#90 .....G.....A.....G.....T.....G.
#92 .....A.....Ag.....
#93 .....Aa.....
#95 .....Aa.....
#96 .....Ag.....
#99 .....Aa.....
#101 .....A.....
#248 .....Ag.....
#227 .....Aa.....G.
#213 .....Aa.....
#211 .....A.....
#209 .....A.....
#12 .....Ag.....
GenBank .....Ag.....
PCR-seq .....Ag.....
cons. ....Ag.....
1644 ACCGGCTGGTTAGCAGGGCTCTTCTATCGGCACAAATTCAACTCTTCAGGCTGTCTGAG 1703
435 T G W L A G L F Y R H K F N S S G C P E 454
```

Figure 9

14/43

1113-1-006

AF

```
#83 .....c.....c.t.....
#84 .....t.....
#86 .....t.....
#87 .....c.t.....c.
#89 .....c.t.....
#90 .....c.t.....
#92 .....c.t.....c.
#93 .....T.....t.....
#95 .....t.....
#96 .....y.....a.....y.t.....
#99 .....t.....
#101 .....t.....
#248 .....G.....t.....
#227 .....t.....
#213 .....t.....
#211 .....c.....c.t.....
#209 .....t.....t.....
#12 .....G.....t.....
GenBank .....t.....
PCR-seq .....t.....
cons. ....t.....
1704 AGGTTGGCCAGCTGCCGACGCCTTACCGATTTGCCAGGGCTGGGGTCCCATCAGTTAT 1763
455 R L A S C R R L T D F A Q G W G P I S Y 474

#83 .....c.....c.....
#84 .....c.....c..T.....A.....
#86 .....c.....c.....A.....
#87 .....Cc.....c.....A.....
#89 .....c.....c.....A.....
#90 .....c.....c.....A.....
#92 .....Cc.....c.....A.....
#93 .....c.....c.....A.....
#95 .....c.....c.....
#96 .....c.....c.....r.....
#99 .....c.....c.....
#101 .....c.....c.....
#248 .....c.t.....c.....
#227 .....c.....c.....c.....A.....
#213 .....c.....c.....
#211 .....c.....c.....c.....
#209 .....c.....c.....
#12 .....c.....c.....
GenBank .....c.....c.....
PCR-seq .....c.....c.....
cons. ....c.....c.....
1764 GCCAACGGAAGCGGCCTTGACGAACGCCCTACTGTTGGCACTACCCTCCAAGACCTTGT 1823
475 A N G S G L D E R P Y C W H Y P P R P C 494
```

Figure 9

15/43

1113-1-006

AG

```
#248 .....t.....
#227 ..t.....
#213 .....
#211 ..t.....
#209 .....
#12 .....
GenBank .....
PCR-seq .....
cons. ....
1824 GGCATTGTGCCCGCAAAGAGCGTGTGTGGCCCGGTATATTGCTTCACTCCCAGCCCCGTG 1883
495 G I V P A K S V C G P V Y C F T P S P V 514

#248 .....
#227 .....
#213 .....
#211 .....
#209 .....
#12 .....g.....
GenBank .....
PCR-seq .....
cons. ....
1884 GTGGTGGGAACGACCGACAGTCCGGCGCGCCTACCTACAGCTGGGGTGCAAATGATACG 1943
515 V V G T T D R S G A P T Y S W G A N D T 534

#248 .....t.....A.....C.....
#227 .....
#213 .....
#211 .....C.....
#209 .....
#12 .....t.....
GenBank .....
PCR-seq .....
cons. ....
1944 GATGTCCTTCGTCCCTTAACAACACCCAGGCCACCGCTGGGCAATTGGTTGGTTGTACCTGG 2003
535 D V F V L N N T R P P L G N W F G C T W 554

#248 .....
#227 .....
#213 .....G.....
#211 .....
#209 .....
#12 .....
GenBank .....
PCR-seq .....
cons. ....
2004 ATGAACTCAACTGGATTACCAAAGTGTGCGGAGCGCCCTTGTGTTCATCGGAGGGGTG 2063
555 M N S T G F T K V C G A P P C V I G G V 574
```

Figure 9

16/43

1113-1-006

AH

```
#248 .....t.....g.....
#227 .....t.....g.....
#213 .....t.....g.....
#211 .....t.....g.....
#209 .....c.....g.....
#12 .....t.....g.....
GenBank .....T.....
PCR-seq .....t.....g.....
cons. ....t.....g.....
2064 GGCAACAACACCTTGCTCTGCCCCACTGATGCTTCCGCAAACATCCGGAAGCCACATAC 2123
575 G N N T L L C P T D C F R K H P E A T Y 594

#248 .....A.....
#227 .....A.....
#213 .....A.....
#211 .....A.....
#209 .....A.....
#12 .....A.....
GenBank .....A.....
PCR-seq .....R.....
cons. ....t.....g.....
2124 TCTCGGTGCGGCTCCGGTCCCTGGATTACACCCAGGTGCATGGTCGACTACCCGTATAGG 2183
595 S R C G S G P W I T P R C M V D Y P Y R 614

#248 .....C.....
#227 .....C.....
#213 .....C.....
#211 .....C.....
#209 .....C.....
#12 .....C.....y.....
GenBank .....C.....
PCR-seq .....C.....
cons. ....t.....g.....
2184 CTTTGGCACTATCCTTGTAATCAATTACACCATATTCAAAGTCAGGATGTACGTGGGA 2243
615 L W H Y P C T I N Y T I F K V R M Y V G 634

#248 .....
#227 .....
#213 .....
#211 .....
#209 .....
#12 .....
GenBank .....
PCR-seq .....
cons. ....t.....g.....
2244 GGGGTCGAGCACAGGCTGGAAGCGGCTGCAACTGGACGCGGGGCGAACGCTGTGATCTG 2303
635 G V E H R L E A A C N W T R G E R C D L 654
```

Figure 9

17/43

1113-1-006

AI

```
#248 .....g.....
#227 .....g.....
#213 .....g.....
#211 .....g.....
#209 .....g.....
#12 .....g.....
GenBank .....g.....
cons. ....
2304 GAAGACAGGGACAGGTCCGAGCTCAGCCCATTTGCTGCTGTCCACCACACAGTGGCAGGTC 2363
655 E D R D R S E L S P L L L S T T Q W Q V 674

#248 .....-----.....
#227 .....T.....
#213 .....T.....
#211 .....
#209 .....
#12 .....
GenBank .....
PCR-seq .....
cons. ....
2364 CTTCCGTGTTCTTTACGACCCCTGCCAGCCTTGTCACCGGCCTCATCCACCTCCACCAG 2423
675 L P C S P T T L P A L S T G L I H L H Q 694

#248 .....a.....
#227 .....a.....
#213 .....a.....
#211 .....a.....
#209 .....a.....C.....
#12 .....a.....
GenBank .....a.....
PCR-seq .....a.....
cons. ....a.....
2424 AACATGTGGACGTGCAGTACTTGTACGGGTGGGGTCAAGCATCGCGTCCTGGGCCATT 2483
695 N I V D V Q Y L Y G V G S S I A S W A I 714

#248 .....C.....
#227 .....
#213 .....
#211 .....c.....
#209 .....c.....
#12 .....c.....
GenBank .....t.....
PCR-seq .....
cons. ....
2484 AAGTGGGAGTACGTGTTCTCTCTGTTCTTCTGCTTCAGACGCGCGGCTCTGCTCCTGC 2543
715 K W E Y V V L L F L L L A D A R V C S C 734
```

Figure 9



18/43

1113-1-006

AJ

```
#248 .....G.....
#227 .....A.....
#213 .....G.....
#211 .....
#209 .....
#12 .....
GenBank .....
PCR-seq .....
cons. ....
2544 TTGTGGATGATGTTACTCATATCCCAAGCGGAGGCGGCTTTGGAGAACCTCGTAATACTC 2603
735 L W M M L L I S Q A E A A L E N L V I L 754

#248 .....
#227 .....C.....t.....
#213 .....
#211 .....
#209 .....
#12 .....
GenBank .....t.....
PCR-seq .....
cons. ....
2604 AATGCAGCATCCCTGGCCGGGACGCACGGTCTTGTGTCCTTCCTCGTGTCTTCTGCTTT 2663
755 N A A S L A G T H G L V S F L V F F C F 774

#248 .....T.....
#227 .....
#213 .....T.....
#211 .....
#209 .....
#12 .....
GenBank .....C.....
cons. ....
2664 GCGTGGTATCTGAAGGGTAGGTGGGTGCCCGGAGCGGTCTACGCCCTTCTACGGGATGTGG 2723
775 A W Y L K G R W V P G A V Y A P Y G M W 794

#248 .....G.....
#227 .....
#213 .....
#211 .....t.....g.....
#209 .....t.....g.....
#12 .....C.....t.....g.....
GenBank .....
cons. ....
2724 CCTCTCCTCCTGCTCCTGCTGGCGTTGCCTCAGCGGGCATAACGCACTGGACACGGAGGTG 2783
795 P L L L L L L A L P Q R A Y A L D T E V 814
```

Figure 9

19/43

1113-1-006

AK

```

#248 .....g.....
#227 .....G.....g.....
#213 .....
#211 .....g.....
#209 .....g.....
#12 .....g.....
GenBank .....g.....
PCR-seq .....g.....
cons. ....g.....
2784 GCCGCGTCGTGTGGCGGCGTTGTTCTTGTCTGGGTTAATGGCGCTGACTCTGTCACCATAT 2843
815 A A S C G G V V L V G L M A L T L S P Y 834

```

```

#248 .....
#227 .....G.....
#213 .....G.....
#211 .....C.....
#209 .....C.....
#12 .....C.....
GenBank .....
PCR-seq .....C.....
cons. ....C.....
2844 TACAAGCGCTATATCAGCTGGTGCATGTGGTGGCTTCAGTATTTCTGACCAGAGTAGAA 2903
835 Y K R Y I S W C M W W L Q Y F L T R V E 854

```

```

#248 .....
#227 .....
#213 .....
#211 .....
#209 .....
#12 .....
GenBank .....
PCR-seq .....
cons. ....
2904 GCGCAACTGCACGTGTGGGTTCCCCCCTCAACGTCCGGGGGGGGCGCGATGCCGTCATC 2963
855 A Q L H V W V P P L N V R G G R D A V I 874

```

```

#248 .....a.....c.....G.....
#227 .....a.....c.....
#213 .....a.....c.....
#211 .....T.....
#209 .....
#12 .....c.....
GenBank .....C.....a.....G.c.....
PCR-seq .....f.....y.....
cons. ....
2964 TTAATCATGTGTGTTGTACACCCGACTCTGGTATTTGACATCACCAAATACTCCTGGCC 3023
875 L L M C V V H P T L V F D I T K L L L A 894

```

Figure 9

20/43

1113-1-006

AL

```
#248 .....
#227 .....
#213 .....
#211 .....
#209 .....
#12 .....
GenBank .....
PCR-seq .....
cons. ....
3024 ATCTTCGGACCCCTTTGGATCTTCAAGCCAGTTTGCTTAAAGTCCCTACTTCGTGCGC 3083
895 I F G P L W I L Q A S L L K V P Y F V R 914

#248 .....G.....
#227 .....
#213 .....
#211 .....
#209 .....
#12 .....G.....
GenBank .....
PCR-seq .....
cons. ....
3084 GTTCAAGGCCCTTCTCCGGATCTGCGCGCTAGCGCGGAAGATAGCCGGAGGTCATTACGTG 3143
915 V Q G L L R I C A L A R K I A G G H Y V 934

#248 .....a.....
#227 .....a.....
#213 .....a.....
#211 .....
#209 .....a.....
#12 .....G.....a.....G.....G.t
GenBank .....a.....
PCR-seq .....a.....
cons. ....a.....
3144 CAAATGGCCATCATCAAGTTGGGGCGCTTACTGGCACCTATGTGTATAACCATCTCACC 3203
935 Q M A I I K L G A L T G T Y V Y N H L T 954

#248 .....
#227 .....
#213 .....c.....
#211 .....g.....
#209 .....a.....
#12 .....
GenBank .....
PCR-seq .....
cons. ....
3204 CCTCTTCGAGACTGGGCGCACACGGCCTGCGAGATCTGGCCGTGGCTGTGGAACCAGTC 3263
955 P L R D W A H N G L R D L A V A V E P V 974
```

Figure 9

21/43

1113-1-006

AM

```
#248 .....
#227 .....
#213 .....
#211 .....
#209 .....t.....
#12 .....
GenBank .....
PCR-seq .....
cons. ....
3264 GTCTTCTCCCGAATGGAGACCAAGCTCATCAGTGGGGGGCAGATACCGCCGCGTGCGGT 3323
975 V F S R M E T K L I T W G A D T A A C G 994

#248 .....G.....g...
#227 .....g...
#213 .....C.....g...
#211 .....t.....g...
#209 .....g...
#12 .....A.....g...
GenBank .....g...
PCR-seq .....g...
cons. ....
3324 GACATCATCAACGGCTTGCCCGTCTCTGCCCGTAGGGGCCAGGAGATACTGCTTGGACCA 3383
995 D I I N G L P V S A R R G Q E I L L G P 1014

#248 .....g.....
#227 .....
#213 .....a
#211 .....
#209 .....
#12 .....
GenBank .....
PCR-seq ...
cons. ....
3384 GCCGACGGAATGGTCTCCAAGGGGTGGAGGTGCTGGCGCCCATCAGGCGGTACGCCCAG 3443
1015 A D G M V S K G W R L L A P I T A Y A Q 1034

#248 .....C.....
#227 .....
#213 .....
#211 .....
#209 .....A.....
#12 .....
GenBank .....
cons. ....
3444 CAGACGAGAGGCCTCTAGGGTGTATAATCACCAGCCTGACTGGCCGGGACAAAAACCA 3503
1035 Q T R G L L G C I I T S L T G R D K N Q 1054
```

Figure 9

22/43

1113-1-006

AN

```
#248 .....
#227 .....a.....
#213 .....
#211 .....
#209 .....
#12 .....
GenBank .....g.....
cons.
3504 GTGGAGGGTGAGGTCCAGATCGTGTCAACTGCTACCCAAACCTTCCTGGCAACGTGCATC 3563
1055 V E G E V Q I V S T A T Q T F L A T C I 1074

#248 .....
#227 .....
#213 .....g.....
#211 .....
#209 .....
#12 .....
GenBank .....
PCR-seq .....
cons.
3564 AATGGGGTATGCTGGACTGTCTACACGGGGCCGGAACGAGGACCATCGCATCACCCAAG 3623
1075 N G V C W T V Y H G A G T R T I A S P K 1094

#248 .....
#227 .....c.....
#213 .....
#211 .....
#209 .....
#12 .....
GenBank .....c.....t.....c.....
PCR-seq .....
cons.
3624 GGTCTGTTCATCCAGATGTATACCAATGTGGACCAAGACCTTGTGGGCTGGCCCGCTCCT 3683
1095 G P V I Q M Y T N V D Q D L V G W P A P 1114

#248 .....c.....c.....
#227 .....c.....
#213 .....c.....
#211 .....c.....
#209 .....
#12 .....c.....
GenBank .....c.....
PCR-seq .....c.....
cons.
3684 CAAGGTTCCCGCTCATTGACACCTGCACCTGCGGCTCCTCGGACCTTTACCTGGTTACG 3743
1115 Q G S R S L T P C T C G S S D L Y L V T 1134

#248 .....t.....
#227 .....t.....
#213 .....t.....
#211 G.....
#209 .....
#12 .....t.....
GenBank .....t.....
PCR-seq .....t.....
cons.
3744 AGGCACGCCGACGTCAATTCCCGTGGCGCGGCGAGGTGATAGCAGGGGTAGCCTGCTTTCG 3803
1135 R H A D V I P V R R R G D S R G S L L S 1154
```

Figure 9

23/43

1113-1-006

AO

```
#248 .....t.g.....
#227 .....t.g.....
#213 .....t.g.....
#211 .....t.g.....
#209 .....t.g.....
#12 .....t.g.....
GenBank .....t.g.....
PCR-seq .....t.g.....
cons. ....t.g.....
3804 CCCCCGCCCCATTTCTACCTAAAAGGCTCCTCGGGGGGTCCGCTGTTGTGCCCGCGGGGA 3863
1155 P R P I S Y L K G S S G G P L L C P A G 1174
```

```
#248 .....G.t.....
#227 .....G.t.....
#213 .....G.t.....
#211 .....G.....
#209 .....a.....
#12 .....G.t.....
GenBank .....G.t.....
PCR-seq .....G.t.....
cons. ....G.t.....
3864 CACGCCGTGGGCCTATTCAGGGCCGCGGTGTCACCCGTGGAGTGACCAAGCGGTGGAC 3923
1175 H A V G L F R A A V C T R G V T K A V D 1194
```

```
#248 C.....G.....
#227 .....G.....
#213 .....G.....
#211 .....G.....
#209 .....G.....
#12 .....G.....
GenBank .....G.....
cons. ....G.....
3924 TTTATCCCTGTGGAGAACCTAGAGACAACCATGAGATCCCGGTGTTACGGACAACCTCC 3983
1195 F I P V E N L E T T M R S P V P T D N S 1214
```

```
#248 .....C.....
#227 .....C.....
#213 .....C.....
#211 .....C.....
#209 .....C.....
#12 .....C.....
GenBank .....C.....
cons. ....C.....
3984 TCTCCACCAGCAGTGCCCCAGAGCTTCCAGGTGGCCACCTGCATGCTCCACCGGCAGT 4043
1215 S P P A V P Q S F Q V A H L H A P T G S 1234
```

```
#248 .....
#227 .....
#213 A.....
#211 .....
#209 .....
#12 .....
GenBank .....A.....
cons. ....A.....
4044 GGTAAGAGCACCAAGGTCCCGGCTGCGTACGCAGCCAGGGCTACAAGGTGTTGGTGCTC 4103
1235 G K S T K V P A A Y A A Q G Y K V L V L 1254
```

Figure 9

24/43

1113-1-006

AP

```
#248 .....t
#227 .....t
#213 .....t
#211 .....A.....
#209 .....t
#12 .....t
GenBank .....a.....t
cons. ....
4104 AACCCCTCTGTGCTGCAACGCTGGGCTTTGGTGCTTACATGTCCAAGGCCCATGGGGTC 4163
1255 N P S V A A T L G F G A Y M S K A H G V 1274

#248 .....t.....
#227 .....C.....
#213 .....
#211 .....
#209 .....
#12 .....g.....
GenBank .....
cons. ....
4164 GATCCTAATATCAGGACCGGGGTGAGAACAATTACCACTGGCAGCCCCATCAGTACTCC 4223
1275 D P N I R T G V R T I T T G S P I T Y S 1294

#248 .....t.....
#227 .....t.....
#213 .....t.....
#211 .....t.....
#209 .....
#12 .....C.....t.....
GenBank .....C.....t.....
cons. ....
4224 ACCTACGGCAAAGTTCCTTGCCGACGGCGGGTGCTCAGGAGGCGCTTATGACATAATAATT 4283
1295 T Y G K F L A D G G C S G G A Y D I I I 1314

#248 .....
#227 .....
#213 .....
#211 .....
#209 .....
#12 .....C.....
GenBank .....C.....
cons. ....
4284 TGTGACGAGTGCCACTCCACGGATGCCACATCCATCTGGGCATCGGCACTGTCCTTGAC 4343
1315 C D E C H S T D A T S I L G I G T V L D 1334

#248 .....C.....
#227 .....C.....
#213 .....C.....
#211 .....
#209 .....
#12 .....C.....
GenBank .....C.....
cons. ....
4344 CAAGCAGAGACTGCGGGGGCGAGATTGGTTGTGCTCGCCACTGCTACCCCTCGGGGCTCC 4403
1335 Q A E T A G A R L V V L A T A T P P G S 1354
```

Figure 9

25143

1113-1-006

AQ

```
#248 .....c
#227 .....y
#213 .....
#211 .....
#209 .....
#12 .....
GenBank .....c
cons. ....
4404 GTCAC TGTG TCCCAT CCTAAC ATCG AGGAG GTTG CTCT GTTCC ACCAC CGGAG AGATCC CT 4463
1355 V T V S H P N I E E V A L S T T G E I P 1374

#248 ..t.....c
#227 ..t.....c
#213 ..t.....c
#211 ..t.....c
#209 ..t.....c
#12 ..t.....G.....c
GenBank ..t.....c
PCR-seq ..t.....c
cons. ..t.....c
4464 TTCTAC GGC AAGGCTATCCCCCTCGAGGTGATCAAGGGGGGAAGACATCTCATCTTCTGT 4523
1375 P Y G K A I P L E V I K G G R H L I F C 1394

#248 .....
#227 .....
#213 .....
#211 .....A.....
#209 .....t.....
#12 .....
GenBank .....
PCR-seq .....
cons. ....
4524 CACTCAAAGAAGAAGTGCGACGAGCTCGCCGCGAAGCTGGTGGCATTTGGGCATCAATGCC 4583
1395 H S K K K C D E L A A K L V A L G I N A 1414

#248 .....t.....G.....
#227 .....t.....G.....A.....
#213 .....t.c.....G.....
#211 .....t.c.....G.....
#209 .....G.....
#12 .....G.....
GenBank .....t.....G.....
PCR-seq .....t.....G.....
cons. .....t.....G.....
4584 GTGGCCTACTACCGCGGACTTGACGTGTCTGTTCATCCCGACCAACGGCGATGTTGTCGTC 4643
1415 V A Y Y R G L D V S V I P T N G D V V V 1434

#248 .....
#227 .....
#213 .....t.....
#211 .....
#209 .....
#12 .....
GenBank .....
PCR-seq .....
cons. ....
4644 GTGTGACCGATGCTCTCATGACTGGCTTTACCGGCGACTTCGACTCTGTGATAGACTGC 4703
1435 V S T D A L M T G F T G D F D S V I D C 1454
```

Figure 9



26/43

1113-1-006

AR

```
#248 .....
#227 .....
#213 .....
#211 .....
#209 .....
#12 .....G.....
GenBank .....t.....
PCR-seq .....
cons. ....
4704 AACACGTGTGTCACCTCAGACAGTCGATTTTCAGCCTTGACCCCTACCTTTACCATTGAGACA 4763
1455 N T C V T Q T V D F S L D P T F T I E T 1474

#248 .....a.....
#227 .....a.....G.....
#213 .....a.....
#211 .....a.....
#209 .....
#12 .....
GenBank .....a.....
PCR-seq .....a.....
cons. ....a.....
4764 ACCACGCTCCCCAGGATGCTGTCTCCAGGACTCAGCGCCGGGGCAGGACTGGCAGGGGG 4823
1475 T T L P Q D A V S R T Q R R G R T G R G 1494

#248 .....t.A.....
#227 .....a.....
#213 .....
#211 .....
#209 .....
#12 .....
GenBank .....t.....
cons. ....
4824 AAGCCAGGCATCTACAGATTGTGGCACCGGGGAGCGCCCTCCGGCATGTTGCACTCG 4883
1495 K P G I Y R F V A P G E R P S G H F D S 1514

#248 .....C.....
#227 .....t.....C.....
#213 .....C.....
#211 .....C.....
#209 .....G.....C.....
#12 .....C.....
GenBank .....C.....
cons. ....C.....
4884 TCCGTCTCTGTGAGTGCTATGACGCGGGCTGTGCTTGGTATGAGCTCATGCCCGCCGAG 4943
1515 S V L C E C Y D A G C A W Y E L M P A E 1534

#248 .....
#227 .....
#213 .....
#211 .....
#209 .....
#12 .....
GenBank .....
cons. ....
4944 ACTACAGTTAGGCTACGAGCGTACATGAACACCCCGGGGCTTCCCGTGTGCCAGGACCAT 5003
1535 T T V R L R A Y M N T P G L P V C Q D H 1554
```

Figure 9

27/43

1113-1-006

AS

```
#248 .....t.....
#227 .....t.....
#213 .....a.....t.....
#211 ...G.....a.....t.....
#209 .....
#12 .....
GenBank ...G.....t.....
cons. ....t.....
5004 CTTGAATTTTGGGAGGGCGTCTTTACGGGCCTCACCCTATAGATGCCCACTTTCTATCC 5063
1555 L E F W E G V F T G L T H I D A H F L S 1574

#248 .....
#227 .....
#213 .....c.....t.....
#211 .....c.....
#209 .....
#12 .....
GenBank .....
cons. ....
5064 CAGACAAAGCAGAGTGGGAGAACTTCTTACCTGGTAGCGTACCAAGCCACCGTGTGC 5123
1575 Q T K Q S G E N F P Y L V A Y Q A T V C 1594

#248 .....
#227 .....
#213 .....
#211 .....
#209 .....
#12 .....
GenBank .....C.....
cons. ....
5124 GCTAGGGCTCAAGCCCTCCCTCCCTGCTGGGACCAGATGTGGAAGTGTTCGATCCGCTT 5183
1595 A R A Q A P P P S W D Q M W K C L I R L 1614

#248 .....
#227 .....
#213 .....
#211 .....
#209 .....
#12 .....
GenBank .....
cons. ....
5184 AAACCCACCCTCCATGGGCCAACACCCCTGCTATACAGACTGGGCGCTGTTTCAGATGAA 5243
1615 K P T L H G P T P L L Y R L G A V Q N E 1634

#248 .....
#227 .....
#213 .....
#211 .....
#209 .....
#12 .....
GenBank .....
cons. ....
5244 GTCACCCTGACGCACCCAATCACCAATACATCATGACATGCATGTCGGCCGACCTGGAG 5303
1635 V T L T H P I T K Y I M T C M S A D L E 1654
```

Figure 9

28/43

1113-1-006

AT

```
#248 .....
#227 .....
#213 .....
#211 .....
#209 .....
#12 .....
GenBank .....
cons. ....
5304 GTCGTCACGAGCACCTGGGTGCTCGTTGGCGGCGTCCTGGCTGCTCTGGCCGCGTATTGC 5363
1655 V V T S T W V L V G G V L A A L A A Y C 1674

#248 .....C.....
#227 .....
#213 .....
#211 .....
#209 .....
#12 .....
GenBank .....C.....
cons. ....
5364 CTGTCAACAGGCTGCGTGGTCATAGTGGGCAGGATTGTCTTGTCCGGAAGCCGGCAATT 5423
1675 L S T G C V V I V G R I V L S G K P A I 1694

#248 .....
#227 .....
#213 .....
#211 .....
#209 .....
#12 .....
GenBank .....
cons. ....
5424 ATACCTGACAGGGAGGTTCTCTACCAGGAGTTCGATGAGATGGAAGAGTGCTCTCAGCAC 5483
1695 I P D R E V L Y Q E F D E M E E C S Q H 1714

#248 .....
#227 .....
#213 .....
#211 .....
#209 .....
#12 .....
GenBank .....
cons. ....
5484 TTACCGTACATCGAGCAAGGGATGATGCTCGCTGAGCAGTTCAAGCAGAAGGCCCTCGGC 5543
1715 L P Y I E Q G M M L A E Q F K Q K A L G 1734

#248 .....
#227 .....A.....
#213 .....A.....C.....
#211 .....A.....C.....
#209 .....
#12 .....C.....G.....
GenBank .....
cons. ....A.....
5544 CTCCTGCAGACCGCTCCCGCCATGCAGAGGTTATCACCCCTGCTGTCCAGACCAACTGG 5603
1735 L L Q T A S R H A E V I T P A V Q T N W 1754
```

Figure 9

29/43

1113-1-006

AU

```
#248 .....t.....c
#227 .....c.....c
#213 .....a....t.....g..c
#211 .....t.....g..c
#209 .....c
#12 .....c
GenBank .....c
cons. ....c
5604 CAGAAACTCGAGGTCTTCTGGGCGAAGCACATGTGGAATTTCATCAGTGGGATACAATAT 5663
1755 Q K L E V F W A K H M W N F I S G I Q Y 1774

#248 .....
#227 .....
#213 .....
#211 .....
#209 .....
#12 .....
GenBank .....
cons. ....
5664 TTGGCGGGCCTGTCAACGCTGCCCTGGTAACCCCGCCATTGCTTCATTGATGGCTTTTACA 5723
1775 L A G L S T L P G N P A I A S L M A F T 1794

#248 .....
#227 .....
#213 .....t.....
#211 .....t.....
#209 .....
#12 .....
GenBank .....
cons. ....
5724 GCTGCCGTCACCGCCCACTAACCAGTGGCCAAACCCCTCCTCTCAACATATTGGGGGGG 5783
1795 A A V T S P L T T G Q T L L F N I L G G 1814

#248 .....t.....c..
#227 .....
#213 .....
#211 .....
#209 .....t.....
#12 .....a.....
GenBank .....
cons. ....
5784 TGGGTGGCTGCCAGCTCGCCGCCCGGTGCCGCTACCGCCTTGTGGGCGCTGGCTTA 5843
1815 W V A A Q L A A P G A A T A F V G A G L 1834

#248 .....
#227 .....
#213 .....
#211 .....c.....
#209 .....
#12 .....a...A.....c
GenBank .....aC...A.....c
cons. ....
5844 GCTGGCGCCGCCATCGGCAGCGTTGGACTGGGAAGGTCCTCGTGGACATTCTTGCAGGG 5903
1835 A G A A I G S V G L G K V L V D I L A G 1854
```

Figure 9

30/43

1113-1-006

AV

```
#248 .....
#227 .....g.....
#213 .....g.....
#211 .....g.....c.....
#209 .....
#12 .....
GenBank .....g.....
cons.
5904 TATGGCGCGGGCGTGGCGGGAGCTCTTGTAGCATTCAGATCATGAGCGGTGAGGTCCCC 5963
1855 Y G A G V A G A L V A P K I M S G E V P 1874

#248 .....
#227 .....
#213 .....
#211 .....
#209 .....
#12 .....
GenBank .....a.....c.....
cons.
5964 TCCACGGAGGACCTGGTCAATCTGCTGCCCGCCATCCTCTCGCCTGGAGCCCTTGTAGTC 6023
1875 S T E D L V N L L P A I L S P G A L V V 1894

#248 .....
#227 .....
#213 .....
#211 .....
#209 .....
#12 .....c.....
GenBank .....Tt...T.....Gt.....
cons.
6024 GGTGTGGTCTGCCGAGCAATACTGCCCGGCACGTTGGCCCGGGCAGGGGGCAGTGCAA 6083
1895 G V V C A A I L R R H V G P G E G A V Q 1914

#248 .....
#227 .....
#213 .....t.....
#211 .....
#209 .....
#12 .....
GenBank .....a.....
PCR-seq .....
cons.
6084 TGGATGAACCGGCTAATAGCCTTCGCCTCCCGGGGAACCATGTTTCCCCCAGCACTAC 6143
1915 W M N R L I A F A S R G N H V S P T H Y 1934

#248 .....
#227 .....
#213 .....
#211 .....
#209 .....
#12 .....
GenBank .....
PCR-seq .....
cons.
6144 GTGCCGGAGAGCGATGCAGCCGCCCGGTCCTACTGCCATACTCAGCAGCCTCACTGTAAAC 6203
1935 V P E S D A A A R V T A I L S S L T V T 1954
```

Figure 9

31/43

1113-1-006

AW

```
#248 .....
#227 .....t
#213 .....g.....t
#211 .....g.....T.....t
#209 .....g.....g.....t
#12 .....g.....t
GenBank .....g.....t
PCR-seq .....g.....t
cons. ....g.....t
6204 CAGCTCCTGAGGCGACTACATCAGTGGATAAGCTCGGAGTGTACCACTCCATGCTCCGGC 6263
1955 Q L L R R L H Q W I S S E C T T P C S G 1974
```

```
#248 .....
#227 .....
#213 .....
#211 .....
#209 .....
#12 .....
GenBank .....
PCR-seq .....
cons. ....
6264 TCCTGGCTAAGGGACATCTGGGACTGGATATGCGAGGTGCTGAGCGACTTTAAGACCTGG 6323
1975 S W L R D I W D W I C E V L S D F K T W 1994
```

```
#248 .....
#227 .....
#213 .....
#211 .....
#209 .....
#12 .....
GenBank .....C.
PCR-seq .....
cons. ....
6324 CTGAAAGCCAAGCTCATGCCACAACCTGCCTGGGATTCCCTTTGTGTCCTGCCAGGCGGG 6383
1995 L K A K L M P Q L P G I P F V S C Q R G 2014
```

```
#248 .....
#227 .....
#213 .....
#211 .....
#209 .....
#12 .....
GenBank .....
PCR-seq .....
cons. ....
6384 TATAGGGGGGTCTGGCGAGGAGACGGCATTATGCACACTCGCTGCCACTGTGGAGCTGAG 6443
2015 Y R G V W R G D G I M H T R C H C G A E 2034
```

Figure 9

32/43

1113-1-006

AX

```
#248 .....
#227 .....
#213 .....c.....
#211 .....
#209 .....g.....
#12 .....g.....A....
GenBank .....
PCR-seq .....
cons. ....
6444 ATCACTGGACATGTCAAAAACGGGACGATGAGGATCGTCGGTCCTAGGACCTGCAGGAAC 6503
2035 I T G H V K N G T M R I V G P R T C R N 2054

#248 .....
#227 .....
#213 .....
#211 .....
#209 .....
#12 .....
GenBank .....TT.....t.....
cons. ....
6504 ATGTGGAGTGGGACGTTCGCCATTAAACGCCTACACCACGGGCCCTGTACTCCCTTCCT 6563
2055 M W S G T F P I N A Y T T G P C T P L P 2074

#248 .....
#227 .....
#213 .....
#211 .....
#209 .....c.....
#12 .....c.....
GenBank .....
cons. ....
6564 GCGCCGAACATATAAGTTCGCGCTGTGGAGGGTGTCTGCAGAGGAATACGTGGAGATAAGG 6623
2075 A P N Y K F A L W R V S A E E Y V E I R 2094

#248 .....
#227 .....
#213 .....
#211 .....
#209 .....
#12 .....
GenBank .....c.....c.....
cons. ....
6624 CGGGTGGGGGACTTCCACTACGTATCGGGTATGACTACTGACAATCTTAAATGCCCGTGC 6683
2095 R V G D F H Y V S G M T T D N L K C P C 2114

#248 .....
#227 .....
#213 .....c.....
#211 .....
#209 .....
#12 .....
GenBank .....
cons. ....
6684 CAGATCCCATCGCCCGAATTTTCACAGAATTGGACGGGGTGCGCCTACATAGGTTTGGC 6743
2115 Q I P S P E F F T E L D G V R L H R F A 2134
```

Figure 9

1113-1-006

AY




Figure 9.



34/43

1113-1-006

AZ

```
#248 .....a.....
#227 .....
#213 .....
#211 .....
#209 .....
#12 .....
GenBank .....
cons. ....
7044 CAGGAGATGGGCGGCAACATCACCAGGGTTGAGTCAGAGAACAAGTGGTGATTCTGGAC 7103
2235 Q E M G G N I T R V E S E N K V V I L D 2254

#248 .....
#227 .....
#213 .....t.....
#211 .....
#209 .....
#12 .....
GenBank .....
cons. ....
7104 TCCTTCGATCCGCTTGTGGCAGAGGAGGATGAGCGGGAGGTCTCCGTACCCGAGAAATT 7163
2255 S F D P L V A E E D E R E V S V P A E I 2274

#248 .....T.....
#227 .....
#213 .....c.....
#211 .....
#209 .....T.....
#12 .....c.....
GenBank .....Ca.....c.....
cons. ....
7164 CTGCGGAAGTCTCGGAGATTCGCCCCGGCCCTGCCCCGTTGGGCGCGGCGGACTACAAC 7223
2275 L R K S R R F A R A L P V W A R P D Y N 2294

#248 .....T.....
#227 .....
#213 .....A.....
#211 .....A.....
#209 .....gA.....
#12 .....g.....
GenBank .....T.....
cons. ....
7224 CCCCCGCTAGTAGAGACGTGAAAAAGCCTGACTACGAAACACCTGTGGTCCATGGCTGC 7283
2295 P P L V E T W K K P D Y E P P V V H G C 2314

#248 .....
#227 .....
#213 .....A.....
#211 .....
#209 .....g.....
#12 .....g.....
GenBank .....
cons. ....
7284 CCGCTACCACCTCCACGGTCCCCCTCCTGTGCCTCCGCCTCGAAAAAGCGTACGGTGGTC 7343
2315 P L P P P R S P P V P P P R K K R T V V 2334
```

Figure 9

35/43

1113-1-006

BA

```

#248 .....T.....
#227 .....T.....
#213 .....T.....
#211 .....T.....
#209 .....T.....C.....
#12 .....T.....
GenBank .....T.....
cons. ....T.....
7344 CTCACCGAATCAACCCCTACCTACTGCCTTGGCCGAGCTTGCCACCAAAAGTTTGGCAGC 7403
2335 L T E S T L P T A L A E L A T K S F G S 2354

#248 .....C.....
#227 .....C.....
#213 .....C.....
#211 .....C.....
#209 .....C.....
#12 .....C.....
GenBank .....C.....
cons. ....C.....
7404 TCCTCAACTTCCGGCATTACGGGCGACAATATGACAACATCCTCTGAGCCCCCCTTCT 7463
2355 S S T S G I T G D N M T T S S E P A P S 2374

#248 .....
#227 .....
#213 .....
#211 .....
#209 .....
#12 .....
GenBank .....
cons. ....
7464 GGCTGCCCCCCCCGACTCCGACGTTGAGTTCCTATTCTTCCATGCCCCCCTGGAGGGGGAG 7523
2375 G C P P D S D V E S Y S S M P P L E G E 2394

#248 .....
#227 .....
#213 .....C.....
#211 .....
#209 .....C.....
#12 .....C.....
GenBank .....C.....
PCR-seq .....
cons. ....C.....
7524 CCTGGGGATCCGGATTTCAGCGACGGGTCAATGGTTCGACGGTCAGTAGTGGGGCCGACACG 7583
2395 P G D P D F S D G S W S T V S S G A D T 2414

#248 .....T.....
#227 .....T.....
#213 .....T.....
#211 .....T.....
#209 .....T.....
#12 .....g.....T.....
GenBank .....T.....
PCR-seq .....T.....
cons. ....T.....
7584 GAAGATGTCGTGCTGCTCAATGTCTTATACCTGGACAGGCGCACTCGTCACCCCGTGC 7643
2415 E D V V C C S M S Y T W T G A L V T P C 2434

```

Figure 9

36/u3

1113-1-006

BB

```
#248 .....
#227 .....
#213 .....
#211 .....
#209 .....
#12 .....t.....t.....
GenBank .....g.....
PCR-seq .....
cons. ....
7644 GCTGCGGAAGAACAAAACTGCCCATCAACGCACTGAGCAACTCGTTGCTACGCCATCAC 7703
2435 A A E E Q K L P I N A L S N S L L R H H 2454

#248 .....
#227 .....
#213 .....g.....
#211 .....g.....
#209 .....g.....a.....
#12 .....a.g.....
GenBank .....g.....A.....
PCR-seq .....g.....
cons. ....g.....
7704 AATCTGGTATATTCCACCACTTCACGCAGTGTGCTGCCAAAGGCAGAGAAGAAAGTCACATTT 7763
2455 N L V Y S T T S R S A C Q R Q K K V T F 2474

#248 .....
#227 .....
#213 .....
#211 .....
#209 .....
#12 .....
GenBank .....
PCR-seq .....
cons. ....
7764 GACAGACTGCAAGTTCTGGACAGCCATTACCAGGACGTGCTCAAGGAGGTCAAAGCAGCG 7823
2475 D R L Q V L D S H Y Q D V L K E V K A A 2494

#248 .....
#227 .....
#213 .....
#211 .....
#209 .....
#12 .....C.....
GenBank .....G.....
PCR-seq .....
cons. ....
7824 CCGTCAAAAGTGAAGGCTAACTTGCTATCCGTAGAGGAAGCTTGACAGCCTGACGCCCCCA 7883
2495 A S K V K A N L L S V E E A C S L T P P 2514
```

Figure 9

37/43

1113-1-006

BC

```
#248 .....t.....
#227 .....
#213 .....
#211 .....t.....
#209 .....
#12 .....
GenBank .....
PCR-seq .....
cons. ....
7884 CATTTCAGCCAAATCCAAGTTTGGCTATGGGGCAAAAGACGTCCGTTGCCATGCCAGAAAG 7943
2515 H S A K S K F G Y G A K D V R C H A R K 2534

#248 .....
#227 .....
#213 .....
#211 .....
#209 .....
#12 .....
GenBank .....
PCR-seq .....
cons. ....
7944 GCCGTAGCCACATCAACTCCGTGTGGAAAGACCTTCTGGAAGACAGTGTAACACCAATA 8003
2535 A V A H I N S V W K D L L E D S V T P I 2554

#248 .....C.....t.....a.....
#227 .....C.....
#213 .....C.....t.....a.....
#211 .....C.....t.....a.....
#209 .....C.....t.....
#12 .....C.....t.....
GenBank .....C.....t.....
PCR-seq .....C.....t.....
cons. ....C.....t.....
8004 GACACTATCATCATGGCCAAGAACGAGGTCTTCTGCGTTCAGCCTGAGAAGGGGGTTCGT 8063
2555 D T I I M A K N E V F C V Q P E K G G R 2574

#248 .....C.....
#227 .....
#213 .....
#211 .....
#209 .....
#12 .....
GenBank .....
PCR-seq .....
cons. ....
8064 AAGCCAGCTCGTCTCATCGTGTCCCGACCTGGGCGTGCGCGTGCGAGAAGATGGCC 8123
2575 K P A R L I V F P D L G V R V C E K M A 2594

#248 .....g.....
#227 .....
#213 .....g.....
#211 .....g.....
#209 .....g.....
#12 .....g.....
GenBank .....g.....t.....
cons. ....g.....
8124 CTGTACGACGTGGTTAGCAAACTCCCCCTGGCCGTGATGGGAAGCTCCTACGGATTCCAA 8183
2595 L Y D V V S K L P L A V M G S S Y G F Q 2614
```

Figure 9

1113-1-006

BD

```
#248 .....
#227 .....
#213 .....
#211 .....
#209 .....
#12 .....
GenBank .....
cons. ....
8184 TACTCACCAGGACAGCGGGTTGAATTCCTCGTGCAAGCGTGGAAGTCCAAGAAGACCCCG 8243
2615 Y S P G Q R V E F L V Q A W K S K K T P 2634

#248 .....T.....
#227 .....T.....
#213 .....T.....
#211 .....T.....
#209 .....T.....
#12 .....T.....
GenBank .....T.....
cons. ....T.....
8244 ATGGGGTTCCCGTATGATACCCGCTGTTTGTGACTCCACAGTCACTGAGAGCGACATCCGT 8303
2635 M G F P Y D T R C F D S T V T E S D I R 2654

#248 .....
#227 .....
#213 .....
#211 .....
#209 .....
#12 .....
GenBank .....
cons. ....
8304 ACGGAGGAGGCAATTTACCAATGTTGTGACCTGGACCCCAAGCCGCGTGGCCATCAAG 8363
2655 T E E A I Y Q C C D L D P Q A R V A I K 2674

#248 .....
#227 .....
#213 .....
#211 .....
#209 .....
#12 .....
GenBank .....
cons. ....
8364 TCCCTCACTGAGAGGCTTTATGTTGGGGCCCTCTTACCAATTCAGGGGGGAAACTGC 8423
2675 S L T E R L Y V G G P L T N S R G E N C 2694

#248 .....C.....
#227 .....C.....
#213 .....C.....
#211 .....C.....
#209 .....C.....
#12 .....C.....
GenBank .....C.....
cons. ....C.....
8424 GGCTATCGCAGGTGCCGCGGAGCGGGCTACTGACAACTAGCTGTGGTAACACCCTCACT 8483
2695 G Y R R C R A S G V L T T S C G N T L T 2714
```

Figure 9

39/43

1113-1-006

BE

```
#248 .....T.C.....
#227 .....T.....
#213 .....T.....
#211 .....T.....
#209 .....T.....A.....
#12 .....T.....
GenBank C.....T.....
cons. ....T.....
8484 TGCTACATCAAGGCCCGGGCAGCCCGTCGAGCCGCAGGGCTCCAGGACTGCACCATGCTC 8543
2715 C Y I K A R A A R R A A G L Q D C T M L 2734

#248 .....A.....
#227 .....A.....
#213 .....A.....
#211 .....t.....
#209 .....t.....
#12 .....C.....
GenBank .....C.....
cons. ....C.....
8544 GTGTGTGGCGACGACTTAGTCGTTATCTGTGAAAGTCCGGGGGTCCAGGAGGACGCGGCG 8603
2735 V C G D D L V V I C E S A G V Q E D A A 2754

#248 .....C.....
#227 .....C.....
#213 .....C.....
#211 .....C.....
#209 .....C.....
#12 .....C.....
GenBank .....C.....
cons. ....C.....
8604 AGCCTGAGAGCCTTTACGGAGGCTATGACCAGGTACTCCGCCCCCCCCGGGACCCCCCA 8663
2755 S L R A F T E A M T R Y S A P P G D P P 2774

#248 .....C.....
#227 .....C.....
#213 .....C.....
#211 .....C.....
#209 .....t.....
#12 .....C.....
GenBank .....C.....
cons. ....C.....
8664 CAACCAGAATACGACTTGGAGCTTATAACATCATGCTCCTCCAACGTGTCAGTCGCCAC 8723
2775 Q P E Y D L E L I T S C S S N V S V A H 2794

#248 .....G.....
#227 .....G.....
#213 .....G.....C.....
#211 .....G.....C.....
#209 .....G.....t.....
#12 .....G.....
GenBank .....G.....
cons. ....G.....
8724 GACGGCGCTGGAAAAGGGTCTACTACCTTACCCGTGACCCCTACAACCCCCCTCGCGAGA 8783
2795 D G A G K R V Y Y L T R D P T T P L A R 2814
```

Figure 9

40/43

1113-1-006

BF

```
#248 .....
#227 .....
#213 .....
#211 .....
#209 .....
#12 .....
GenBank .....
cons. ....
8784 GCCGCGTGGGAGACAGCAAGACACACTCCAGTCAATTCTGGCTAGGCAACATAATCATG 8843
2815 A A W E T A R H T P V N S W L G N I I M 2834
```

```
#248 .....
#227 .....
#213 .....
#211 .....C.....
#209 .....
#12 .....
GenBank .....C.....
cons. ....
8844 TTTGCCCCCAGACTGTGGGCGAGGATGATACTGATGACCCATTCTTTAGCGTCTCATA 8903
2835 P A P T L W A R N I L M T H F F S V L I 2854
```

```
#248 .....G.....
#227 .....G.....
#213 .....G.....
#211 .....G.....
#209 .....G.....
#12 .....C.....G.....
GenBank .....C.....G.....
cons. ....G.....
8904 GCCAGGGATCAGCTTGAACAGGCTCTTAAGTGTGAGATCTACGCAGCCTGCTACTCCATA 8963
2855 A R D Q L E Q A L N C E I Y A A C Y S I 2874
```

```
#248 .....G.....C.....
#227 .....C.....
#213 .....C.....
#211 .....C.....
#209 .....C.....
#12 .....C.....
GenBank .....C.....
cons. ....C.....
8964 GAACCACTGGATCTACCTCCAATCATTCAAAGACTCCATGGCCTCAGCGCATTTTACTC 9023
2875 E P L D L P P I I Q R L H G L S A F L L 2894
```

```
#248 .....A.....
#227 .....A.....
#213 .....A.....
#211 .....A.....
#209 .....A.....
#12 .....A.....
GenBank .....A.t.....
PCR-seq .....
cons. ....A.....
9024 CACAGTTACTCTCCAGGTGAAGTCAATAGGGTGGCCGATGCCCTCAGAAAAGTGGGGTC 9083
2895 H S Y S P G E V N R V A A C L R K L G V 2914
```

Figure 9

1113-1-006

BG

```
#248 .....t.....
#227 .....
#213 .....a
#211 .....t.....
#209 .....a
#12 .....g.....t.....
GenBank .....T.....G...a
PCR-seq .....a
cons. ....a
9084 CCGCCCTTGCGAGCTTGGAGACACCGGGCCGGAGCGTCCGCGCTAGGCTTCTGTCCAGG 9143
2915 P P L R A W R H R A R S V R A R L L S R 2934

#248 .....
#227 .....
#213 .....
#211 .....
#209 .....
#12 .....G.....
GenBank .....A.....
cons. ....
9144 GGAGGCAGGGCTGCCATATGTGGCAAGTACCTCTTCAACTGGGCAGTAAGAACAAGCTC 9203
2935 G G R A A I C G K Y L F N W A V R T K L 2954

#248 .....
#227 .....
#213 .....
#211 .....
#209 .....
#12 .....
GenBank .....g...A.....
PCR-seq .....
cons. ....
9204 AAACCTCACTCCAATAGCGGCGCTGGCCGGCTGGACTTGTCCGGTTGGTTCACGGCTGGC 9263
2955 K L T P I A A A G R L D L S G W F T A G 2974
```

Figure 9



1113-1-006




Figure 10

1113-1-006




Figure 11

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/04428**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) : A61K 39/29; C12N 1/15, 1/21, 5/10, 5/14, 5/16; C12Q 1/70;

US CL : 424/93.6, 228.1; 435/5, 252.3, 254.2, 320.1, 325, 348, 419

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/93.2, 93.6, 199.1, 228.1; 435/5, 6, 91.33, 172.3, 235.1, 236, 252.3, 252.33, 254.2, 254.21, 320.1, 325, 348, 363, 370, 419

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
T	CLARKE et al. Developments in Hepatitis C during 1996-1997. Expert Opinions in Therapeutic Patents. September 1997, Vol. 7, No. 9, pages 979-987, especially pages 983, column 2, -984.	1-21, 25, 26, 30-33, 40-43, 48, 49, 57, 58, 67, and 68.
X	YOO et al. Transfection of a Differentiated Human Hepatoma Cell Line (Huh7) with In Vitro-Transcribed Hepatitis C Virus (HCV) RNA and Establishment of a Long-Term Culture Persistently Infected with HCV. Journal of Virology. January 1995, Vol. 69, No. 1, pages 32-38, see entire document.	1, 2, 4, 5, 9, 14-16, 20, 25, 26, 32, 33, 40-42, 57, and 58.
X	US 5,106,726 A (C. Y. WANG) 21 April 1992, column 36, lines 35-68.	67 and 68

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

## \* Special categories of cited documents:

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*B\* earlier document published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\*

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\*

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\*

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

\*A\*

document member of the same patent family

Date of the actual completion of the international search

29 MAY 1998

Date of mailing of the international search report

16 JUL 1998

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

THOMAS G. LARSON, PH.D.

Telephone No. (703) 308-0196

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/04428

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☒ Claims Nos.: 3, 6, 7, 8, 17, 18, and 59  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:  
  
The claims are drawn to specific SEQ. ID. NOS, but a Sequence Listing in computer readable format has not been provided, as evidenced by form PCT/RO/101, Box No. VII, item No. 7. Claims 10-16, 19-21, 32, 33, 40-43, 48, and 49 have only been searched to the extent possible without a sequence search.
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
1-21, 25, 26, 30-33, 40-43, 48, 49, 57, 58, 67 and 68.

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/04428

### B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, STN (Biosis, CAPLUS, INPADOC, LifeSci, Medline, WPIDS)

Search Terms: HCV, Hepatitis C Virus, infectious clone, functional clone, infectious transcript, recombinant, viral vector, vector, vaccine, kit, cell line, permissive, replication, infection.

### BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1.

Group I, claim(s) 1-21, 25, 26, 30-33, 40-43, 48, 49, 57-59, 67, and 68 drawn to genetically engineer HCL clones, vectors, cells, vaccines, and kits comprising said clones, method of using clones to identify cells permissive for HCL replication and method for making HCL clones.

Group II, claims 22, 27-29 and 34-35, drawn to method of infecting or identifying animals permissive for HCL infection.

Group III, claim(s) 23 and 24, drawn to method of selecting HCL having adaptive mutations.

Group IV, claim 36, drawn to method of making viral particles in an animal.

Group V, claims 37-39, drawn to method of making viral particles in cultured cell lines.

Group VI, claims 44-47, drawn to method of making antibodies.

Group VII, claims 50-52, drawn to method of screening for agent that modulates HCL replication in animals.

Group VIII, claims 53-56 and 60, drawn to method of screening for agent that modulates HCL infection in cell lines.

Group I, claims 61 and 62, drawn to methods of detecting HCL antibodies by binding to viral particles.

Group X, claims 63-66, drawn to methods of detecting HCL infection in a sample using engineered cells.

The inventions listed as Groups I to X do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The method of determining unity of invention under PCT Rule 13 permits, in addition to and independent claim to a product, an independent claim to a process of making and an independent claim to a process of using said product. In the instant case unity of invention exists between the compositions comprising engineered HCV nucleic acids, the method of making an engineered HCV nucleic acid (claims 57-59) and the method of using engineered HCV nucleic acids to identify and/or infect permissive cell lines. Independent claims to additional methods of using engineered HCV nucleic acids of groups II-X are not considered to be linked by a "special technical feature". Therefore, unity of invention does not exist between the method of using engineered HCV nucleic acids to identify and/or infect permissive cell lines of group I, the method of using engineered HCV nucleic acids to identify and/or infect animals permissive for HCV infection of group II, the method of selecting adaptive mutations of group III, the method of making viral particles in an animal of group IV, the method of making viral particles in a cell line of group V, the method of making antibodies of group VI, the method of screening for agents that modulate HCV replication in animals of group VII, the method of screening for agents that modulate HCV replication in a cell line of group VIII, the method of detecting antibodies of group IX, and the method of detecting HCV infection using engineered cell of group X. Therefore, the claims of groups I-IX are not so linked by a special technical feature within the meaning of PCT Rule 13.2 to form a single inventive concept.

